
<html lang="en"     class="pb-page"  data-request-id="7c2de605-a878-421e-a2f5-c24b7670657a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-23;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.0c01345;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="SAR Investigation and Discovery of Water-Soluble 1-Methyl-1,4-dihydroindeno[1,2-c]pyrazoles as Potent Tubulin Polymerization Inhibitors" /></meta><meta name="dc.Creator" content="Ying-Jie  Cui" /></meta><meta name="dc.Creator" content="Chao  Liu" /></meta><meta name="dc.Creator" content="Chen-Chen  Ma" /></meta><meta name="dc.Creator" content="Ya-Ting  Ji" /></meta><meta name="dc.Creator" content="Yi-Li  Yao" /></meta><meta name="dc.Creator" content="Long-Qian  Tang" /></meta><meta name="dc.Creator" content="Cheng-Mei  Zhang" /></meta><meta name="dc.Creator" content="Jing-De  Wu" /></meta><meta name="dc.Creator" content="Zhao-Peng  Liu" /></meta><meta name="dc.Description" content="Taking the previously discovered 1-methyl-1,4-dihydroindeno[1,2c]pyrazol derivative LL01 as a lead, systematic structural modifications were made at the phenolic 6- and 7-positions and the aniline ..." /></meta><meta name="Description" content="Taking the previously discovered 1-methyl-1,4-dihydroindeno[1,2c]pyrazol derivative LL01 as a lead, systematic structural modifications were made at the phenolic 6- and 7-positions and the aniline ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 17, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01345" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01345" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01345" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01345" /></link>
        
    
    

<title>SAR Investigation and Discovery of Water-Soluble 1-Methyl-1,4-dihydroindeno[1,2-c]pyrazoles as Potent Tubulin Polymerization Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01345" /></meta><meta property="og:title" content="SAR Investigation and Discovery of Water-Soluble 1-Methyl-1,4-dihydroindeno[1,2-c]pyrazoles as Potent Tubulin Polymerization Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0018.jpeg" /></meta><meta property="og:description" content="Taking the previously discovered 1-methyl-1,4-dihydroindeno[1,2c]pyrazol derivative LL01 as a lead, systematic structural modifications were made at the phenolic 6- and 7-positions and the aniline at the 3-position of the indenopyrazole core to investigate the SARs and to improve water solubility. Among the designed indenopyrazoles ID01–ID33, a series of potent MTAs were identified. As the hydrochloride salt(s), ID09 and ID33 showed excellent aqueous solubility and favorable Log P value and displayed noteworthily low nanomolar potency against a variety of tumor cells, including those taxol-resistant ones. They inhibited tubulin polymerization, disrupted cellular microtubule networks by targeting the colchicine site, and promoted HepG2 cell cycle arrest and cell apoptosis. In the HepG2 xenograft mouse model, ID09 and ID33 effectively inhibited tumor growth at an oral dose of 25 mg/kg. At an intravenous (iv) injection dose of 10 mg/kg every other day, ID09 suppressed tumor growth by 68% without obvious toxicity." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01345"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01345">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01345&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01345&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01345&amp;href=/doi/10.1021/acs.jmedchem.0c01345" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 14840-14866</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01243" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01303" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">SAR Investigation and Discovery of Water-Soluble 1-Methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazoles as Potent Tubulin Polymerization Inhibitors</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Ying-Jie Cui</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ying-Jie Cui</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ying-Jie++Cui">Ying-Jie Cui</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chao Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chao Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chao++Liu">Chao Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chen-Chen Ma</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chen-Chen Ma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Central Laboratory, The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250012, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chen-Chen++Ma">Chen-Chen Ma</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ya-Ting Ji</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ya-Ting Ji</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ya-Ting++Ji">Ya-Ting Ji</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yi-Li Yao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yi-Li Yao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yi-Li++Yao">Yi-Li Yao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Long-Qian Tang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Long-Qian Tang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Long-Qian++Tang">Long-Qian Tang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cheng-Mei Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cheng-Mei Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cheng-Mei++Zhang">Cheng-Mei Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jing-De Wu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jing-De Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#f582809f9c9b929190c2c5b5869180db909180db969b"><span class="__cf_email__" data-cfemail="186f6d7271767f7c7d2f28586b7c6d367d7c6d367b76">[email protected]</span></a>, Tel. +86 (0)531 88382006.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jing-De++Wu">Jing-De Wu</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Zhao-Peng Liu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhao-Peng Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#aec2c7dbd4c6cfc1deeeddcadb80cbcadb80cdc0"><span class="__cf_email__" data-cfemail="bed2d7cbc4d6dfd1cefecddacb90dbdacb90ddd0">[email protected]</span></a>, Tel. +86 (0)531 88382006.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhao-Peng++Liu">Zhao-Peng Liu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9429-8028" title="Orcid link">http://orcid.org/0000-0001-9429-8028</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01345&amp;href=/doi/10.1021%2Facs.jmedchem.0c01345" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 14840–14866</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 17, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 August 2020</li><li><span class="item_label"><b>Published</b> online</span>17 November 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01345" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01345</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D14840%26pageCount%3D27%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYing-Jie%2BCui%252C%2BChao%2BLiu%252C%2BChen-Chen%2BMa%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D23%26contentID%3Dacs.jmedchem.0c01345%26title%3DSAR%2BInvestigation%2Band%2BDiscovery%2Bof%2BWater-Soluble%2B1-Methyl-1%252C4-dihydroindeno%255B1%252C2-c%255Dpyrazoles%2Bas%2BPotent%2BTubulin%2BPolymerization%2BInhibitors%26numPages%3D27%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D14866%26publicationDate%3DDecember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01345"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1159</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01345" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;SAR Investigation and Discovery of Water-Soluble 1-Methyl-1,4-dihydroindeno[1,2-c]pyrazoles as Potent Tubulin Polymerization Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Ying-Jie&quot;,&quot;last_name&quot;:&quot;Cui&quot;},{&quot;first_name&quot;:&quot;Chao&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Chen-Chen&quot;,&quot;last_name&quot;:&quot;Ma&quot;},{&quot;first_name&quot;:&quot;Ya-Ting&quot;,&quot;last_name&quot;:&quot;Ji&quot;},{&quot;first_name&quot;:&quot;Yi-Li&quot;,&quot;last_name&quot;:&quot;Yao&quot;},{&quot;first_name&quot;:&quot;Long-Qian&quot;,&quot;last_name&quot;:&quot;Tang&quot;},{&quot;first_name&quot;:&quot;Cheng-Mei&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Jing-De&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Zhao-Peng&quot;,&quot;last_name&quot;:&quot;Liu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;17&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;14840-14866&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01345&quot;},&quot;abstract&quot;:&quot;Taking the previously discovered 1-methyl-1,4-dihydroindeno[1,2c]pyrazol derivative LL01 as a lead, systematic structural modifications were made at the phenolic 6- and 7-positions and the aniline at the 3-position of the indenopyrazole core to investigate the SARs and to improve water solubility. Among the designed indenopyrazoles ID01–ID33, a series of potent MTAs were identified. As the hydrochloride salt(s), ID09 and ID33 showed excellent aqueous solubility and favorable Log P value and displayed noteworthily low nanomolar potency against a variety of tumor cells, including those taxol-resistant ones. They inhibited tubulin polymerization, disrupted cellular microtubule networks by targeting the colchicine site, and promoted HepG2 cell cycle arrest and cell apoptosis. In the HepG2 xenograft mouse model, ID09 and ID33 effectively inhibited tumor growth at an oral dose of 25 mg/kg. At an intravenous (iv) injection dose of 10 mg/kg every other day, ID09 suppressed tumor growth by 68% without obvious toxicity&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01345&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01345" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01345&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01345" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01345&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01345" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01345&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01345&amp;href=/doi/10.1021/acs.jmedchem.0c01345" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01345" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01345" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (10 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01345%26sid%3Dliteratum%253Aachs%26pmid%3D33201714%26genre%3Darticle%26aulast%3DCui%26date%3D2020%26atitle%3DSAR%2BInvestigation%2Band%2BDiscovery%2Bof%2BWater-Soluble%2B1-Methyl-1%252C4-dihydroindeno%255B1%252C2-c%255Dpyrazoles%2Bas%2BPotent%2BTubulin%2BPolymerization%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D23%26spage%3D14840%26epage%3D14866%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=291149" title="Apoptosis">Apoptosis</a>,</li><li><a href="/action/doSearch?ConceptID=292232" title="Polymerization">Polymerization</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/jmcmar.2020.63.issue-23/20201210/jmcmar.2020.63.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Taking the previously discovered 1-methyl-1,4-dihydroindeno[1,2<i>c</i>]pyrazol derivative LL01 as a lead, systematic structural modifications were made at the phenolic 6- and 7-positions and the aniline at the 3-position of the indenopyrazole core to investigate the SARs and to improve water solubility. Among the designed indenopyrazoles <b>ID01</b>–<b>ID33</b>, a series of potent MTAs were identified. As the hydrochloride salt(s), <b>ID09</b> and <b>ID33</b> showed excellent aqueous solubility and favorable Log <i>P</i> value and displayed noteworthily low nanomolar potency against a variety of tumor cells, including those taxol-resistant ones. They inhibited tubulin polymerization, disrupted cellular microtubule networks by targeting the colchicine site, and promoted HepG2 cell cycle arrest and cell apoptosis. In the HepG2 xenograft mouse model, <b>ID09</b> and <b>ID33</b> effectively inhibited tumor growth at an oral dose of 25 mg/kg. At an intravenous (iv) injection dose of 10 mg/kg every other day, <b>ID09</b> suppressed tumor growth by 68% without obvious toxicity.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82128" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82128" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Microtubules are formed by the polymerization of α- and β-tubulin heterodimers and serve as an integral part of the cytoskeleton.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1−4)</a> The dynamic features of microtubule polymerization/depolymerization play critical roles in multiple cell functions, including cell division, cell cytoskeleton maintenance, cell signaling, and organelle transport.<a onclick="showRef(event, 'ref5 ref6 ref7 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8 ref9 ref10">(5−10)</a> Interfering with tubulin dynamics becomes an effective strategy in antitumor drug discovery.<a onclick="showRef(event, 'ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13">(11−13)</a> Microtubule-targeting agents (MTAs) are categorized as microtubule stabilizers and microtubule destabilizers. The microtubule-stabilizing agents promote the α- and β-tubulin assembly, thereby increasing the density of microtubules, while the microtubule-destabilizing agents initiate microtubule depolymerization, leading to microtubule disassembly and a decrease in microtubule density. Until now, six well-known tubulin-binding sites have been identified.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> The colchicine,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> vinca,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> maytanine,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and pironetin<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> site-binding agents are microtubule destabilizers, while the taxane and laulimalide/peloruside<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> site-binding agents are microtubule stabilizers. Currently, all of the Food and Drug Administration (FDA)-approved MTAs are natural products or their derivatives,<a onclick="showRef(event, 'ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23">(21−23)</a> including the vinca site-destabilizing MTAs,<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24−26)</a> vinblastine, vincristine, vinorelbine, vindesine, vinflunine, and eribulin, and the taxane-site stabilizing MTAs, paclitaxel (taxol), docetaxel, cabazitaxel, and ixabepilone.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> These drugs are widely used and highly effective for the treatment of solid and hematological tumors. However, these MTAs suffer from some neurotoxicity and myelosuppression-related toxicity as well as formulation issues due to low water solubility.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> In addition, the appearance of multidrug resistance also limits their antitumor efficiency.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> To reduce the side effects of MTAs and overcome their drug resistance, highly potent and cytotoxic MTAs, such as dolastatin 10 analogues, monomethyl auristatin E, maytansine derivatives, cryptophycins, and tubulysins, are used as powerful drug warheads and linked to cancer-targeted monoclonal antibodies to make antibody–drug conjugates (ADCs), where the monoclonal antibodies recognize the tumor and deliver the MTAs into the target tissue.<a onclick="showRef(event, 'ref30 ref31 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32 ref33">(30−33)</a> The FDA approved the ADC drugs trastuzumab emtansine for HER2-positive metastatic breast cancer and brentuximab vedotin for the treatment of CD30-expressing T-cell lymphoma, primary cutaneous anaplastic large cell lymphoma, and Hodgkin’s lymphoma.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34,35)</a> The success of ADCs for cancer treatment has expanded the applications of MTAs. Besides the traditional roles of MTAs as antimitotic agents, the multiple-hit mode of action of MTAs in nondividing cells, including the inhibition of cellular transport, the inhibition of metabolism, and the impairment of cellular signaling important for carcinogenesis, is of major concern.<a onclick="showRef(event, 'ref36 ref37 ref38 ref39 ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38 ref39 ref40 ref41 ref42">(36−42)</a> Therefore, the continued discovery and development of new MTAs will contribute to cancer therapy.</div><div class="NLM_p">Colchicine (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) is the first MTA to be identified. As a destabilizing MTA, it does not have an acceptable therapeutic window for the treatment of cancer. Unlike the taxane and vinca site MTAs, the colchicine site-binding agents in general are not the substrate of the MDR efflux pump and can overcome the multidrug resistance mediated by P-gp.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> Moreover, the colchicine site-binding agents may serve as vascular disrupting agents,<a onclick="showRef(event, 'ref45 ref46 ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref45 ref46 ref47 ref48">(45−48)</a> represented by the nature-derived combretastatin A-4 (CA-4, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). In our previous studies, we applied the privileged indenopyrazole scaffold in the rational design of the colchicine site-binding agents and discovered the lead compounds LL01 and LL02 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) that displayed strong inhibition (∼nM) against a variety of tumor cells.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> As a hydroxamic acid, LL02 was found unstable in the liver microsome stability assay, while the acetamide LL01 was metabolically stable with acceptable pharmacokinetic (PK) properties.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Further studies confirmed that LL01 was not a P-gp substrate and effective for multidrug-resistant tumor cells. In HepG2 and KB/V tumor models, LL01 effectively inhibited tumor growth via oral or subcutaneous administration.<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(50,51)</a> Molecular docking simulations indicated that LL01 may have a distinct binding mode with the colchicine site,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> in that, the 1-methyl-1,4-dihydroindeno-[1,2-<i>c</i>]pyrazole portion made hydrophobic interactions with zone II pocket and the <i>m</i>-ethoxyaniline group penetrated into zone III and formed hydrogen bonding with Tyrβ202 and Asnβ167. The 6-ethoxy group of LL01 interacted with the hydrophobic zone I only partially; however, the 7-acetamide substituent protruded into a new region on the interfacial surface and formed a critical hydrogen bond with Serα178. This unique binding pattern of LL01 may be closely related to its high antitumor activity. These promising results with these new types of inhibitors prompted us to elucidate the structure–activity relationships (SARs) as well as to improve the water solubility of these indenopyrazole analogues to develop potential new drug candidates. Therefore, we maintained the 1-methyl-1,4-dihydroindeno-[1,2-<i>c</i>]pyrazole core and made modifications on the phenolic 6- and 7-positions and the 3-aniline portion (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). We first changed the ethyl group in 6-ethoxy of LL01 from hydrogen and methyl to other larger groups (Pr, Bu, <i>p</i>-methoxybenzyl) to determine the influences of these groups on the interaction with zone 1. A reversion of the positions of 7-oxaacetaminde and 6-alkyloxy was also made to confirm the importance of the interactions with Serα178 on the interfacial surface. Next, we made modifications at the phenolic 7-position by introducing different substituents with terminal hydroxyl or amino groups to maintain the interaction with Serα178 and to increase the solubility of these indenopyrazole analogues. Finally, keeping the optimized substituents at both the 6- and 7-positions, we made modifications at 3-aniline through introducing different groups at the meta- or para-position as well as replacing the phenyl with a pyridyl to find the suitable groups for the interaction with zone III. Herein, we report the SAR investigation and the discovery of water-soluble 1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazoles as potent tubulin polymerization inhibitors targeting the colchicine site with good in vitro and in vivo antitumor efficiency.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Colchicine site ligands.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of indenopyrazole derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77734" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77734" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">Depending on the modifications at the different positions and the nature of the different substituents, five synthetic routes were designed to prepare these indenpyrazole derivatives. The first series of compounds <b>ID01</b>–<b>ID05</b> were made by modifications at the 6-phenolic position while keeping the other portions of LL01 intact. The preparation of these analogues is shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. 5,6-Dihydroxy-1-indanone (<b>1</b>) was first reacted with chloromethyl methyl ether (MOMCl) in the presence of <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA) in <i>N</i>,<i>N</i>-dimetylformamide (DMF) to selectively protect the 5-phenolic hydroxyl group (65%) and then with <i>tert</i>-butyldimethylsilyl chloride (TBSCl) to protect the 6-phenolic hydroxyl group (86%). After the treatment of indanone <b>3</b> with lithium hexamethyldisilazide (LiHMDS) in anhydrous tetrahydrofuran (THF), the following reaction with 3-ethoxyphenylisothiocyanate generated a thioamide intermediate, which underwent cyclization with hydrazine hydrate and subsequent NH methylation with dimethyl sulfate in dichloromethane (DCM) to give 1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazole intermediate <b>4</b> (18%, three steps). The TBS group in <b>4</b> was removed with tetrabutylammonium fluoride (TBAF), and the resulting indenopyrazole <b>5</b> (75%) was reacted with methyl chloroacetate using K<sub>2</sub>CO<sub>3</sub> as a base under the reflux conditions to provide methyl ester <b>6</b> (84%). After the aminolysis of ester <b>6</b> with ammonia, amide <b>7</b> was obtained (83%). The subsequent removal of the MOM protective group in <b>7</b> with camphorsulfonic acid (CSA) provided the 6-hyroxyindenopyrazole derivative <b>ID01</b> in 90% yield. The alkylation of 6-phenolic hydroxyl group in <b>ID01</b> with dimethyl sulfate, <i>n</i>-bromopropane, <i>n</i>-bromobutane, and <i>p</i>-methoxychlorobenzyl in DMF using K<sub>2</sub>CO<sub>3</sub> as a base generated the corresponding indenopyrazole derivatives <b>ID02</b>–<b>ID05</b> (66–82%).</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0012.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 1-Methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazoles <b>ID01</b>–<b>ID06</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) MOMCl, DIPEA, DMF, rt, 12 h; (b) TBSCl, imidazole, DMF, rt, 4 h; (c) (1) LiHMDS, 3-EtOPhNCS, THF, −78 °C to rt, 17 h; (2) NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O, 1,4-dioxane/EtOH, 55 °C; 36 h; (3) (CH<sub>3</sub>)<sub>2</sub>SO<sub>4</sub>, DIPEA, DCM, rt, 7 h; (d) TBAF, THF, rt, 0.5 h; (e) ClCH<sub>2</sub>CO<sub>2</sub>Me, K<sub>2</sub>CO<sub>3</sub>, acetone, 65 °C, 6 h; (f) NH<sub>3</sub>·H<sub>2</sub>O, MeOH, reflux, 1.5 h; (g) CSA, MeOH, 40 °C, 2 h; (h) (CH<sub>3</sub>)<sub>2</sub>SO<sub>4</sub> or PrBr or BuBr or <i>p</i>-MeOBnCl, K<sub>2</sub>CO<sub>3</sub>, DMF, 40 °C, 2.5–8 h; (i) PrBr, K<sub>2</sub>CO<sub>3</sub>, acetone, 65 °C, 8 h; (j) CSA, MeOH, 40 °C, 2 h.</p></p></figure><div class="NLM_p">The indenopyrazole derivative <b>ID06</b> featured with a position reversion of 7-oxaacetaminde and 6-alkyloxy to confirm the importance of the supposed interactions with Serα178 on the interfacial surface. The synthesis of <b>ID06</b> is shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Propyl ether formation was achieved by the reaction of <b>5</b> with <i>n</i>-bromopropane to give 7-propoxyindenopyrazole <b>8</b> (90%). Following similar procedures to those for the preparation of <b>ID02</b>–<b>ID05</b> via the removal of the MOM protective group (80%), the Williamson etherification with methyl chloroacetate (87%), and the subsequent ammonolysis with ammonia (76%), <b>ID06</b> was prepared.</div><div class="NLM_p">To further verify the contribution of 7-oxaacetaminde in LL01 to the tubulin polymerization inhibition, this substituent was changed to 7-oxaacetic acid (<b>ID07</b>). As shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, following similar procedures to those for the construction of the 1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazole scaffold, the 7-hydroxyl and methyl 7-oxaacetic acid intermediates <b>13a</b> and <b>14a</b> were transformed from indanone <b>11</b>.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Methyl 7-oxaacetic acid <b>14a</b><a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> was hydrolyzed with lithium hydroxide (LiOH) in an aqueous methanol solution to give 7-oxaacetic acid derivative <b>ID07</b> in 85% yield. Next, we changed 7-oxaacetaminde in LL01 to 7-(3-hydroxyproxy) (<b>ID08</b>) and 7-(3-aminoproxy) (<b>ID09</b>) to investigate the effects of the terminal amino or hydroxyl group on the interaction with α-tubulin. The reaction of 5-ethoxy-6-hydroxy-1-indanone <b>15</b><a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> with 3-bromopropanol in the presence of K<sub>2</sub>CO<sub>3</sub> provided 5-ethoxy-6-(3-hydroxypropoxy)-1-indanone <b>16</b> (79%). After the protection of the primary hydroxyl group with the MOM group, indanone <b>17</b> was similarly transformed into 1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazole intermediate <b>18a</b> (16%, three steps). Deprotection of the MOM group in <b>18a</b> with CSA furnished the synthesis of <b>ID08</b> (75%). 7-Hydroxyindenopyrazole <b>13a</b> was reacted with <i>N</i>-Boc-3-bromopropylamine to give <b>19a</b> (87%). After the removal of the Boc protective group in a mixed solution of acetyl chloride and ethanol, <b>ID09</b> was obtained as a hydrochloride salt in 88% yield. Acetylation of the terminal amino group in <b>ID09</b> gave indenopyrazole derivative <b>ID10</b> (92%). To further confirm the importance of the terminal hydroxyl or amino group, the 7-propoxy derivative <b>ID11</b> was designed for comparison. <b>ID11</b> was prepared from <b>13a</b> via the propyl ether formation by the reaction with propyl bromide (64%) (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0013.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 1-Methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazoles <b>ID07</b>–<b>ID11</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (1) LiHMDS, 3-EtOPhNCS, THF, −78 °C to rt; 16 h; (2) NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O, 1,4-dioxane/EtOH, 55 °C, 26 h; (3) (CH<sub>3</sub>)<sub>2</sub>SO<sub>4</sub>, DIPEA, DCM, rt; 6 h; (b) TBAF, THF, rt, 1 h; (c) ClCH<sub>2</sub>CO<sub>2</sub>Me, K<sub>2</sub>CO<sub>3</sub>, acetone, 65 °C, 6 h; (d) LiOH, MeOH/H<sub>2</sub>O, 30 °C, 2 h; (e) 3-bromo-1-propanol, K<sub>2</sub>CO<sub>3</sub>, DMF, 75 °C, 10 h; (f) MOMCl, DIPEA, DMF, rt, 8 h; (g) CSA, MeOH, 40 °C, 2 h; (h) BocNHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>Br, K<sub>2</sub>CO<sub>3</sub>, acetone, 65 °C, 8 h; (i) CH<sub>3</sub>COCl, EtOH, rt, 0.5 h; (j) (CH<sub>3</sub>CO)<sub>2</sub>O, Et<sub>3</sub>N, DCM, rt, 4 h; (k) PrBr, K<sub>2</sub>CO<sub>3</sub>, acetone, 65 °C, 12 h.</p></p></figure><div class="NLM_p">Further structural modifications of LL01 were made at the indenopyrazole 3-aniline position by changing the <i>meta</i>-ethoxy to the para-position or by introducing different substituents at the meta-position as well as replacing 3-aniline with pyridyl-2-amine. The synthesis of these indenopyrazole derivatives is shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0014.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 1-Methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazoles <b>ID12</b>–<b>ID22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (1) LiHMDS, R-Ph-NCS, THF, −78 °C to rt, 16–20 h; (2) NH<sub>2</sub>NH<sub>2</sub><b>·</b>H<sub>2</sub>O, 1,4-dioxane/EtOH, 55 °C, 20–36 h; (3) (CH<sub>3</sub>)<sub>2</sub>SO<sub>4</sub>, DIPEA, DCM, rt, 8–16 h; (b) TBAF, THF, rt, 1 h; (c) ClCH<sub>2</sub>CO<sub>2</sub>Me, K<sub>2</sub>CO<sub>3</sub>, acetone, 65 °C, 8–12 h; (d) NH<sub>3</sub><b>·</b>H<sub>2</sub>O, MeOH, reflux, 2–4 h; (e) CH<sub>3</sub>COCl, EtOH, rt, 1 h; (f) CH<sub>3</sub>NH<sub>2</sub>, MeOH, reflux, 4 h; (g) (1) LiHMDS, 6-EtO-Py-2-NCS, THF, −78 °C to rt, 18 h; (2) NH<sub>2</sub>NH<sub>2</sub><b>·</b>H<sub>2</sub>O, 1,4-dioxane/EtOH, 55 °C, 30 h; (3) (CH<sub>3</sub>)<sub>2</sub>SO<sub>4</sub>, DIPEA, DCM, rt, 14 h.</p></p></figure><div class="NLM_p">5-Ethoxy-6-<i>tert</i>-butyldimethylsiloxy-1-indanone <b>11</b> was transformed into 1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazoles <b>12b</b>–<b>j</b> (13–22%) via the reaction with a variety of substituted aryl isothiocyanate isothiocyanates following the general protocols. The removal of the TBS protective group by TBAF afforded 7-phenolic derivatives <b>13b</b>–<b>g</b> and <b>13j</b> (71–91%). The simultaneous deprotection of the TBS and Boc or the acetal groups by acetyl chloride in EtOH generated compounds <b>13h</b> and <b>13i</b> in 98 and 89% yields, respectively. These phenolic intermediates <b>13b</b>–<b>j</b> underwent the Williamson etherification with methyl chloroacetate and subsequent ammonolysis with ammonia to give indenopyrazole derivatives <b>ID12</b>–<b>ID19</b> and <b>ID22</b> (73–95%). Aminolysis of the methyl esters <b>14c</b> and <b>14d</b> with methylamine provided the corresponding <i>N-</i>methylamides <b>ID20</b> (83%) and <b>ID21</b> (92%) (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><div class="NLM_p">Following the general protocols to build up the 1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazole core and similar transformations, indeopyrazoles <b>ID23</b>–<b>ID30</b> with 3-hydroxyprpoxy at the 7-position and variations at the 3-position were prepared (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0015.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of 1-Methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazoles <b>ID23</b>–<b>ID30</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (1) LiHMDS or NaH, R-Ph-NCS, THF, −78 °C to rt, 16–20 h; (2) NH<sub>2</sub>NH<sub>2</sub><b>·</b>H<sub>2</sub>O, 1,4-dioxane/EtOH, 55 °C, 20–34 h; (3) (CH<sub>3</sub>)<sub>2</sub>SO<sub>4</sub>, DIPEA, DCM, rt, 8–12 h; (b) CSA, MeOH, rt, 2 h; (c) LiOH, MeOH, H<sub>2</sub>O, 40 °C, 2 h; (d) (1) LiHMDS, 6-EtO-Py-2NCS, THF, −78 °C to rt, 18 h; (2) NH<sub>2</sub>NH<sub>2</sub><b>·</b>H<sub>2</sub>O, 1,4-dioxane/EtOH, 55 °C, 26 h; (3) (CH<sub>3</sub>)<sub>2</sub>SO<sub>4</sub>, DIPEA, DCM, rt, 12 h.</p></p></figure><div class="NLM_p">Indenpyrazole derivatives <b>ID30</b>–<b>ID33</b> are characterized by a 3-aminoprpoxy group at the 7-position and variations at the 3-position. The preparation of these derivatives is shown in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. 7-Phenolic intermediates <b>13c</b>, <b>13i</b>, and <b>13j</b> were reacted with <i>N</i>-Boc-3-bromopropylamine to give <b>19c</b>, <b>19i</b>, and <b>19j</b> (70–76%), respectively. The removal of the Boc protective group in <b>19c</b> with trifluoroacetic acid (TFA) provided indenopyazole <b>ID31</b> (90%) with a <i>meta</i>-cyanoaniline at the 3-position. Using acetyl chloride in ethanol to remove the Boc protective groups in <b>19i</b> and <b>19j</b> gave the <i>meta</i>-propionylaniline derivative <b>ID32</b> (88%) and the 6-ethoxypyridyl-2-amine derivative <b>ID33</b> (90%), respectively, as hydrochloride salts.</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0016.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of 1-Methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazoles <b>ID31</b>–<b>ID33</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BocNHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>Br, K<sub>2</sub>CO<sub>3</sub>, acetone, 65 °C, 12–18 h; (b) TFA, DCM, rt, 2 h; (c) CH<sub>3</sub>COCl, EtOH, rt, 0.5 h.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> In Vitro Tubulin Polymerization and Tumor Cell Growth Inhibitory Activity and SAR Analysis</h3><div class="NLM_p">The newly synthesized indenopyrazole derivatives <b>ID01–ID33</b> were evaluated for their tubulin polymerization inhibitory activity and antiproliferative activity against HepG2 (human liver carcinoma), A549 (human lung adenocarcinoma), and HCT116 (human colorectal carcinoma) cells using LL01 and CA-4 as positive controls. The results are given in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Tubulin Polymerization and Tumor Cell Growth Inhibitory Activities of <b>ID01–ID33</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0017.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">SD, standard deviation.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Hydrochloride salt.</p></div></div><div></div></div><div class="NLM_p">To establish SAR of LL01, we first made variations at the indenopyrazole 6-position. The 6-hydroxy derivative <b>ID01</b> lost its tubulin polymerization inhibitory activity as well as weak antitumor cell proliferative activity. The 6-methoxy analogue <b>ID02</b> was more than threefold less potent in the tubulin assay but maintained a similar cellular activity as that of LL01. The 6-propoxy derivative <b>ID03</b> was more than twofold less potent in tubulin activity and more than fivefold less potent in the cellular assay than LL01. With the increase of the length and bulkiness of the substituents at this position, 6-butoxy (<b>ID04</b>) and 6-<i>p</i>-methoxybenzyloxy (<b>ID05</b>) derivatives lost both the tubulin potency and cellular potency. Therefore, the 6-ethoxy group was the best for the high tubulin inhibitory activity. The indenopyrazole derivative <b>ID06</b> with a position reversion of the substituents in LL01, 6-oxaacetamide, and a propoxy to maintain the proper chain length at the 7-position lost its activity. This result is in agreement with the docking simulations that the interaction of the 7-terminal amide in LL01 with Serα178 at the α/β interface might be very important for binding with the tubulin colchicine site.</div><div class="NLM_p">Next, we tried to find more suitable substituents at the indenopyrazole 7-phenolic position. When 7-oxaacetamide was changed to 7-oxaacetic acid, compound <b>ID07</b> lost its tubulin and cellular potency, indicating that a terminal acid group was not favored for interaction with tubulin. The 7-(3-hydroxypropxy)indenopyrazole derivative <b>ID08</b> showed similar tubulin and cellular potency as that of LL01. As a hydrochloride salt, 7-(3-aminopropxy)indenopyrazole <b>ID09</b> was a more potent tubulin polymerization inhibitor than LL01 and exhibited more potent or similar antiproliferative activity as that of CA-4. When the terminal amine in <b>ID09</b> was acetylated, the resulting <b>ID10</b> lost tubulin activity and its tumor cell inhibitory potency was greatly reduced. Without the terminal amino or hydroxyl group, the 7-propoxy derivative <b>ID11</b> had very weak tubulin polymerization and tumor cell proliferative inhibitory activity, indicating that the hydrophobic interaction with tubulin in this area also played some roles, but a terminal functional group as a hydrogen bond donor at the indenopyrazole 7-position was much more important for potent tubulin polymerization inhibition, possibly through hydrogen binding with Serα178 at the α/β interface.</div><div class="NLM_p">In LL01, indenpyrazole 3-aniline was supposed to occupy zone III at the colchicine site and <i>meta</i>-ethoxy acted as a hydrogen acceptor to interact with Tyrβ202 and Asnβ167. When the ethoxy group was transferred from the meta- to the para-position, compound <b>ID12</b> lost its activity, indicating the substitution at the para-position was not tolerated. Therefore, we focused on the structural modifications at the aniline meta-position. A cyano at the meta-position (<b>ID13</b>) decreased its tubulin potency by more than twofold. When a carbonyl oxygen was introduced to act as a hydrogen bond acceptor, ethyl ester <b>ID15</b> and methyl ester <b>ID14</b> as well as ethyl ketone <b>ID19</b> showed similar or slightly increased tubulin polymerization inhibitory activity as well as antiproliferative activity as that of LL01, while <i>iso</i>-propyl ester <b>ID16</b> was much less potent than LL01, stressing the steric requirements in this region. In contrast, the <i>N</i>-methylbenzamide <b>ID17</b> was not active, possibly due to the different orientation of the carbonyl group. Moreover, a <i>meta</i>-ethylamine (<b>ID18</b>) was not favored, leading to a more than twofold decrease in tubulin and a tenfold decrease in cellular potency. To increase the water solubility of LL01, the aniline was replaced by pyridyl-2-amine. The 6-ethoxypyridin-2-amine derivative <b>ID22</b> maintained the high tubulin and antiproliferative activity of LL01. In comparison with the parent compounds <b>ID13</b> and <b>ID14</b>, the <i>N</i>-methylation of 7-oxaacetamide decreased the potency but was somewhat tolerated since the <i>N</i>-methyl 7-oxaacetamide derivative <b>ID21</b> was still a potent tubulin polymerization inhibitor (IC<sub>50</sub> = 6.33 μM) and highly active against tumor cells.</div><div class="NLM_p">A combination of the 7-(3-hydroxypropoxy) group with the variation of the substituents at the indenopyrazole 3-position showed similar SARs to the 7-oxaacetamide derivatives. A <i>meta</i>-cyano at 3-aniline (<b>ID23</b>) decreased the tubulin potency, a <i>N</i>-methyl amide (<b>ID27</b>) was detrimental for the activity, and a <i>meta</i>-propionyl (<b>ID28</b>) or replacement of 3-aniline by pyridin-2-amine (<b>ID30</b>) maintained the high potency of the parent compound <b>ID08</b>. Among the esters, ethyl ester (<b>ID25</b>) was the most favored with improved potency in comparison with <b>ID08</b>, methyl ester (<b>ID24</b>) maintained high potency, while isopropyl ester (<b>ID26</b>) exhibited reduced activity. In addition, the hydrolysis of the ester into a carboxylic acid (<b>ID29</b>) led to the loss of activity.</div><div class="NLM_p">A combination of the 7-(3-aminopropoxy) group with variation of the substituents at the indenopyrazole 3-position led to the discovery of two very potent tubulin polymerization inhibitors, a <i>meta</i>-propionyl derivative <b>ID32</b> and a 6-ethoxypyridin-2-amine derivative <b>ID33</b>.</div><div class="NLM_p">In summary, through the systematic modification of LL01 at the indenopyrazole 6-, 7-, and 3-positions, a series of potent tubulin polymerization inhibitors with strong antitumor cell proliferative activity were identified. Among them, compounds <b>ID09</b>, <b>ID14</b>, <b>ID15</b>, <b>ID25</b>, <b>ID32</b>, and <b>ID33</b> were more potent than LL01 and as potent as CA-4 in the inhibition of tumor cell proliferation. The SARs supported the predicted binding mode of LL01 and were summarized as follows: (1) an ethoxy group at the indenopyrazole 6-position was the best for high tubulin polymerization inhibition, followed by <i>n</i>-propyl and methyl groups; (2) the substituents at indenopyrazole 7-phenolic hydroxyl should be of proper length and contain a terminal functional group as a hydrogen bond donor to interact with α-tubulin at the α/β interface, and the preferred substituents were in the order −CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub> > −CH<sub>2</sub>CONH<sub>2</sub> > −CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH > −CH<sub>2</sub>CONHOH > −CH<sub>2</sub>CONHCH<sub>3</sub>; (3) a substitution at the para-position of the indenopyrazole 3-aniline was not tolerated; and (4) a functional group, such as an ethoxy, a propionyl, an ethyl ester, and a methyl ester, as a hydrogen bond acceptor at the indenopyrazole 3-aniline meta-position was favored for interaction with zone III at the colchicine site, a cyano group and ethylamine were moderately tolerated, while carboxylic acid and <i>N</i>-methyl amide were detrimental for the activity; and (5) the replacement of <i>meta</i>-ethoxyaniline by 6-ethoxypyridin-2-amine was also well tolerated and favorable for the water solubility improvement of these indenopyrazoles.</div><div class="NLM_p">As the hydrochloride salt, indenopyrazoles <b>ID09</b> and <b>ID33</b> showed good tubulin polymerization inhibitory activity as well as excellent antiproliferative activity against three tested tumor cell lines, and their effects on normal liver LO2 cells and taxol-resistant A549 cells (A549/Tax) were further investigated. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, compounds <b>ID09</b> and <b>ID33</b> showed lower toxicity toward normal liver LO2 cells with GI<sub>50</sub> values of 283.9 and 218.0 nM, respectively. In comparison with paclitaxel and CA-4, <b>ID09</b> and <b>ID33</b> were more selective for the tumor HepG2 cells over the normal liver LO2 cells. For the A549/Tax cells, <b>ID09</b> and <b>ID33</b> were still highly potent with only two- to fivefold decrease in activity (vs A549 cell), comparable to that of CA-4. Therefore, <b>ID09</b> and <b>ID33</b> were effective against taxol-resistant tumor cells and had the potential to overcome multidrug resistance.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Growth Inhibitory Effects of <b>ID09</b> and <b>ID33</b> on LO2 and A549/Tax Cells</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">GI<sub>50</sub> ± SD<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (nM)</th><th class="rowsep1 colsep0" align="center" char=".">SF<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">GI<sub>50</sub> ± SD<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (nM)</th><th class="rowsep1 colsep0" align="center" char=".">RF<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char="±">HepG2</th><th class="colsep0 rowsep0" align="center" char="±">LO2</th><th class="colsep0 rowsep0" align="left" char="."> </th><th class="colsep0 rowsep0" align="center" char="±">A549</th><th class="colsep0 rowsep0" align="center" char="±">A549/Tax</th><th class="colsep0 rowsep0" align="left" char="."> </th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>ID09</b></td><td class="colsep0 rowsep0" align="char" char="±">2.4 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">283.9 ± 25.9</td><td class="colsep0 rowsep0" align="char" char=".">118</td><td class="colsep0 rowsep0" align="char" char="±">3.7 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">14.7 ± 0.3</td><td class="colsep0 rowsep0" align="char" char=".">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>ID33</b></td><td class="colsep0 rowsep0" align="char" char="±">3.2 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">218.0 ± 31.4</td><td class="colsep0 rowsep0" align="char" char=".">68</td><td class="colsep0 rowsep0" align="char" char="±">5.5 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">10.7 ± 0.3</td><td class="colsep0 rowsep0" align="char" char=".">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CA-4</td><td class="colsep0 rowsep0" align="char" char="±">6.1 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">332.6 ± 67.6</td><td class="colsep0 rowsep0" align="char" char=".">55</td><td class="colsep0 rowsep0" align="char" char="±">4.8 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">20.4 ± 2.4</td><td class="colsep0 rowsep0" align="char" char=".">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">paclitaxel</td><td class="colsep0 rowsep0" align="char" char="±">2.5 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">30.8 ± 3.5</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char="±">3.8 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">935.3 ± 143.6</td><td class="colsep0 rowsep0" align="char" char=".">246</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">SD, standard deviation.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Selectivity factor = GI<sub>50</sub> human normal cells/GI<sub>50</sub> HepG2.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">RF (resistant fold) = GI<sub>50</sub> against resistant cells/GI<sub>50</sub> against sensitive cells.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> ID09 and ID33 Interrupted Cellular Microtubule Network and Bound to the Tubulin Colchicine-Binding Site</h3><div class="NLM_p">The effects of <b>ID09</b> and <b>ID33</b> on microtubule cytoskeletons were further evaluated by the immunofluorescence staining assay in HepG2 cells using colchicine as a positive control. HepG2 cells were treated with <b>ID09</b> or <b>ID33</b> at 2.5, 5, and 10 nM or colchicine at 10 nM for 24 h. An anti-α-tubulin antibody (red) and Hoechst 33342 (blue) were used for the microtubule and cell nucleus visualization, respectively. As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, in the absence of drug treatment, the microtubule network in HepG2 cells exhibited a normal arrangement and tissue morphology, which permeated the whole cell and maintain the integrity of cell structure. The treatment with colchicine at 10 nM led to dramatic changes in the microtubule network; the microtubule cytoskeleton was destroyed and shrunk to the cell border. Similar results were observed when the cells were treated with <b>ID09</b> or <b>ID33</b>. Almost no complete microtubules were found in the cytosol in HepG2 cells treated with <b>ID09</b> or <b>ID33</b> at the concentration of 10 nM. These results were in agreement with the potent in vitro tubulin polymerization inhibitory activity of <b>ID09</b> and <b>ID33</b>.</div><figure id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effects of <b>ID09</b> and <b>ID33</b> on cellular microtubule networks. HepG2 cells were treated with dimethyl sulfoxide (DMSO), <b>ID09</b> (2.5, 5, and 10 nM), <b>ID33</b> (2.5, 5, and 10 nM), and colchicine (10 nM) for 24 h. Microtubules were visualized with an anti-α-tubulin antibody (red), and the cell nucleus was visualized with Hoechst 33342 (blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To verify whether compounds <b>ID09</b> and <b>ID33</b> directly targeted the tubulin colchicine-binding site, the EBI competition assay was carried out in HepG2 cells. <i>N</i>,<i>N</i>′-Ethylene-bis(iodoacetamide) (EBI) is an alkylating agent that can specifically cross-link the Cys239 and Cys354 residues of β-tubulin at the colchicine-binding site to form a β-tubulin adduct that is easily detected by western blotting as a second immunoreactive β-tubulin band that migrates faster than the β-tubulin itself.<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52,53)</a> In the presence of the colchicine site targeting agents, the formation of the EBI/β-tubulin adduct is inhibited. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, in the EBI (100 μM) treatment group, a second band below the β-tubulin band appeared. Coincubation with <b>ID09</b> or <b>ID33</b> (0.2, 1, 5, and 25 μM) inhibited the β-tubulin adduct formation in a dose-dependent way, resulting in the disappearance of the adduct band, which was consistent with the effect of colchicine at 5 μM. In contrast, the vinca site-binding agent, vincristine (VCR), had little effects on the formation of the β-tubulin adduct, supporting that these indenopyrazole derivatives directly targeted colchicine-binding sites and inhibited tubulin polymerization.</div><figure id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. EBI assay confirmed that <b>ID09</b> and <b>ID33</b> targeted the colchicine-binding site: the competition assay of <b>ID09</b> and <b>ID33</b> (0.2, 1, 5, 25 μM), VCR (5 μM), and colchicine (5 μM) with EBI (100 μM) on HepG2 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> ID09 and ID33 Induced HepG2 Cell G2/M Arrest and Apoptosis</h3><div class="NLM_p">To investigate whether the cytotoxicity of <b>ID09</b> and <b>ID33</b> was due to the cell cycle arrest, we first examined their effects on HepG2 cell cycle progression using propidium iodide (PI) staining by flow cytometry analysis. As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, the treatment with <b>ID09</b> or <b>ID33</b> for 24 h caused a remarkable and concentration-dependent G2/M arrest in HepG2 cells, whereas the control cells were primarily in the G1 and S phases. <b>ID09</b> and <b>ID33</b> induced the obvious G2/M arrest at 20 nM. The percentage of HepG2 cells in G2/M was 12.6%; when cells were exposed to 20 nM <b>ID09</b> or <b>ID33</b>, the percentage of G2/M phase increased to 88.5 or 85.2%, respectively.</div><figure id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0006.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of <b>ID09</b> and <b>ID33</b> on HepG2 cell cycle progress. Cells were treated with <b>ID09</b> or <b>ID33</b> at 5, 10, and 20 nM for 24 h and then analyzed by flow cytometry.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To further verify the effects of <b>ID09</b> and <b>ID33</b> on cell apoptosis, HepG2 cells treated with <b>ID09</b> or <b>ID33</b> were stained with annexin V-PE and 7-aminoactinomycin D (7-AAD) and analyzed by flow cytometry. Dual staining for annexin V-PE and 7-ADD permitted the discrimination among live cells (annexin V-PE<sup>–</sup>/7-AAD<sup>–</sup>), early apoptotic cells (annexin V-PE<sup>–</sup>/7-AAD<sup>–</sup>), late apoptotic cells (annexin V-PE<sup>–</sup>/7-AAD<sup>–</sup>), and necrotic cells (annexin V-PE<sup>–</sup>/7-AAD<sup>–</sup>). As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, the percentages of apoptotic HepG2 cells were 9.2, 13.9, and 20.9% for <b>ID09</b> at the concentrations of 5, 10, and 20 nM at 12 h and increased to 14.1%, 23.9%, and 47.3%, respectively, at 24 h. Similar tendency were observed for <b>ID33</b>. At the concentrations of 5, 10, and 20 nM, <b>ID33</b> induced cell apoptosis from 7.0 to 17.2% at 12 h and 10.9 to 39.0% for 24 h. Therefore, <b>ID09</b> and <b>ID33</b> induced cell apoptosis in both time- and concentration-dependent manners.</div><figure id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0007.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. <b>ID09</b> and <b>ID33</b> induce HepG2 cell apoptosis. Exposed to <b>ID09</b> or <b>ID33</b> for 12h (A) or 24 h (B), HepG2 cells were harvested and stained with annexin V-PE/7-AAD for analysis. The different cell stages were assigned as live (annexin V-PE<sup>–</sup>/7-AAD<sup>–</sup>), early apoptotic (annexin V-PE<sup>+</sup>/7-AAD<sup>–</sup>), late apoptotic (annexin V-PE<sup>+</sup>/ 7-AAD<sup>+</sup>), and necrotic cells (annexin V-PE<sup>–</sup>/7-AAD<sup>+</sup>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Bcl family proteins play important roles in cell apoptosis through the regulation of the mitochondria-mediated intrinsic pathway, in which the proapoptotic (Bax and others) and antiapoptotic (Bcl-2 and others) proteins are activated or inhibited depending on upstream signaling.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Cells undergoing intrinsic mitochondrial apoptosis show downregulation of Bcl-2 and upregulation of Bax. To investigate the pathway involved in these indenopyrazole-mediated apoptosis pathways, the HepG2 cells were treated with <b>ID09</b> at different concentrations (2.5, 5, 10, 20 nM) for 24 followed by the apoptotic hallmark analysis.</div><div class="NLM_p">As shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, <b>ID09</b> caused dose-dependent increases in proapoptotic protein Bax and decreases in antiapoptotic protein Bcl-2, indicating that <b>ID09</b> perturbed the key proteins involved in the intrinsic apoptosis pathway. Caspases are the final facilitator of apoptosis and are composed of two distinct classes, the initiators and the executioner. Caspase-3 is one of the major executive enzymes that is cleaved and activated during apoptosis. <b>ID09</b> induced dose-dependent activation of caspase-3 through the upregulation of the cleaved caspase-3 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). The caspase-dependent cleavage of poly(ADP-ribose) polymerase (PARP), a marker of apoptosis, was also detected in <b>ID09</b>–treated HepG2 cells, similar to that of colchicine. Therefore, <b>ID09</b> induced HepG2 cell apoptosis possibly through the mitochondria-mediated intrinsic apoptotic pathway as well as the activation of caspase-3.</div><figure id="fig7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0008.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effects of <b>ID09</b> on apoptosis-related proteins. HepG2 cells were incubated with <b>ID09</b> (2.5, 5, 10, and 20 nM) and colchicine 20 nM for 24 h followed by the analysis of the expression of Bax, Bcl-2, cleaved caspase-3, and cleaved PARP by western blotting. *<i>P</i> < 0.05, <sup>**</sup><i>P</i> < 0.01, <sup>***</sup><i>P</i> < 0.001 vs control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> ID09 Inhibited HepG2 Cell Migration</h3><div class="NLM_p">Metastasis is responsible for 90% of cancer patient deaths, and it remains a major hurdle in cancer treatment. Tumor cells invade through the basement membrane and migrate to distant sites to form metastatic lesions during metastatic progression. A scratch-migration or wound-healing assay was used to investigate the effects of <b>ID09</b> on HepG2 cell migration using CA-4 as a positive control. The typical images of the wound at the beginning of the experiment (0 h) and the final treatment with <b>ID09</b> (24 h) at different concentrations (2.5, 5, and 10 nM) are shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>. In comparison with the vehicle (DMSO) group, <b>ID09</b> significantly suppressed the wound closure of the cell migration. At 10 nM, <b>ID09</b> significantly inhibited cell migration by 58%. At the same concentration, CA-4 caused 47% inhibition of HepG2 cell migration. Therefore, <b>ID09</b> may have the potential to inhibit tumor cell migration and metastasis.</div><figure id="fig8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0009.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Effect of <b>ID09</b> on HepG2 cell migration. HepG2 cells (5 × 10<sup>5</sup> cells) suspended in free serum DMEM containing <b>ID09</b> and CA-4 (2.5, 5, and 10 nM) for 24 h were photographed by phase contrast microscopy (magnification, 200×). *<i>P</i> < 0.05, <sup>**</sup><i>P</i> < 0.01, <sup>***</sup><i>P</i> < 0.001 vs control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Druglike Properties of ID09 and ID33 and Their Antitumor Activity in Vivo</h3><div class="NLM_p">One of the problems of the MTAs used in clinics or under clinical investigations is their low water solubility. The water solubility of a drug or drug candidate is closely related to its druglike properties like ADME/Tox (absorption, distribution, metabolism, elimination, toxicity) and its formulations. One of the goals of this study is to improve the water solubility of the lead LL01; therefore, we measured the aqueous solubility and log<i> P</i> values of <b>ID09</b> and <b>ID33</b> at pH 7.4 according to the reported methods.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> The results are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. As the hydrochloride salt, indenopyrazoles <b>ID09</b> and <b>ID33</b> showed very good and much improved aqueous solubility (>1 mg/mL) than LL01 (>200-fold). They also had lower log P values than those of <b>LL01</b> and fell into a desirable druglike range (0 < log<i> P</i> < 3, pH = 7.4). Therefore, <b>ID09</b> and <b>ID33</b> have a good balance between their high cellular as well as tubulin potency and the improved aqueous solubility and druglike properties and thus might be potential drug candidates for further developments.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Aqueous Solubility and Log <i>P</i> of <b>ID09</b> and <b>ID33</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="left"> </th><th class="rowsep1 colsep0" colspan="2" align="center">pH 7.4</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">aqueous solubility</th><th class="colsep0 rowsep0" align="center" char="±">Log <i>P</i></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>ID09</b></td><td class="colsep0 rowsep0" align="left">>1 mg/mL</td><td class="colsep0 rowsep0" align="char" char="±">1.70 ± 0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>ID33</b></td><td class="colsep0 rowsep0" align="left">>1 mg/mL</td><td class="colsep0 rowsep0" align="char" char="±">0.97 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>LL01</b></td><td class="colsep0 rowsep0" align="left"><5 μg/mL</td><td class="colsep0 rowsep0" align="char" char="±">3.18 ± 0.13</td></tr></tbody></table></div></div><div class="NLM_p">To further validate the antitumor efficiency in vivo, nude mouse HepG2 xenograft models were established, and compounds <b>ID09</b> and <b>ID33</b> were administered by intragastric administration at a dose of 25 mg/kg (aqueous solution) one time every day for 21 consecutive days. The results are summarized in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>. In comparison with the vehicle (distilled water) group, the oral administration of <b>ID09</b> and <b>ID33</b> at 25 mg/kg resulted in 57 and 54% reduction in tumor volume, respectively. The treatment with <b>ID09</b> or <b>ID33</b> did not cause significant differences in body weight changes (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) and had no other adverse effects. The similar in vivo antitumor efficiency of <b>ID09</b> and <b>ID33</b> is in agreement with their similar in vitro tubulin and tumor cell growth inhibitory activities and druglike properties. In previous investigations, the oral administration of LL01 as a 0.5% MC (carboxymethylcellulose sodium) suspension resulted in a 50% reduction in tumor volume in an established HepG2 xenograft model.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a><b>ID09</b> and <b>ID33</b> exhibited slightly better orally antitumor efficiency than that of LL01 despite the formulation differences.</div><figure id="fig9" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0010.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Orally antitumor efficiency of <b>ID09</b> and <b>ID33</b> on HepG2 xenografts. (A) Tumor images, (B) tumor volume changes, (C) body weight changes, and (D) tumor weight changes. <sup>**</sup><i>P</i> < 0.01, <sup>***</sup><i>P</i> < 0.001 vs vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Effects of <b>ID09</b> and <b>ID33</b> on Body Weight in Nude Mice</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">groups</th><th class="colsep0 rowsep0" align="center">administration</th><th class="colsep0 rowsep0" align="center" char="±">body weight (g) initial/end</th><th class="colsep0 rowsep0" align="center" char=".">body weight changes (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vehicle</td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="char" char="±">20.3 ± 0.8/16.8 ± 0.5</td><td class="colsep0 rowsep0" align="char" char=".">–17.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>ID09</b> 25 mg/kg</td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="char" char="±">19.4 ± 0.5/15.8 ± 0.6</td><td class="colsep0 rowsep0" align="char" char=".">–18.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>ID33</b> 25 mg/kg</td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="char" char="±">19.9 ± 0.5/16.2 ± 0.5</td><td class="colsep0 rowsep0" align="char" char=".">–18.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vehicle</td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="char" char="±">20.6 ± 0.3/22.2 ± 0.6</td><td class="colsep0 rowsep0" align="char" char=".">+7.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>ID09</b> 5 mg/kg</td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="char" char="±">20.3 ± 0.3/22.0 ± 0.5</td><td class="colsep0 rowsep0" align="char" char=".">+8.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>ID09</b> 10 mg/kg</td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="char" char="±">20.2 ± 0.4/21.6 ± 0.7</td><td class="colsep0 rowsep0" align="char" char=".">+6.9</td></tr></tbody></table></div></div><div class="NLM_p">After the demonstration of the orally antitumor efficiency of <b>D09</b> and <b>ID33</b>, we further investigated the antitumor efficiency of <b>ID09</b> on HepG2 xenograft models via intravenous injection (iv). The nude mice were randomly divided into three groups: vehicle (distilled water) group and <b>ID09</b> dose (aqueous solution) groups (5 and 10 mg/kg). Five nude mice in each group were administrated intravenously once every two days for 21 consecutive days. The results are summarized in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>.</div><figure id="fig10" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0011.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Antitumor efficiency of <b>ID09</b> on HepG2 xenografts via iv injection injection. (A) Tumor images, (B) tumor volume changes, (C) body weight changes, and (D) tumor weight changes. <sup>**</sup><i>P</i> < 0.01, <sup>***</sup><i>P</i> < 0.001 vs vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last"><b>ID09</b> dose-dependently inhibited the tumor growth. At the doses of 5 and 10 mg/kg, <b>ID09</b> caused 54 and 68% tumor volume reduction, respectively. No other adverse signs were observed during the experiments, and <b>ID09</b> had no significant effects on animal weight changes (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47456" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47456" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Like that of LL01, a common drawback of most of the MTAs is their low water solubility. To address this issue and to investigate the SARs of the indenpyrazoles as tubulin polymerization inhibitors targeting the colchicine-binding site, we used LL01 as a lead, maintained the 1-methyl-1,4-dihydroindeno-[1,2-<i>c</i>]pyrazole core, and made systematic modifications on the phenolic 6- and 7-positions and the 3-aniline portion. The indenopyrazole derivatives <b>ID01</b>–<b>ID33</b> were designed, synthesized, and evaluated for their tubulin polymerization and tumor cell growth inhibitory activities, resulting in the discovery of a series of potent MTAs. The SARs were in agreement with the predicted binding mode of LL01 with tubulin. In general, an ethoxy group at the indenopyrazole 6-position was the best choice, and the substituents at the indenopyrazole 7-position should be of proper length and contained a terminal functional group as a hydrogen bond donor, such as 3-aminoproxy, oxaacetamide, and 3-hydroxypropoxy groups. For the indenopyrazole 3-aniline moiety, an ethoxy, a propionyl, and an ethyl or methyl ester at the meta-position serving as a hydrogen bond acceptor were favored. The replacement of the 3-<i>meta</i>-ethoxyaniline by a 6-ethoxypyridin-2-amine was also well tolerated. As the hydrochloride salt(s), indenpyrazole derivatives <b>ID09</b> and <b>ID33</b> have excellent aqueous solubility and favorable Log <i>P</i> values. <b>ID09</b> and <b>ID33</b> targeted the tubulin colchicine-binding site, potently inhibited tubulin polymerization with the IC<sub>50</sub> values of 3.65 and 3.13 μM, respectively, and inhibited tubulin assembly in HepG2 cells. They showed strong antiproliferative activities for a variety of tumor cells including those with taxol resistance, with the GI<sub>50</sub> values ranging from 2.4 to 14.7 nM. <b>ID09</b> and <b>ID33</b> caused the arrest at the G2/M phase and induced the caspase-dependent and mitochondrial apoptosis in HepG2 cells. <b>ID09</b> also had the ability to inhibit HepG2 cell migration. In HepG2 xenograft mouse models, <b>ID09</b> and <b>ID33</b> demonstrated their oral antitumor efficiency at the dose of 25 mg/kg, reducing the tumor growth by more than 50% without obvious signs of toxicity. The iv injection of <b>ID09</b> at the dose of 10 mg/kg, one time for every other day, resulted in 68% inhibition of tumor growth without obvious toxicity. Therefore, <b>ID09</b> and <b>ID33</b> could serve as potential anticancer drug candidates for further developments.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46828" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46828" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Chemistry</h3><div class="NLM_p last">Melting points were determined on an RY-1 melting point tester. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded at room temperature on a Bruker-400 NMR or Bruker-600 NMR spectrometer with DMSO-<i>d</i><sub>6</sub> or CDCl<sub>3</sub> solution. MS spectra data were acquired by an API 4000 instrument. High-resolution mass spectrometry (HRMS) data were acquired by a Q-TOF6540 instrument. The compound purity was determined using an Agilent 1200 series equipment (column, Diamonil C18, 4.6 mm × 150 mm, 5 μm; mobile phase, methanol/H<sub>2</sub>O/CF<sub>3</sub>COOH (70:30:0.1%); flow rate, 1.0 mL/min; UV wavelength, 254 nm). All the compounds used in the bioassay are of high purity (>95%). Column chromatography was performed on silica gel (200–300 mesh). All chemicals were from commercial sources and used without purification. THF was distilled from sodium/benzophenone immediately prior to use.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 6-Hydroxy-5-(methoxymethoxy)-1-indanone (<b>2</b>)</h3><div class="NLM_p last">To a solution of 5,6-dihydroxy-1-indanone (<b>1</b>, 2.0 g, 13 mmol) in DMF (30 mL) were added K<sub>2</sub>CO<sub>3</sub> (2.2 g, 16 mmol) and MOMCl (1.23 mL, 15 mmol). The mixture was stirred at room temperature for 12 h. Water (180 mL) was added, extracted with EtOAc (200 mL × 3), washed with brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration and evaporation, the residue was purified by chromatography (ethyl acetate/hexanes = 1:3) to give 1.52 g (65%) of <b>2</b> as a white solid, mp 129–131 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.28 (s, 1H), 7.11 (s, 1H), 5.73 (s, 1H), 5.33 (s, 2H), 3.53 (s, 3H), 3.03 (t, <i>J</i> = 5.6 Hz, 2H), 2.65 (t, <i>J</i> = 5.6 Hz, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 205.9, 150.4, 148.9, 146.1, 131.5, 110.8, 108.5, 95.2, 56.7, 36.5, 25.5.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 6-((<i>tert</i>-Butyldimethylsilyl)oxy)-5-methoxymethoxy-1-indanone (<b>3</b>)</h3><div class="NLM_p last">To a solution of 6-hydroxy-5-methoxymethoxy-1-indanone (<b>2</b>, 2.0 g, 10.4 mmol) in DMF (25 mL), TBSCl (2.4 g, 16.0 mmol) and imidazole (1.1 g, 16.1 mmol) were added and stirred at room temperature for 4 h. Distilled water (200 mL) was added, and the mixture was stirred for 1 h. The resulting precipitate was filtered, washed with hexanes, and dried to give 2.7 g (86%) of <b>3</b> as a white solid, mp 165–167 °C. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.17 (s, 1H), 7.10 (s, 1H), 5.22 (s, 2H), 3.49 (s, 3H), 3.00 (t, <i>J</i> = 5.5 Hz, 1H), 2.71 (t, <i>J</i> = 5.5 Hz, 2H), 0.98 (s, 9H), 0.15 (s, 6H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 205.8, 154.9, 150.4, 145.5, 131.1, 114.5, 111.8, 94.7, 56.5, 36.7, 25.6, 25.5, −4.6.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 7-((<i>tert</i>-Butyldimethylsilyl)oxy)-<i>N</i>-(3-ethoxyphenyl)-6-(methoxymethoxy)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-amine (<b>4</b>)</h3><div class="NLM_p last">After the solution of 6-((<i>tert</i>-butyldimethylsilyl)oxy)-5-methoxymethoxy-1-indanone (<b>3</b>, 700 mg, 2.17 mmol) in anhydrous THF (15 mL) was cooled to −78 °C under a nitrogen atmosphere, LiHMDS (3.26 mL, 3.26 mmol) was added dropwise and stirred for 2.5 h. The reaction mixture was warmed to −45 °C, and a solution of 1-ethoxy-3-isothiocyanatobenzene (580 mg, 3.26 mmol) in anhydrous THF (8 mL) was added and stirred at room temperature overnight. The reaction mixture was adjusted to pH 7 by the addition of the saturated KHSO<sub>4</sub> aqueous solution and then extracted with EtOAc (50 mL × 3). The organic phase was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration and evaporation, the residue was purified by column chromatography (ethyl acetate/hexanes = 1:15) to give the resulting thioamide intermediate, which was dissolved in 1,4-dioxane (15 mL) and ethanol (15 mL). Hydrazine hydrate (1.09 mL, 17.39 mmol) was added dropwise, and the reaction mixture was heated to 55 °C and stirred for 36 h. Distilled water (60 mL) was added, and the mixture was extracted with EtOAc (80 mL × 3). The organic phase was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration and evaporation, the residue was purified by column chromatography (ethyl acetate/hexanes = 1:3) to give an oil (340 mg), which was dissolved in DCM (10 mL), and DIPEA (0.18 mL, 1.42 mmol) and dimethyl sulfate (0.13 mL, 1.42 mmol) were added and stirred at room temperature for 7 h. Distilled water (20 mL) was added, and the mixture was extracted with EtOAc (30 mL × 3), washed with brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration and evaporation, the residue was purified by chromatography (ethyl acetate/hexanes = 1:7) to give 190 mg (18%) of <b>4</b> as a yellow solid, mp 81–82 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.38 (s, 1H), 7.30 (s, 1H), 7.13 (s, 1H), 7.05 (t, <i>J</i> = 8.1 Hz, 1H), 6.97 (t, <i>J</i> = 2.0 Hz, 1H), 6.82 (dd, <i>J</i> = 8.1, 2.0 Hz, 1H), 6.28 (dd, <i>J</i> = 8.1, 2.0 Hz, 1H), 5.19 (s, 2H), 3.97 (q, <i>J</i> = 7.0 Hz, 2H), 3.92 (s, 3H), 3.43 (s, 3H), 3.38 (s, 2H), 1.32 (t, <i>J</i> = 7.0 Hz, 3H), 1.01 (s, 9H), 0.19 (s, 6H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.6, 147.2, 145.9, 144.3, 143.7, 143.3, 141.5, 128.7, 125.3, 114.2, 112.1, 110.7, 107.2, 103.3, 100.7, 94.2, 61.9, 55.2, 36.4, 28.2, 25.0, 17.6, 14.2, −5.2. MS (ESI) calcd for C<sub>27</sub>H<sub>38</sub>N<sub>3</sub>O<sub>4</sub>Si [M + H]<sup>+</sup>: 496.3, found: 496.2.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 3-((3-Ethoxyphenyl)amino)-6-methoxymethoxy-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-ol (<b>5</b>)</h3><div class="NLM_p last">To a solution of <b>4</b> (190 mg, 0.38 mmol) in THF (8 mL) was added TBAF (200 mg, 0.76 mmol). The mixture was stirred at room temperature for 0.5 h. After distilled water (40 mL) was added, the resulting precipitate was filtered and dried to give 110 mg (75%) of <b>5</b> as a white solid, mp 136–138 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.11 (s, 1H), 8.36 (s, 1H), 7.23 (s, 1H), 7.14 (s, 1H), 7.06 (t, <i>J</i> = 8.1 Hz, 1H), 6.97 (t, <i>J</i> = 2.2 Hz, 1H), 6.83 (dd, <i>J</i> = 8.1, 2.2 Hz, 1H), 6.28 (dd, <i>J</i> = 8.1, 2.2 Hz, 1H), 5.17 (s, 2H), 3.97 (q, <i>J</i> = 7.0 Hz, 2H), 3.90 (s, 3H), 3.44 (s, 3H), 3.34 (s, 2H), 1.32 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.7, 148.6, 147.1, 145.4, 144.8, 143.8, 139.8, 129.8, 126.7, 116.1, 113.2, 108.3, 107.2, 104.3, 101.8, 95.7, 63.0, 56.2, 37.4, 29.1, 15.3. MS (ESI) calcd for C<sub>21</sub>H<sub>24</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 382.2, found: 382.1.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Methyl 2-((3-((3-Ethoxyphenyl)amino)-6-(methoxymethoxy)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)acetate (<b>6</b>)</h3><div class="NLM_p last">To a solution of <b>5</b> (100 mg, 0.26 mmol) in acetone (8 mL) were added methyl chloroacetate (50 μL, 0.52 mmol) and K<sub>2</sub>CO<sub>3</sub> (64 mg, 0.52 mmol). The mixture was heated to 65 °C and stirred for 6 h. After distilled water (20 mL) was added, the resulting precipitate was filtered and dried to give 100 mg (75%) of <b>6</b> as a yellow solid, mp 130–131 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.39 (s, 1H), 7.33 (s, 1H), 7.32 (s, 1H), 7.06 (t, <i>J</i> = 8.1 Hz, 1H), 6.99 (t, <i>J</i> = 2.0 Hz, 1H), 6.83 (dd, <i>J</i> = 8.1, 2.0 Hz, 1H), 6.29 (dd, <i>J</i> = 8.1, 2.0 Hz, 1H), 5.21 (s, 2H), 4.93 (s, 2H), 3.98 (q, <i>J</i> = 7.0 Hz, 2H), 3.95 (s, 2H), 3.72 (s, 3H), 3.44 (s, 3H), 3.38 (s, 2H), 1.32 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.7, 158.7, 147.3, 146.8, 144.2, 144.2, 143.8, 141.3, 128.7, 125.5, 115.6, 112.1, 107.2, 104.8, 103.3, 100.8, 94.7, 65.1, 61.9, 55.2, 51.2, 36.5, 28.1, 14.2. MS (ESI) calcd for C<sub>24</sub>H<sub>28</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup>: 454.2, found: 454.1.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 2-((3-((3-Ethoxyphenyl)amino)-6-(methoxymethoxy)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)acetamide (<b>7</b>)</h3><div class="NLM_p last">To a solution of <b>6</b> (100 mg, 0.24 mmol) in MeOH (5 mL) was added aqueous ammonia (25%, 2 mL). The reaction mixture was refluxed for 1.5 h. After that, the mixture was stirred at 0 °C for 1 h, and a white solid was precipitated out. It was filtered, washed with water, and dried to give 80 mg (83%) of <b>7</b> as a white solid, mp 188–190 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.40 (s, 1H), 7.50 (s, 1H), 7.40 (s, 1H), 7.37 (s, 1H), 7.33 (s, 1H), 7.06 (t, <i>J</i> = 8.1 Hz, 1H), 6.99 (t, <i>J</i> = 1.9 Hz, 1H), 6.84 (dd, <i>J</i> = 8.1, 1.9 Hz, 1H), 6.29 (dd, <i>J</i> = 8.1, 1.9 Hz, 1H), 5.23 (s, 2H), 4.57 (s, 2H), 3.98 (q, <i>J</i> = 7.0 Hz, 2H), 3.96 (s, 3H), 3.45 (s, 3H), 3.39 (s, 2H), 1.32 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.6, 159.7, 148.3, 148.0, 145.6, 145.3, 144.9, 142.7, 129.8, 126.6, 116.4, 113.2, 108.3, 107.0, 104.4, 101.8, 95.9, 69.3, 63.0, 56.4, 37.5, 29.3, 15.3. MS (ESI) calcd for C<sub>23</sub>H<sub>27</sub>N<sub>4</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 439.2, found: 439.1.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 2-((3-((3-Ethoxyphenyl)amino)-6-hydroxy-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)acetamide (ID01)</h3><div class="NLM_p last">To a solution of <b>7</b> (80 mg, 0.18 mmol) in MeOH (5 mL) was added CSA (170 mg, 0.73 mmol). The reaction mixture was heated to 40 °C and stirred for 2 h. Distilled water (25 mL) was then added, and the resulting precipitate was filtered and dried to give 65 mg (90%) of <b>ID01</b> as a yellow solid, HPLC purity: 99.9%, mp: 150–151 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.10 (s, 1H), 8.36 (s, 1H), 8.01 (s, 1H), 7.58 (s, 1H), 7.35 (s, 1H), 7.06 (t, <i>J</i> = 8.1 Hz, 1H), 7.02 (s, 1H), 6.97 (t, <i>J</i> = 2.1 Hz, 1H), 6.81 (dd, <i>J</i> = 8.1, 2.1 Hz, 1H), 6.28 (dd, <i>J</i> = 8.1, 2.1 Hz, 1H), 4.54 (s, 2H), 3.98 (q, <i>J</i> = 6.9 Hz, 2H), 3.96 (s, 3H), 3.33 (s, 2H), 1.32 (t, <i>J</i> = 6.9 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.7, 159.7, 148.9, 145.6, 145.4, 145.0, 144.8, 143.1, 129.8, 123.8, 114.8, 112.3, 108.2, 105.7, 104.3, 101.8, 68.7, 63.0, 37.5, 29.1, 15.3. HRMS (ESI) calcd for C<sub>21</sub>H<sub>23</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 395.1714, found: 395.1723.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 2-((3-((3-Ethoxyphenyl)amino)-6-methoxy-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)acetamide (ID02)</h3><div class="NLM_p last">To a solution of <b>ID01</b> (40 mg, 0.10 mmol) in DMF (3 mL) was added dimethyl sulfate (20 μL, 0.20 mmol) and K<sub>2</sub>CO<sub>3</sub> (28 mg, 0.20 mmol). The reaction mixture was stirred at 40 °C for 2.5 h. Distilled water (180 mL) was added, and the mixture was extracted with EtOAc (100 mL), washed with brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration and evaporation, the residue was purified by chromatography (ethyl acetate/hexanes = 4:1) to give 31 mg (75%) of <b>ID02</b> as a white solid, HPLC purity: 97.7%, mp: 197–198 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.41 (s, 1H), 7.50 (s, 1H), 7.38 (s, 1H), 7.37 (s, 1H), 7.29 (s, 1H), 7.06 (t, <i>J</i> = 8.1 Hz, 1H), 7.00 (t, <i>J</i> = 2.1 Hz, 1H), 6.84 (dd, <i>J</i> = 8.1, 2.1 Hz, 1H), 6.29 (dd, <i>J</i> = 8.1, 2.1 Hz, 1H), 4.53 (s, 2H), 3.98 (q, <i>J</i> = 6.9 Hz, 2H), 3.95 (s, 3H), 3.84 (s, 3H), 3.36 (s, 2H), 1.32 (t, <i>J</i> = 6.9 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.8, 159.7, 148.6, 148.5, 146.8, 145.3, 144.9, 143.1, 129.8, 124.8, 112.6, 111.5, 108.3, 106.9, 104.3, 101.8, 69.4, 63.0, 56.3, 37.5, 29.5, 15.3. HRMS (ESI) calcd for C<sub>22</sub>H<sub>25</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 409.1870, found: 409.1878.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 2-((3-((3-Ethoxyphenyl)amino)-1-methyl-6-propoxy-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)acetamide (ID03)</h3><div class="NLM_p last">Following similar procedures to those described for preparing <b>ID02</b>, compound <b>ID03</b> was prepared from <b>ID01</b> (40 mg, 0.10 mmol), K<sub>2</sub>CO<sub>3</sub> (28 mg, 0.20 mmol), 1-bromopropane (18 μL, 0.20 mmol) in 80% yield as a white solid, HPLC purity: 99.2%, mp: 114–115 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.43 (s, 1H), 7.58 (s, 1H), 7.46 (s, 1H), 7.39 (s, 1H), 7.33 (s, 1H), 7.12 (t, <i>J</i> = 8.1 Hz, 1H), 7.04 (t, <i>J</i> = 2.0 Hz, 1H), 6.89 (dd, <i>J</i> = 8.1, 2.0 Hz, 1H), 6.34 (dd, <i>J</i> = 8.1, 2.0 Hz, 1H), 4.58 (s, 2H), 4.06 (t, <i>J</i> = 7.4 Hz, 2H), 4.02 (q, <i>J</i> = 7.0 Hz, 2H), 3.44 (s, 2H), 1.96–1.70 (m, 2H), 1.37 (t, <i>J</i> = 7.0 Hz, 3H), 1.06 (t, <i>J</i> = 7.4 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.9, 159.7, 148.6, 148.2, 147.1, 145.3, 144.9, 143.5, 129.8, 124.9, 112.8, 112.7, 108.3, 107.8, 104.4, 101.8, 70.6, 69.9, 63.0, 37.5, 29.5, 22.7, 15.3, 10.9. HRMS (ESI) calcd for C<sub>24</sub>H<sub>29</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 437.2183, found: 437.2188.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 2-((6-Butoxy-3-((3-ethoxyphenyl)amino)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)acetamide (ID04)</h3><div class="NLM_p last">Following the procedures described for preparing <b>ID02</b>, compound <b>ID04</b> was prepared from <b>ID01</b> (45 mg, 0.11 mmol), K<sub>2</sub>CO<sub>3</sub> (30 mg, 0.22 mmol), <i>n</i>-butyl bromide (19 μL, 0.22 mmol) in 82% yield as a white solid, HPLC purity: 98.9%, mp: 169–170 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.41 (s, 1H), 7.55 (s, 1H), 7.41 (s, 1H), 7.34 (s, 1H), 7.28 (s, 1H), 7.06 (t, <i>J</i> = 8.1 Hz, 1H), 6.99 (t, <i>J</i> = 2.0 Hz, 1H), 6.83 (dd, <i>J</i> = 8.1, 2.0 Hz, 1H), 6.29 (dd, <i>J</i> = 8.1, 2.0 Hz, 1H), 4.52 (s, 2H), 4.03 (t, <i>J</i> = 6.5 Hz, 2H), 3.97 (q, <i>J</i> = 7.1 Hz, 2H), 3.94 (s, 3H), 3.39 (s, 2H), 1.79–1.68 (m, 2H), 1.55–1.41 (m, 2H), 1.32 (t, <i>J</i> = 7.1 Hz, 3H), 0.95 (t, <i>J</i> = 7.4 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.9, 159.7, 148.6, 148.2, 147.0, 145.3, 144.9, 143.4, 129.8, 124.9, 112.7, 112.6, 108.3, 107.8, 104.3, 101.8, 69.8, 68.7, 63.0, 37.5, 31.4, 29.5, 19.3, 15.3, 14.2. HRMS (ESI) calcd for C<sub>25</sub>H<sub>31</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 451.2343, found: 451.2340.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 2-((3-((3-Ethoxyphenyl)amino)-6-((4-methoxybenzyl)oxy)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)acetamide (ID05)</h3><div class="NLM_p last">Following the procedures described for preparing <b>ID02</b>, compound <b>ID05</b> was prepared from <b>ID01</b> (50 mg, 0.13 mmol), K<sub>2</sub>CO<sub>3</sub> (28 mg, 0.26 mmol), <i>p</i>-methoxybenzyl chloride (35 μL, 0.26 mmol) in 66% yield as a white solid, HPLC purity: 99.8%, mp: 201–202 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.41 (s, 1H), 7.50 (s, 1H), 7.43–7.40 (m, 3H), 7.38 (s, 1H), 7.33 (s, 1H), 7.06 (t, <i>J</i> = 8.1 Hz, 1H), 6.99 (t, <i>J</i> = 1.8 Hz, 1H), 6.97 (s, 1H), 6.95 (s, 1H), 6.83 (dd, <i>J</i> = 8.1, 1.8 Hz, 1H), 6.29 (dd, <i>J</i> = 8.1, 1.8 Hz, 1H), 5.07 (s, 2H), 4.54 (s, 2H), 3.98 (q, <i>J</i> = 6.9 Hz, 2H), 3.95 (s, 3H), 3.76 (s, 3H), 3.39 (s, 2H), 1.32 (t, <i>J</i> = 6.9 Hz, 3H);<sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.7, 158.6, 158.4, 147.4, 146.7, 146.2, 144.2, 143.8, 142.1, 129.1, 128.9, 128.7, 128.2, 124.1, 113.2, 113.1, 112.4, 111.6, 107.2, 106.3, 103.2, 100.7, 69.6, 68.5, 61.9, 54.4, 36.3, 28.3, 14.1. HRMS (ESI) calcd for C<sub>29</sub>H<sub>31</sub>N<sub>4</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 515.2289, found: 515.2295.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>N</i>-(3-Ethoxyphenyl)-6-(methoxymethoxy)-1-methyl-7-propoxy-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-amine (<b>8</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>6</b>, compound <b>8</b> was prepared from <b>5</b> (500 mg, 1.31 mmol), K<sub>2</sub>CO<sub>3</sub> (362 mg, 2.62 mmol), 1-bromopropane (248 μL, 2.62 mmol) in 90% yield as a white solid, mp: 133–135 °C. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.13 (t, <i>J</i> = 7.8 Hz, 1H), 7.07 (s, 1H), 6.62 (s, 1H), 6.59 (d, <i>J</i> = 7.8 Hz, 1H), 6.42 (d, <i>J</i> = 7.8 Hz, 1H), 5.97 (s, 1H), 5.22 (s, 2H), 4.05 (t, <i>J</i> = 7.2 Hz, 4H), 4.00 (s, 3H), 3.55 (s, 3H), 3.38 (s, 2H), 1.83–1.95 (m, 2H), 1.39 (t, <i>J</i> = 7.2 Hz, 3H), 1.08 (t, <i>J</i> = 7.2 Hz, 3H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 160.0, 149.6, 148.9, 145.8, 144.7, 144.2, 141.7, 129.8, 126.8, 116.2, 114.2, 108.6, 105.7, 104.9, 102.4, 96.1, 71.3, 63.3, 56.3, 37.4, 29.7, 22.7, 14.9, 10.6. MS (ESI) calcd for C<sub>24</sub>H<sub>30</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 424.2, found: 424.4.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 3-((3-Ethoxyphenyl)amino)-1-methyl-7-propoxy-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-6-ol (<b>9</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>ID01</b>, compound <b>9</b> was prepared from <b>8</b> (0.5 g, 1.18 mmol), CSA methanol solution (0.5 M, 10 mL) in 80% yield as a yellow solid, mp: 186–189 °C. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.14 (t, <i>J</i> = 7.8 Hz, 1H), 7.06 (s 1H), 7.01 (s, 1H), 6.58–6.61 (m, 2H), 6.43 (d, <i>J</i> = 7.8 Hz, 1H), 6.05 (s, 1H), 5.82 (s, 1H), 4.08 (t, <i>J</i> = 6.6 Hz, 2H), 4.00 (q, <i>J</i> = 7.2 Hz, 2H), 4.00 (s, 3H), 3.37 (s, 2H), 1.87–1.93 (m, 2H), 1.39 (t, <i>J</i> = 7.2 Hz, 3H), 1.09 (t, <i>J</i> = 7.2 Hz, 3H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 144.9, 144.6, 144.1, 142.3, 129.8, 124.1, 113.3, 112.8, 108.6, 105.7, 102.6, 102.4, 71.0, 63.3, 37.2, 29.8, 22.6, 14.9, 10.5. MS (ESI) calcd for C<sub>25</sub>H<sub>26</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 380.2, found: 380.4.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Methyl 2-((3-((3-Ethoxyphenyl)amino)-1-methyl-7-propoxy-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-6-yl)oxy)acetate (<b>10</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>6</b>, compound <b>10</b> was prepared from <b>9</b> (150 mg, 0.40 mmol), methyl chloroacetate (69 μL, 0.79 mmol), K<sub>2</sub>CO<sub>3</sub> (109 mg, 0.79 mmol) in 87% yield as a white solid, mp: 154–156 °C. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 8.38 (s, 1H), 7.87 (d, <i>J</i> = 1.8 Hz, 1H), 7.34 (s, 1H), 7.23 (s, 1H), 7.06 (t, <i>J</i> = 7.8 Hz, 1H), 6.98 (s, 1H), 6.83 (dd, <i>J</i> = 7.8, 1.8 Hz, 1H), 6.29 (dd, <i>J</i> = 7.8, 1.8 Hz, 1H), 4.48 (s, 2H), 4.07 (t, <i>J</i> = 6.6 Hz, 2H), 3.97 (q, <i>J</i> = 7.2 Hz, 2H), 3.96 (s, 3H), 3.69 (s, 3H), 3.37 (s, 2H), 1.75–1.82 (m, 2H), 1.32 (t, <i>J</i> = 7.2 Hz, 3H), 1.04 (t, <i>J</i> = 7.2 Hz, 3H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 168.8, 159.7, 148.7, 146.8, 145.3, 144.8, 141.4, 129.8, 126.7, 115.3, 113.1, 108.3, 105.5, 104.4, 101.8, 70.9, 70.1, 63.0, 40.5, 37.6, 29.2, 25.8, 22.7, 15.3, 10.9. MS (ESI) calcd for C<sub>25</sub>H<sub>30</sub>N<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 452.1, found: 452.4.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 2-((3-((3-Ethoxyphenyl)amino)-1-methyl-7-propoxy-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-6-yl)oxy)acetamide (ID06)</h3><div class="NLM_p last">Following the procedures described for preparing <b>7</b>, compound <b>ID06</b> was prepared from <b>10</b> (30 mg, 0.07 mmol), aqueous ammonia (25%, 0.6 mL) in 76% yield as a white solid, HPLC purity: 98.5%, mp: 162–164 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.38 (s, 1H), 7.48 (s, 1H), 7.34 (s 1H), 7.32 (s, 1H), 7.22 (s, 1H), 7.06 (t, <i>J</i> = 8.4 Hz, 1H), 6.92 (t, <i>J</i> = 2.4 Hz, 1H), 6.83 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 6.29 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 4.46 (s, 2H), 4.07 (t, <i>J</i> = 6.6 Hz, 2H), 3.97 (q, <i>J</i> = 7.2 Hz, 2H), 3.97 (s, 3H), 3.37 (s, 2H), 1.77–1.84 (m, 2H), 1.32 (t, <i>J</i> = 7.2 Hz, 3H), 1.03 (t, <i>J</i> = 7.2 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.7, 159.7, 148.5, 146.8, 145.3, 144.8, 141.5, 129.8, 126.4, 114.7, 112.9, 108.3, 105.4, 104.4, 101.8, 70.9, 69.4, 63.0, 40.5, 37.6, 29.3, 22.7, 15.3, 11.0. HRMS (ESI) calcd for C<sub>24</sub>H<sub>29</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 437.2183, found: 437.2191.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> <b>7-((</b><i><b>tert</b></i>-Butyldimethylsilyl)oxy)-6-ethoxy-<i><b>N</b></i><b>-(3-ethoxyphenyl)-1-methyl-1,4-</b>dihydroindeno[1,2-<i>c</i>]pyrazol-3-amine (<b>12a</b>)</h3><div class="NLM_p last">Following similar procedures to those described for preparing <b>4</b>, compound <b>12a</b> was prepared from <b>11</b> (1.0 g, 3.2 mmol), LiHMDS (3.9 mL, 3.9 mmol), 1-ethoxy-3-isothiocyanatobenzene (698 mg, 3.9 mmol), hydrazine hydrate (4.9 mL, 31.2 mmol), DIPEA (401 mL, 2.4 mmol), and dimethyl sulfate (232 mL, 2.4 mmol) in 18% yield as a white solid, mp: 110–112 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) <i>δ</i> 8.36 (s, 1H), 7.22 (s, 1H), 7.12 (s, 1H), 7.06 (t, <i>J</i> = 7.8 Hz, 1H), 6.96 (t, <i>J</i> = 1.8 Hz, 1H), 6.82 (dd, <i>J</i> = 7.8, 1.8 Hz, 1H), 6.29 (dd, <i>J</i> = 7.8, 1.8 Hz, 1H), 4.06 (q, <i>J</i> = 7.2 Hz, 2H), 3.97 (q, <i>J</i> = 7.2 Hz, 2H), 3.91 (s, 3H), 3.37 (s, 2H), 1.37 (t, <i>J</i> = 7.2 Hz, 3H), 1.32 (t, <i>J</i> = 7.2 Hz, 3H), 1.00 (s, 9H), 0.17 (s, 6H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) <i>δ</i> 160.1, 149.9, 149.5, 144.7, 144.1, 142.6, 129.8, 124.6, 113.3, 111.5, 111.3, 108.7, 105.8, 102.5, 64.2, 63.3, 37.1, 30.0, 25.7, 18.4, 14.9, 14.9, −4.5. MS (ESI) calcd for C<sub>27</sub>H<sub>38</sub>N<sub>3</sub>O<sub>3</sub>Si [M + H]<sup>+</sup>: 480.3, found: 480.5.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 6-Ethoxy-3-((3-ethoxyphenyl)amino)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-ol (<b>13a</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>5</b>, compound <b>13a</b> was prepared from <b>12a</b> (1.0 g, 2.3 mmol) and TBAF (1.2 g, 4.6 mmol) in 90% yield as a white solid, mp: 153–155 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.83 (s, 1H), 8.34 (s, 1H), 7.15 (s, 1H), 7.11 (s, 1H), 7.05 (t, <i>J</i> = 7.8 Hz, 1H), 6.96 (s, 1H), 6.83 (d, <i>J</i> = 7.8 Hz, 1H), 6.27 (d, <i>J</i> = 7.8 Hz, 1H), 4.06 (q, <i>J</i> = 7.2 Hz, 2H), 3.97 (q, <i>J</i> = 7.2 Hz, 2H), 3.89 (s, 3H), 3.32 (s, 2H), 1.35(t, <i>J</i> = 7.2 Hz, 3H), 1.32 (t, <i>J</i> = 7.2 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.73, 148.8, 146.3, 145.9, 145.4, 144.7, 140.1, 129.8, 125.1, 112.7, 112.6, 108.3, 106.7, 104.3, 101.8, 64.7, 63.0, 37.3, 29.3, 15.3, 15.2. MS (ESI) calcd for C<sub>21</sub>H<sub>23</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 366.2, found: 366.3.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Methyl 2-((6-Ethoxy-3-((3-ethoxyphenyl)amino)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)acetate (<b>14a</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>6</b>, compound <b>14a</b> was prepared from <b>13a</b> (1.10 g, 3.01 mmol), K<sub>2</sub>CO<sub>3</sub> (832 mg, 6.02 mmol), and methyl chloroacetate (0.55 mL, 6.26 mmol) in 74% yield as a white solid, mp: 139–141 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) <i>δ</i> 8.38 (s, 1H), 7.27 (s, 1H), 7.24 (s, 1H), 7.06 (t, <i>J</i> = 12.1 Hz, 1H), 6.98 (s, 1H), 6.83 (d, <i>J</i> = 12.1 Hz, 1H), 6.29 (d, <i>J</i> = 10.2 Hz, 1H), 4.88 (s, 2H), 4.09 (q, <i>J</i> = 10.2 Hz, 2H), 3.98 (q, <i>J</i> = 10.2 Hz, 2H), 3.93 (s, 3H), 3.72 (s, 3H), 3.38 (s, 2H), 1.35(t, <i>J</i> = 10.2 Hz, 3H), 1.32 (t, <i>J</i> = 10.2 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) <i>δ</i> 169.9, 159.7, 148.6, 147.6, 146.9, 145,3, 144.8, 142.9, 129.7, 124.8, 113.1, 112.7, 108.3, 106.2, 104.4, 101.9, 66.4, 64.7, 63.1, 52.2, 37.5, 29.4, 15.3, 15.2. MS (ESI) calcd for C<sub>24</sub>H<sub>28</sub>N<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 438.2, found: 438.5.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 2-((6-Ethoxy-3-((3-ethoxyphenyl)amino)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)acetic acid (ID07)</h3><div class="NLM_p last">To a solution of <b>14a</b> (40 mg, 0.09 mmol) in MeOH (3 mL) was added LiOH aqueous solution (1 M, 1.5 mL). The mixture was stirred at 30 °C for 2 h. The resulting solution was adjusted to pH 4 by the addition of 2 M HCl aqueous solution. After distilled water was added, a white solid was precipitated out. It was filtered and dried to give 34 mg (85%) of <b>ID07</b> as a white solid, HPLC purity: 98.9%, mp: 199–200 °C, <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.97 (s, 1H), 8.39 (s, 1H), 7.25 (s, 1H), 7.23 (s, 1H), 7.06 (t, <i>J</i> = 8.1 Hz, 1H), 6.99 (t, <i>J</i> = 2.1 Hz, 1H), 6.83 (dd, <i>J</i> = 8.1, 2.1 Hz, 1H), 6.28 (dd, <i>J</i> = 8.1, 2.1 Hz, 1H), 4.78 (s, 2H), 4.08 (q, <i>J</i> = 7.0 Hz, 2H), 3.97 (q, <i>J</i> = 7.0 Hz, 2H), 3.93 (s, 3H), 3.35 (s, 2H), 1.35 (t, <i>J</i> = 7.0 Hz, 3H), 1.32 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.9, 159.7, 148.6, 147.4, 147.0, 145.3, 144.8, 142.4, 129.8, 124.7, 112.8, 112.6, 108.2, 105.5, 104.3, 101.7, 66.0, 64.6, 63.0, 37.4, 29.4, 15.3, 15.2. HRMS (ESI) calcd for C<sub>23</sub>H<sub>26</sub>N<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 424.1867, found: 424.1873.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 5-Ethoxy-6-(3-hydroxypropoxy)-1-indanone (<b>16</b>)</h3><div class="NLM_p last">To a mixture of 5-ethoxy-6-hydroxyl-1-indanone <b>15</b> (0.57 g, 2.95 mmol) and K<sub>2</sub>CO<sub>3</sub> (0.48 g, 3.54 mmol) in DMF (8 mL), 1-chloro-3-hydroxypropane (0.21 mL, 3.54 mmol) was added at 75 °C and stirred for 10 h. Distilled water (40 mL) was added, and the mixture was extracted with EtOAc (50 mL × 3), washed with brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration and evaporation, the residue was purified by chromatography (ethyl acetate/hexanes = 1:1) to give 580 mg (79%) of <b>16</b> as a white solid, mp: 98–99 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.10 (s, 1H), 7.06 (s, 1H), 4.14 (q, <i>J</i> = 6.9 Hz, 2H), 4.06 (t, <i>J</i> = 6.5 Hz, 2H), 3.61–3.52 (m, 2H), 3.03–2.93 (m, 2H), 2.60–2.52 (m, 2H), 1.92–1.81 (m, 2H), 1.37 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 204.9, 154.8, 150.8, 148.6, 129.3, 109.5, 105.4, 65.9, 64.4, 57.6, 36.2, 32.4, 25.5.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 5-Ethoxy-6-(3-(methoxymethoxy)propoxy)-2,3-dihydro-1<i>H</i>-inden-1-one (<b>17</b>)</h3><div class="NLM_p last">To a solution of 5-ethoxy-6-hydroxyl-1-indanone <b>16</b> (0.52 g, 2.08 mmol) in DCM (8 mL), DIPEA (0.83 mL, 4.16 mmol) and MOMCl (0.31 mL, 4.16 mmol) were added, and the mixture was stirred for 8 h at room temperature. Distilled water (30 mL) was added, and the mixture was extracted with EtOAc (40 mL × 3), washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration and evaporation, the residue was purified by chromatography (ethyl acetate/hexanes = 1:3) to give 420 mg (69%) of <b>17</b> as a white solid, mp: 87–89 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.11 (s, 1H), 7.07 (s, 1H), 4.56 (s, 2H), 4.14 (q, <i>J</i> = 7.0 Hz, 2H), 4.07 (t, <i>J</i> = 6.5 Hz, 2H), 3.62 (t, <i>J</i> = 6.3 Hz, 2H), 3.23 (s, 3H), 3.01–2.95 (m, 2H), 2.56 (dd, <i>J</i> = 6.5, 4.6 Hz, 2H), 1.97 (t, <i>J</i> = 6.3 Hz, 2H), 1.37 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 205.2, 154.8, 150.2, 148.3, 129.6, 110.1, 106.1, 95.8, 65.9, 64.4, 63.8, 55.1, 36.5, 29.6, 25.3.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 6-Ethoxy-<i>N</i>-(3-ethoxyphenyl)-7-(3-(methoxymethoxy)propoxy)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-amine (<b>18a</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>4</b>, compound <b>18a</b> was prepared from <b>17</b> (300 mg, 1.02 mmol), LiHMDS (1.22 mL, 1.22 mmol), 1-ethoxy-3-isothiocyanatobenzene (219 mg, 1.22 mmol), hydrazine hydrate (0.51 mL, 8.16 mmol), DIPEA (70 mL, 0.42 mmol), and dimethyl sulfate (40 mL, 0.42 mmol) in 16% yield as a yellow solid, mp: 118–119 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.82 (s, 1H), 7.88 (d, <i>J</i> = 7.5 Hz, 1H), 7.58 (s, 1H), 7.41 (t, <i>J</i> = 7.5 Hz, 1H), 7.26 (s, 1H), 6.92 (s, 1H), 6.75 (d, <i>J</i> = 7.5 Hz, 1H), 4.50 (s, 2H), 4.32 (t, <i>J</i> = 6.3 Hz, 2H), 4.29 (q, <i>J</i> = 6.9 Hz, 2H), 4.07 (q, <i>J</i> = 6.9 Hz, 2H), 3.95 (s, 3H), 3.68 (t, <i>J</i> = 6.3 Hz, 2H), 3.36 (s, 2H), 3.27 (s, 3H), 1.97 (p, <i>J</i> = 6.3 Hz, 2H), 1.42 (t, <i>J</i> = 6.9 Hz, 3H), 1.34 (t, <i>J</i> = 6.9 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.1, 158.9, 148.4, 145.2, 144.0, 138.4, 131.1, 130.8, 130.5, 110.4, 109.7, 109.5, 104.4, 102.8, 99.5, 96.3, 65.3, 65.0, 64.9, 64.6, 55.6, 37.9, 29.4, 24.9, 14.8, 14.7. MS (ESI) calcd for C<sub>26</sub>H<sub>33</sub>N<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 523.2, found: 523.3.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 3-((6-Ethoxy-3-((3-ethoxyphenyl)amino)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)propan-1-ol (ID08)</h3><div class="NLM_p last">Compound <b>18a</b> (50 mg, 0.11 mmol) was dissolved in a CSA methanol solution (1 M, 2 mL), and the mixture was heated to 40 °C and stirred for 2 h. Distilled water (20 mL) was added, and the mixture was extracted with EtOAc (25 mL × 3), washed with brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration and evaporation, the residue was purified by chromatography (ethyl acetate/hexanes = 5:1) to give 32 mg (75%) of <b>ID08</b> as a white solid, HPLC purity: 99.9%, mp: 162–163 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.37 (s, 1H), 7.30 (s, 1H), 7.20 (s, 1H), 7.11–7.04 (t, <i>J</i> = 7.0 Hz, 1H), 6.99 (s, 1H), 6.84 (d, <i>J</i> = 7.0 Hz, 1H), 6.29 (d, <i>J</i> = 7.0 Hz, 1H), 4.55 (s, 1H), 4.14 (t, <i>J</i> = 4.6 Hz, 2H), 4.05 (q, <i>J</i> = 6.4 Hz, 2H), 3.99–3.90 (m, 5H), 3.61 (t, <i>J</i> = 4.6 Hz, 2H), 3.37 (s, 2H), 1.95–1.83 (m, 2H), 1.36 (t, <i>J</i> = 6.4 Hz, 3H), 1.36 (t, <i>J</i> = 6.5 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.7, 148.8, 148.2, 147.7, 145.4, 144.8, 141.8, 129.8, 125.1, 112.9, 112.6, 108.3, 105.5, 104.3, 101.8, 66.7, 64.7, 63.0, 58.0, 37.5, 32.8, 29.4, 15.4, 15.2. MS (ESI) calcd for C<sub>24</sub>H<sub>29</sub>N<sub>3</sub>O<sub>4</sub> [M + Na]<sup>+</sup>: 446.2, found: 446.3.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> <i>tert</i>-Butyl (3-((6-Ethoxy-3-((3-ethoxyphenyl)amino)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)propyl)carbamate (<b>19a</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>6</b>, compound <b>19a</b> was prepared from <b>13a</b> (40 mg, 0.11 mmol), K<sub>2</sub>CO<sub>3</sub> (30 mg, 0.22 mmol), and <i>N</i>-Boc-3-bromopropylamine (50 mg, 0.22 mmol) in 87% yield as a white solid, mp: 137–138 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.36 (s, 1H), 7.29 (s, 1H), 7.21 (s, 1H), 7.06 (t, <i>J</i> = 8.0 Hz, 1H), 6.98 (s, 1H), 6.83 (s, 1H), 6.82 (d, <i>J</i> = 8.0 Hz, 2H), 6.28 (d, <i>J</i> = 8.0 Hz, 1H), 4.19–4.02 (m, 4H), 4.02–3.83 (m, 5H), 3.37 (s, 2H), 3.14 (q, <i>J</i> = 6.0 Hz, 2H), 1.86 (p, <i>J</i> = 6.1 Hz, 1H), 1.38 (s, 9H), 1.36–1.24 (m, 6H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.7, 156.1, 148.8, 148.0, 147.8, 145.3, 144.8, 142.1, 129.8, 125.0, 112.9, 112.6, 108.2, 106.1, 104.3, 101.8, 77.9, 67.7, 64.7, 63.0, 37.7, 37.5, 29.9, 29.3, 28.7, 15.3, 15.2. MS (ESI) calcd for C<sub>29</sub>H<sub>39</sub>N<sub>4</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 523.3, found: 523.2.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 7-(3-Aminopropoxy)-6-ethoxy-<i>N</i>-(3-ethoxyphenyl)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-amine hydrochloride (ID09)</h3><div class="NLM_p last">Acetyl chloride (2.5 mL) was added to ethanol (5 mL) and stirred for 15 min. To the resulting solution (2 mL), <b>19a</b> (45 mg, 0.09 mmol) was added, and the mixture was stirred for 20 min. The resulting precipitate was filtered and dried to give 35 mg (88%) of <b>ID09</b> as a white solid, HPLC purity: 99.7%, mp: 156–158 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.09 (s, 3H), 7.39 (s, 1H), 7.26 (s, 1H), 7.10 (t, <i>J</i> = 8.1 Hz, 1H), 6.96 (s, 1H), 6.83 (d, <i>J</i> = 8.1 Hz, 1H), 6.36 (d, <i>J</i> = 8.1 Hz, 1H), 4.19 (t, <i>J</i> = 6.2 Hz, 2H), 4.08 (q, <i>J</i> = 6.9 Hz, 2H), 4.00 (s, 2H), 3.97 (d, <i>J</i> = 7.0 Hz, 1H), 3.05–2.98 (m, 2H), 2.13 (p, <i>J</i> = 6.2 Hz, 2H), 1.36 (t, <i>J</i> = 6.9 Hz, 3H), 1.33 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.7, 150.7, 148.8, 147.7, 144.0, 143.7, 143.1, 130.1, 123.5, 112.2, 111.5, 109.3, 106.6, 106.0, 103.0, 67.3, 64.6, 63.1, 37.3, 36.9, 29.9, 27.3, 15.2, 15.1. HRMS (ESI) calcd for C<sub>24</sub>H<sub>31</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 423.2391, found: 423.2394; anal. calcd for C<sub>24</sub>H<sub>31</sub>ClN<sub>4</sub>O<sub>3</sub>: C, 62.80; H, 6.81; Cl, 7.72; N, 12.21; found: C, 62.92; H, 6.64; Cl, 7.86; N, 12.32.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> <i>N</i>-(3-((6-Ethoxy-3-((3-ethoxyphenyl)amino)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)propyl)acetamide (ID10)</h3><div class="NLM_p last">To a solution of <b>ID09</b> (50 mg, 0.14 mmol) in THF (6 mL) were added Et<sub>3</sub>N (58 μL, 0.42 mmol) and acetic anhydride (22 μL, 0.21 mmol). The mixture was stirred at room temperature for 4 h. Distilled water was added, and the resulting precipitate was filtered and dried to give 46 mg (92%) of <b>ID10</b> as a white solid, HPLC purity: 99.5%, mp: 173–174 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.36 (s, 1H), 7.90 (s, 1H), 7.31 (s, 1H), 7.22 (s, 1H), 7.07 (t, <i>J</i> = 8.0 Hz, 1H), 6.99 (s, 1H), 6.84 (d, <i>J</i> = 8.0 Hz, 1H), 6.29 (d, <i>J</i> = 8.0 Hz, 1H), 4.15–4.03 (m, 4H), 4.00–3.98 (m, 5H), 3.38 (s, 2H), 3.24 (q, <i>J</i> = 6.1 Hz, 2H), 1.94–1.85 (m, 2H), 1.82 (s, 3H), 1.36 (t, <i>J</i> = 7.4 Hz, 3H), 1.32 (t, <i>J</i> = 7.1 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.6, 159.7, 148.8, 148.0, 147.9, 145.4, 144.8, 142.1, 129.8, 125.1, 113.1, 112.6, 108.3, 106.1, 104.3, 101.8, 67.5, 64.7, 63.0, 37.5, 36.2, 29.5, 29.3, 23.1, 15.4, 15.2. MS (ESI) calcd for C<sub>26</sub>H<sub>32</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 465.2, found: 465.4.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 6-Ethoxy-<i>N</i>-(3-ethoxyphenyl)-1-methyl-7-propoxy-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-amine (ID11)</h3><div class="NLM_p last">Following the procedures described for preparing <b>6</b>, compound <b>ID11</b> was prepared from <b>13a</b> (70 mg, 0.19 mmol), 1-bromopropane (50 μL, 0.38 mmol), K<sub>2</sub>CO<sub>3</sub> (60 mg, 0.38 mmol) in 64% yield as a white solid, HPLC purity: 98.7%, mp: 142–143 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.38 (s, 1H), 7.28 (s, 1H), 7.20 (s, 1H), 7.06 (t, <i>J</i> = 8.1 Hz, 1H), 6.99 (t, <i>J</i> = 2.0 Hz, 1H), 6.83 (dd, <i>J</i> = 8.1, 2.0 Hz, 1H), 6.28 (dd, <i>J</i> = 8.1, 2.0 Hz, 1H), 4.05 (q, <i>J</i> = 7.0 Hz, 2H), 4.02 (t, <i>J</i> = 6.6 Hz, 2H), 3.98 (q, <i>J</i> = 6.9 Hz, 2H), 3.96 (s, 3H), 3.36 (s, 2H), 1.83–1.71 (m, 2H), 1.34 (t, <i>J</i> = 6.9 Hz, 3H), 1.32 (t, <i>J</i> = 7.0 Hz, 3H), 1.02 (t, <i>J</i> = 7.4 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.6, 147.7, 147.1, 146.6, 144.2, 143.7, 140.7, 128.7, 123.9, 111.8, 111.5, 107.1, 104.6, 103.2, 100.7, 69.8, 63.5, 61.9, 36.4, 28.2, 21.6, 14.3, 14.2, 9.9. HRMS (ESI) calcd for C<sub>24</sub>H<sub>30</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 408.2282, found: 408.2288.</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> <b>7-((</b><i><b>tert</b></i>-Butyldimethylsilyl)oxy)-6-ethoxy-<i>N</i>-(4-ethoxyphenyl)-1-methyl-1,4<b>-</b>dihydroindeno[1,2-<i>c</i>]pyrazol-3-amine (<b>12b</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>4</b>, compound <b>12b</b> was prepared from <b>11</b> (500 mg, 1.63 mmol), LiHMDS (2.45 mL, 2.45 mmol), 1-ethoxy-4-isothiocyanatobenzene (436 mg, 2.45 mmol), hydrazine hydrate (0.82 mL, 13.04 mmol), DIPEA (182 μL, 1.10 mmol), and dimethyl sulfate (104 μL, 1.10 mmol) in 17% yield as a white solid, mp: 168–169 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.07 (s, 1H), 7.25 (d, <i>J</i> = 9.0 Hz, 2H), 7.19 (s, 1H), 7.09 (s, 1H), 6.79 (d, <i>J</i> = 9.0 Hz, 2H), 4.04 (q, <i>J</i> = 7.0 Hz, 2H), 3.93 (q, <i>J</i> = 7.0 Hz, 2H), 3.88 (s, 3H), 3.34 (s, 2H), 1.36 (t, <i>J</i> = 7.0 Hz, 3H), 1.29 (t, <i>J</i> = 7.0 Hz, 3H), 1.00 (s, 9H), 0.16 (s, 6H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 150.6, 147.9, 147.4, 144.6, 142.5, 141.9, 136.8, 123.8, 115.9, 114.2, 111.0, 110.7, 110.5, 63.0, 62.5, 36.3, 28.4, 25.0, 17.6, 14.3, 14.2, −5.3. MS (ESI) calcd for C<sub>27</sub>H<sub>38</sub>N<sub>3</sub>O<sub>3</sub>Si [M + H]<sup>+</sup>: 480.3, found: 480.3.</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 3-((7-((<i>tert</i>-Butyldimethylsilyl)oxy)-6-ethoxy-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)benzonitrile (<b>12c</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>4</b>, compound <b>12c</b> was prepared from <b>11</b> (350 mg, 1.14 mmol), LiHMDS (2.06 mL, 2.06 mmol), 3-isothiocyanatobenzonitrile (329 mg, 2.06 mmol), hydrazine hydrate (0.57 mL, 9.12 mmol), DIPEA (144 μL, 0.86 mmol), and dimethyl sulfate (88 μL, 0.86 mmol) in 21% yield as a white solid, mp: 110–112 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.93 (s, 1H), 7.83 (d, <i>J</i> = 1.6 Hz, 1H), 7.57 (dd, <i>J</i> = 8.0, 1.6 Hz, 1H), 7.45 (dd, <i>J</i> = 8.0, 1.6 Hz, 1H), 7.39 (t, <i>J</i> = 8.0 Hz, 1H), 7.24 (s, 1H), 7.14 (s, 1H), 4.06 (q, <i>J</i> = 6.9 Hz, 2H), 3.95 (s, 3H), 3.42 (s, 2H), 1.38 (t, <i>J</i> = 6.9 Hz, 3H), 1.00 (s, 9H), 0.17 (s, 6H);<sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 149.2, 148.8, 144.7, 143.9, 143.6, 142.9, 130.5, 124.6, 121.7, 120.1, 119.9, 117.4, 112.7, 112.1, 111.9, 111.8, 64.1, 40.6, 40.4, 40.2, 39.9, 39.8, 39.6, 39.4, 37.6, 29.2, 26.1, 18.7, 15.3, −4.2. MS (ESI) calcd for C<sub>26</sub>H<sub>33</sub>N<sub>4</sub>O<sub>2</sub>Si [M + H]<sup>+</sup>: 461.2, found: 461.6.</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Methyl 3-((7-((<i>tert</i>-Butyldimethylsilyl)oxy)-6-ethoxy-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)benzoate (<b>12d</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>4</b>, compound <b>12d</b> was prepared from <b>11</b> (3 g, 9.8 mmol), LiHMDS (14.6 mL, 14.6 mmol), methyl 3-isothiocyanatobenzoate (2.84 g, 14.6 mmol), hydrazine hydrate (4.9 mL, 78.4 mmol), DIPEA (1.21 mL, 7.0 mmol), and dimethyl sulfate (0.68 mL, 7.0 mmol) in 18% yield as a white solid, mp: 122–123 °C. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.69 (s, 1H), 7.53 (d, <i>J</i> = 7.6 Hz, 1H), 7.31 (t, <i>J</i> = 7.6 Hz, 1H), 7.23 (d, <i>J</i> = 7.6 Hz, 1H), 7.02 (s, 1H), 6.99 (s, 1H), 6.22 (s, 1H), 4.05 (q, <i>J</i> = 7.0 Hz, 2H), 3.98 (s, 3H), 3.89 (s, 3H), 3.38 (s, 2H), 1.46 (t, <i>J</i> = 7.0 Hz, 3H), 1.04 (s, 9H), 0.20 (s, 6H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 162.5, 144.9, 139.4, 138.7, 138.0, 126.3, 124.4, 119.7, 116.1, 115.6, 111.7, 106.8, 106.5, 59.4, 47.4, 32.4, 25.2, 21.1, 21.0, 13.7, 10.2, −9.3. MS (ESI) calcd for C<sub>27</sub>H<sub>36</sub>N<sub>3</sub>O<sub>4</sub>Si [M + H]<sup>+</sup>: 495.2, found: 495.4.</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Ethyl 3-((7-((<i>tert</i>-Butyldimethylsilyl)oxy)-6-ethoxy-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)benzoate (<b>12e</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>4</b>, compound <b>12e</b> was prepared from <b>11</b> (500 mg, 1.63 mmol), LiHMDS (5 mL, 4.89 mmol), ethyl 3-isothiocyanatobenzoate (970 mg, 4.89 mmol), hydrazine hydrate (0.82 mL, 13.04 mmol), DIPEA (200 μL, 1.0 mmol), and dimethyl sulfate (110 μL, 1.0 mmol) in 19% yield as a yellow solid, mp: 160–161 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.71 (s, 1H), 7.89 (s, 1H), 7.63 (d, <i>J</i> = 6.8 Hz, 1H), 7.43–7.27 (m, 2H), 7.22 (s, 1H), 7.12 (s, 1H), 4.29 (q, <i>J</i> = 7.0 Hz, 2H), 4.05 (q, <i>J</i> = 6.9 Hz, 2H), 3.92 (s, 3H), 3.39 (s, 2H), 1.37 (t, <i>J</i> = 6.9 Hz, 3H), 1.31 (t, <i>J</i> = 7.0 Hz, 3H), 1.00 (s, 9H), 0.17 (s, 6H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.1, 148.6, 148.2, 143.9, 143.8, 143.1, 142.4, 130.3, 129.1, 124.2, 119.2, 118.4, 115.3, 112.2, 111.6, 111.2, 63.6, 60.5, 37.0, 28.9, 25.6, 18.2, 14.7, 14.2, −4.6. MS (ESI) calcd for C<sub>28</sub>H<sub>38</sub>N<sub>3</sub>O<sub>4</sub>Si [M + H]<sup>+</sup>: 508.3, found: 508.2.</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Isopropyl 3-((7-((<i>tert</i>-Butyldimethylsilyl)oxy)-6-ethoxy-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)benzoate (<b>12f</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>4</b>, compound <b>12f</b> was prepared from <b>11</b> (300 mg, 0.98 mmol), LiHMDS (1.96 mL, 1.96 mmol), isopropyl 3-isothiocyanatobenzoate (430 mg, 1.96 mmol), hydrazine hydrate (0.49 mL, 7.84 mmol), DIPEA (76 μL, 0.46 mmol), and dimethyl sulfate (44 μL, 0.46 mmol) in 13% yield as a yellow solid, mp: 114–116 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.70 (s, 1H), 7.87 (d, <i>J</i> = 1.6 Hz, 1H), 7.66–7.59 (m, 1H), 7.37–7.28 (m, 2H), 7.21 (s, 1H), 7.12 (s, 1H), 5.12 (hept, <i>J</i> = 6.3 Hz, 1H), 4.04 (q, <i>J</i> = 7.0 Hz, 2H), 3.92 (s, 3H), 3.39 (s, 2H), 1.36 (t, <i>J</i> = 7.0 Hz, 3H), 1.31 (d, <i>J</i> = 6.3 Hz, 6H), 1.00 (s, 9H), 0.16 (s, 6H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.0, 148.0, 147.6, 143.3, 142.5, 141.8, 130.1, 128.4, 123.6, 118.6, 117.9, 114.7, 111.6, 110.9, 110.6, 67.2, 63.0, 36.4, 28.3, 25.0, 21.1, 17.6, 14.1, −5.2. MS (ESI) calcd for C<sub>29</sub>H<sub>40</sub>N<sub>3</sub>O<sub>4</sub>Si [M + H]<sup>+</sup>: 522.3, found: 522.2.</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 3-((7-((<i>tert</i>-Butyldimethylsilyl)oxy)-6-ethoxy-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)-<i>N</i>-methylbenzamide (<b>12g</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>4</b>, compound <b>12g</b> was prepared from <b>11</b> (1.5 g, 4.90 mmol), LiHMDS (5.64 mL, 5.64 mmol), 3-isothiocyanato-<i>N</i>-methylbenzamide (1.08 g, 5.64 mmol), hydrazine hydrate (2.45 mL, 39.2 mmol), DIPEA (0.45 mL, 2.72 mmol), and dimethyl sulfate (0.26 mL, 2.72 mmol) in 18% yield as a yellow solid, mp: 106–108 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.59 (s, 1H), 8.31 (q, <i>J</i> = 4.4 Hz, 1H), 7.62 (s, 1H), 7.44 (d, <i>J</i> = 8.1 Hz, 1H), 7.25 (t, <i>J</i> = 8.1 Hz, 1H), 7.21 (s, 1H), 7.14 (d, <i>J</i> = 8.1 Hz, 1H), 7.12 (s, 1H), 4.07–3.99 (m, 2H), 3.91 (s, 3H), 3.36 (s, 2H), 2.74 (d, <i>J</i> = 4.4 Hz, 3H), 1.36 (t, <i>J</i> = 6.8 Hz, 3H), 0.99 (s, 9H), 0.16 (s, 6H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.7, 149.1, 148.7, 144.4, 144.3, 143.5, 142.9, 135.7, 129.1, 124.6, 117.8, 116.6, 114.3, 112.8, 111.9, 111.7, 64.0, 37.5, 29.5, 26.7, 26.1, 18.7, 15.3, −4.2. MS (ESI) calcd for C<sub>27</sub>H<sub>37</sub>N<sub>4</sub>O<sub>3</sub>Si [M + H]<sup>+</sup>: 493.3, found: 493.7.</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 6-Ethoxy-3-((4-ethoxyphenyl)amino)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-ol (<b>13b</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>5</b>, compound <b>13b</b> was prepared from <b>12b</b> (140 mg, 0.29 mmol) and TBAF (150 mg, 0.58 mmol) in 76% yield as a white solid, mp: 183–184 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.81 (s, 1H), 8.06 (s, 1H), 7.25 (d, <i>J</i> = 9.0 Hz, 2H), 7.14 (s, 1H), 7.10 (s, 1H), 6.79 (d, <i>J</i> = 9.0 Hz, 2H), 4.05 (q, <i>J</i> = 7.0 Hz, 2H), 3.93 (q, <i>J</i> = 7.0 Hz, 2H), 3.87 (s, 3H), 3.30 (s, 2H), 1.35 (t, <i>J</i> = 7.0 Hz, 3H), 1.29 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 150.6, 147.7, 145.1, 144.8, 144.6, 139.0, 136.8, 124.1, 115.9, 114.2, 111.5, 110.8, 105.6, 63.6, 62.5, 36.2, 28.1, 14.3, 14.2. MS (ESI) calcd for C<sub>21</sub>H<sub>24</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 366.2, found: 366.2.</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 3-((6-Ethoxy-7-hydroxy-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)benzonitrile (<b>13c</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>5</b>, compound <b>13c</b> was prepared from <b>12c</b> (180 mg, 0.39 mmol) and TBAF (110 mg, 0.78 mmol) in 81% yield as a white solid, mp: 130–132 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.90 (s, 1H), 8.87 (s, 1H), 7.79 (d, <i>J</i> = 8.1 Hz, 1H), 7.57 (d, <i>J</i> = 8.1 Hz, 1H), 7.32 (t, <i>J</i> = 8.1 Hz 1H), 7.17 (s, 1H), 7.14 (s, 1H), 4.07 (q, <i>J</i> = 7.0 Hz, 2H), 3.93 (s, 3H), 3.38 (s, 2H), 1.36 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 149.1, 146.3, 146.1, 144.73 143.9, 140.1, 130.4, 124.9, 121.6, 120.0, 119.9, 117.4, 112.7, 112.5, 111.9, 106.8, 64.6, 37.4, 28.9, 15.2. MS (ESI) calcd for C<sub>20</sub>H<sub>19</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 347.1, found: 347.3.</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Methyl 3-((6-Ethoxy-7-hydroxy-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)benzoate (<b>13d</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>5</b>, compound <b>13d</b> was prepared from <b>12d</b> (100 mg, 0.20 mmol) and TBAF (106 mg, 0.40 mmol) in 79% yield as a white solid, mp: 153–155 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.89 (s, 1H), 8.69 (s, 1H), 7.89 (s, 1H), 7.61 (d, <i>J</i>= 8.2 Hz, 1H), 7.32 (t, <i>J</i> = 8.2 Hz, 1H), 7.16 (s, 1H), 7.12 (d, <i>J</i> = 8.2 Hz, 1H), 4.06 (q, <i>J</i> = 7.0 Hz, 2H), 3.92 (s, 3H), 3.84 (s, 3H), 3.35 (s, 2H), 1.36 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.2, 149.1, 146.3, 146.1, 144.5, 144.3, 140.1, 130.6, 129.6, 125.0, 119.8, 119.0, 115.8, 112.8, 112.6, 106.8, 64.7, 52.5, 37.4, 29.2, 15.3. MS (ESI) calcd for C<sub>21</sub>H<sub>22</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 380.2, found: 380.1.</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Ethyl 3-((6-Ethoxy-7-hydroxy-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)benzoate (<b>13e</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>5</b>, compound <b>13e</b> was prepared from <b>12e</b> (120 mg, 0.24 mmol) and TBAF (126 mg, 0.48 mmol) in 86% yield as a white solid, mp: 184–185 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.86 (s, 1H), 8.70 (s, 1H), 7.90 (s, 1H), 7.64 (d, <i>J</i> = 7.3 Hz, 1H), 7.48–7.28 (m, 2H), 7.16 (s, 1H), 7.14 (s, 1H), 4.30 (q, <i>J</i> = 7.1 Hz, 2H), 4.07 (q, <i>J</i> = 7.0 Hz, 2H), 3.92 (s, 3H), 3.36 (s, 2H), 1.36 (t, <i>J</i> = 7.0 Hz, 3H), 1.32 (t, <i>J</i> = 7.1 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.6, 149.0, 146.2, 146.0, 144.4, 144.3, 140.1, 130.8, 129.5, 125.0, 119.7, 118.9, 115.7, 112.7, 112.5, 106.7, 64.6, 60.9, 37.3, 29.2, 15.2, 14.6. MS (ESI) calcd for C<sub>22</sub>H<sub>24</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 394.2, found: 394.2.</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Isopropyl 3-((6-Ethoxy-7-hydroxy-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)benzoate (<b>13f</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>5</b>, compound <b>13f</b> was prepared from <b>12f</b> (100 mg, 0.19 mmol) and TBAF (100 mg, 0.38 mmol) in 80% yield as a white solid, mp: 151–152 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.85 (s, 1H), 8.69 (s, 1H), 7.88 (s, 1H), 7.67–7.60 (m, 1H), 7.39–7.26 (m, 2H), 7.16 (s, 1H), 7.13 (s, 1H), 5.12 (hept, <i>J</i> = 6.2 Hz, 1H), 4.06 (q, <i>J</i> = 7.0 Hz, 2H), 3.96 (s, 3H), 3.36 (s, 2H), 1.35 (t, <i>J</i> = 7.0 Hz, 3H), 1.31 (d, <i>J</i> = 6.2 Hz, 6H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.1, 149.0, 146.2, 146.1, 144.4, 144.3, 140.1, 131.1, 129.5, 125.0, 119.6, 118.9, 115.7, 112.6, 112.5, 106.8, 68.3, 64.6, 37.4, 29.2, 22.2, 15.3. MS (ESI) calcd for C<sub>23</sub>H<sub>26</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 408.2, found: 408.3.</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 3-((6-Ethoxy-7-hydroxy-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)-<i>N</i>-methylbenzamide (<b>13g</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>5</b>, compound <b>13g</b> was prepared from <b>12g</b> (90 mg, 0.18 mmol) and TBAF (95.5 mg, 0.36 mmol) in 89% yield as a white solid, mp: 123–124 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.90 (s, 1H), 8.58 (s, 1H), 8.31 (q, <i>J</i> = 4.3 Hz, 1H), 7.62 (d, <i>J</i> = 8.0 Hz, 1H), 7.47 (d, <i>J</i> = 8.0 Hz, 1H), 7.25 (t, <i>J</i> = 8.0 Hz, 1H), 7.15 (s, 1H), 7.13 (s, 1H), 4.07–4.03 (m, 2H), 3.91 (s, 3H), 3.33 (s, 2H), 2.75 (d, <i>J</i> = 4.3 Hz, 3H), 1.35 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO<i>-d</i><sub>6</sub>) δ 167.7, 149.0, 146.2, 144.4, 144.3, 140.1, 135.8, 124.9, 117.7, 116.5, 112.8, 112.4, 106.7, 64.5, 60.2, 37.36, 29.3, 26.7, 21.2, 15.3, 14.5. MS (ESI) calcd for C<sub>21</sub>H<sub>23</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 379.2, found: 379.6.</div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> Methyl 2-((6-Ethoxy-3-((4-ethoxyphenyl)amino)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)acetate (<b>14b</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>6</b>, compound <b>14b</b> was prepared from <b>13b</b> (100 mg, 0.27 mmol), methyl chloroacetate (48 μL, 0.54 mmol), K<sub>2</sub>CO<sub>3</sub> (76 mg, 0.54 mmol) in 71% yield as a white solid, mp: 155–157 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.09 (s, 1H), 7.30–7.24 (m, 3H), 7.22 (s, 1H), 6.79 (d, <i>J</i> = 9.0 Hz, 2H), 4.88 (s, 2H), 4.07 (q, <i>J</i> = 7.0 Hz, 2H), 3.93 (q, <i>J</i> = 7.0 Hz, 2H), 3.91 (s, 3H), 3.71 (s, 3H), 3.34 (s, 2H), 1.34 (t, <i>J</i> = 7.0 Hz, 3H), 1.29 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.8, 150.6, 147.4, 146.4, 145.8, 144.7, 141.8, 136.7, 123.8, 115.9, 114.1, 111.9, 110.8, 105.0, 65.3, 63.6, 62.5, 51.1, 36.3, 28.3, 14.3, 14.2. MS (ESI) calcd for C<sub>24</sub>H<sub>28</sub>N<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 438.2, found: 438.1.</div></div><div id="sec4_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> Methyl 2-((3-((3-Cyanophenyl)amino)-6-ethoxy-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)acetate (<b>14c</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>6</b>, compound <b>14c</b> was prepared from <b>13c</b> (110 mg, 0.32 mmol), methyl chloroacetate (60 μL, 0.64 mmol), K<sub>2</sub>CO<sub>3</sub> (87 mg, 0.64 mmol) in 91% yield as a white solid, mp: 151–152 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.93 (s, 1H), 7.85 (s, 1H), 7.58 (d, <i>J</i> = 7.9 Hz, 1H), 7.39 (t, <i>J</i> = 7.9 Hz, 1H), 7.30 (s, 1H), 7.26 (s, 1H), 7.14 (d, <i>J</i> = 7.9 Hz, 1H), 4.89 (s, 2H), 4.09 (q, <i>J</i> = 6.9 Hz, 2H), 3.98 (s, 3H), 3.72 (s, 3H), 3.42 (s, 3H), 1.36 (t, <i>J</i> = 6.9 Hz, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.8, 148.9, 147.8, 147.0, 144.7, 144.0, 142.9, 130.4, 124.7, 121.7, 120.11, 119.9, 117.5, 113.1, 112.8, 111.9, 106.3, 66.5, 64.7, 52.1, 37.6, 29.1, 15.2. MS (ESI) calcd for C<sub>23</sub>H<sub>23</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 419.2, found: 419.4.</div></div><div id="sec4_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Methyl 3-((6-Ethoxy-7-(2-methoxy-2-oxoethoxy)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)benzoate (<b>14d</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>6</b>, compound <b>14d</b> was prepared from <b>13d</b> (60 mg, 0.16 mmol), methyl chloroacetate (28 μL, 0.32 mmol), K<sub>2</sub>CO<sub>3</sub> (44 mg, 0.32 mmol) in 71% yield as a white solid, mp: 136–137 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.71 (s, 1H), 7.89–7.86 (m, 2H), 7.62 (s, 1H), 7.33 (s, 1H), 7.29 (s, 1H), 7.26 (s, 1H), 4.89 (s, 2H), 4.09 (q, <i>J</i> = 6.9 Hz, 2H), 3.96 (s, 3H), 3.84 (s, 3H), 3.72 (s, 3H), 1.35 (t, <i>J</i> = 6.9 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.9, 167.2, 148.8, 147.8, 147.0, 144.5, 144.4, 143.0, 130.6, 129.6, 124.8, 119.9, 119.1, 115.8, 113.1, 112.9, 106.3, 66.5, 64.8, 52.5, 52.2, 37.5, 29.3, 15.2. MS (ESI) calcd for C<sub>24</sub>H<sub>26</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup>: 452.2, found: 452.5.</div></div><div id="sec4_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Ethyl 3-((6-Ethoxy-7-(2-methoxy-2-oxoethoxy)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)benzoate (<b>14e</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>6</b>, compound <b>14e</b> was prepared from <b>13e</b> (80 mg, 0.20 mmol), methyl chloroacetate (50 μL, 0.40 mmol), K<sub>2</sub>CO<sub>3</sub> (70 mg, 0.40 mmol) in 77% yield as a white solid, mp: 155–156 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.73 (s, 1H), 7.91 (s, 1H), 7.64 (d <i>J</i> = 7.3 Hz, 1H), 7.35–7.30 (m, 2H), 7.29 (s, 1H), 7.25 (s, 1H), 4.89 (s, 2H), 4.30 (q, <i>J</i> = 7.1 Hz, 2H), 4.08 (q, <i>J</i> = 7.0 Hz, 2H), 3.96 (s, 3H), 3.72 (s, 3H), 3.40 (s, 2H), 1.35 (t, <i>J</i> = 7.0 Hz, 3H), 1.32 (t, <i>J</i> = 7.1 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.9, 166.6, 148.7, 147.7, 146.9, 144.4, 144.3, 142.8, 130.8, 129.5, 124.7, 119.7, 119.0, 115.8, 112.9, 112.7, 106.1, 66.3, 64.6, 60.8, 52.2, 37.5, 29.3, 15.2, 14.6. MS (ESI) calcd for C<sub>25</sub>H<sub>27</sub>N<sub>3</sub>O<sub>6</sub>Na [M + Na]<sup>+</sup>: 480.2, found: 480.5.</div></div><div id="sec4_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Isopropyl 3-((6-Ethoxy-7-(2-methoxy-2-oxoethoxy)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)benzoate (<b>14f</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>6</b>, compound <b>14f</b> was prepared from <b>13f</b> (62 mg, 0.16 mmol), methyl chloroacetate (35 μL, 0.32 mmol), K<sub>2</sub>CO<sub>3</sub> (44 mg, 0.32 mmol) in 78% yield as a white solid, mp: 123–124 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.72 (s, 1H), 7.89 (s, 1H), 7.68–7.59 (m, 1H), 7.38–7.28 (m, 3H), 7.25 (s, 1H), 5.12 (hept, <i>J</i> = 6.2 Hz, 1H), 4.89 (s, 2H), 4.08 (q, <i>J</i> = 7.0 Hz, 2H), 3.96 (s, 3H), 3.72 (s, 3H), 3.40 (s, 2H), 1.35 (t, <i>J</i> = 7.0 Hz, 3H), 1.31 (d, <i>J</i> = 6.2 Hz, 6H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.9, 166.1, 148.7, 147.7, 146.9, 144.5, 144.3, 142.8, 131.2, 129.5, 124.7, 119.7, 119.0, 115.8, 112.9, 112.7, 106.2, 68.3, 66.4, 64.7, 52.2, 37.5, 29.4, 22.2, 15.3. MS (ESI) calcd for C<sub>26</sub>H<sub>30</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup>: 480.2, found: 480.2.</div></div><div id="sec4_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Methyl 2-((6-Ethoxy-1-methyl-3-((3-(methylcarbamoyl)phenyl)amino)-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)acetate (<b>14g</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>6</b>, compound <b>14g</b> was prepared from <b>13g</b> (30 mg, 0.08 mmol), methyl chloroacetate (0.01 mL, 0.16 mmol), K<sub>2</sub>CO<sub>3</sub> (21.9 mg, 0.16 mmol) in 86% yield as a white solid, mp: 136–137 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.60 (s, 1H), 8.32–8.27 (m, 2H), 7.64 (s, 1H), 7.47 (d, <i>J</i> = 7.6 Hz, 1H), 7.28 (t, <i>J</i> = 7.6 Hz, 1H), 7.24 (s, 1H), 7.14 (d, <i>J</i> = 7.6 Hz, 1H), 4.89 (s, 2H), 4.07 (q, <i>J</i> = 7.0 Hz, 2H), 3.94 (s, 3H), 3.71 (s, 3H), 3.36 (s, 2H), 2.74 (d, <i>J</i> = 4.4 Hz, 3H), 1.34 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.9, 167.6, 148.7, 147.6, 146.8, 144.5, 142.8, 135.7, 132.1, 132.0, 129.4, 124.6, 117.7, 116.6, 114.4, 112.7, 105.9, 66.2, 65.5, 52.2, 37.5, 30.4, 19.3, 14.0. MS (ESI) calcd for C<sub>24</sub>H<sub>27</sub>N<sub>4</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 451.2, found: 451.5.</div></div><div id="sec4_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 2-((6-Ethoxy-3-((4-ethoxyphenyl)amino)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)acetamide (<b>ID12</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>7</b>, compound <b>ID12</b> was prepared from <b>14b</b> (86 mg, 0.13 mmol), aqueous ammonia (25%, 2 mL) in 91% yield as a white solid, HPLC purity: 99.4%, mp: 198–200 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.13 (s, 1H), 7.52 (s, 1H), 7.38 (s, 2H), 7.27 (d, <i>J</i> = 9.0 Hz, 2H), 7.25 (s, 1H), 6.80 (d, <i>J</i> = 9.0 Hz, 2H), 4.53 (s, 2H), 4.09 (q, <i>J</i> = 7.0 Hz, 2H), 3.94 (q, <i>J</i> = 7.0 Hz, 1H), 3.91 (s, 3H), 1.37 (t, <i>J</i> = 7.0 Hz, 3H), 1.30 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.9, 151.6, 148.5, 147.8, 147.0, 145.7, 143.3, 137.7, 124.9, 116.9, 115.1, 112.6, 111.7, 107.4, 69.7, 64.5, 63.5, 37.3, 29.4, 15.3, 15.3. HRMS (ESI) calcd for C<sub>23</sub>H<sub>27</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 423.2027, found: 423.2034.</div></div><div id="sec4_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> 2-((3-((3-Cyanophenyl)amino)-6-ethoxy-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)acetamide (<b>ID13</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>7</b>, compound <b>ID13</b> was prepared from <b>14c</b> (30 mg, 0.07 mmol), aqueous ammonia (25%, 2 mL) in 95% yield as a white solid, HPLC purity: 96.0%, mp: 133–135 °C. 1H NMR (400 MHz, DMSO-<i>d</i>6) δ 8.93 (s, 1H), 8.93 (s, 1H), 7.86 (s, 1H), 7.86 (s, 1H), 7.58 (d, <i>J</i> = 7.2 Hz, 1H), 7.51 (s, 1H), 7.41–7.25 (m, 3H), 7.14 (d, <i>J</i> = 7.2 Hz, 1H), 4.54 (s, 2H), 4.10 (q, <i>J</i> = 6.9 Hz, 2H), 3.98 (s, 3H), 3.43 (s, 2H), 1.38 (t, <i>J</i> = 6.9 Hz, 3H); 13C NMR (100 MHz, DMSO-<i>d</i>6) δ 170.9, 148.8, 148.1, 147.2, 144.7, 144.0, 143.4, 130.5, 124.7, 121.7, 120.1, 119.9, 117.5, 112.7, 111.9, 107.6, 69.7, 64.7, 37.6, 29.2, 15.2. HRMS (ESI) calcd for C<sub>22</sub>H<sub>22</sub>N<sub>5</sub>O<sub>3</sub> [M + H] +: 404.1717, found: 404.1723.</div></div><div id="sec4_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Methyl 3-((7-(2-Amino-2-oxoethoxy)-6-ethoxy-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)benzoate (<b>ID14</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>7</b>, compound <b>ID14</b> was prepared from <b>14d</b> (1.1 g, 2.43 mmol), aqueous ammonia (25%, 10 mL) in 92% yield as a white solid, HPLC purity: 99.7%, mp: 216–217 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.72 (s, 1H), 7.94 (s, 1H), 7.62–7.59 (m, 1H), 7.51 (s, 1H), 7.40 (s, 1H), 7.32–7.28 (m, 3H), 7.27 (s, 1H), 4.53 (s, 2H), 4.17–4.03 (q, <i>J</i> = 7.0 Hz, 2H), 3.94 (s, 3H), 3.81 (s, 3H), 1.37 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.0, 167.2, 148.8, 148.0, 147.1, 144.4, 143.4, 130.6, 129.6, 124.8, 119.9, 119.1, 115.8, 112.8, 112.7, 110.2, 107.6, 69.7, 64.7, 52.5, 37.5, 29.4, 15.2. HRMS (ESI) calcd for C<sub>23</sub>H<sub>25</sub>N<sub>4</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 437.1819, found: 437.1823.</div></div><div id="sec4_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Ethyl 3-((7-(2-Amino-2-oxoethoxy)-6-ethoxy-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)benzoate (<b>ID15</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>7</b>, compound <b>ID15</b> was prepared from <b>14e</b> (40 mg, 0.08 mmol), aqueous ammonia (25%, 2 mL) in 84% yield as a white solid, HPLC purity: 99.2%, mp: 177–179 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.73 (s, 1H), 7.90 (s, 1H), 7.65–7.62 (m, 1H), 7.50 (s, 1H), 7.41 (s, 1H), 7.38–7.29 (m, 3H), 7.27 (s, 1H), 4.53 (s, 2H), 4.30 (q, <i>J</i> = 7.1 Hz, 2H), 4.10 (q, <i>J</i> = 6.9 Hz, 2H), 3.96 (s, 3H), 3.41 (s, 2H), 1.37 (t, <i>J</i> = 6.9 Hz, 3H), 1.32 (t, <i>J</i> = 7.1 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.9, 166.6, 148.7, 147.9, 147.1, 144.5, 144.3, 143.3, 130.8, 129.5, 124.7, 119.8, 119.0, 115.8, 112.7, 112.6, 107.5, 69.7, 64.5, 61.0, 37.5, 29.4, 15.2, 14.6. HRMS (ESI) calcd for C<sub>24</sub>H<sub>27</sub>N<sub>4</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 451.1976, found: 451.1984.</div></div><div id="sec4_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Isopropyl 3-((7-(2-Amino-2-oxoethoxy)-6-ethoxy-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)benzoate (<b>ID16</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>7</b>, compound <b>ID16</b> was prepared from <b>14f</b> (50 mg, 0.11 mmol), aqueous ammonia (25%, 2 mL) in 73% yield as a white solid, HPLC purity: 97.2%, mp: 179–181 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.76 (s, 1H), 7.89 (s, 1H), 7.68–7.61 (m, 1H), 7.53 (s, 1H), 7.41 (s, 1H), 7.39 (s, 1H), 7.36–7.29 (m, 2H), 7.27 (s, 1H), 5.12 (hept, <i>J</i> = 6.2 Hz, 1H), 4.54 (s, 2H), 4.10 (q, <i>J</i> = 7.0 Hz, 2H), 3.96 (s, 3H), 3.41 (s, 2H), 1.37 (t, <i>J</i> = 7.0 Hz, 3H), 1.32 (d, <i>J</i> = 6.2 Hz, 6H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.9, 166.1, 148.7, 147.8, 147.1, 144.5, 144.3, 143.3, 131.2, 129.5, 124.8, 119.6, 119.0, 115.8, 112.6, 112.6, 107.5, 69.6, 68.2, 64.6, 37.5, 29.4, 22.1, 15.2. HRMS (ESI) calcd for C<sub>25</sub>H<sub>29</sub>N<sub>4</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 465.2132, found: 465.2140.</div></div><div id="sec4_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> 3-((7-(2-Amino-2-oxoethoxy)-6-ethoxy-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)-<i>N</i>-methylbenzamide (<b>ID17</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>7</b>, compound <b>ID17</b> was prepared from <b>14g</b> (20 mg, 0.04 mmol), aqueous ammonia (25%, 2 mL) in 79% yield as a white solid, HPLC purity: 99.7%, mp: 196–197 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.61 (s, 1H), 8.34 (s, 1H), 7.65 (s, 1H), 7.54 (s, 1H), 7.49 (dd, <i>J</i> =8.0, 1.7, 1H), 7.40 (s, 2H), 7.28–7.23 (m, 2H), 7.15 (d, <i>J</i> = 8.0 Hz, 1H), 4.54 (s, 2H), 4.13–4.05 (m, 2H), 3.96 (s, 3H), 2.76 (s, 3H), 1.37 (t, <i>J</i> = 6.9, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.0, 167.7, 148.7, 148.0, 147.1, 144.6, 144.3, 143.4, 135.8, 129.1, 124.8, 117.81, 116.7, 114.5, 112.9, 112.7, 107.6, 69.7, 64.6, 37.5, 29.5, 26.7, 15.2. HRMS (ESI) calcd for C<sub>23</sub>H<sub>30</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 436.1979, found: 436.1983.</div></div><div id="sec4_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> <i>tert</i>-Butyl (3-((7-((<i>tert</i>-Butyldimethylsilyl)oxy)-6-ethoxy-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)phenyl)(ethyl)carbamate (<b>12h</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>4</b>, compound <b>12h</b> was prepared from <b>11</b> (400 mg, 1.31 mmol), LiHMDS (1.70 mL, 1.70 mmol), <i>tert</i>-butyl ethyl(3-isothiocyanatophenyl)carbamate (454 mg, 1.70 mmol), hydrazine hydrate (0.65 mL, 10.48 mmol), DIPEA (111 μL, 0.68 mmol), and dimethyl sulfate (63 μL, 0.68 mmol) in 13% yield as a white solid, mp: 172–173 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.45 (s, 1H), 7.24 (s, 1H), 7.20 (s, 1H), 7.17–7.13 (m, 2H), 7.11 (s, 1H), 6.64–6.49 (m, 1H), 4.05 (q, <i>J</i> = 7.0 Hz, 2H), 3.90 (s, 3H), 3.56 (q, <i>J</i> = 7.0 Hz, 2H), 3.39 (s, 2H), 1.39 (s, 9H), 1.36 (q, <i>J</i> = 7.0 Hz, 3H), 1.08 (t, <i>J</i> = 7.0 Hz, 3H), 1.00 (s, 9H), 0.17 (s, 6H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 154.0, 149.0, 148.6, 144.7, 144.5, 143.6, 143.1, 142.9, 129.1, 124.8, 116.6, 113.9, 113.0, 112.6, 112.0, 111.6, 79.4, 64.1, 37.5, 29.3, 28.4, 26.1, 18.7, 15.3, 14.2, −4.2. MS (ESI) calcd for C<sub>32</sub>H<sub>47</sub>N<sub>4</sub>O<sub>4</sub>Si [M + H]<sup>+</sup>: 579.3, found: 579.0.</div></div><div id="sec4_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> 7-((<i>tert</i>-Butyldimethylsilyl)oxy)-6-ethoxy-<i>N</i>-(3-(2-ethyl-1,3-dioxolan-2-yl)phenyl)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-amine (<b>12i</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>4</b>, compound <b>12i</b> was prepared from <b>11</b> (100 mg, 0.33 mmol), LiHMDS (0.59 mL, 0.59 mmol), 2-ethyl-2-(3-isothiocyanatophenyl)-1,3-dioxolane (138 mg, 0.59 mmol), hydrazine hydrate (0.17 mL, 2.64 mmol), DIPEA (40 μL, 0.24 mmol), and dimethyl sulfate (23 μL, 0.24 mmol) in 22% yield as a white solid, mp: 141–142 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.40 (s, 1H), 7.30 (d, <i>J</i> = 7.8, Hz, 1H), 7.20 (s, 1H), 7.20 (s, 1H), 7.15 (t, <i>J</i> = 7.8 Hz, 1H), 7.11 (s, 1H), 6.73 (d, <i>J</i> = 7.8 Hz, 1H), 4.05 (q, <i>J</i> = 7.0 Hz, 2H), 3.95 (t, <i>J</i> = 7.7 Hz, 2H), 3.90 (s, 3H), 3.71 (t, <i>J</i> = 7.7 Hz, 2H), 3.37 (s, 2H), 1.81 (q, <i>J</i> = 7.4 Hz, 2H), 1.37 (t, <i>J</i> = 7.0 Hz, 3H), 1.00 (s, 9H), 0.81 (t, <i>J</i> = 7.4 Hz, 4H), 0.17 (s, 6H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 149.1, 148.6, 144.7, 144.0, 143.6, 143.3, 142.8, 128.9, 124.8, 115.7, 114.6, 112.7, 112.6, 112.0, 111.6, 110.6, 64.6, 64.1, 37.4, 33.3, 29.5, 26.2, 26.1, 18.6, 15.2, 8.5, −4.1. MS (ESI) calcd for C<sub>30</sub>H<sub>42</sub>N<sub>3</sub>O<sub>4</sub>Si [M + H]<sup>+</sup>: 536.3, found: 536.2.</div></div><div id="sec4_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> 6-Ethoxy-3-((3-(ethylamino)phenyl)amino)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-ol (<b>13h</b>)</h3><div class="NLM_p last">Acetyl chloride (2.5 mL) was added to ethanol (5 mL) and stirred for 15 min. To the resulting solution (2 mL), <b>12h</b> (45 mg, 0.09 mmol) was added, and the mixture was stirred for 2 h. After concentration, the resulting mixture was adjusted to pH 7 by the addition of a saturated NaHCO<sub>3</sub> aqueous solution. The resulting precipitate was filtered, washed with hexane, and dried to give 55 mg (98%) of <b>13h</b> as a white solid, mp: 143–145 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.81 (s, 1H), 7.99 (s, 1H), 7.14 (s, 1H), 7.10 (s, 1H), 6.86 (t, <i>J</i> = 7.8 Hz, 1H), 6.59–6.35 (m, 2H), 5.97 (d, <i>J</i> = 7.8 Hz, 1H), 5.28 (t, <i>J</i> = 5.3 Hz, 1H), 4.05 (q, <i>J</i> = 7.0 Hz, 2H), 3.87 (s, 3H), 3.32 (s, 2H), 3.10–2.91 (m, 2H), 1.35 (t, <i>J</i> = 7.0 Hz, 3H), 1.15 (t, <i>J</i> = 7.1 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 149.0, 147.7, 145.1, 144.8, 143.9, 139.0, 128.4, 124.1, 114.2, 111.9, 111.5, 105.6, 103.2, 102.3, 98.2, 63.6, 36.8, 36.2, 28.5, 14.2, 13.9. MS (ESI) calcd for C<sub>21</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 365.2, found: 365.2.</div></div><div id="sec4_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> 1-(3-((6-Ethoxy-7-hydroxy-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)phenyl)propan-1-one (<b>13i</b>)</h3><div class="NLM_p last">Acetyl chloride (2.5 mL) was added to ethanol (5 mL) and stirred for 15 min. To the resulting solution (2 mL), <b>12i</b> (175 mg, 0.33 mmol) was added, and the mixture stirred for 2 h. After concentration, the resulting mixture was adjusted to pH 7 by the addition of a saturated NaHCO<sub>3</sub> aqueous solution. The resulting precipitate filtered, washed with hexane, and dried to give 110 mg (89%) of <b>13i</b> as a white solid, mp: 181–182 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.85 (s, 1H), 8.64 (s, 1H), 7.84 (s, 1H), 7.61 (s, 1H), 7.34 (s, 2H), 7.16 (s, 1H), 7.13 (s, 1H), 4.06 (q, <i>J</i> = 7.0 Hz, 2H), 3.92 (s, 3H), 3.35 (s, 2H), 3.00 (q, <i>J</i> = 6.8 Hz, 2H), 1.35 (t, <i>J</i> = 6.8 Hz, 3H), 1.09 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 201.1, 149.1, 146.3, 146.1, 144.5, 144.4, 140.1, 137.7, 129.5, 125.0, 119.7, 118.1, 114.2, 112.7, 112.6, 106.8, 64.7, 37.4, 31.7, 29.2, 15.3, 8.8. MS (ESI) calcd for C<sub>22</sub>H<sub>24</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 378.2, found: 378.3.</div></div><div id="sec4_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Methyl 2-((6-Ethoxy-3-((3-(ethylamino)phenyl)amino)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)acetate (<b>14h</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>6</b>, compound <b>14h</b> was prepared from <b>13h</b> (55 mg, 0.13 mmol), methyl chloroacetate (31 μL, 0.26 mmol), and K<sub>2</sub>CO<sub>3</sub> (48 mg, 0.26 mmol) in 81% yield as a white solid, mp: 147–148 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.03 (s, 1H), 7.26 (s, 1H), 7.23 (s, 1H), 6.87 (t, <i>J</i> = 8.2 Hz, 1H), 6.45–6.44 (m, 2H), 5.97 (d, <i>J</i> = 8.2 Hz, 1H), 5.28 (t, <i>J</i> = 5.3 Hz, 1H), 4.88 (s, 2H), 4.07 (q, <i>J</i> = 7.0 Hz, 2H), 3.92 (s, 3H), 3.72 (s, 3H), 3.36 (s, 2H), 3.18–2.91 (m, 2H), 1.34 (t, <i>J</i> = 7.0 Hz, 3H), 1.15 (t, <i>J</i> = 7.1 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.8, 149.0, 147.5, 146.5, 145.8, 144.0, 143.9, 141.8, 128.4, 123.8, 111.9, 111.8, 105.0, 103.2, 102.3, 98.3, 65.3, 63.6, 51.1, 36.8, 36.3, 28.7, 14.2, 13.9. MS (ESI) calcd for C<sub>24</sub>H<sub>29</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 437.2, found: 437.2.</div></div><div id="sec4_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Methyl 2-((6-Ethoxy-1-methyl-3-((3-propionylphenyl)amino)-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)acetate (<b>14i</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>6</b>, compound <b>14i</b> was prepared from <b>13i</b> (110 mg, 0.29 mmol), methyl chloroacetate (60 μL, 0.58 mmol), and K<sub>2</sub>CO<sub>3</sub> (80 mg, 0.58 mmol) in 85% yield as a white solid, mp: 133–134 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.68 (s, 1H), 7.86 (s, 1H), 7.65–7.59 (m, 1H), 7.39–7.31 (m, 2H), 7.29 (s, 1H), 7.25 (s, 1H), 4.89 (s, 2H), 4.08 (q, <i>J</i> = 7.0 Hz, 2H), 3.96 (s, 3H), 3.72 (s, 3H), 3.39 (s, 2H), 3.00 (q, <i>J</i> = 7.2 Hz, 2H), 1.35 (t, <i>J</i> = 7.0 Hz, 3H), 1.09 (t, <i>J</i> = 7.2 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 201.1, 169.9, 148.7, 147.7, 146.9, 144.5, 144.5, 142.9, 137.7, 129.5, 124.7, 119.8, 118.2, 114.4, 112.9, 112.7, 106.2, 66.4, 64.7, 52.2, 37.5, 31.7, 29.3, 15.3, 8.7. MS (ESI) calcd for C<sub>25</sub>H<sub>28</sub>N<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 450.2, found: 450.2.</div></div><div id="sec4_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> 2-((6-Ethoxy-3-((3-(ethylamino)phenyl)amino)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)acetamide (<b>ID18</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>7</b>, compound <b>ID18</b> was prepared from <b>14h</b> (40 mg, 0.09 mmol), aqueous ammonia (2 mL) in 92% yield as a white solid, HPLC purity: 99.5%, mp: 195–196 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.03 (s, 1H), 7.50 (s, 1H), 7.38 (s, 1H), 7.36 (s, 1H), 7.25 (s, 1H), 6.87 (t, <i>J</i> = 7.9 Hz, 1H), 6.48–6.40 (m, 2H), 5.98 (d, <i>J</i> = 7.9 Hz, 1H), 5.30 (s, 1H), 4.53 (s, 2H), 4.09 (q, <i>J</i> = 6.9 Hz, 2H), 3.92 (s, 3H), 3.37 (s, 3H), 2.99 (q, <i>J</i> = 6.5 Hz, 2H), 1.37 (t, <i>J</i> = 6.9 Hz, 3H), 1.15 (t, <i>J</i> = 6.5 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 175.7, 154.8, 153.2, 152.6, 151.9, 149.9, 149.7, 148.1, 134.2, 129.7, 117.7, 117.5, 112.3, 109.0, 108.2, 104.1, 74.5, 69.4, 42.6, 42.1, 34.5, 20.0, 19.8. MS (ESI) calcd for C<sub>23</sub>H<sub>27</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 422.2, found: 422.4.</div></div><div id="sec4_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> 2-((6-Ethoxy-1-methyl-3-((3-propionylphenyl)amino)-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)acetamide (<b>ID19</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>7</b>, compound <b>ID19</b> was prepared from <b>14i</b> (86 mg, 0.19 mmol), aqueous ammonia (2 mL) in 72% yield as a white solid, HPLC purity: 95.9%, mp: 218–219 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.71 (s, 1H), 7.87 (s, 1H), 7.67–7.59 (m, 1H), 7.53 (s, 1H), 7.41 (s, 1H), 7.38 (s, 1H), 7.36–7.31 (m, 2H), 7.27 (s, 1H), 4.54 (s, 2H), 4.10 (q, <i>J</i> = 7.0 Hz, 2H), 3.96 (s, 3H), 3.40 (s, 2H), 3.00 (q, <i>J</i> = 7.2 Hz, 2H), 1.37 (t, <i>J</i> = 7.0 Hz, 3H), 1.09 (t, <i>J</i> = 7.2 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 200.0, 169.8, 147.6, 146.9, 146.0, 143.4, 143.3, 142.2, 136.6, 128.4, 123.7, 118.6, 117.1, 113.1, 111.6, 111.5, 106.4, 68.6, 63.5, 36.4, 30.6, 28.3, 14.1, 7.6. HRMS (ESI) calcd for C<sub>24</sub>H<sub>27</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 435.2027, found: 435.2027.</div></div><div id="sec4_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> 2-((3-((3-Cyanophenyl)amino)-6-ethoxy-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)-<i>N</i>-methylacetamide (<b>ID20</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>7</b>, compound <b>ID20</b> was prepared from <b>14c</b> (30 mg, 0.07 mmol), aqueous methylamine solution (25%, 1 mL) in 83% yield as a white solid, HPLC purity: 96.5%, mp: 149–151 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.95 (s, 1H), 7.91 (s, 1H), 7.85 (s, 1H), 7.58 (d, <i>J</i> = 8.1 Hz, 1H), 7.41 (s, 1H), 7.39 (t, <i>J</i> = 8.1 Hz, 1H), 7.29 (s, 1H), 7.14 (d, <i>J</i> = 8.1 Hz, 1H), 4.56 (s, 2H), 4.11 (q, <i>J</i> = 7.0 Hz, 2H), 3.98 (s, 3H), 3.43 (s, 2H), 3.35 (s, 3H), 1.38 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.9, 148.8, 148.2, 147.1, 144.6, 144.0, 143.6, 130.5, 124.7, 121.7, 120.1, 119.9, 117.4, 114.3, 112.7, 111.9, 108.0, 70.2, 64.6, 37.6, 29.2, 25.8, 15.3. HRMS (ESI) calcd for C<sub>23</sub>H<sub>24</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 418.1874, found: 418.1883.</div></div><div id="sec4_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Methyl 3-((6-Ethoxy-1-methyl-7-(2-(methylamino)-2-oxoethoxy)-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)benzoate (<b>ID21</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>7</b>, compound <b>ID21</b> was prepared from <b>14d</b> (52 mg, 0.12 mmol), aqueous methylamine solution (25%, 2 mL) in 92% yield as a white solid, HPLC purity: 96.3%, mp: 184–186 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.72 (s, 1H), 7.90 (s, 2H), 7.63 (d, <i>J</i> = 7.3 Hz, 1H), 7.40 (t, <i>J</i> = 7.3 Hz, 1H), 7.32 (s, 1H), 7.26 (d, <i>J</i> = 7.3 Hz, 1H), 4.55 (s, 2H), 4.10 (q, <i>J</i> = 6.8 Hz, 2H), 3.95 (s, 3H), 3.83 (s, 3H), 3.40 (s, 2H), 2.71 (s, 3H), 1.37 (t, <i>J</i> = 6.8 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.0, 167.1, 148.72, 148.2, 147.1, 145.3, 144.4, 143.62, 130.6, 129.6, 124.8, 119.8, 119.1, 115.85, 112.8, 112.2, 108.1, 70.3, 64.6, 52.5, 37.5, 29.4, 25.8, 15.3. HRMS (ESI) calcd for C<sub>24</sub>H<sub>27</sub>N<sub>4</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 451.1976, found: 451.1985.</div></div><div id="sec4_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> 7-((<i>tert</i>-Butyldimethylsilyl)oxy)-6-ethoxy-<i>N</i>-(6-ethoxypyridin-2-yl)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-amine (12j)</h3><div class="NLM_p last">Following the procedures described for preparing <b>4</b>, compound <b>12j</b> was prepared from <b>11</b> (220 mg, 0.72 mmol), LiHMDS (1.44 mL, 1.44 mmol), 2-ethoxy-6-isothiocyanatopyridine (274 mg, 1.44 mmol), hydrazine hydrate (0.36 mL, 5.76 mmol), DIPEA (76 μL, 0.46 mmol), and dimethyl sulfate (45 μL, 0.46 mmol) in 20% yield as a white solid, mp: 147–148 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.88 (s, 1H), 7.46 (t, <i>J</i> = 7.9 Hz, 1H), 7.20 (s, 1H), 7.11 (s, 1H), 6.90 (d, <i>J</i> = 7.9 Hz, 1H), 6.09 (d, <i>J</i> = 7.9 Hz, 1H), 4.22 (q, <i>J</i> = 7.0 Hz, 2H), 4.04 (q, <i>J</i> = 7.0 Hz, 2H), 3.91 (s, 3H), 3.46 (s, 2H), 1.36 (t, <i>J</i> = 7.0 Hz, 3H), 1.29 (t, <i>J</i> = 7.0 Hz, 3H), 1.00 (s, 9H), 0.16 (s, 6H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 162.9, 154.4, 149.0, 148.6, 143.5, 142.9, 142.9, 140.6, 124.7, 114.4, 112.0, 111.6, 101.1, 99.0, 64.1, 61.2, 37.4, 30.0, 26.1, 18.6, 15.2, 15.2, −4.1. MS (ESI) calcd for C<sub>26</sub>H<sub>37</sub>N<sub>4</sub>O<sub>3</sub>Si [M + H]<sup>+</sup>: 481.2, found: 481.5.</div></div><div id="sec4_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> 6-Ethoxy-3-((6-ethoxypyridin-2-yl)amino)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-ol (<b>13j</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>5</b>, compound <b>13j</b> was prepared from <b>12j</b> (120 mg, 0.25 mmol) and TBAF (110 mg, 0.50 mmol) in 81% yield as a white solid, mp: 201–202 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.86 (s, 1H), 8.82 (s, 1H), 7.46 (t, <i>J</i> = 7.9 Hz, 1H), 7.14 (s, 1H), 7.12 (s, 1H), 6.92 (d, <i>J</i> = 7.9 Hz, 1H), 6.09 (d, <i>J</i> = 7.9 Hz, 1H), 4.23 (q, <i>J</i> = 7.0 Hz, 2H), 4.06 (q, <i>J</i> = 7.0 Hz, 2H), 3.91 (s, 3H), 3.42 (s, 2H), 1.35 (t, <i>J</i> = 7.0 Hz, 3H), 1.29 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 162.9, 154.5, 148.8, 146.2, 146.0, 142.9, 140.6, 140.1, 125.1, 114.5, 112.5, 106.7, 101.0, 99.0, 64.6, 61.2, 37.3, 29.8, 15.3, 15.2. MS (ESI) calcd for C<sub>20</sub>H<sub>23</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 367.2, found: 367.1.</div></div><div id="sec4_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> Methyl 2-((6-Ethoxy-3-((6-ethoxypyridin-2-yl)amino)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)acetate (<b>14j</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>6</b>, compound <b>14j</b> was prepared from <b>13j</b> (74 mg, 0.20 mmol), methyl chloroacetate (60 μL, 0.40 mmol), and K<sub>2</sub>CO<sub>3</sub> (55 mg, 0.40 mmol) in 81% yield as a white solid, mp: 111–112 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.89 (s, 1H), 7.47 (t, <i>J</i> = 7.9 Hz, 1H), 7.27 (s, 1H), 7.23 (s, 1H), 6.92 (d, <i>J</i> = 7.9 Hz, 1H), 6.09 (d, <i>J</i> = 7.9 Hz, 1H), 4.88 (s, 2H), 4.23 (q, <i>J</i> = 7.0 Hz, 2H), 4.08 (q, <i>J</i> = 7.0 Hz, 2H), 3.95 (s, 3H), 3.72 (s, 3H), 3.46 (s, 2H), 1.35 (t, <i>J</i> = 7.0 Hz, 3H), 1.29 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.9, 162.9, 154.4, 148.6, 147.6, 146.8, 143.0, 142.9, 140.6, 124.7, 114.5, 112.8, 106.1, 101.1, 99.0, 66.4, 64.6, 61.2, 52.2, 37.5, 30.0, 15.3, 15.2. MS (ESI) calcd for C<sub>23</sub>H<sub>27</sub>N<sub>4</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 439.2, found: 439.3.</div></div><div id="sec4_66" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> 2-((6-Ethoxy-3-((6-ethoxypyridin-2-yl)amino)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)acetamide (<b>ID22</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>7</b>, compound <b>ID22</b> was prepared from <b>14j</b> (70 mg, 0.16 mmol), aqueous ammonia (2 mL) in 82% yield as a white solid, HPLC purity: 98.1%, mp: 148–149 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.91 (s, 1H), 7.50 (s, 1H), 7.47 (t, <i>J</i> = 7.9 Hz, 1H), 7.39 (s, 1H), 7.36 (s, 1H), 7.25 (s, 1H), 6.92 (d, <i>J</i> = 7.9 Hz, 1H), 6.09 (d, <i>J</i> = 7.9 Hz, 1H), 4.53 (s, 2H), 4.22 (q, <i>J</i> = 7.0 Hz, 2H), 4.10 (q, <i>J</i> = 7.0 Hz, 2H), 3.95 (s, 3H), 3.47 (s, 2H), 1.37 (t, <i>J</i> = 7.0 Hz, 3H), 1.29 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.9, 162.9, 154.4, 148.5, 147.9, 147.0, 143.4, 143.0, 140.6, 124.8, 114.4, 112.5, 107.5, 101.1, 99.1, 69.7, 64.6, 61.2, 37.4, 30.1, 15.3, 15.2. HRMS (ESI) calcd for C<sub>22</sub>H<sub>26</sub>N<sub>5</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 424.1979, found: 424.1984.</div></div><div id="sec4_67" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> 3-((6-Ethoxy-7-(3-(methoxymethoxy)propoxy)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)benzonitrile (<b>18b</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>4</b>, compound <b>18b</b> was prepared from <b>17</b> (0.40 g, 1.36 mmol), NaH (220 mg, 5.44 mmol), 3-isothiocyanatobenzonitrile (0.327 g, 2.04 mmol), hydrazine hydrate (0.47 mL, 8.0 mmol), DIPEA (104 μL, 0.63 mmol), and dimethyl sulfate (61 μL, 0.63 mmol) in 14% yield as a yellow solid, mp: 122–124 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.92 (s, 1H), 7.88 (s, 1H), 7.58 (d, <i>J</i> = 8.0 Hz, 1H), 7.39 (t, <i>J</i> = 8.0 Hz, 1H), 7.33 (s, 1H), 7.23 (s, 1H), 7.14 (d, <i>J</i> = 8.0 Hz, 1H), 4.59 (s, 2H), 4.15 (t, <i>J</i> = 6.3 Hz, 2H), 4.06 (q, <i>J</i> = 7.0 Hz, 2H), 3.99 (s, 3H), 3.67 (t, <i>J</i> = 6.3 Hz, 2H), 3.41 (s, 2H), 3.25 (s, 3H), 2.05–1.95 (m, 2H), 1.35 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 149.1, 148.1, 148.0, 144.7, 143.9, 142.1, 130.5, 124.9, 121.7, 120.1, 119.9, 117.4, 113.0, 112.7, 111.9, 106.1, 96.2, 66.7, 64.70, 64.2, 55.0, 37.6, 29.8, 29.1, 15.3. MS (ESI) calcd for C<sub>25</sub>H<sub>29</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 449.2, found: 449.5.</div></div><div id="sec4_68" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> Methyl 3-((6-Ethoxy-7-(3-(methoxymethoxy)propoxy)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)benzoate (<b>18c</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>4</b>, compound <b>18c</b> was prepared from <b>17</b> (500 mg, 1.70 mmol), LiHMDS (2.50 mL, 2.50 mmol), methyl 3-isothiocyanatobenzoate (490 mg, 2.5 mmol), hydrazine hydrate (0.85 mL, 13.6 mmol), DIPEA (212 μL, 1.28 mmol), and dimethyl sulfate (124 μL, 1.28 mmol) in 19% yield as a yellow solid, mp: 117–119 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.71 (s, 1H), 7.90 (s, 1H), 7.68–7.57 (dt, <i>J</i> = 7.5, 2.0 Hz, 1H), 7.41–7.28 (m, 3H), 7.21 (s, 1H), 4.59 (s, 2H), 4.15 (t, <i>J</i> = 6.3 Hz, 2H), 4.06 (q, <i>J</i> = 7.0 Hz, 2H), 3.98 (s, 3H), 3.84 (s, 3H), 3.66 (t, <i>J</i> = 6.3 Hz, 2H), 3.38 (s, 2H), 3.25 (s, 3H), 2.00 (p, <i>J</i> = 6.3 Hz, 2H), 1.34 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.1, 148.9, 148.1, 147.9, 144.5, 144.3, 142.1, 130.6, 129.6, 125.0, 119.8, 118.9, 115.8, 113.0, 112.7, 106.1, 96.1, 66.6, 64.7, 64.2, 55.0, 52.4, 37.6, 29.8, 29.2, 15.3. MS (ESI) calcd for C<sub>26</sub>H<sub>32</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup>: 482.2, found: 482.1.</div></div><div id="sec4_69" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> Ethyl 3-((6-Ethoxy-7-(3-(methoxymethoxy)propoxy)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)benzoate (<b>18d</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>4</b>, compound <b>18d</b> was prepared from <b>17</b> (500 mg, 1.70 mmol), LiHMDS (5.1 mL, 5.10 mmol), ethyl 3-isothiocyanatobenzoate (1.0 g, 5.10 mmol), hydrazine hydrate (0.85 mL, 13.6. mmol), DIPEA (185 μL, 1.12 mmol), and dimethyl sulfate (108 μL, 1.12 mmol) in 13% yield as a yellow solid, mp: 138–139 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.72 (s, 1H), 7.91 (s, 1H), 7.65 (dt, <i>J</i> = 7.3, 2.2 Hz, 1H), 7.45–7.27 (m, 3H), 7.21 (s, 1H), 4.59 (s, 2H), 4.30 (q, <i>J</i> = 7.1 Hz, 2H), 4.15 (t, <i>J</i> = 6.3 Hz, 2H), 4.06 (q, <i>J</i> = 6.9 Hz, 2H), 3.98 (s, 3H), 3.67 (t, <i>J</i> = 6.3 Hz, 2H), 3.39 (s, 2H), 3.26 (s, 3H), 2.00 (p, <i>J</i> = 6.3 Hz, 2H), 1.35 (t, <i>J</i> = 6.9 Hz, 3H), 1.32 (t, <i>J</i> = 7.1 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.6, 148.9, 148.0, 147.9, 144.4, 144.3, 142.1, 130.8, 129.5, 125.0, 119.7, 118.9, 115.8, 112.9, 112.6, 106.1, 96.1, 66.6, 64.7, 64.1, 60.9, 55.0, 37.5, 29.8, 29.3, 15.3, 14.6. MS (ESI) calcd for C<sub>27</sub>H<sub>34</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup>: 496.2, found: 496.2.</div></div><div id="sec4_70" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> Isopropyl 3-((6-Ethoxy-7-(3-(methoxymethoxy)propoxy)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)benzoate (<b>18e</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>4</b>, compound <b>18e</b> was prepared from <b>17</b> (500 mg, 1.70 mmol), LiHMDS (4.25 mL, 4.25 mmol), isopropyl 3-isothiocyanatobenzoate (930 mg, 5.10 mmol), hydrazine hydrate (0.85 mL, 13.6. mmol), DIPEA (234 μL, 1.42 mmol), and dimethyl sulfate (138 μL, 1.42 mmol) in 23% yield as a yellow solid, mp: 120–121 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.72 (s, 1H), 7.89 (s, 1H), 7.69 (dd, <i>J</i> = 7.6, 1.8 Hz, 1H), 7.40–7.27 (m, 3H), 7.21 (s, 1H), 5.13 (hept, <i>J</i> = 6.3 Hz, 1H), 4.59 (s, 2H), 4.15 (t, <i>J</i> = 6.3 Hz, 2H), 4.06 (q, <i>J</i> = 7.0 Hz, 2H), 3.98 (s, 3H), 3.67 (t, <i>J</i> = 6.3 Hz, 2H), 3.39 (s, 2H), 3.34 (s, 3H), 2.00 (p, <i>J</i> = 6.3 Hz, 2H), 1.34 (t, <i>J</i> = 7.0 Hz, 3H), 1.32 (d, <i>J</i> = 6.3 Hz, 6H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.1, 148.9, 148.1, 147.9, 144.4, 144.4, 142.1, 131.2, 129.4, 125.0, 119.6, 118.9, 115.7, 112.9, 112.6, 106.0, 96.1, 68.2, 66.6, 64.7, 64.2, 55.0, 37.5, 29.8, 29.3, 22.1, 15.3. MS (ESI) calcd for C<sub>28</sub>H<sub>36</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup>: 510.3, found: 510.1.</div></div><div id="sec4_71" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> 3-((6-Ethoxy-7-(3-(methoxymethoxy)propoxy)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)-<i>N</i>-methylbenzamide (<b>18f</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>4</b>, compound <b>18f</b> was prepared from <b>17</b> (250 mg, 0.85 mmol), LiHMDS (1.28 mL, 1.28 mmol), 3-isothiocyanato-<i>N</i>-methylbenzamide (245 mg, 1.28 mmol), hydrazine hydrate (0.43 mL, 6.80 mmol), DIPEA (89 μL, 0.54 mmol), and dimethyl sulfate (52 μL, 0.54 mmol) in 15% yield as a yellow solid, mp: 162–164 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.56 (s, 1H), 8.27 (dd, <i>J</i> = 8.0, 1.7 Hz, 1H), 7.65 (t, <i>J</i> = 1.7 Hz, 1H), 7.47 (dd, <i>J</i> = 8.0, 1.7 Hz, 1H), 7.32 (s, 1H), 7.25 (t, <i>J</i> = 8.0 Hz, 1H), 7.20 (s, 1H), 7.15 (d, <i>J</i> = 8.0 Hz, 1H), 4.58 (s, 2H), 4.14 (t, <i>J</i> = 6.3 Hz, 2H), 4.05 (q, <i>J</i> = 7.0 Hz, 2H), 3.97 (s, 3H), 3.66 (t, <i>J</i> = 6.3 Hz, 2H), 3.36 (s, 3H), 2.76 (d, <i>J</i> = 4.5 Hz, 3H), 2.00 (p, <i>J</i> = 6.2 Hz, 2H), 1.34 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.6, 147.8, 146.9, 146.8, 143.4, 143.2, 141.0, 134.7, 127.9, 123.9, 116.7, 115.5, 113.4, 111.9, 111.7, 105.0, 95.1, 65.6, 63.6, 63.1, 53.9, 36.4, 28.7, 28.3, 25.6, 14.2. MS (ESI) calcd for C<sub>26</sub>H<sub>33</sub>N<sub>4</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 481.2, found: 481.2.</div></div><div id="sec4_72" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> 6-Ethoxy-<i>N</i>-(3-(2-ethyl-1,3-dioxolan-2-yl)phenyl)-7-(3-(methoxymethoxy)propoxy)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-amine (<b>18g</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>4</b>, compound <b>18g</b> was prepared from <b>17</b> (250 mg, 0.85 mmol), LiHMDS (1.70 mL, 1.70 mmol), 2-ethyl-2-(3-isothiocyanatophenyl)-1,3-dioxolane (399 mg, 1.70 mmol), hydrazine hydrate (0.41 mL, 6.80 mmol), DIPEA (123 μL, 0.74 mmol), and dimethyl sulfate (72 μL, 0.74 mmol) in 21% yield as a yellow solid, mp: 162–164 °C°C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.41 (s, 1H), 7.37–7.27 (m, 2H), 7.21 (s, 1H), 7.20 (s, 1H), 7.16 (t, <i>J</i> = 7.8 Hz, 1H), 6.73 (d, <i>J</i> = 7.8 Hz, 1H), 4.58 (s, 2H), 4.14 (t, <i>J</i> = 6.3 Hz, 2H), 4.05 (q, <i>J</i> = 7.0 Hz, 2H), 3.99–3.91 (m, 5H), 3.71 (dd, <i>J</i> = 7.6, 6.1 Hz, 2H), 3.66 (t, <i>J</i> = 6.3 Hz, 2H), 3.36 (s, 2H), 3.25 (s, 3H), 1.99 (p, <i>J</i> = 6.3 Hz, 2H), 1.81 (q, <i>J</i> = 7.4 Hz, 2H), 1.34 (t, <i>J</i> = 7.0 Hz, 3H), 0.81 (t, <i>J</i> = 7.4 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 147.7, 146.9, 146.8, 143.6, 142.9, 142.2, 141.0, 127.8, 124.0, 114.6, 113.5, 111.9, 111.6, 109.5, 105.0, 95.1, 65.6, 63.6, 63.5, 63.1, 53.9, 36.4, 32.2, 28.7, 28.3, 14.2, 7.4. MS (ESI) calcd for C<sub>29</sub>H<sub>38</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup>: 524.3, found: 524.3.</div></div><div id="sec4_73" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> 3-((6-Ethoxy-7-(3-hydroxypropoxy)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)benzonitrile (<b>ID23</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>ID08</b>, compound <b>ID23</b> was prepared from <b>18b</b> (70 mg, 0.16 mmol) and CSA methanol solution (1 M, 4 mL) in 83% yield as a white solid, HPLC purity: 96.6%, mp: 170–172 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.93 (s, 1H), 7.85 (s, 1H), 7.58 (d, <i>J</i> = 8.0 Hz, 1H), 7.39 (t, <i>J</i> = 8.0 Hz, 1H), 7.33 (s, 1H), 7.22 (s, 1H), 7.14 (d, <i>J</i> = 8.0 Hz, 1H), 4.14 (t, <i>J</i> = 6.4 Hz, 2H), 4.06 (q, <i>J</i> = 7.0 Hz, 2H), 4.00 (s, 3H), 3.40 (s, 2H), 1.90 (p, <i>J</i> = 6.3 Hz, 2H), 1.35 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 149.2, 148.2, 147.9, 144.7, 143.9, 141.8, 130.5, 124.9, 121.7, 120.1, 119.9, 117.5, 112.9, 112.7, 111.9, 105.4, 66.7, 64.7, 58.0, 37.59, 32.8, 29.1, 15.3. HRMS (ESI) calcd for C<sub>23</sub>H<sub>25</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 405.1921, found: 405.1928.</div></div><div id="sec4_74" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> Methyl 3-((6-Ethoxy-7-(3-hydroxypropoxy)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)benzoate (<b>ID24</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>ID08</b>, compound <b>ID24</b> was prepared from <b>18c</b> (26 mg, 0.05 mmol) and CSA methanol solution (1 M, 2 mL) in 63% yield as a white solid, HPLC purity: 99.4%, mp: 164–165 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.71 (s, 1H), 7.91 (s, 1H), 7.65 (dd, <i>J</i> = 7.0, 2.0 Hz, 1H), 7.38–7.28 (m, 3H), 7.21 (s, 1H), 4.14 (t, <i>J</i> = 6.4 Hz, 2H), 4.05 (q, <i>J</i> = 7.0 Hz, 2H), 3.98 (s, 3H), 3.84 (s, 3H), 3.61 (t, <i>J</i> = 6.3 Hz, 2H), 3.38 (s, 2H), 1.93–1.86 (m, 2H), 1.34 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.1, 149.1, 148.2, 147.8, 144.5, 144.3, 141.8, 130.6, 129.5, 124.9, 119.8, 119.0, 115.8, 112.8, 112.7, 105.6, 66.6, 64.6, 58.0, 52.4, 37.5, 32.8, 29.2, 15.3. HRMS (ESI) calcd for C<sub>25</sub>H<sub>30</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 438.2038, found: 438.2023.</div></div><div id="sec4_75" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> Ethyl 3-((6-Ethoxy-7-(3-hydroxypropoxy)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)benzoate (<b>ID25</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>ID08</b>, compound <b>ID25</b> was prepared from <b>18d</b> (60 mg, 0.12 mmol) and CSA methanol solution (1 M, 2 mL) in 85% yield as a white solid, HPLC purity: 95.2%, mp: 169–170 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.74 (s, 1H), 7.90 (s, 1H), 7.65 (dt, <i>J</i> = 7.5, 1.8 Hz, 1H), 7.40–7.25 (m, 3H), 7.21 (s, 1H), 4.56 (t, <i>J</i> = 6.1 Hz, 1H), 4.30 (q, <i>J</i> = 7.1 Hz, 2H), 4.14 (t, <i>J</i> = 6.4 Hz, 2H), 4.05 (q, <i>J</i> = 6.9 Hz, 2H), 3.98 (s, 3H), 3.61 (q, <i>J</i> = 6.1 Hz, 2H), 3.38 (s, 2H), 1.90 (p, <i>J</i> = 6.1 Hz, 2H), 1.34 (t, <i>J</i> = 6.9 Hz, 3H), 1.32 (t, <i>J</i> = 7.1 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.6, 149.0, 148.1, 147.7, 144.4, 144.3, 141.7, 130.8, 129.5, 124.9, 119.7, 118.9, 115.7, 112.7, 112.6, 105.5, 66.5, 64.6, 60.9, 58.0, 37.5, 32.8, 29.3, 15.3, 14.6. HRMS (ESI) calcd for C<sub>25</sub>H<sub>30</sub>N<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 452.2180, found: 452.2187.</div></div><div id="sec4_76" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> Isopropyl 3-((6-Ethoxy-7-(3-hydroxypropoxy)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)benzoate (<b>ID26</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>ID08</b>, compound <b>ID26</b> was prepared from <b>18e</b> (60 mg, 0.12 mmol) and CSA methanol solution (1 M, 2 mL) in 83% yield as a white solid, HPLC purity: 97.9%, mp: 159–160 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.74 (s, 1H), 7.88 (s, 1H), 7.65 (d, <i>J</i> = 7.7 Hz, 1H), 7.37–7.27 (m, 3H), 7.21 (s, 1H), 5.12 (hept, <i>J</i> = 6.2 Hz, 1H), 4.56 (t, <i>J</i> = 6.3 Hz, 1H), 4.14 (t, <i>J</i> = 6.3 Hz, 2H), 4.05 (q, <i>J</i> = 7.0 Hz, 2H), 3.97 (s, 3H), 3.61 (q, <i>J</i> = 6.3 Hz, 2H), 3.39 (s, 2H), 1.90 (p, <i>J</i> = 6.3 Hz, 2H), 1.34 (t, <i>J</i> = 7.0 Hz, 3H), 1.31 (d, <i>J</i> = 6.2 Hz, 6H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.1, 148.9, 148.1, 147.7, 144.3, 141.7, 131.2, 129.5, 124.9, 119.6, 118.9, 115.7, 112.7, 112.5, 105.5, 68.3, 66.6, 64.6, 58.0, 37.6, 32.8, 29.3, 26.8, 22.2, 15.3. HRMS (ESI) calcd for C<sub>26</sub>H<sub>32</sub>N<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 466.2336, found: 466.2342.</div></div><div id="sec4_77" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> 3-((6-Ethoxy-7-(3-hydroxypropoxy)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)-<i>N</i>-methylbenzamide (<b>ID27</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>ID08</b>, compound <b>ID27</b> was prepared from <b>18f</b> (48 mg, 0.10 mmol) and CSA methanol solution (1 M, 2 mL) in 72% yield as a white solid, HPLC purity: 95.7%, mp: 219–220 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.56 (s, 1H), 8.28 (s, 1H), 7.65 (s, 1H), 7.48 (d, <i>J</i> = 7.7 Hz, 1H), 7.32 (s, 1H), 7.26 (t, <i>J</i> = 7.7 Hz, 1H), 7.20 (s, 1H), 7.15 (d, <i>J</i> = 7.7 Hz, 1H), 4.55 (s, 1H), 4.14 (t, <i>J</i> = 6.0 Hz, 2H), 4.05 (q, <i>J</i> = 6.6 Hz, 2H), 3.97 (s, 3H), 3.61 (t, <i>J</i> = 6.0 Hz, 2H), 3.36 (s, 3H), 2.76 (s, 3H), 1.91 (p, <i>J</i> = 6.0 Hz, 1H), 1.34 (t, <i>J</i> = 6.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.7, 149.0, 148.1, 147.7, 144.5, 144.4, 141.8, 135.8, 129.0, 125.0, 117.7, 116.6, 114.5, 112.9, 112.8, 105.6, 66.7, 64.6, 58.0, 37.5, 32.8, 29.4, 26.7, 15.3. HRMS (ESI) calcd for C<sub>24</sub>H<sub>29</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 437.2183, found: 437.2180.</div></div><div id="sec4_78" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> 1-(3-((6-Ethoxy-7-(3-hydroxypropoxy)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)phenyl)propan-1-one (<b>ID28</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>ID08</b>, compound <b>ID28</b> was prepared from <b>18g</b> (30 mg, 0.06 mmol) and CSA methanol solution (1 M, 2 mL) in 67% yield as a white solid, HPLC purity: 95.2%, mp: 218–220 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.75 (s, 1H), 7.85 (s, 1H), 7.62 (dt, <i>J</i> = 7.0, 2.0 Hz, 1H), 7.43–7.29 (m, 3H), 7.21 (s, 1H), 4.14 (t, <i>J</i> = 6.3 Hz, 2H), 4.05 (q, <i>J</i> = 7.0 Hz, 2H), 3.98 (s, 3H), 3.61 (t, <i>J</i> = 6.3 Hz, 2H), 3.38 (s, 2H), 3.01 (q, <i>J</i> = 7.2 Hz, 2H), 1.90 (p, <i>J</i> = 6.3 Hz, 2H), 1.34 (t, <i>J</i> = 7.0 Hz, 3H), 1.09 (t, <i>J</i> = 7.2 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 201.0, 149.2, 148.1, 147.8, 144.3, 144.2, 141.8, 137.6, 129.5, 124.7, 119.8, 118.3, 114.3, 112.7, 112.4, 105.5, 66.6, 64.5, 57.9, 37.5, 32.7, 31.6, 29.3, 15.3, 8.7. HRMS (ESI) calcd for C<sub>25</sub>H<sub>30</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 436.2231, found: 436.2240.</div></div><div id="sec4_79" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> 3-((6-Ethoxy-7-(3-hydroxypropoxy)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)benzoic acid (<b>ID29</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>ID07</b>, compound <b>ID24</b> was prepared from <b>ID29</b> (25 mg, 0.06 mmol) and LiOH aqueous solution (1 M, 1.5 mL) in 83% yield as a white solid, HPLC purity: 97.8%, mp: 234–235 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.69 (s, 1H), 7.86 (s, 1H), 7.61–7.51 (m, 1H), 7.32 (s, 1H), 7.32 (s, 1H), 7.31 (s, 1H), 7.21 (s, 1H), 4.14 (t, <i>J</i> = 6.3 Hz, 2H), 4.05 (q, <i>J</i> = 7.0 Hz, 2H), 3.98 (s, 3H), 3.61 (t, <i>J</i> = 6.3 Hz, 2H), 3.37 (s, 2H), 1.90 (p, <i>J</i> = 6.3 Hz, 2H), 1.34 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.2, 149.1, 148.1, 147.7, 144.3, 144.2, 141.7, 131.6, 129.4, 124.8, 119.5, 119.3, 116.0, 112.7, 112.6, 105.5, 66.5, 64.5, 57.9, 37.5, 32.7, 29.3, 15.3. HRMS (ESI) calcd for C<sub>23</sub>H<sub>26</sub>N<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 424.1867, found: 424.1870.</div></div><div id="sec4_80" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> 6-Ethoxy-<i>N</i>-(6-ethoxypyridin-2-yl)-7-(3-(methoxymethoxy)propoxy)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-amine (<b>18h</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>4</b>, compound <b>18h</b> was prepared from <b>17</b> (400 mg, 1.36 mmol l), LiHMDS (2.00 mL, 2.00 mmol), 2-ethyl-2-(3-isothiocyanatophenyl)-1,3-dioxolane (367 mg, 2.00 mmol), hydrazine hydrate (l0.68 mL, 10.88 mmol), DIPEA (174 μL, 0.10 mmol), and dimethyl sulfate (98 μL, 0.10 mmol) in 17% yield as a yellow solid, mp: 98–99 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.88 (s, 1H), 7.47 (t, <i>J</i> = 7.9 Hz, 1H), 7.31 (s, 1H), 7.19 (s, 1H), 6.92 (d, <i>J</i> = 7.9 Hz, 1H), 6.09 (d, <i>J</i> = 7.9 Hz, 1H), 4.58 (s, 2H), 4.23 (q, <i>J</i> = 7.0 Hz, 2H), 4.14 (t, <i>J</i> = 6.3 Hz, 2H), 4.05 (q, <i>J</i> = 7.0 Hz, 2H), 3.96 (s, 3H), 3.66 (t, <i>J</i> = 6.3 Hz, 2H), 3.45 (s, 2H), 3.33 (s, 3H), 1.99 (p, <i>J</i> = 6.3 Hz, 2H), 1.34 (t, <i>J</i> = 7.0 Hz, 3H), 1.29 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 162.9, 154.4, 148.8, 148.0, 147.9, 142.9, 142.2, 140.6, 125.0, 114.5, 112.9, 106.0, 101.1, 99.1, 96.1, 66.6, 64.7, 64.2, 61.2, 55.0, 37.5, 29.9, 29.8, 15.3, 15.2. MS (ESI) calcd for C<sub>25</sub>H<sub>33</sub>N<sub>4</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 469.2, found: 469.6.</div></div><div id="sec4_81" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> 3-((6-Ethoxy-3-((6-ethoxypyridin-2-yl)amino)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)propan-1-ol (<b>ID30</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>ID08</b>, compound <b>ID30</b> was prepared from <b>18h</b> (60 mg, 0.13 mmol) and CSA methanol solution (1 M, 2 mL) in 74% yield as a white solid, HPLC purity: 99.0%, mp: 157–159 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.83 (s, 1H), 7.38 (t, <i>J</i> = 7.8 Hz, 1H), 7.22 (s, 1H), 7.10 (s, 1H), 6.84 (d, <i>J</i> = 7.8 Hz, 1H), 6.01 (d, <i>J</i> = 7.8 Hz, 1H), 4.47 (s, 1H), 4.14 (q, <i>J</i> = 6.7 Hz, 2H), 4.04 (t, <i>J</i> = 5.3 Hz, 2H), 3.96 (q, <i>J</i> = 6.9 Hz, 2H), 3.88 (s, 3H), 3.52 (q, <i>J</i> = 5.3 Hz, 2H), 3.36 (s, 2H), 1.82 (p, <i>J</i> = 5.3 Hz, 2H), 1.25 (t, <i>J</i> = 6.7 Hz, 3H), 1.20 (t, <i>J</i> = 6.9 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 162.9, 154.4, 148.8, 148.0, 147.7, 142.9, 141.8, 140.6, 124.9, 114.4, 112.7, 105.4, 101.1, 99.0, 66.6, 64.6, 61.2, 58.0, 37.5, 32.8, 29.9, 15.3, 15.2. HRMS (ESI) calcd for C<sub>23</sub>H<sub>29</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 425.2183, found: 425.2193.</div></div><div id="sec4_82" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> <i>tert</i>-Butyl (3-((3-((3-Cyanophenyl)amino)-6-ethoxy-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)propyl)carbamate (<b>19c</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>6</b>, compound <b>19c</b> was prepared from <b>13c</b> (100 mg, 0.29 mmol), K<sub>2</sub>CO<sub>3</sub> (64 mg, 0.58 mmol), and <i>N</i>-Boc-3-bromopropylamine (109 mg, 0.58 mmol) in 76% yield as a white solid, mp: 136–138 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.92 (s, 1H), 7.85 (s, 1H), 7.57 (d, <i>J</i> = 7.8 Hz, 1H), 7.40 (t, <i>J</i> = 7.8 Hz, 1H), 7.31 (s, 1H), 7.23 (s, 1H), 7.13 (d, <i>J</i> = 7.8 Hz, 1H), 6.84 (s, 1H), 4.15–4.02 (m, 4H), 3.99 (s, 3H), 3.41 (s, 2H), 3.14 (t, <i>J</i> = 6.4 Hz, 2H), 1.86 (p, <i>J</i> = 6.4 Hz, 2H), 1.38 (s, 9H), 1.35 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 156.1, 149.1, 148.0, 144.6, 143.9, 142.1, 130.4, 124.8, 121.7, 120.1, 119.9, 117.4, 112.8, 112.6, 111.9, 106.1, 77.9, 67.7, 64.6, 37.7, 37.6, 29.8, 29.0, 28.7, 15.3. MS (ESI) calcd for C<sub>28</sub>H<sub>34</sub>N<sub>5</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 504.3, found: 504.1.</div></div><div id="sec4_83" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> <i>tert</i>-Butyl (3-((6-Ethoxy-1-methyl-3-((3-propionylphenyl)amino)-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)propyl)carbamate (<b>19i</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>6</b>, compound <b>19i</b> was prepared from <b>13i</b> (80 mg, 0.21 mmol), K<sub>2</sub>CO<sub>3</sub> (59 mg, 0.42 mmol), and <i>N</i>-Boc-3-bromopropylamine (113 mg, 0.42 mmol) in 74% yield as a white solid, mp: 152–153 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.67 (s, 1H), 7.86 (s, 1H), 7.62 (s, 1H), 7.36–7.31 (m, 3H), 7.22 (s, 1H), 6.84 (s, 1H), 4.10–4.06 (m, 4H), 3.98 (s, 3H), 3.39 (s, 2H), 3.15 (t, <i>J</i> = 5.7 Hz, 2H), 3.01 (q, <i>J</i> = 7.1 Hz, 2H), 1.91–1.81 (p, <i>J</i> = 5.7 Hz 2H), 1.39 (s, 9H), 1.35 (t, <i>J</i> = 7.1 Hz, 3H), 1.10 (t, <i>J</i> = 7.1 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 156.1, 148.9, 148.0, 147.9, 144.5, 142.1, 137.7, 129.5, 124.9, 119.7, 118.1, 114.2, 112.9, 112.6, 106.1, 77.9, 67.7, 64.6, 37.7, 37.5, 31.6, 29.8, 29.3, 28.7, 15.3, 8.7. MS (ESI) calcd for C<sub>28</sub>H<sub>38</sub>N<sub>5</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 535.3, found: 535.1.</div></div><div id="sec4_84" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> 3-((7-(3-Aminopropoxy)-6-ethoxy-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)benzonitrile (<b>ID31</b>)</h3><div class="NLM_p last">To a solution of <b>19c</b> (90 mg, 0.18 mmol) in DCM (5 mL) was added trifluoroacetic acid (200 μL) and stirred at room temperature for 2 h. After concentration, the resulting mixture was adjusted to pH 7 by the addition of a saturated NaHCO<sub>3</sub> aqueous solution. The resulting precipitate filtered, washed with hexane, and dried to give 62 mg (90%) of <b>ID31</b> as a white solid, HPLC purity: 98.9%, mp: 190–191 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.99 (s, 1H), 7.87 (s, 1H), 7.59 (d, <i>J</i> = 7.9 Hz, 1H), 7.39 (t, <i>J</i> = 7.9 Hz, 1H), 7.33 (s, 1H), 7.22 (s, 1H), 7.14 (d, <i>J</i> = 7.9 Hz, 1H), 4.13 (t, <i>J</i> = 6.6 Hz, 2H), 4.05 (q, <i>J</i> = 7.0 Hz, 2H), 4.00 (s, 3H), 3.41 (s, 2H), 2.76 (t, <i>J</i> = 6.6 Hz, 2H), 1.84 (p, <i>J</i> = 6.6 Hz, 2H), 1.34 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 149.1, 148.1, 147.8, 144.6, 143.9, 141.8, 130.5, 124.8, 121.6, 120.1, 119.9, 117.4, 112.6, 112.5, 111.9, 105.5, 67.6, 64.5, 38.9, 37.6, 32.7, 29.0, 15.3. HRMS (ESI) calcd for C<sub>23</sub>H<sub>26</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 404.2081, found: 404.2087.</div></div><div id="sec4_85" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> 1-(3-((7-(3-Aminopropoxy)-6-ethoxy-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)amino)phenyl)propan-1-one hydrochloride (<b>ID32</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>ID09</b>, compound <b>ID32</b> was prepared from <b>19i</b> (50 mg, 0.09 mmol), acetyl chloride (2.5 mL) and ethanol (5 mL) in 88% yield as a white solid, HPLC purity: 99.2%, mp: 170–171 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.15 (s, 3H), 7.87 (s, 1H), 7.61 (d, <i>J</i> = 7.8 Hz, 1H), 7.40 (s, 1H), 7.39 (d, <i>J</i> = 7.8 Hz, 1H), 7.37 (t, <i>J</i> = 7.8 Hz, 1H), 7.25 (s, 1H), 4.19 (t, <i>J</i> = 6.1 Hz, 2H), 4.08 (q, <i>J</i> = 7.0 Hz, 2H), 4.02 (s, 3H), 3.14–2.92 (m, 4H), 2.08 (p, <i>J</i> = 6.1 Hz, 1H), 1.36 (t, <i>J</i> = 7.0 Hz, 3H), 1.09 (t, <i>J</i> = 7.2 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 201.0, 149.7, 148.3, 147.6, 144.0, 143.9, 142.7, 137.7, 129.6, 124.2, 120.3, 118.8, 114.7, 112.5, 112.2, 106.3, 67.2, 64.6, 37.5, 37.0, 31.7, 29.6, 27.3, 15.2, 8.7. HRMS (ESI) calcd for C<sub>25</sub>H<sub>31</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 435.2391, found: 435.2394; anal. calcd for C<sub>25</sub>H<sub>31</sub>ClN<sub>4</sub>O<sub>3</sub>: C, 63.75; H, 6.63; Cl, 7.53; N, 11.90; found: C, 63.62; H, 6.75; Cl, 7.71; N, 11.76.</div></div><div id="sec4_86" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> <i>tert</i>-Butyl (3-((6-Ethoxy-3-((6-ethoxypyridin-2-yl)amino)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-7-yl)oxy)propyl)carbamate (<b>19j</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>6</b>, compound <b>19j</b> was prepared from <b>13j</b> (90 mg, 0.25 mmol), K<sub>2</sub>CO<sub>3</sub> (60 mg, 0.50 mmol), and <i>N</i>-Boc-3-bromopropylamine (116 mg, 0.50 mmol) in 70% yield as a white solid, mp: 155–156 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.89 (s, 1H), 7.47 (t, <i>J</i> = 7.9 Hz, 1H), 7.29 (s, 1H), 7.20 (s, 1H), 6.92 (d, <i>J</i> = 7.9 Hz, 1H), 6.83 (s, 1H), 6.09 (d, <i>J</i> = 7.9 Hz, 1H), 4.23 (q, <i>J</i> = 7.0 Hz, 2H), 4.16–4.02 (m, 4H), 3.97 (s, 3H), 3.45 (s, 2H), 3.14 (q, <i>J</i> = 6.4 Hz, 2H), 1.86 (p, <i>J</i> = 6.4 Hz, 2H), 1.38 (s, 9H), 1.34 (t, <i>J</i> = 7.0 Hz, 3H), 1.29 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 162.9, 156.1, 154.4, 148.8, 147.5, 147.8, 142.9, 142.2, 140.6, 124.9, 114.4, 112.8, 106.1, 101.1, 99.0, 77.9, 67.7, 64.6, 61.2, 37.7, 37.5, 30.0, 29.8, 28.7, 15.3, 15.2. MS (ESI) calcd for C<sub>28</sub>H<sub>38</sub>N<sub>5</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 524.3, found: 524.2.</div></div><div id="sec4_87" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107"> 7-(3-Aminopropoxy)-6-ethoxy-<i>N</i>-(6-ethoxypyridin-2-yl)-1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-amine dihydrochloride (<b>ID33</b>)</h3><div class="NLM_p last">Following the procedures described for preparing <b>ID09</b>, compound <b>ID33</b> was prepared from <b>19j</b> (31 mg, 0.06 mmol), acetyl chloride (2.5 mL), and ethanol (5 mL) in 90% yield as a white solid, HPLC purity: 99.8%, mp: 230–231 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 9.86 (s, 1H), 8.17 (s, 3H), 7.61 (t, <i>J</i> = 8.0 Hz, 1H), 7.43 (s, 1H), 7.27 (s, 1H), 6.90 (d, <i>J</i> = 8.0 Hz, 1H), 6.25 (d, <i>J</i> = 8.0 Hz, 1H), 4.28 (q, <i>J</i> = 7.0 Hz, 2H), 4.20 (t, <i>J</i> = 6.2 Hz, 2H), 4.09 (q, <i>J</i> = 7.0 Hz, 2H), 4.05 (s, 3H), 3.04–2.98 (td, <i>J</i> = 5.7, 6.2 Hz, 2H), 2.07 (p, <i>J</i> = 6.2 Hz, 2H), 1.36 (t, <i>J</i> = 7.0 Hz, 3H), 1.32 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 162.1, 152.9, 150.1, 148.7, 147.6, 143.0, 141.8, 141.7, 123.8, 113.5, 112.3, 106.5, 102.2, 99.4, 67.3, 64.6, 62.3, 37.5, 37.0, 30.1, 27.3, 15.3, 15.1. HRMS (ESI) calcd for C<sub>23</sub>H<sub>30</sub>N<sub>5</sub>O<sub>3</sub> [M + 2H]<sup>2+</sup>: 212.6208, found: 212.6216; anal. calcd for C<sub>24</sub>H<sub>32</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>3</sub>: C, 58.18; H, 6.51; Cl, 14.31; N, 11.31; found: C, 58.36; H, 6.75; Cl, 14.12; N, 11.24.</div></div><div id="sec4_88" class="NLM_sec NLM_sec_level_2"><div id="ac_i108" class="anchor-spacer"></div><h3 class="article-section__title" id="_i108"> In Vitro Tubulin Polymerization Assay</h3><div class="NLM_p last">The tubulin polymerization assay was performed using the Tubulin Polymerization Assay Kit (BK011P, Cytoskeleton) according to the manual. The tubulin reaction mix contained 2 mg/mL porcine brain tubulin, 2 mM MgCl<sub>2</sub>, 0.5 mM ethylene glycol-bis(2-aminoethylether)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetraacetic acid (EGTA), 1 mM guanosine triphosphate (GTP), and 15% glycerol. A 96-well plate was incubated with 5 μL of the tested compounds in various concentrations at 37 °C for 1 min. Then, the tubulin reaction mix (50 μL) was added rapidly. The fluorescence intensity enhancement was monitored by excitation at 355 nm and emission at 460 nm every 60 s for 60 min in a multifunction microplate reader. The IC<sub>50</sub> values were defined as the compound concentration inhibiting the polymerization by 50% after 60 min. The IC<sub>50</sub> values were calculated by GraphPad Prism 5 software and expressed as the mean ± SD from the dose–response curves of at least three independent experiments.</div></div><div id="sec4_89" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> Cell Lines and Culture</h3><div class="NLM_p last">Human liver carcinoma HepG2 (HB-8065), human lung adenocarcinoma A549 (CCL-185), human colorectal carcinoma HCT116 (CCL-247), and normal liver LO2 (CRL-12461) cell lines were purchased from American Type Culture Collection (ATCC, Manassas, VA). Paclitaxel selected MDR subline A549/Tax was obtained from the Second Hospital of Shandong University (Shandong, China). All of these cells were cultured in RPMI-1640 medium containing 10% fetal bovine serum (FBS) at 37 °C in a humidified atmosphere of 5% CO<sub>2</sub> and 95% air.</div></div><div id="sec4_90" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> Cell Growth Inhibitory Assay</h3><div class="NLM_p last">The tested compounds were evaluated for their antiproliferative activity by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The exponentially growing cells were seeded into 96-well cell plates (4–7 × 10<sup>3</sup> cells/well) and allowed to adhere overnight. The cells were exposed to various concentrations of the test compounds. After 72 h of incubation in the incubator, 20 μL of MTT (2.5 mg/mL) was added to each well and incubated for 4 h. After the suspension was discarded, DMSO (150 μL) was added to dissolve the crystals. The absorbance at 570 nm was measured by a microplate spectrophotometer. The GI<sub>50</sub> values of the test compounds were defined as the molar drug concentrations required to cause 50% tumor cell growth inhibition, were calculated by GraphPad Prism 5 software and expressed as the mean ± SD from the dose–response curves of at least three independent experiments.</div></div><div id="sec4_91" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111"> Immunofluorescence Staining</h3><div class="NLM_p last">The exponentially growing HepG2 cells were seeded into 24-well cell plates (5 × 10<sup>4</sup> cells/well) containing coverslips and allowed to adhere overnight. The HepG2 cells were exposed to the tested compounds for 24 h. After fixed in a mixture of ice-cold methanol/acetic acid (3:1) for 10 min, the HepG2 cells were permeabilized with 0.3% Triton X-100 for 10 min and blocked with 5% bovine serum albumin for 30 min. Then, they were incubated with mouse antitubulin antibody at 4 °C overnight. On the next day, the cells were incubated with goat antimouse IgG-TRITC antibody for 2 h at 37 °C in the dark. Hoechst 33342 was used to stain the nucleus in the dark at room temperature for 10 min. The coverslips were immediately visualized on a Zeiss LSM 880 laser scanning confocal microscope (Carl Zeiss, Germany).</div></div><div id="sec4_92" class="NLM_sec NLM_sec_level_2"><div id="ac_i112" class="anchor-spacer"></div><h3 class="article-section__title" id="_i112"> EBI Competition Assay</h3><div class="NLM_p last">The exponentially growing HepG2 cells were seeded into six-well cell plates at 5 × 10<sup>5</sup> cells per well. After overnight adherence, the cells were first exposed to the tested compounds for 2 h and afterward treated with EBI (100 μM) for another 1.5 h. The cells were harvested, and cell extracts were prepared for Western blot analysis. The total protein sample (20 μg) was separated by 10% polyacrylamide gel under the condition of an ice bath. The protein was transferred to the poly(vinylidene fluoride) (PVDF) membrane and blocked with 5% nonfat milk at room temperature for 1 h. Then, the PVDF membrane was incubated with anti-β-tubulin antibody for 16 h at 4 °C. On the next day, the membranes were incubated with HRP-conjugated secondary antibody for 1 h. Immunoreactive proteins were finally detected by chemiluminescence.</div></div><div id="sec4_93" class="NLM_sec NLM_sec_level_2"><div id="ac_i113" class="anchor-spacer"></div><h3 class="article-section__title" id="_i113"> Cell Cycle Analysis</h3><div class="NLM_p last">The exponentially growing HepG2 cells were seeded into six-well cell plates (3 × 10<sup>5</sup> cells/well) and allowed to adhere overnight. They were incubated with various concentrations of <b>ID09</b> and <b>ID33</b> for 24 h. Then, cells were harvested and fixed in cold 70% ethanol overnight at 4 °C. After being washed with ice-cold phosphate-buffered saline (PBS), the cells were incubated with staining buffer (485 μL), PI solution (5 μL), and RNaseA solution (10 μL) at 37 °C for 15 min. Cell cycle distribution was analyzed using a flow cytometer.</div></div><div id="sec4_94" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> Apoptosis Analysis</h3><div class="NLM_p last">The exponentially growing HepG2 cells were seeded in six-well plates (3 × 10<sup>5</sup> cells/well). After overnight adherence, they were incubated in the presence or absence of compounds <b>ID09</b> and <b>ID33</b> with different concentrations for 12 or 24 h. Then, the cells were harvested, suspended in Annexin V binding buffer, and subsequently stained by Annexin V-PE and 7-AAD for 15 min in the dark at room temperature. The samples were detected by a flow cytometer.</div></div><div id="sec4_95" class="NLM_sec NLM_sec_level_2"><div id="ac_i115" class="anchor-spacer"></div><h3 class="article-section__title" id="_i115"> Wound-Healing Assay</h3><div class="NLM_p last">The exponentially growing HepG2 cells were seeded into six-well cell plates (3 × 10<sup>5</sup> cells/well) and allowed to grow to full confluence in six-well plates. Monolayer cells were wounded by scratching with a pipette tip and washed with PBS. The cells were incubated in serum-free DMEM medium and treated with the tested compounds at the different concentrations for 24 h. The cell images of 0 and 24 h were detected by a fluorescence inverted microscope.</div></div><div id="sec4_96" class="NLM_sec NLM_sec_level_2"><div id="ac_i116" class="anchor-spacer"></div><h3 class="article-section__title" id="_i116"> Western Blot Analysis</h3><div class="NLM_p last">The exponentially growing HepG2 cells were seeded into six-well cell plates at 5 × 10<sup>5</sup> cells per well and allowed to adhere overnight. The HepG2 cells were incubated with various concentrations of the test compounds for 24 h. The cells were harvested, and cell extracts were prepared for western blot analysis. The total protein samples (20 μg) were separated by 10% polyacrylamide gel under the condition of the ice bath. The protein was transferred to the PVDF membrane and blocked with 5% nonfat milk at room temperature for 1 h. Then, the PVDF membrane was incubated with primary antibodies for 16 h at 4 °C. The primary antibodies included cleaved caspase-3, PARP, Bcl-2, and Bax. On the next day, the membranes were incubated with the HRP-conjugated secondary antibody for 1 h. Immunoreactive bands were visualized using an enhanced chemiluminescence reagent and quantified by densitometry using a G:BOX chemi XR5 molecular imager. The intensities of the blots were quantified by Gel-Pro32.</div></div><div id="sec4_97" class="NLM_sec NLM_sec_level_2"><div id="ac_i117" class="anchor-spacer"></div><h3 class="article-section__title" id="_i117"> Aqueous Solubility Study</h3><div class="NLM_p last">The tested compounds were initially dissolved in DMSO at a concentration of 10 mg/mL and then diluted to five concentration gradients with methanol. The peak area under various concentrations was determined by HPLC, and the standard curve was established. The tested compounds were added into 1 mL of buffer solution to prepare a saturated solution. The absorption peak area of the saturated solution was analyzed by HPLC. The saturated solubility of the tested compounds was calculated using the standard curve equation. The absorption peak area was determined using an Agilent 1200 series equipment (column, Diamonil C18, 4.6 mm × 150 mm, 5 μm; mobile phase, methanol/H<sub>2</sub>O/CF<sub>3</sub>COOH (65:35:0.1%); flow rate, 1.0 mL/min; UV wavelength, 254 nm).</div></div><div id="sec4_98" class="NLM_sec NLM_sec_level_2"><div id="ac_i118" class="anchor-spacer"></div><h3 class="article-section__title" id="_i118"> Log <i>P</i> Measurement</h3><div class="NLM_p last">The tested compounds were initially dissolved in DMSO at a concentration of 5 mg/mL; 20 μL of the resulting solution was added into a mixture solution of <i>n</i>-octanol (1 mL) and distilled water (1 mL). The mixture was stirred at room temperature for 10 h and left at 4 °C overnight. The aqueous and organic phases of the mixture were analyzed by HPLC, separately. The instruments and conditions were the same as those for the aqueous solubility assay. The Log <i>P</i> was calculated by the peak area ratio in <i>n</i>-octanol and water.</div></div><div id="sec4_99" class="NLM_sec NLM_sec_level_2"><div id="ac_i119" class="anchor-spacer"></div><h3 class="article-section__title" id="_i119"> Antitumor Activity In Vivo</h3><div class="NLM_p last">The experimental procedures conformed to the animal experiment guidelines of the Animal Care and Welfare Committee of Shandong University. Five-week-old pathogen-free female Balb/c-nu mice were obtained from the Animal Centre of China Academy of Medical Sciences (Beijing, China). The HepG2 xenograft model was established by injecting 200 μL PBS containing HepG2 cells (1 × 10<sup>7</sup> cells/mL) subcutaneously in the right armpit of mice. When the tumor volume reached 90 mm<sup>3</sup>, nude mice were randomly divided into groups with five mice per group: vehicle group (distilled water, po, <i>n</i> = 5), <b>ID09</b> (25 mg/kg, po, <i>n</i> = 5) group, <b>ID33</b> (25 mg/kg, po, <i>n</i> = 5) group, vehicle group (distilled water, iv, <i>n</i> = 5), <b>ID09</b> (5 mg/kg, iv, <i>n</i> = 5), and <b>ID09</b> (10 mg/kg, iv, <i>n</i> = 5). <b>ID09</b> and <b>ID33</b> were dissolved in distilled water to form a 2.5 mg/mL solution for intragastric administration. <b>ID09</b> was dissolved in distilled water to form a 2.0 mg/mL solution for intravenous injection. The drugs and the vehicle were administrated by po once a day or iv every two days for 21 consecutive days. Tumor volumes and body weights were recorded every 3 days after drug treatment. At the end of the experiment, the mice were sacrificed, and the tumors were removed and weighed. Tumor volumes were calculated with a formula of L (long axis) × W<sup>2</sup> (short axis)/2. Relative tumor volume = mean tumor volume at day 21/mean tumor volume at day 0. The therapeutic effect of drugs was evaluated by the relative tumor inhibition rate = (1 – relative tumor volume of treated group/relative tumor volume of vehicle group) × 100%.</div></div><div id="sec4_100" class="NLM_sec NLM_sec_level_2"><div id="ac_i120" class="anchor-spacer"></div><h3 class="article-section__title" id="_i120"> Statistical Analysis</h3><div class="NLM_p last">Prism Software 5.0 was used for data analyses. The statistical significance (<i>P</i> < 0.05) was determined by one-way analysis of variance (ANOVA), followed by Dunnett’s multiple comparison test, comparing each treated group to the control.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i121"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01345" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37113" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37113" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01345?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01345</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Results of the in vitro tubulin polymerization assay as well as some bioassays, NMR spectra, and HPLC charts for all of the screening compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01345/suppl_file/jm0c01345_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01345/suppl_file/jm0c01345_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01345/suppl_file/jm0c01345_si_001.pdf">jm0c01345_si_001.pdf (6.04 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01345/suppl_file/jm0c01345_si_002.csv">jm0c01345_si_002.csv (3.4 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01345" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31340" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31340" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing-De Wu</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry
of Education), School of Pharmaceutical Sciences, Cheeloo College
of Medicine, Shandong University, Jinan 250012, P. R. China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c0b7b5aaa9aea7a4a5f7f080b3a4b5eea5a4b5eea3ae"><span class="__cf_email__" data-cfemail="6512100f0c0b0201005255251601104b0001104b060b">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhao-Peng Liu</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry
of Education), School of Pharmaceutical Sciences, Cheeloo College
of Medicine, Shandong University, Jinan 250012, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9429-8028" title="Orcid link">http://orcid.org/0000-0001-9429-8028</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4b27223e31232a243b0b382f3e652e2f3e652825"><span class="__cf_email__" data-cfemail="1b77726e61737a746b5b687f6e357e7f6e357875">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ying-Jie Cui</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry
of Education), School of Pharmaceutical Sciences, Cheeloo College
of Medicine, Shandong University, Jinan 250012, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chao Liu</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry
of Education), School of Pharmaceutical Sciences, Cheeloo College
of Medicine, Shandong University, Jinan 250012, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chen-Chen Ma</span> - <span class="hlFld-Affiliation affiliation">Central
Laboratory, The Affiliated Hospital of Shandong
University of Traditional Chinese Medicine, Jinan 250012, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ya-Ting Ji</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry
of Education), School of Pharmaceutical Sciences, Cheeloo College
of Medicine, Shandong University, Jinan 250012, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yi-Li Yao</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry
of Education), School of Pharmaceutical Sciences, Cheeloo College
of Medicine, Shandong University, Jinan 250012, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Long-Qian Tang</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry
of Education), School of Pharmaceutical Sciences, Cheeloo College
of Medicine, Shandong University, Jinan 250012, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cheng-Mei Zhang</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry
of Education), School of Pharmaceutical Sciences, Cheeloo College
of Medicine, Shandong University, Jinan 250012, P. R. China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Y.-J.C. and C.L. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e9203-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i123">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12620" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12620" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the National Natural Science Foundation of China (NSFC, Grant No. 81573275), the Key Research and Development Program of Shandong Province (2017CXGC1401), and the Fundamental Research Funds of Shandong University (Grant Nos. 21310082033116 and 21310072064056).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">MTAs</td><td class="NLM_def"><p class="first last">microtubule-targeting agents</p></td></tr><tr><td class="NLM_term">ADCs</td><td class="NLM_def"><p class="first last">antibody–drug conjugates</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">CA-4</td><td class="NLM_def"><p class="first last">combretastatin A-4</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">LiHMDS</td><td class="NLM_def"><p class="first last">lithium hexamethyldisilazide</p></td></tr><tr><td class="NLM_term">CSA</td><td class="NLM_def"><p class="first last">camphorsulfonic acid</p></td></tr><tr><td class="NLM_term">EBI</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>′-ethylene-bis(iodoacetamide)</p></td></tr><tr><td class="NLM_term">VCR</td><td class="NLM_def"><p class="first last">vincristine</p></td></tr><tr><td class="NLM_term">GTP</td><td class="NLM_def"><p class="first last">guanosine triphosphate</p></td></tr><tr><td class="NLM_term">EGTA</td><td class="NLM_def"><p class="first last">ethylene glycol-bis(2-aminoethylether)-<i>N</i>,<i>N</i>,<i>N′</i>,<i>N′</i>-tetraacetic acid</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">(3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2<i>H</i>-tetrazolium bromide)</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">propidium iodide</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i125">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80725" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80725" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 55 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schummel, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, R.</span></span> <span> </span><span class="NLM_article-title">Modulation of the polymerization kinetics of α/β-tubulin by osmolytes and macromolecular crowding</span>. <i>ChemPhysChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1002/cphc.201601032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1002%2Fcphc.201601032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=27813294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFOgsrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=189-197&author=P.+H.+Schummelauthor=M.+Gaoauthor=R.+Winter&title=Modulation+of+the+polymerization+kinetics+of+%CE%B1%2F%CE%B2-tubulin+by+osmolytes+and+macromolecular+crowding&doi=10.1002%2Fcphc.201601032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of the Polymerization Kinetics of α/β-Tubulin by Osmolytes and Macromolecular Crowding</span></div><div class="casAuthors">Schummel, Paul Hendrik; Gao, Mimi; Winter, Roland</div><div class="citationInfo"><span class="NLM_cas:title">ChemPhysChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">189-197</span>CODEN:
                <span class="NLM_cas:coden">CPCHFT</span>;
        ISSN:<span class="NLM_cas:issn">1439-4235</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Tubulin is one of the main components of the cytoskeleton and can be found in nearly all eukaryotic cells.  In this study, we explored the effects of kosmotropic and chaotropic osmolytes, such as trimethylamine-N-oxide (TMAO) and the metabolic waste product urea, as well as the crowding agents Ficoll and sucrose on the polymn. reaction of α/β-tubulin.  Time-dependent turbidimetry and fluorescence anisotropy expts. were performed to explore the kinetics of the polymn. reaction.  Under different solvent conditions, diverse changes in the lag time, the half-life of the polymn. reaction, and the crit. concn. of the polymn. reaction were obsd.  The apparent growth rate of the formation of microtubules was dramatically decreased in the presence of urea but significantly increased in the presence of TMAO.  Measurements using mixts. of these two cosolvents showed that TMAO was able to counteract the deteriorating effect of urea on the polymn. reaction of tubulin.  To create a more cell-like environment, Ficoll was added as a macromol. crowding agent.  The presence of 10 wt % Ficoll increased the apparent growth rate by one order of magnitude.  Our results clearly show that the polymn. of tubulin is very sensitive to the surrounding solvent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEUW8oqtQSqrVg90H21EOLACvtfcHk0lixQMIrOipKoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFOgsrjJ&md5=25efe4c88864f4860ea81c8d84436e77</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fcphc.201601032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcphc.201601032%26sid%3Dliteratum%253Aachs%26aulast%3DSchummel%26aufirst%3DP.%2BH.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DWinter%26aufirst%3DR.%26atitle%3DModulation%2520of%2520the%2520polymerization%2520kinetics%2520of%2520%25CE%25B1%252F%25CE%25B2-tubulin%2520by%2520osmolytes%2520and%2520macromolecular%2520crowding%26jtitle%3DChemPhysChem%26date%3D2017%26volume%3D18%26spage%3D189%26epage%3D197%26doi%3D10.1002%2Fcphc.201601032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Honore, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braguer, D.</span></span> <span> </span><span class="NLM_article-title">Understanding microtubule dynamics for improved cancer therapy</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3039</span>– <span class="NLM_lpage">3056</span>, <span class="refDoi"> DOI: 10.1007/s00018-005-5330-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1007%2Fs00018-005-5330-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=16314924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BD28Xms1Grug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2005&pages=3039-3056&author=S.+Honoreauthor=E.+Pasquierauthor=D.+Braguer&title=Understanding+microtubule+dynamics+for+improved+cancer+therapy&doi=10.1007%2Fs00018-005-5330-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding microtubule dynamics for improved cancer therapy</span></div><div class="casAuthors">Honore, S.; Pasquier, E.; Braguer, D.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">3039-3056</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review.  Microtubules (MTs), key components of the cytoskeleton, are dynamic polymers of tubulin that form a well-organized network of polarized tube filaments.  MT dynamics are highly regulated both spacially and temporally by several MT-related proteins, themselves regulated by several kinases and phosphatases via signaling cascades, and also by coordinated interactions with actin cytoskeleton and adhesion sites.  Regulation of MT dynamics is crucial for mitosis, cell migration, cell signaling and trafficking.  MT-targeted drugs (MTDs), which constitute a major anticancer drug family with antimitotic and antiangiogenic properties, inhibit tumor progression mainly by altering MT dynamics in both cancer and endothelial cells.  Identification of proteins regulating the MT network will lead to a better understanding of tumor progression regulators and will be helpful in improving cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEtWtWfzglTLVg90H21EOLACvtfcHk0liaFxpJDxl8kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xms1Grug%253D%253D&md5=a34099222d0c01876f46c1b704c3d995</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs00018-005-5330-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-005-5330-x%26sid%3Dliteratum%253Aachs%26aulast%3DHonore%26aufirst%3DS.%26aulast%3DPasquier%26aufirst%3DE.%26aulast%3DBraguer%26aufirst%3DD.%26atitle%3DUnderstanding%2520microtubule%2520dynamics%2520for%2520improved%2520cancer%2520therapy%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2005%26volume%3D62%26spage%3D3039%26epage%3D3056%26doi%3D10.1007%2Fs00018-005-5330-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cantero, M. D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarinci, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantiello, H. F.</span></span> <span> </span><span class="NLM_article-title">Two-dimensional brain microtubule structures behave as memristive devices</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">12398</span> <span class="refDoi"> DOI: 10.1038/s41598-019-48677-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1038%2Fs41598-019-48677-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=31455820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A280%3ADC%252BB3Mrit1Krsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&author=M.+D.+R.+Canteroauthor=P.+L.+Perezauthor=N.+Scarinciauthor=H.+F.+Cantiello&title=Two-dimensional+brain+microtubule+structures+behave+as+memristive+devices&doi=10.1038%2Fs41598-019-48677-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Two-Dimensional Brain Microtubule Structures Behave as Memristive Devices</span></div><div class="casAuthors">Cantero Maria Del Rocio; Perez Paula L; Scarinci Noelia; Cantiello Horacio F</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12398</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Microtubules (MTs) are cytoskeletal structures that play a central role in a variety of cell functions including cell division and cargo transfer.  MTs are also nonlinear electrical transmission lines that produce and conduct electrical oscillations elicited by changes in either electric field and/or ionic gradients.  The oscillatory behavior of MTs requires a voltage-sensitive gating mechanism to enable the electrodiffusional ionic movement through the MT wall.  Here we explored the electrical response of non-oscillating rat brain MT sheets to square voltage steps.  To ascertain the nature of the possible gating mechanism, the electrical response of non-oscillating rat brain MT sheets (2D arrays of MTs) to square pulses was analyzed under voltage-clamping conditions.  A complex voltage-dependent nonlinear charge movement was observed, which represented the summation of two events.  The first contribution was a small, saturating, voltage-dependent capacitance with a maximum charge displacement in the range of 4 fC/μm(2).  A second, major contribution was a non-saturating voltage-dependent charge transfer, consistent with the properties of a multistep memristive device.  The memristive capabilities of MTs could drive oscillatory behavior, and enable voltage-driven neuromorphic circuits and architectures within neurons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0DeQVzutqW9K0qsdY6Nc1fW6udTcc2eZwARFr9VFOl7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mrit1Krsg%253D%253D&md5=f0842c5cb0ac7c4fbd48d9870fd05dd6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-48677-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-48677-1%26sid%3Dliteratum%253Aachs%26aulast%3DCantero%26aufirst%3DM.%2BD.%2BR.%26aulast%3DPerez%26aufirst%3DP.%2BL.%26aulast%3DScarinci%26aufirst%3DN.%26aulast%3DCantiello%26aufirst%3DH.%2BF.%26atitle%3DTwo-dimensional%2520brain%2520microtubule%2520structures%2520behave%2520as%2520memristive%2520devices%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26doi%3D10.1038%2Fs41598-019-48677-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akhmanova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span> <span> </span><span class="NLM_article-title">Control of microtubule organization and dynamics: two ends in the limelight</span>. <i>Nat. Rev. Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">726</span>, <span class="refDoi"> DOI: 10.1038/nrm4084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1038%2Fnrm4084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=26562752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVOgt7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=711-726&author=A.+Akhmanovaauthor=M.+O.+Steinmetz&title=Control+of+microtubule+organization+and+dynamics%3A+two+ends+in+the+limelight&doi=10.1038%2Fnrm4084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Control of microtubule organization and dynamics: two ends in the limelight</span></div><div class="casAuthors">Akhmanova, Anna; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">711-726</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Microtubules have fundamental roles in many essential biol. processes, including cell division and intracellular transport.  They assemble and disassemble from their two ends, denoted the plus end and the minus end.  Significant advances have been made in our understanding of microtubule plus-end-tracking proteins (+TIPs) such as end-binding protein 1 (EB1), XMAP215, selected kinesins and dynein.  By contrast, information on microtubule minus-end-targeting proteins (-TIPs), such as the calmodulin-regulated spectrin-assocd. proteins (CAMSAPs) and Patronin, has only recently started to emerge.  Here, we review our current knowledge of factors, including microtubule-targeting agents, that assoc. with microtubule ends to control the dynamics and function of microtubules during the cell cycle and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps4xzvh0o6PbVg90H21EOLACvtfcHk0liaFxpJDxl8kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVOgt7%252FI&md5=7c941bcce8d5d51aef6a8deb140356d3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrm4084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm4084%26sid%3Dliteratum%253Aachs%26aulast%3DAkhmanova%26aufirst%3DA.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DControl%2520of%2520microtubule%2520organization%2520and%2520dynamics%253A%2520two%2520ends%2520in%2520the%2520limelight%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell.%2520Biol.%26date%3D2015%26volume%3D16%26spage%3D711%26epage%3D726%26doi%3D10.1038%2Fnrm4084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bakhoum, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compton, D. A.</span></span> <span> </span><span class="NLM_article-title">Kinetochores and disease: keeping microtubule dynamics in check!</span>. <i>Curr. Opin. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/j.ceb.2011.11.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.ceb.2011.11.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=22196931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjtlyjt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2012&pages=64-70&author=S.+F.+Bakhoumauthor=D.+A.+Compton&title=Kinetochores+and+disease%3A+keeping+microtubule+dynamics+in+check%21&doi=10.1016%2Fj.ceb.2011.11.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetochores and disease: keeping microtubule dynamics in check!</span></div><div class="casAuthors">Bakhoum, Samuel F.; Compton, Duane A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">64-70</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The essential role of microtubules in cell division has long been known.  Yet the mechanism by which microtubule attachment to chromosomes at kinetochores is regulated has only been recently revealed.  Here, we review the role of kinetochore-microtubule (kMT) attachment dynamics in the cell cycle as well as emerging evidence linking deregulation of kMT attachments to diseases where chromosome mis-segregation and aneuploidy play a central role.  Evidence indicates that the dynamic behavior of kMTs must fall within narrow permissible boundaries, which simultaneously allow a level of stability sufficient to establish and maintain chromosome-microtubule attachments and a degree of instability that permits error correction required for accurate chromosome segregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpULXbDP_rma7Vg90H21EOLACvtfcHk0liaFxpJDxl8kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjtlyjt7c%253D&md5=bc1e4555cf34706ca3698b3152a0f6a3</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2011.11.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2011.11.012%26sid%3Dliteratum%253Aachs%26aulast%3DBakhoum%26aufirst%3DS.%2BF.%26aulast%3DCompton%26aufirst%3DD.%2BA.%26atitle%3DKinetochores%2520and%2520disease%253A%2520keeping%2520microtubule%2520dynamics%2520in%2520check%2521%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2012%26volume%3D24%26spage%3D64%26epage%3D70%26doi%3D10.1016%2Fj.ceb.2011.11.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vildanova, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smirnova, E. A.</span></span> <span> </span><span class="NLM_article-title">Specific organization of Golgi apparatus in plant cells</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">894</span>– <span class="NLM_lpage">906</span>, <span class="refDoi"> DOI: 10.1134/S0006297914090065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1134%2FS0006297914090065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=25385017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFCgs7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2014&pages=894-906&author=M.+S.+Vildanovaauthor=W.+Wangauthor=E.+A.+Smirnova&title=Specific+organization+of+Golgi+apparatus+in+plant+cells&doi=10.1134%2FS0006297914090065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Specific organization of Golgi apparatus in plant cells</span></div><div class="casAuthors">Vildanova, M. S.; Wang, W.; Smirnova, E. A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry (Moscow)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">894-906</span>CODEN:
                <span class="NLM_cas:coden">BIORAK</span>;
        ISSN:<span class="NLM_cas:issn">0006-2979</span>.
    
            (<span class="NLM_cas:orgname">SP MAIK Nauka/Interperiodica</span>)
        </div><div class="casAbstract">A review.  Microtubules, actin filaments, and Golgi app. are connected both directly and indirectly, but it is manifested differently depending on the cell organization and specialization, and these connections are considered in many original studies and reviews.  In this review we would like to discuss what underlies differences in the structural organization of the Golgi app. in animal and plant cells: specific features of the microtubule cytoskeleton organization, the use of different cytoskeleton components for Golgi app. movement and maintenance of its integrity, or specific features of synthetic and secretory processes.  We suppose that a dispersed state of the Golgi app. in higher plant cells cannot be explained only by specific features of the microtubule system organization and by the absence of centrosome as an active center of their organization because the Golgi app. is organized similarly in the cells of other organisms that possess the centrosome and centrosomal microtubules.  One of the key factors detg. the Golgi app. state in plant cells is the functional uniformity or functional specialization of stacks.  The functional specialization does not suggest the joining of the stacks to form a ribbon; therefore, the disperse state of the Golgi app. needs to be supported, but it also can exist "by default".  We believe that the dispersed state of the Golgi app. in plants is supported, on one hand, by dynamic connections of the Golgi app. stacks with the actin filament system and, on the other hand, with the endoplasmic reticulum exit sites distributed throughout the endoplasmic reticulum.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLnei71jhXVLVg90H21EOLACvtfcHk0lhDpKtPgx699w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFCgs7bN&md5=5ccbcb308e57938c3ab094c88a41e93b</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1134%2FS0006297914090065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1134%252FS0006297914090065%26sid%3Dliteratum%253Aachs%26aulast%3DVildanova%26aufirst%3DM.%2BS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSmirnova%26aufirst%3DE.%2BA.%26atitle%3DSpecific%2520organization%2520of%2520Golgi%2520apparatus%2520in%2520plant%2520cells%26jtitle%3DBiochemistry%26date%3D2014%26volume%3D79%26spage%3D894%26epage%3D906%26doi%3D10.1134%2FS0006297914090065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janke, C.</span></span> <span> </span><span class="NLM_article-title">The tubulin code: molecular components, readout mechanisms and functions</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>206</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">472</span>, <span class="refDoi"> DOI: 10.1083/jcb.201406055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1083%2Fjcb.201406055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=25135932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVWrtLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=206&publication_year=2014&pages=461-472&author=C.+Janke&title=The+tubulin+code%3A+molecular+components%2C+readout+mechanisms+and+functions&doi=10.1083%2Fjcb.201406055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The tubulin code: molecular components, readout mechanisms, and functions</span></div><div class="casAuthors">Janke, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">206</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">461-472</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">A review.  Microtubules are cytoskeletal filaments that are dynamically assembled from α/β-tubulin heterodimers.  The primary sequence and structure of the tubulin proteins and, consequently, the properties and architecture of microtubules are highly conserved in eukaryotes.  Despite this conservation, tubulin is subject to heterogeneity that is generated in two ways: by the expression of different tubulin isotypes and by posttranslational modifications (PTMs).  Identifying the mechanisms that generate and control tubulin heterogeneity and how this heterogeneity affects microtubule function are long-standing goals in the field.  Recent work on tubulin PTMs has shed light on how these modifications could contribute to a "tubulin code" that coordinates the complex functions of microtubules in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDsM7qNQVrL7Vg90H21EOLACvtfcHk0lhDpKtPgx699w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVWrtLjN&md5=b4419d7fa17ea78a978b6e28c61e5993</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1083%2Fjcb.201406055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.201406055%26sid%3Dliteratum%253Aachs%26aulast%3DJanke%26aufirst%3DC.%26atitle%3DThe%2520tubulin%2520code%253A%2520molecular%2520components%252C%2520readout%2520mechanisms%2520and%2520functions%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2014%26volume%3D206%26spage%3D461%26epage%3D472%26doi%3D10.1083%2Fjcb.201406055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.-X.</span></span> <span> </span><span class="NLM_article-title">Kinesins in MAPK cascade: how kinesin motors are involved in the MAPK pathway</span>. <i>Gene</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>684</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1016/j.gene.2018.10.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.gene.2018.10.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=30342167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOnur7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=684&publication_year=2019&pages=1-9&author=Y.-J.+Liangauthor=W.-X.+Yang&title=Kinesins+in+MAPK+cascade%3A+how+kinesin+motors+are+involved+in+the+MAPK+pathway&doi=10.1016%2Fj.gene.2018.10.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Kinesins in MAPK cascade: How kinesin motors are involved in the MAPK pathway?</span></div><div class="casAuthors">Liang, Ya-Jing; Yang, Wan-Xi</div><div class="citationInfo"><span class="NLM_cas:title">Gene</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">684</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-9</span>CODEN:
                <span class="NLM_cas:coden">GENED6</span>;
        ISSN:<span class="NLM_cas:issn">0378-1119</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Kinesins are essential for the transport and positioning of several biomols. through moving along the microtubule in eukaryotic cells.  Up to now, there are 14 kinesin family proteins known.  The MAPK pathway which is composed of multiple proteins constituting a complex cascade also plays important roles in cell proliferation, differentiation and apoptosis in eukaryotic cells.  MAPK pathway includes three main kinases: MAPK Kinase Kinase, MAPK Kinase and mitogen-activated protein kinase that activate and phosphorylate downstream step by step in which abundant proteins scaffold together in complex ways.  To accomplish the transmission of a variety of signals, nos. of kinesins are closely assocd. with the MAPK cascade such as Kinesin-1, Kinesin-3, Kinesin-5, Kinesin-8, Kinesin-11 and Kinesin-13 families in mammals and two kinds of kinesin-like proteins in plants.  Studies have indicated that Kinesin-1 light chain KLC1, Kinesin-1 heavy chain KIF5B and Kinesin-11 family motor KIF26B interact with extracellular signal-regulated kinase ERK closely to regulate neuronal differentiation and mediate the chemosensitivity of osteosarcoma cells to drugs, Kinesin-3 family motor KIF13B and Kinesin-5 family motor Eg5 perform functions in regulating p38 to regulate the myelination of nervous system and facilitate the spindle elongation and tension, Kinesin-8 family motor MS-KIF18A and three isoforms of kinesin-13 can also connect and interact with MAPK pathway to transport estrogen receptor to the nucleus and control cell migration.  In plant cells, NPK1-activating kinesin-like protein 1 NACK and AtNACK1 (HIK) kinesin-like protein HINKEL are two members of the plant-specific kinesin-7.  They function as Ras at the upstream of MAPK pathway to regulate cytokinesis.  This review summarizes the novel roles of kinesins in MAPK cascade and tries to discuss the mechanism of the interaction between them using mammalian and plant cells as models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8wxknZIiBWbVg90H21EOLACvtfcHk0lhaX_UExQoBeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOnur7O&md5=82e54bc4dd19e82db139452c1c2cad6e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.gene.2018.10.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gene.2018.10.042%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DY.-J.%26aulast%3DYang%26aufirst%3DW.-X.%26atitle%3DKinesins%2520in%2520MAPK%2520cascade%253A%2520how%2520kinesin%2520motors%2520are%2520involved%2520in%2520the%2520MAPK%2520pathway%26jtitle%3DGene%26date%3D2019%26volume%3D684%26spage%3D1%26epage%3D9%26doi%3D10.1016%2Fj.gene.2018.10.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalous, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tetkova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubelka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Susor, A.</span></span> <span> </span><span class="NLM_article-title">Importance of ERK1/2 in regulation of protein translation during oocyte meiosis</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">698</span>, <span class="refDoi"> DOI: 10.3390/ijms19030698</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.3390%2Fijms19030698" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVOntrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=698&author=J.+Kalousauthor=A.+Tetkovaauthor=M.+Kubelkaauthor=A.+Susor&title=Importance+of+ERK1%2F2+in+regulation+of+protein+translation+during+oocyte+meiosis&doi=10.3390%2Fijms19030698"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Importance of ERK1/2 in regulation of protein translation during oocyte meiosis</span></div><div class="casAuthors">Kalous, Jaroslav; Tetkova, Anna; Kubelka, Michal; Susor, Andrej</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">698/1-698/21</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Although the involvement of the extracellular signal-regulated kinases 1 and 2 (ERK1/2) pathway in the regulation of cytostatic factor (CSF) activity; as well as in microtubules organization during meiotic maturation of oocytes; has already been described in detail; rather less attention has been paid to the role of ERK1/2 in the regulation of mRNA translation.  However; important data on the role of ERK1/2 in translation during oocyte meiosis have been documented.  This review focuses on recent findings regarding the regulation of translation and the role of ERK1/2 in this process in the meiotic cycle of mammalian oocytes.  The specific role of ERK1/2 in the regulation of mammalian target of rapamycin (mTOR); eukaryotic translation initiation factor 4E (eIF4E) and cytoplasmic polyadenylation element binding protein 1 (CPEB1) activity is addressed along with addnl. focus on the other key players involved in protein translation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSNTBV1Ab8DbVg90H21EOLACvtfcHk0lhaX_UExQoBeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVOntrjJ&md5=e1557d9f6a9f7eea269f72982ca5dfcc</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3390%2Fijms19030698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19030698%26sid%3Dliteratum%253Aachs%26aulast%3DKalous%26aufirst%3DJ.%26aulast%3DTetkova%26aufirst%3DA.%26aulast%3DKubelka%26aufirst%3DM.%26aulast%3DSusor%26aufirst%3DA.%26atitle%3DImportance%2520of%2520ERK1%252F2%2520in%2520regulation%2520of%2520protein%2520translation%2520during%2520oocyte%2520meiosis%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26spage%3D698%26doi%3D10.3390%2Fijms19030698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laflamme, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leary, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascariu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DʼAmours, D.</span></span> <span> </span><span class="NLM_article-title">Interphase microtubules safeguard mitotic progression by suppressing an Aurora B-dependent arrest induced by DNA replication stress</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2875</span>– <span class="NLM_lpage">2889</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2019.02.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.celrep.2019.02.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=30865880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVelu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=2875-2889&author=G.+Laflammeauthor=S.+Simauthor=A.+Learyauthor=M.+Pascariuauthor=J.+Vogelauthor=D.+D%CA%BCAmours&title=Interphase+microtubules+safeguard+mitotic+progression+by+suppressing+an+Aurora+B-dependent+arrest+induced+by+DNA+replication+stress&doi=10.1016%2Fj.celrep.2019.02.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Interphase Microtubules Safeguard Mitotic Progression by Suppressing an Aurora B-Dependent Arrest Induced by DNA Replication Stress</span></div><div class="casAuthors">Laflamme, Guillaume; Sim, Shannon; Leary, Allen; Pascariu, Mirela; Vogel, Jackie; D'Amours, Damien</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2875-2889.e3</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The segregation of chromosomes is a crit. step during cell division.  This process is driven by the elongation of spindle microtubules and is tightly regulated by checkpoint mechanisms.  It is unknown whether microtubules affect checkpoint responses as passive contributors or active regulators of the process.  We show here that interphase microtubules are essential to temporally restrict the effects of DNA replication stress to S phase in Saccharomyces cerevisiae.  Tubulin mutants hypersensitive to DNA damage experience a strong but delayed mitotic checkpoint arrest after exposure to genotoxic stress in S phase.  This untimely arrest is dependent on the Aurora B kinase but, surprisingly, not on the DNA damage checkpoint.  Impaired microtubule-kinetochore interaction is the apparent cause for this unusual phenotype.  Collectively, our results reveal that core components of microtubules potentiate the detection of DNA lesions created in S phase, thereby suppressing untimely activation of mitotic checkpoints after DNA replication stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9S9nYbylbhLVg90H21EOLACvtfcHk0lhaX_UExQoBeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVelu7o%253D&md5=e73e067130396d37caaf9131cc72a19d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2019.02.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2019.02.051%26sid%3Dliteratum%253Aachs%26aulast%3DLaflamme%26aufirst%3DG.%26aulast%3DSim%26aufirst%3DS.%26aulast%3DLeary%26aufirst%3DA.%26aulast%3DPascariu%26aufirst%3DM.%26aulast%3DVogel%26aufirst%3DJ.%26aulast%3DD%25CA%25BCAmours%26aufirst%3DD.%26atitle%3DInterphase%2520microtubules%2520safeguard%2520mitotic%2520progression%2520by%2520suppressing%2520an%2520Aurora%2520B-dependent%2520arrest%2520induced%2520by%2520DNA%2520replication%2520stress%26jtitle%3DCell%2520Rep.%26date%3D2019%26volume%3D26%26spage%3D2875%26epage%3D2889%26doi%3D10.1016%2Fj.celrep.2019.02.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vindya, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethiraj, K. R.</span></span> <span> </span><span class="NLM_article-title">Tubulins–the target for anticancer therapy</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">82</span>, <span class="refDoi"> DOI: 10.2174/1568026615666150112115805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.2174%2F1568026615666150112115805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=25579568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKgsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=73-82&author=N.+G.+Vindyaauthor=N.+Sharmaauthor=M.+Yadavauthor=K.+R.+Ethiraj&title=Tubulins%E2%80%93the+target+for+anticancer+therapy&doi=10.2174%2F1568026615666150112115805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulins - The Target for Anticancer Therapy</span></div><div class="casAuthors">Vindya, N. G.; Sharma, Nishant; Yadav, Mukesh; Ethiraj, K. R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-82</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Tubulin has picked up great focus as a major target in drug discovery and consequently, tubulin inhibitors have pulling in a considerable attention as anticancer agents.  Numerable naturally occurring agents have focused on tubulin system act as an imperative target of cancer chemotherapy.  Substantial no. of tubulin inhibitors has been discovered so far and these agents are classified as indicated by their interaction.  They are colchicine site binder, vinca- alkaloid related drugs and those interacting with the Taxol binding site and functioning as stabilizing agents.  We review the recent advances in the advancement of tubulin interfering agents and will render the current trend in the improvement of tubulin inhibitors as anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3tIyc1PffELVg90H21EOLACvtfcHk0lhLh-Cjk-k4jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKgsbo%253D&md5=8805a32e1f038693336ceb464c67193d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2174%2F1568026615666150112115805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026615666150112115805%26sid%3Dliteratum%253Aachs%26aulast%3DVindya%26aufirst%3DN.%2BG.%26aulast%3DSharma%26aufirst%3DN.%26aulast%3DYadav%26aufirst%3DM.%26aulast%3DEthiraj%26aufirst%3DK.%2BR.%26atitle%3DTubulins%25E2%2580%2593the%2520target%2520for%2520anticancer%2520therapy%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2015%26volume%3D15%26spage%3D73%26epage%3D82%26doi%3D10.2174%2F1568026615666150112115805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stanton, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gernert, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nettles, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aneja, R.</span></span> <span> </span><span class="NLM_article-title">Drugs that target dynamic microtubules: a new molecular perspective</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1002/med.20242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1002%2Fmed.20242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=21381049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksVKlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=443-481&author=R.+A.+Stantonauthor=K.+M.+Gernertauthor=J.+H.+Nettlesauthor=R.+Aneja&title=Drugs+that+target+dynamic+microtubules%3A+a+new+molecular+perspective&doi=10.1002%2Fmed.20242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs that target dynamic microtubules: A new molecular perspective</span></div><div class="casAuthors">Stanton, Richard A.; Gernert, Kim M.; Nettles, James H.; Aneja, Ritu</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">443-481</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Microtubules have long been considered an ideal target for anticancer drugs because of the essential role they play in mitosis, forming the dynamic spindle app.  As such, there is a wide variety of compds. currently in clin. use and in development that act as antimitotic agents by altering microtubule dynamics.  Although these diverse mols. are known to affect microtubule dynamics upon binding to one of the three established drug domains (taxane, vinca alkaloid, or colchicine site), the exact mechanism by which each drug works is still an area of intense speculation and research.  In this study, we review the effects of microtubule-binding chemotherapeutic agents from a new perspective, considering how their mode of binding induces conformational changes and alters biol. function relative to the mol. vectors of microtubule assembly or disassembly.  These "biol. vectors" can thus be used as a spatiotemporal context to describe mol. mechanisms by which microtubule-targeting drugs work. © 2011 Wiley Periodicals, Inc.  Med Res Rev, 31, No. 3, 443-481, 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB6_lcUQbXYrVg90H21EOLACvtfcHk0lhLh-Cjk-k4jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksVKlsLs%253D&md5=acce5b9cc89581a7dab0236072b68c72</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2Fmed.20242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20242%26sid%3Dliteratum%253Aachs%26aulast%3DStanton%26aufirst%3DR.%2BA.%26aulast%3DGernert%26aufirst%3DK.%2BM.%26aulast%3DNettles%26aufirst%3DJ.%2BH.%26aulast%3DAneja%26aufirst%3DR.%26atitle%3DDrugs%2520that%2520target%2520dynamic%2520microtubules%253A%2520a%2520new%2520molecular%2520perspective%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2011%26volume%3D31%26spage%3D443%26epage%3D481%26doi%3D10.1002%2Fmed.20242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coderch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morreale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gago, F.</span></span> <span> </span><span class="NLM_article-title">Tubulin-based structure-affinity relationships for antimitotic vinca alkaloids</span>. <i>Anticancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.2174/187152012800228841</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.2174%2F187152012800228841" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=22044006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A280%3ADC%252BC38zntVarsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=219-225&author=C.+Coderchauthor=A.+Morrealeauthor=F.+Gago&title=Tubulin-based+structure-affinity+relationships+for+antimitotic+vinca+alkaloids&doi=10.2174%2F187152012800228841"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulin-based structure-affinity relationships for antimitotic Vinca alkaloids</span></div><div class="casAuthors">Coderch Claire; Morreale Antonio; Gago Federico</div><div class="citationInfo"><span class="NLM_cas:title">Anti-cancer agents in medicinal chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">219-25</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Vinca alkaloids are a group of widely used anticancer drugs, originally extracted from the Madagascar periwinkle, that disrupt microtubule dynamics in mammalian cells by interfering with proper assembly of α,β-tubulin heterodimers.  They favor curved tubulin assemblies that destabilize microtubules and induce formation of spiral aggregates.  Their binding energy profiles have been characterized by means of sedimentation velocity assays and the binding site of vinblastine at the interface between two tubulin dimers (α1β1 .replace. α2β2) has been ascertained by X-ray crystallographic studies on a complex of tubulin with the stathmin-like domain of protein RB3, albeit at relatively low resolution.  Here we use molecular modeling and simulation techniques to build, refine and perform a comparative analysis of the three-dimensional complexes of vinblastine, vincristine, vinorelbine and vinflunine with a β1α2-tubulin interface in explicit water to rationalize the binding affinity differences in structural and energetic terms.  Our results shed some more light into the binding determinants and the structure-activity relationships of these clinically useful agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcROoDr1706CUb0AGQpJZWpJfW6udTcc2eYtrCwKEBhvcrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38zntVarsw%253D%253D&md5=204cce5f118540a0d8a6c9af29adfb16</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F187152012800228841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152012800228841%26sid%3Dliteratum%253Aachs%26aulast%3DCoderch%26aufirst%3DC.%26aulast%3DMorreale%26aufirst%3DA.%26aulast%3DGago%26aufirst%3DF.%26atitle%3DTubulin-based%2520structure-affinity%2520relationships%2520for%2520antimitotic%2520vinca%2520alkaloids%26jtitle%3DAnticancer%2520Agents%2520Med.%2520Chem.%26date%3D2012%26volume%3D12%26spage%3D219%26epage%3D225%26doi%3D10.2174%2F187152012800228841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span> <span> </span><span class="NLM_article-title">Microtubule-targeting agents: strategies to hijack the cytoskeleton</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">776</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1016/j.tcb.2018.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.tcb.2018.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=29871823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpslaksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=776-792&author=M.+O.+Steinmetzauthor=A.+E.+Prota&title=Microtubule-targeting+agents%3A+strategies+to+hijack+the+cytoskeleton&doi=10.1016%2Fj.tcb.2018.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton</span></div><div class="casAuthors">Steinmetz, Michel O.; Prota, Andrea E.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">776-792</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Microtubule-targeting agents (MTAs) such as paclitaxel and the vinca alkaloids are among the most important medical weapons available to combat cancer.  MTAs interfere with intracellular transport, inhibit eukaryotic cell proliferation, and promote cell death by suppressing microtubule dynamics.  Recent advances in the structural anal. of MTAs have enabled the extensive characterization of their interactions with microtubules and their building block tubulin.  We review here our current knowledge on the mol. mechanisms used by MTAs to hijack the microtubule cytoskeleton, and discuss dual inhibitors that target both kinases and microtubules.  We further formulate some outstanding questions related to MTA structural biol. and present possible routes for future investigations of this fascinating class of antimitotic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0akrt04GstbVg90H21EOLACvtfcHk0lhLh-Cjk-k4jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpslaksL0%253D&md5=b6ec960a802f658b3f21e030e687c60e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2018.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2018.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26aulast%3DProta%26aufirst%3DA.%2BE.%26atitle%3DMicrotubule-targeting%2520agents%253A%2520strategies%2520to%2520hijack%2520the%2520cytoskeleton%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2018%26volume%3D28%26spage%3D776%26epage%3D792%26doi%3D10.1016%2Fj.tcb.2018.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shuai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and anticancer properties of isocombretapyridines as potent colchicine binding site inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>197</i></span>, <span class="NLM_elocation-id">112308</span> <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.ejmech.2020.112308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=32339853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BB3cXosVSqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=197&publication_year=2020&author=W.+Shuaiauthor=X.+Liauthor=W.+Liauthor=F.+Xuauthor=L.+Luauthor=H.+Yaoauthor=L.+Yangauthor=H.+Zhuauthor=S.+Xuauthor=Z.+Zhuauthor=J.+Xu&title=Design%2C+synthesis+and+anticancer+properties+of+isocombretapyridines+as+potent+colchicine+binding+site+inhibitors&doi=10.1016%2Fj.ejmech.2020.112308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and anticancer properties of isocombretapyridines as potent colchicine binding site inhibitors</span></div><div class="casAuthors">Shuai, Wen; Li, Xinnan; Li, Wenlong; Xu, Feijie; Lu, Lixue; Yao, Hong; Yang, Limei; Zhu, Huajian; Xu, Shengtao; Zhu, Zheying; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">197</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112308</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel isocombretapyridines were designed and synthesized based on a lead compd. isocombretastatin A-4 (isoCA-4) by replacing 3,4,5-trimethoxylphenyl with substituent pyridine nucleus.  The MTT assay results showed that compd. I possessed the most potent activities against all tested cell lines with IC50 values at nanomolar concn. ranges.  Moreover, I inhibited tubulin polymn. at a micromolar level and also displayed potent anti-vascular activity in vitro.  Further mechanistic studies were conducted to demonstrate that compd. I could bind to the colchicine site of tubulin,and disrupte the cell microtubule networks, induce G2/M phase arrest, promote apoptosis and depolarize mitochondria of K562 cells in a dose-dependent manner.  Notably, I exhibited more potent tumor growth inhibition activity with 68.7% tumor growth inhibition than that of isoCA-4 in H22 allograft mouse model without apparent toxicity.  The present results suggested that compd. I may serve as a promising potent microtubule-destabilizing agent candidate for the development of therapeutics to treat cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMDR0o7MfBmLVg90H21EOLACvtfcHk0lhCuvZIEgzC4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosVSqsLs%253D&md5=c448b8f1e4636a50908a1fd31d2fbc5c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112308%26sid%3Dliteratum%253Aachs%26aulast%3DShuai%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520anticancer%2520properties%2520of%2520isocombretapyridines%2520as%2520potent%2520colchicine%2520binding%2520site%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D197%26doi%3D10.1016%2Fj.ejmech.2020.112308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lobert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correia, J. J.</span></span> <span> </span><span class="NLM_article-title">Energetics of vinca alkaloid interactions with tubulin</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>323</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1016/S0076-6879(00)23362-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2FS0076-6879%2800%2923362-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10944748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsVGhsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2000&pages=77-103&author=S.+Lobertauthor=J.+J.+Correia&title=Energetics+of+vinca+alkaloid+interactions+with+tubulin&doi=10.1016%2FS0076-6879%2800%2923362-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Energetics of vinca alkaloid interactions with tubulin</span></div><div class="casAuthors">Lobert, Sharon; Correia, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">Energetics of Biological Macromolecules, Part C</span>),
    <span class="NLM_cas:pages">77-103</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review with 71 refs. is presented regarding the energetics of interactions between Vinca rosa L. (vinca) alkaloids, antimitotic chemotherapeutic agents, and tubulin, the major protein constituent of microtubules and the mitotic spindle.  Topics discussed include the use of sedimentation velocity, the qual. fitting of wt. av. sedimentation coeff. data, and its applicability to extg. the energetics of vinca alkaloid-tubulin interactions.  Also, results obtained with four clin. useful vinca alkaloid congeners were compared.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_d0_exxQc1bVg90H21EOLACvtfcHk0lhCuvZIEgzC4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsVGhsrw%253D&md5=bf6f2b0002d85e0a9e1789d7a8b28554</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2800%2923362-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252800%252923362-4%26sid%3Dliteratum%253Aachs%26aulast%3DLobert%26aufirst%3DS.%26aulast%3DCorreia%26aufirst%3DJ.%2BJ.%26atitle%3DEnergetics%2520of%2520vinca%2520alkaloid%2520interactions%2520with%2520tubulin%26jtitle%3DMethods%2520Enzymol.%26date%3D2000%26volume%3D323%26spage%3D77%26epage%3D103%26doi%3D10.1016%2FS0076-6879%2800%2923362-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargsten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuevas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liniger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuhaus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span> <span> </span><span class="NLM_article-title">A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">13817</span>– <span class="NLM_lpage">13821</span>, <span class="refDoi"> DOI: 10.1073/pnas.1408124111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1073%2Fpnas.1408124111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=25114240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCju7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=13817-13821&author=A.+E.+Protaauthor=K.+Bargstenauthor=J.+F.+Diazauthor=M.+Marshauthor=C.+Cuevasauthor=M.+Linigerauthor=C.+Neuhausauthor=J.+M.+Andreuauthor=K.-H.+Altmannauthor=M.+O.+Steinmetz&title=A+new+tubulin-binding+site+and+pharmacophore+for+microtubule-destabilizing+anticancer+drugs&doi=10.1073%2Fpnas.1408124111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs</span></div><div class="casAuthors">Prota, Andrea E.; Bargsten, Katja; Diaz, J. Fernando; Marsh, May; Cuevas, Carmen; Liniger, Marc; Neuhaus, Christian; Andreu, Jose M.; Altmann, Karl-Heinz; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">13817-13821</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The recent success of antibody-drug conjugates (ADCs) in the treatment of cancer has led to a revived interest in microtubule-destabilizing agents.  Here, we detd. the high-resoln. crystal structure of the complex between tubulin and maytansine, which is part of an ADC that is approved by the US Food and Drug Administration (FDA) for the treatment of advanced breast cancer.  We found that the drug binds to a site on β-tubulin that is distinct from the vinca domain and that blocks the formation of longitudinal tubulin interactions in microtubules.  We also solved crystal structures of tubulin in complex with both a variant of rhizoxin and the phase 1 drug PM060184.  Consistent with biochem. and mutagenesis data, we found that the two compds. bound to the same site as maytansine and that the structures revealed a common pharmacophore for the three ligands.  Our results delineate a distinct mol. mechanism of action for the inhibition of microtubule assembly by clin. relevant agents.  They further provide a structural basis for the rational design of potent microtubule-destabilizing agents, thus opening opportunities for the development of next-generation ADCs for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX4icqk698gLVg90H21EOLACvtfcHk0lhCuvZIEgzC4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCju7vM&md5=798cae320e427ff76c2099387d9e6ba4</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1408124111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1408124111%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DDiaz%26aufirst%3DJ.%2BF.%26aulast%3DMarsh%26aufirst%3DM.%26aulast%3DCuevas%26aufirst%3DC.%26aulast%3DLiniger%26aufirst%3DM.%26aulast%3DNeuhaus%26aufirst%3DC.%26aulast%3DAndreu%26aufirst%3DJ.%2BM.%26aulast%3DAltmann%26aufirst%3DK.-H.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DA%2520new%2520tubulin-binding%2520site%2520and%2520pharmacophore%2520for%2520microtubule-destabilizing%2520anticancer%2520drugs%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2014%26volume%3D111%26spage%3D13817%26epage%3D13821%26doi%3D10.1073%2Fpnas.1408124111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waight, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargsten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span> <span> </span><span class="NLM_article-title">Pironetin binds covalently to αCys316 and perturbs a major loop and helix of α-tubulin to inhibit microtubule formation</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>428</i></span>,  <span class="NLM_fpage">2981</span>– <span class="NLM_lpage">2988</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2016.06.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.jmb.2016.06.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=27395016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFentL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=428&publication_year=2016&pages=2981-2988&author=A.+E.+Protaauthor=J.+Setterauthor=A.+B.+Waightauthor=K.+Bargstenauthor=J.+Murgaauthor=J.+F.+Diazauthor=M.+O.+Steinmetz&title=Pironetin+binds+covalently+to+%CE%B1Cys316+and+perturbs+a+major+loop+and+helix+of+%CE%B1-tubulin+to+inhibit+microtubule+formation&doi=10.1016%2Fj.jmb.2016.06.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Pironetin binds covalently to αCys316 and perturbs a major loop and helix of α-tubulin to inhibit microtubule formation</span></div><div class="casAuthors">Prota, Andrea E.; Setter, Jocelyn; Waight, Andrew B.; Bargsten, Katja; Murga, Juan; Diaz, Jose Fernando; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">428</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2981-2988</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Microtubule-targeting agents are among the most powerful drugs used in chemotherapy to treat cancer patients.  Pironetin (I) is a natural product that displays promising anticancer properties by binding to and potently inhibiting tubulin assembly into microtubules; however, its mol. mechanism of action remained obscure.  Here, the authors solved the crystal structure of the tubulin-I complex and found that the compd. covalently binds to Cys-316 of α-tubulin.  The structure further revealed that I perturbs the T7 loop and helix H8 of α-tubulin.  Since both of these elements are essential for establishing longitudinal tubulin contacts in microtubules, this result explains how I inhibits the formation of microtubules.  Together, the data define the mol. details of the I binding site on α-tubulin and thus offer a promising basis for the rational design of I variants with improved activity profiles.  They further extend knowledge on strategies evolved by natural products to target and perturb the microtubule cytoskeleton.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYXbbv8loGDLVg90H21EOLACvtfcHk0liy-DtlFMPpWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFentL%252FP&md5=66e945caa3adaf0f3a5a20a702b3b406</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2016.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2016.06.023%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DSetter%26aufirst%3DJ.%26aulast%3DWaight%26aufirst%3DA.%2BB.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DMurga%26aufirst%3DJ.%26aulast%3DDiaz%26aufirst%3DJ.%2BF.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DPironetin%2520binds%2520covalently%2520to%2520%25CE%25B1Cys316%2520and%2520perturbs%2520a%2520major%2520loop%2520and%2520helix%2520of%2520%25CE%25B1-tubulin%2520to%2520inhibit%2520microtubule%2520formation%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2016%26volume%3D428%26spage%3D2981%26epage%3D2988%26doi%3D10.1016%2Fj.jmb.2016.06.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botting, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naismith, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Pironetin reacts covalently with cysteine-316 of α-tubulin to destabilize microtubule</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">12103</span> <span class="refDoi"> DOI: 10.1038/ncomms12103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1038%2Fncomms12103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=27357539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFSqtLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&author=J.+Yangauthor=Y.+Wangauthor=T.+Wangauthor=J.+Jiangauthor=C.+H.+Bottingauthor=H.+Liuauthor=Q.+Chenauthor=J.+H.+Naismithauthor=X.+Zhuauthor=L.+Chen&title=Pironetin+reacts+covalently+with+cysteine-316+of+%CE%B1-tubulin+to+destabilize+microtubule&doi=10.1038%2Fncomms12103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Pironetin reacts covalently with cysteine-316 of α-tubulin to destabilize microtubule</span></div><div class="casAuthors">Yang, Jianhong; Wang, Yuxi; Wang, Taijing; Jiang, Jian; Botting, Catherine H.; Liu, Huanting; Chen, Qiang; Yang, Jinliang; Naismith, James H.; Zhu, Xiaofeng; Chen, Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12103</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mols. that alter the normal dynamics of microtubule assembly and disassembly include many anticancer drugs in clin. use.  So far all such therapeutics target β-tubulin, and structural biol. has explained the basis of their action and permitted design of new drugs.  However, by shifting the profile of β-tubulin isoforms, cancer cells become resistant to treatment.  Compds. that bind to α-tubulin are less well characterized and unexploited.  The natural product pironetin is known to bind to α-tubulin and is a potent inhibitor of microtubule polymn.  Previous reports had identified that pironetin reacts with lysine-352 residue however analogs designed on this model had much lower potency, which was difficult to explain, hindering further development.  We report crystallog. and mass spectrometric data that reveal that pironetin forms a covalent bond to cysteine-316 in α-tubulin via a Michael addn. reaction.  These data provide a basis for the rational design of α-tubulin targeting chemotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpA2PMsYegjrbVg90H21EOLACvtfcHk0liy-DtlFMPpWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFSqtLfM&md5=25eadc388dddb3f88581651762d09aa5</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fncomms12103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms12103%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DBotting%26aufirst%3DC.%2BH.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DNaismith%26aufirst%3DJ.%2BH.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DPironetin%2520reacts%2520covalently%2520with%2520cysteine-316%2520of%2520%25CE%25B1-tubulin%2520to%2520destabilize%2520microtubule%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26doi%3D10.1038%2Fncomms12103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barakat, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huzil, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuszynski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schriemer, D. C.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of the laulimalide-microtubule binding mode by mass shift perturbation mapping</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">725</span>– <span class="NLM_lpage">734</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.chembiol.2010.05.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=20659685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptleitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=725-734&author=M.+J.+Bennettauthor=K.+Barakatauthor=J.+T.+Huzilauthor=J.+Tuszynskiauthor=D.+C.+Schriemer&title=Discovery+and+characterization+of+the+laulimalide-microtubule+binding+mode+by+mass+shift+perturbation+mapping&doi=10.1016%2Fj.chembiol.2010.05.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of the Laulimalide-Microtubule Binding Mode by Mass Shift Perturbation Mapping</span></div><div class="casAuthors">Bennett, Melissa J.; Barakat, Khaled; Huzil, J. Torin; Tuszynski, Jack; Schriemer, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">725-734</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Conventional approaches to site mapping have so far failed to identify the laulimalide binding site on microtubules.  Using mass shift perturbation anal. and data-directed docking, we demonstrate that laulimalide binds to the exterior of the microtubule on β-tubulin, in a region previously unknown to support ligand binding and well removed from the paclitaxel site.  Shift maps for docetaxel and laulimalide are otherwise identical, indicating a common state of microtubule stability induced by occupancy of the distinct sites.  The preferred binding mode highlights the penetration of the laulimalide side chain into a deep, narrow cavity through a unique conformation not strongly populated in soln., akin to a "striking cobra".  This mode supports the development of a pharmacophore model and reveals the importance of the C1-C15 axis in the macrocycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbYV4W7lV1KLVg90H21EOLACvtfcHk0liy-DtlFMPpWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptleitLo%253D&md5=0219ce6a7590b9e2990be4d9a9170de5</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DBennett%26aufirst%3DM.%2BJ.%26aulast%3DBarakat%26aufirst%3DK.%26aulast%3DHuzil%26aufirst%3DJ.%2BT.%26aulast%3DTuszynski%26aufirst%3DJ.%26aulast%3DSchriemer%26aufirst%3DD.%2BC.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520the%2520laulimalide-microtubule%2520binding%2520mode%2520by%2520mass%2520shift%2520perturbation%2520mapping%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D725%26epage%3D734%26doi%3D10.1016%2Fj.chembiol.2010.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rohena, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooberry, S. L.</span></span> <span> </span><span class="NLM_article-title">Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities</span>. <i>Nat. Prod. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">355</span>, <span class="refDoi"> DOI: 10.1039/C3NP70092E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1039%2FC3NP70092E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=24481420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVagsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2014&pages=335-355&author=C.+C.+Rohenaauthor=S.+L.+Mooberry&title=Recent+progress+with+microtubule+stabilizers%3A+new+compounds%2C+binding+modes+and+cellular+activities&doi=10.1039%2FC3NP70092E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities</span></div><div class="casAuthors">Rohena, Cristina C.; Mooberry, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">335-355</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Covering: late 2008 to August 2013Nature has yielded numerous classes of chem. distinct microtubule stabilizers.  Several of these, including paclitaxel (Taxol) and docetaxel (Taxotere), are important drugs used in the treatment of cancer.  New microtubule stabilizers and novel formulations of these agents continue to provide advances in cancer therapy.  In this review we cover recent progress in the chem. and biol. of these diverse microtubule stabilizers focusing on the wide range of organisms that produce these compds., their mechanisms of inhibiting microtubule-dependent processes, mechanisms of drug resistance, and their interactions with tubulin including their distinct binding sites and modes.  A new potential role for microtubule stabilizers in neurodegenerative diseases is reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGbuNICZ6-bLVg90H21EOLACvtfcHk0lhP0--lG-B9tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVagsro%253D&md5=50febeef8c139e67374a92250e7e2a7a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1039%2FC3NP70092E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC3NP70092E%26sid%3Dliteratum%253Aachs%26aulast%3DRohena%26aufirst%3DC.%2BC.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DRecent%2520progress%2520with%2520microtubule%2520stabilizers%253A%2520new%2520compounds%252C%2520binding%2520modes%2520and%2520cellular%2520activities%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2014%26volume%3D31%26spage%3D335%26epage%3D355%26doi%3D10.1039%2FC3NP70092E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, L.</span></span> <span> </span><span class="NLM_article-title">Microtubules as a target for anticancer drugs</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.1038/nrc1317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1038%2Fnrc1317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=15057285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=253-265&author=M.+A.+Jordanauthor=L.+Wilson&title=Microtubules+as+a+target+for+anticancer+drugs&doi=10.1038%2Fnrc1317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubules as a target for anticancer drugs</span></div><div class="casAuthors">Jordan, Mary Ann; Wilson, Leslie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">253-265</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Highly dynamic mitotic-spindle microtubules are among the most successful targets for anticancer therapy.  Microtubule-targeted drugs, including paclitaxel and Vinca alkaloids, were previously considered to work primarily by increasing or decreasing the cellular microtubule mass.  Although these effects might have a role in their chemotherapeutic actions, we now know that at lower concns., microtubule-targeted drugs can suppress microtubule dynamics without changing microtubule mass; this action leads to mitotic block and apoptosis.  In addn. to the expanding array of chem. diverse antimitotic agents, some microtubule-targeted drugs can act as vascular-targeting agents, rapidly depolymg. microtubules of newly formed vasculature to shut down the blood supply to tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRJbrFnzwqjbVg90H21EOLACvtfcHk0lhP0--lG-B9tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D&md5=bbbf212e03ffe6763098fc41f21a8158</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnrc1317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1317%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DM.%2BA.%26aulast%3DWilson%26aufirst%3DL.%26atitle%3DMicrotubules%2520as%2520a%2520target%2520for%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D253%26epage%3D265%26doi%3D10.1038%2Fnrc1317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dumontet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, M. A.</span></span> <span> </span><span class="NLM_article-title">Microtubule-binding agents: a dynamic field of cancer therapeutics</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">790</span>– <span class="NLM_lpage">803</span>, <span class="refDoi"> DOI: 10.1038/nrd3253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1038%2Fnrd3253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=20885410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1akur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=790-803&author=C.+Dumontetauthor=M.+A.+Jordan&title=Microtubule-binding+agents%3A+a+dynamic+field+of+cancer+therapeutics&doi=10.1038%2Fnrd3253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-binding agents: a dynamic field of cancer therapeutics</span></div><div class="casAuthors">Dumontet, Charles; Jordan, Mary Ann</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">790-803</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Microtubules are dynamic filamentous cytoskeletal proteins composed of tubulin and are an important therapeutic target in tumor cells.  Agents that bind to microtubules have been part of the pharmacopoeia of anticancer therapy for decades and until the advent of targeted therapy, microtubules were the only alternative to DNA as a therapeutic target in cancer.  The screening of a range of botanical species and marine organisms has yielded promising new antitubulin agents with novel properties.  In the current search for novel microtubule-binding agents, enhanced tumor specificity, reduced neurotoxicity and insensitivity to chemoresistance mechanisms are the three main objectives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ43DyXjdN7rVg90H21EOLACvtfcHk0lhP0--lG-B9tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1akur%252FI&md5=9fc6fd966859785605936ecbe6dca44e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnrd3253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3253%26sid%3Dliteratum%253Aachs%26aulast%3DDumontet%26aufirst%3DC.%26aulast%3DJordan%26aufirst%3DM.%2BA.%26atitle%3DMicrotubule-binding%2520agents%253A%2520a%2520dynamic%2520field%2520of%2520cancer%2520therapeutics%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D790%26epage%3D803%26doi%3D10.1038%2Fnrd3253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noble, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutts, J. H.</span></span> <span> </span><span class="NLM_article-title">Role of chance observations in chemotherapy: vinca rosea</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1958</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">882</span>– <span class="NLM_lpage">894</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.1958.tb54906.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1111%2Fj.1749-6632.1958.tb54906.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=13627916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A280%3ADyaG1M%252FlslCltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1958&pages=882-894&author=R.+L.+Nobleauthor=C.+T.+Beerauthor=J.+H.+Cutts&title=Role+of+chance+observations+in+chemotherapy%3A+vinca+rosea&doi=10.1111%2Fj.1749-6632.1958.tb54906.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Role of chance observations in chemotherapy: Vinca rosea</span></div><div class="casAuthors">NOBLE R L; BEER C T; CUTTS J H</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">1958</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">882-94</span>
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQcvofRkfg0eJotVjB3IRIyfW6udTcc2eZi7Ujq76iOO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaG1M%252FlslCltQ%253D%253D&md5=a728fef90a06da248a734bfbed91a985</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.1958.tb54906.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.1958.tb54906.x%26sid%3Dliteratum%253Aachs%26aulast%3DNoble%26aufirst%3DR.%2BL.%26aulast%3DBeer%26aufirst%3DC.%2BT.%26aulast%3DCutts%26aufirst%3DJ.%2BH.%26atitle%3DRole%2520of%2520chance%2520observations%2520in%2520chemotherapy%253A%2520vinca%2520rosea%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D1958%26volume%3D76%26spage%3D882%26epage%3D894%26doi%3D10.1111%2Fj.1749-6632.1958.tb54906.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svoboda, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlantis, J.</span></span> <span> </span><span class="NLM_article-title">Antitumor principles derived from vinca rosea. I. vincaleukoblastine and leurosine</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1960</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1016</span>– <span class="NLM_lpage">1022</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=14407465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADyaF3sXmt1Sgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1960&pages=1016-1022&author=I.+S.+Johnsonauthor=H.+F.+Wrightauthor=G.+H.+Svobodaauthor=J.+Vlantis&title=Antitumor+principles+derived+from+vinca+rosea.+I.+vincaleukoblastine+and+leurosine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor principles derived from Vinca rosea. I. Vincaleukoblastine and leurosine</span></div><div class="casAuthors">Johnson, Irving S.; Wright, Howard F.; Svobada, Gordon H.; Vlantis, Janet</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1960</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1016-22</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">The exptl. activity of a new clin. confirmed antitumor compd., vincaleukoblastine (C15H58O9N4), (VLB) as the sulfate is described.  Greatest activity was seen against the P-1534 acute lymphocytic leukemia in DBA/2 mice.  Late as well as early stages of this leukemia were significantly affected by this compd.  No synergistic or additive effects were observed in combination with other antitumor compds.  A second indole-indoline alkaloid, leurosine, isomeric with VLB, was also obtained from Vinca rosea, with similar demonstrable exptl. antitumor activity.  Two other alkaloids, vindoline (C25H32O2) and catharanthine (C21H22O2N2), also obtained from V. rosea, were devoid of antitumor activity singly or in equimolar concns., but were postulated as the biogenetic precursors of VLB and leurosine.  Preliminary studies in vitro demonstrated that certain compds. were capable of reversing the growth-inhibitory activity of VLB against human monocytic leukemia cells.  These compds. were coenzyme A, aspartic acid, tryptophan, α-ketoglutaric acid, ornithine, citrulline, arginine, and glutamic acid.  VLB and leurosine are representatives of a new class of clin. active antitumor compds. which may interfere with the cellular metabolic pathways leading from glutamic acid to urea, and from glutamic acid to the citric acid cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrccExPV6hVf7Vg90H21EOLACvtfcHk0lgVt6L-Sgbn4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3sXmt1Sgtg%253D%253D&md5=574735669c0e4c9e267af3f20ce36c22</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DI.%2BS.%26aulast%3DWright%26aufirst%3DH.%2BF.%26aulast%3DSvoboda%26aufirst%3DG.%2BH.%26aulast%3DVlantis%26aufirst%3DJ.%26atitle%3DAntitumor%2520principles%2520derived%2520from%2520vinca%2520rosea.%2520I.%2520vincaleukoblastine%2520and%2520leurosine%26jtitle%3DCancer%2520Res.%26date%3D1960%26volume%3D20%26spage%3D1016%26epage%3D1022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dybdal-Hargreaves, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risinger, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooberry, S. L.</span></span> <span> </span><span class="NLM_article-title">Eribulin Mesylate: mechanism of action of a unique microtubule-targeting agent</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2445</span>– <span class="NLM_lpage">2452</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-3252</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1158%2F1078-0432.CCR-14-3252" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=25838395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXps1aktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2445-2452&author=N.+F.+Dybdal-Hargreavesauthor=A.+L.+Risingerauthor=S.+L.+Mooberry&title=Eribulin+Mesylate%3A+mechanism+of+action+of+a+unique+microtubule-targeting+agent&doi=10.1158%2F1078-0432.CCR-14-3252"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Eribulin Mesylate: Mechanism of Action of a Unique Microtubule-Targeting Agent</span></div><div class="casAuthors">Dybdal-Hargreaves, Nicholas F.; Risinger, April L.; Mooberry, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2445-2452</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Eribulin mesylate (eribulin), an analog of the marine natural product halichondrin B, is a microtubule-depolymg. drug that has utility in the treatment of patients with breast cancer.  Clin. trial results have demonstrated that eribulin treatment provides a survival advantage to patients with metastatic or locally advanced breast cancer previously treated with an anthracycline and a taxane.  Furthermore, a pooled anal. of two pivotal phase III trials has demonstrated that eribulin also improves overall survival in several patient subgroups, including in women with HER2-neg. disease and triple-neg. breast cancer.  This review covers the preclin. research that led to the clin. testing and approval of eribulin, as well as subsequent research that was prompted by distinct and unexpected effects of eribulin in the clinic.  Initial studies with halichondrin B demonstrated unique effects on tubulin binding that resulted in distinct microtubule-dependent events and antitumor actions.  Consistent with the actions of the natural product, eribulin has potent microtubule-depolymg. activities and properties that distinguish it from other microtubule-targeting agents.  Here, we review new results that further differentiate the effects of eribulin from other agents on peripheral nerves, angiogenesis, vascular remodeling, and epithelial-to-mesenchymal transition.  Together, these data highlight the distinct properties of eribulin and begin to delineate the mechanisms behind the increased survival benefit provided by eribulin for patients.  Clin Cancer Res; 21(11); 2445-52. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU-LpLOesxd7Vg90H21EOLACvtfcHk0lgVt6L-Sgbn4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXps1aktb4%253D&md5=a2d259232081c3aa4bfce80110c21eb8</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-3252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-3252%26sid%3Dliteratum%253Aachs%26aulast%3DDybdal-Hargreaves%26aufirst%3DN.%2BF.%26aulast%3DRisinger%26aufirst%3DA.%2BL.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DEribulin%2520Mesylate%253A%2520mechanism%2520of%2520action%2520of%2520a%2520unique%2520microtubule-targeting%2520agent%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D2445%26epage%3D2452%26doi%3D10.1158%2F1078-0432.CCR-14-3252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Canta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiorazzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavaletti, G.</span></span> <span> </span><span class="NLM_article-title">Tubulin: a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1315</span>– <span class="NLM_lpage">1324</span>, <span class="refDoi"> DOI: 10.2174/092986709787846488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.2174%2F092986709787846488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=19355888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltVeqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=1315-1324&author=A.+Cantaauthor=A.+Chiorazziauthor=G.+Cavaletti&title=Tubulin%3A+a+target+for+antineoplastic+drugs+into+the+cancer+cells+but+also+in+the+peripheral+nervous+system&doi=10.2174%2F092986709787846488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulin as a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system</span></div><div class="casAuthors">Canta, Annalisa; Chiorazzi, Alessia; Cavaletti, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1315-1324</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Since the introduction into clin. practice of vinca alkaloids, tubulin has become a key and well-established target of modern antineoplastic chemotherapy.  When taxanes became available their broad spectrum of activity was striking and opened up new horizons for cancer patients' treatment.  However, taxanes' susceptibility to drug resistance caused by the drug efflux pump protein, P-glycoprotein, is not infrequent and their use may be limited by poor soly., synthetic problems and toxicity.  The epothilones are a new class of chemotherapeutic agents with a mechanism of action similar to that of taxanes, but different enough to escape, for example, the multidrug resistance caused by P-glycoprotein.  Moreover, the epothilones (that are strong promoters of tubulin polymn.) have significant antitumor activity against human cancer cells that are taxane-resistant, express the multidrug resistance gene MDR-1, and have acquired tubulin mutations.  Finally, starting from the natural mols., several synthetic analogs have been developed.  Besides their antineoplastic efficacy, all the antitubulin drugs share a common toxicity on the peripheral nervous system and peripheral neurotoxicity is a major, potentially dose-limiting side effect also of the epothilones.  The current knowledge regarding the features of epothilones' peripheral neurotoxicity and their comparison with taxanes will be reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrud9z8vnFGFLVg90H21EOLACvtfcHk0ljS6hG7oszt-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltVeqsbo%253D&md5=88fe8b8400cb3ec5be160439503c914f</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2174%2F092986709787846488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986709787846488%26sid%3Dliteratum%253Aachs%26aulast%3DCanta%26aufirst%3DA.%26aulast%3DChiorazzi%26aufirst%3DA.%26aulast%3DCavaletti%26aufirst%3DG.%26atitle%3DTubulin%253A%2520a%2520target%2520for%2520antineoplastic%2520drugs%2520into%2520the%2520cancer%2520cells%2520but%2520also%2520in%2520the%2520peripheral%2520nervous%2520system%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2009%26volume%3D16%26spage%3D1315%26epage%3D1324%26doi%3D10.2174%2F092986709787846488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, S.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wing, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaney, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorsic, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroetz, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolan, M. E.</span></span> <span> </span><span class="NLM_article-title">Pharmacoethnicity in paclitaxel-induced sensory peripheral neuropathy</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">4337</span>– <span class="NLM_lpage">4346</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-0133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1158%2F1078-0432.CCR-15-0133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=26015512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1antLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=4337-4346&author=M.+Komatsuauthor=H.+E.+Wheelerauthor=S.+Chungauthor=S.-K.+Lowauthor=C.+Wingauthor=S.+M.+Delaneyauthor=L.+K.+Gorsicauthor=A.+Takahashiauthor=M.+Kuboauthor=D.+L.+Kroetzauthor=W.+Zhangauthor=Y.+Nakamuraauthor=M.+E.+Dolan&title=Pharmacoethnicity+in+paclitaxel-induced+sensory+peripheral+neuropathy&doi=10.1158%2F1078-0432.CCR-15-0133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy</span></div><div class="casAuthors">Komatsu, Masaaki; Wheeler, Heather E.; Chung, Suyoun; Low, Siew-Kee; Wing, Claudia; Delaney, Shannon M.; Gorsic, Lidija K.; Takahashi, Atsushi; Kubo, Michiaki; Kroetz, Deanna L.; Zhang, Wei; Nakamura, Yusuke; Dolan, M. Eileen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4337-4346</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Paclitaxel is used worldwide in the treatment of breast, lung, ovarian, and other cancers.  Sensory peripheral neuropathy is an assocd. adverse effect that cannot be predicted, prevented, or mitigated.  To better understand the contribution of germline genetic variation to paclitaxel-induced peripheral neuropathy, we undertook an integrative approach that combines genome-wide assocn. study (GWAS) data generated from HapMap lymphoblastoid cell lines (LCL) and Asian patients.  Methods: GWAS was performed with paclitaxel-induced cytotoxicity generated in 363 LCLs and with paclitaxel-induced neuropathy from 145 Asian patients.  A gene-based approach was used to identify overlapping genes and compare with a European clin. cohort of paclitaxel-induced neuropathy.  Neurons derived from human-induced pluripotent stem cells were used for functional validation of candidate genes.  Results: SNPs near AIPL1 were significantly assocd. with paclitaxel-induced cytotoxicity in Asian LCLs (P < 10-6).  Decreased expression of AIPL1 resulted in decreased sensitivity of neurons to paclitaxel by inducing neurite morphol. changes as measured by increased relative total outgrowth, no. of processes and mean process length.  Using a gene-based anal., there were 32 genes that overlapped between Asian LCL cytotoxicity and Asian patient neuropathy (P < 0.05), including BCR.  Upon BCR knockdown, there was an increase in neuronal sensitivity to paclitaxel as measured by neurite morphol. characteristics.  Conclusions: We identified genetic variants assocd. with Asian paclitaxel-induced cytotoxicity and functionally validated the AIPL1 and BCR in a neuronal cell model.  Furthermore, the integrative pharmacogenomics approach of LCL/patient GWAS may help prioritize target genes assocd. with chemotherapeutic-induced peripheral neuropathy.  Clin Cancer Res; 21(19); 4337-46. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvaD38LNLR5LVg90H21EOLACvtfcHk0ljS6hG7oszt-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1antLrP&md5=7a16c73389400e62255b8f581fdc6b87</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-0133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-0133%26sid%3Dliteratum%253Aachs%26aulast%3DKomatsu%26aufirst%3DM.%26aulast%3DWheeler%26aufirst%3DH.%2BE.%26aulast%3DChung%26aufirst%3DS.%26aulast%3DLow%26aufirst%3DS.-K.%26aulast%3DWing%26aufirst%3DC.%26aulast%3DDelaney%26aufirst%3DS.%2BM.%26aulast%3DGorsic%26aufirst%3DL.%2BK.%26aulast%3DTakahashi%26aufirst%3DA.%26aulast%3DKubo%26aufirst%3DM.%26aulast%3DKroetz%26aufirst%3DD.%2BL.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DNakamura%26aufirst%3DY.%26aulast%3DDolan%26aufirst%3DM.%2BE.%26atitle%3DPharmacoethnicity%2520in%2520paclitaxel-induced%2520sensory%2520peripheral%2520neuropathy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D4337%26epage%3D4346%26doi%3D10.1158%2F1078-0432.CCR-15-0133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eckford, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharom, F. J.</span></span> <span> </span><span class="NLM_article-title">ABC efflux pump-based resistance to chemotherapy drugs</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">2989</span>– <span class="NLM_lpage">3011</span>, <span class="refDoi"> DOI: 10.1021/cr9000226</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr9000226" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlslSmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2009&pages=2989-3011&author=P.+D.+Eckfordauthor=F.+J.+Sharom&title=ABC+efflux+pump-based+resistance+to+chemotherapy+drugs&doi=10.1021%2Fcr9000226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">ABC Efflux Pump-Based Resistance to Chemotherapy Drugs</span></div><div class="casAuthors">Eckford, Paul D. W.; Sharom, Frances J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2989-3011</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Over 1 million new cases of all types of cancer are diagnosed each year in the United States alone, and 559, 650 cancer-related deaths were expected to occur in 2007.  Chemotherapeutic treatment of cancers is an important tool to combat this devastating disease.  However, chemotherapy can fail due to the development of tumor cell resistance to multiple drugs, a phenomenon known as multidrug resistance (MDR), and essentially all cancer-related deaths are considered to be a result of chemotherapy failure.  MDR can have many causes, but one important mechanism of drug resistance is the expression of active drug efflux pumps in the membranes of cancer cells.  The efflux pump proteins mediating MDR in human cancers belong to the ATP-Binding Cassette (ABC) superfamily of proteins.  This is a diverse group of (primarily) active membrane transporters and is one of the largest known protein families.  Its members include proteins that mediate a variety of transport processes, in both prokaryotes (e.g., membrane-embedded importers for sugars and amino acids, and drug exporters) and eukaryotes, where only ABC exporters are known.  The 49 ABC proteins identified in the human genome (there appear to be 48 functional proteins) are involved in the efflux of substrates such as phospholipids, sterols, bile salts, and amphipathic drugs.  While as many as 15 ABC transporters have been obsd. to export chemotherapy drugs using in vitro exptl. systems, only 3 transporters have thus far been implicated as major contributors to MDR in cancer.  Discovered over 30 years ago, P-glycoprotein (Pgp; MDR1; ABCB1), was the first mammalian ABC protein to be identified.  Multidrug resistance-assocd. protein 1 (MRP1 or ABCC1) and more recently ABCG2 (also termed the breast cancer resistance protein, BCRP, or mitoxantrone resistance protein, MXR) also appear to function as clin. relevant drug efflux pumps.  All three proteins were discovered as factors over-expressed in MDR cell lines in culture, and they have since been detected in MDR tumors in patients.  Considerable effort has been made to understand the structure and function of these three drug pumps, which possess a unique ability to recognize and transport a broad array of structurally diverse compds. out of the cell.  The development of compds. known as modulators, which are able to reverse MDR by blocking or inhibiting the ATP-dependent transport function of these proteins, is also an important goal of researchers in this field.  This review will summarize our understanding of the substrate specificity of the mammalian drug efflux pumps, their structure, the mol. mechanisms by which they exert their function, and the progress made to date in reversing pump-mediated MDR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZIkwCqe_qg7Vg90H21EOLACvtfcHk0liHOeR4B0rmug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlslSmtbg%253D&md5=5009e7a7cac6977a296fd5bbf97d7df7</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fcr9000226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr9000226%26sid%3Dliteratum%253Aachs%26aulast%3DEckford%26aufirst%3DP.%2BD.%26aulast%3DSharom%26aufirst%3DF.%2BJ.%26atitle%3DABC%2520efflux%2520pump-based%2520resistance%2520to%2520chemotherapy%2520drugs%26jtitle%3DChem.%2520Rev.%26date%3D2009%26volume%3D109%26spage%3D2989%26epage%3D3011%26doi%3D10.1021%2Fcr9000226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargsten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuevas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liniger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuhaus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span> <span> </span><span class="NLM_article-title">A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">13817</span>– <span class="NLM_lpage">13821</span>, <span class="refDoi"> DOI: 10.1073/pnas.1408124111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1073%2Fpnas.1408124111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=25114240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCju7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=13817-13821&author=A.+E.+Protaauthor=K.+Bargstenauthor=J.+F.+Diazauthor=M.+Marshauthor=C.+Cuevasauthor=M.+Linigerauthor=C.+Neuhausauthor=J.+M.+Andreuauthor=K.+H.+Altmannauthor=M.+O.+Steinmetz&title=A+new+tubulin-binding+site+and+pharmacophore+for+microtubule-destabilizing+anticancer+drugs&doi=10.1073%2Fpnas.1408124111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs</span></div><div class="casAuthors">Prota, Andrea E.; Bargsten, Katja; Diaz, J. Fernando; Marsh, May; Cuevas, Carmen; Liniger, Marc; Neuhaus, Christian; Andreu, Jose M.; Altmann, Karl-Heinz; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">13817-13821</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The recent success of antibody-drug conjugates (ADCs) in the treatment of cancer has led to a revived interest in microtubule-destabilizing agents.  Here, we detd. the high-resoln. crystal structure of the complex between tubulin and maytansine, which is part of an ADC that is approved by the US Food and Drug Administration (FDA) for the treatment of advanced breast cancer.  We found that the drug binds to a site on β-tubulin that is distinct from the vinca domain and that blocks the formation of longitudinal tubulin interactions in microtubules.  We also solved crystal structures of tubulin in complex with both a variant of rhizoxin and the phase 1 drug PM060184.  Consistent with biochem. and mutagenesis data, we found that the two compds. bound to the same site as maytansine and that the structures revealed a common pharmacophore for the three ligands.  Our results delineate a distinct mol. mechanism of action for the inhibition of microtubule assembly by clin. relevant agents.  They further provide a structural basis for the rational design of potent microtubule-destabilizing agents, thus opening opportunities for the development of next-generation ADCs for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX4icqk698gLVg90H21EOLACvtfcHk0liHOeR4B0rmug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCju7vM&md5=798cae320e427ff76c2099387d9e6ba4</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1408124111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1408124111%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DDiaz%26aufirst%3DJ.%2BF.%26aulast%3DMarsh%26aufirst%3DM.%26aulast%3DCuevas%26aufirst%3DC.%26aulast%3DLiniger%26aufirst%3DM.%26aulast%3DNeuhaus%26aufirst%3DC.%26aulast%3DAndreu%26aufirst%3DJ.%2BM.%26aulast%3DAltmann%26aufirst%3DK.%2BH.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DA%2520new%2520tubulin-binding%2520site%2520and%2520pharmacophore%2520for%2520microtubule-destabilizing%2520anticancer%2520drugs%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2014%26volume%3D111%26spage%3D13817%26epage%3D13821%26doi%3D10.1073%2Fpnas.1408124111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnst, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Tubulin inhibitor-based antibody-drug conjugates for cancer therapy</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1281</span>, <span class="refDoi"> DOI: 10.3390/molecules22081281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.3390%2Fmolecules22081281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=28763044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Cls7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1281&author=H.+Chenauthor=Z.+Linauthor=K.+E.+Arnstauthor=D.+D.+Millerauthor=W.+Li&title=Tubulin+inhibitor-based+antibody-drug+conjugates+for+cancer+therapy&doi=10.3390%2Fmolecules22081281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulin inhibitor-based antibody-drug conjugates for cancer therapy</span></div><div class="casAuthors">Chen, Hao; Lin, Zongtao; Arnst, Kinsie E.; Miller, Duane D.; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1281/1-1281/28</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) are a class of highly potent biopharmaceutical drugs generated by conjugating cytotoxic drugs with specific monoclonal antibodies through appropriate linkers.  Specific antibodies used to guide potent warheads to tumor tissues can effectively reduce undesired side effects of the cytotoxic drugs.  An in-depth understanding of antibodies, linkers, conjugation strategies, cytotoxic drugs, and their mol. targets has led to the successful development of several approved ADCs.  These ADCs are powerful therapeutics for cancer treatment, enabling wider therapeutic windows, improved pharmacokinetic/pharmacodynamic properties, and enhanced efficacy.  Since tubulin inhibitors are one of the most successful cytotoxic drugs in the ADC armamentarium, this review focuses on the progress in tubulin inhibitor-based ADCs, as well as lessons learned from the unsuccessful ADCs contg. tubulin inhibitors.  This review should be helpful to facilitate future development of new generations of tubulin inhibitor-based ADCs for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8A0aJYR6aBLVg90H21EOLACvtfcHk0liHOeR4B0rmug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Cls7zI&md5=eb6efd4fdf44b5c0294a9becbeffab86</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22081281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22081281%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DArnst%26aufirst%3DK.%2BE.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DTubulin%2520inhibitor-based%2520antibody-drug%2520conjugates%2520for%2520cancer%2520therapy%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26spage%3D1281%26doi%3D10.3390%2Fmolecules22081281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueras, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borbely, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sewald, N.</span></span> <span> </span><span class="NLM_article-title">Cryptophycins: cytotoxic cyclodepsipeptides with potential for tumor targeting</span>. <i>J. Pept. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">514</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1002/psc.3015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1002%2Fpsc.3015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=28661555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVynsbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=514-531&author=C.+Weissauthor=E.+Figuerasauthor=A.+N.+Borbelyauthor=N.+Sewald&title=Cryptophycins%3A+cytotoxic+cyclodepsipeptides+with+potential+for+tumor+targeting&doi=10.1002%2Fpsc.3015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Cryptophycins: cytotoxic cyclodepsipeptides with potential for tumor targeting</span></div><div class="casAuthors">Weiss, Christine; Figueras, Eduard; Borbely, Adina N.; Sewald, Norbert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">514-531</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Cryptophycins are a class of 16-membered highly cytotoxic macrocyclic depsipeptides isolated from cyanobacteria.  The biol. activity is based on their ability to interact with tubulin.  They interfere with microtubule dynamics and prevent microtubules from forming correct mitotic spindles, which causes cell-cycle arrest and apoptosis.  Their strong antiproliferative activities with 100-fold to 1000-fold potency compared with those of paclitaxel and vinblastine have been obsd.  Cryptophycins are highly promising drug candidates, as their biol. activity is not neg. affected by P-glycoprotein, a drug efflux system commonly found in multidrug-resistant cancer cell lines and solid tumors.  Cryptophycin-52 had been investigated in phase II clin. trials but failed because of its high neurotoxicity.  Recently, cryptophycin conjugates with peptides and antibodies have been developed for targeted delivery in tumor therapy.  Copyright © 2017 European Peptide Society and John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXyzZ4nRHc1rVg90H21EOLACvtfcHk0liHtf2sB_N_Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVynsbjO&md5=7323983af8ce00e5db1fc07fe14b23bd</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fpsc.3015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.3015%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DC.%26aulast%3DFigueras%26aufirst%3DE.%26aulast%3DBorbely%26aufirst%3DA.%2BN.%26aulast%3DSewald%26aufirst%3DN.%26atitle%3DCryptophycins%253A%2520cytotoxic%2520cyclodepsipeptides%2520with%2520potential%2520for%2520tumor%2520targeting%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2017%26volume%3D23%26spage%3D514%26epage%3D531%26doi%3D10.1002%2Fpsc.3015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muniz-Medina, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetzel, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebelatto, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinrichs, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezabeh, B. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimasi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toader, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixit, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osbourn, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coats, S. R.</span></span> <span> </span><span class="NLM_article-title">A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.ccell.2015.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=26766593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC28Xmsl2lsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=117-129&author=J.+Liauthor=S.+R.+Perryauthor=V.+Muniz-Medinaauthor=X.+Wangauthor=L.+K.+Wetzelauthor=M.+C.+Rebelattoauthor=M.+J.+Hinrichsauthor=B.+Z.+Bezabehauthor=R.+L.+Flemingauthor=N.+Dimasiauthor=H.+Fengauthor=D.+Toaderauthor=A.+Yuanauthor=L.+Xuauthor=J.+Linauthor=C.+Gaoauthor=H.+Wuauthor=R.+Dixitauthor=J.+K.+Osbournauthor=S.+R.+Coats&title=A+biparatopic+HER2-targeting+antibody-drug+conjugate+induces+tumor+regression+in+primary+models+refractory+to+or+ineligible+for+HER2-targeted+therapy&doi=10.1016%2Fj.ccell.2015.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy</span></div><div class="casAuthors">Li, John Y.; Perry, Samuel R.; Muniz-Medina, Vanessa; Wang, Xinzhong; Wetzel, Leslie K.; Rebelatto, Marlon C.; Hinrichs, Mary Jane Masson; Bezabeh, Binyam Z.; Fleming, Ryan L.; Dimasi, Nazzareno; Feng, Hui; Toader, Dorin; Yuan, Andy Q.; Xu, Lan; Lin, Jia; Gao, Changshou; Wu, Herren; Dixit, Rakesh; Osbourn, Jane K.; Coats, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">117-129</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Antibody-drug conjugate (ADC) which delivers cytotoxic drugs specifically into targeted cells through internalization and lysosomal trafficking has emerged as an effective cancer therapy.  We show that a bivalent biparatopic antibody targeting two non-overlapping epitopes on HER2 can induce HER2 receptor clustering, which in turn promotes robust internalization, lysosomal trafficking, and degrdn.  When conjugated with a tubulysin-based microtubule inhibitor, the biparatopic ADC demonstrates superior anti-tumor activity over ado-trastuzumab emtansine (T-DM1) in tumor models representing various patient subpopulations, including T-DM1 eligible, T-DM1 ineligible, and T-DM1 relapsed/refractory.  Our findings indicate that this biparatopic ADC has promising potential as an effective therapy for metastatic breast cancer and a broader patient population may benefit from this unique HER2-targeting ADC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp18b-9TGTzUbVg90H21EOLACvtfcHk0liHtf2sB_N_Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xmsl2lsA%253D%253D&md5=bbd94b53427de32f8d636b63507dd139</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DPerry%26aufirst%3DS.%2BR.%26aulast%3DMuniz-Medina%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWetzel%26aufirst%3DL.%2BK.%26aulast%3DRebelatto%26aufirst%3DM.%2BC.%26aulast%3DHinrichs%26aufirst%3DM.%2BJ.%26aulast%3DBezabeh%26aufirst%3DB.%2BZ.%26aulast%3DFleming%26aufirst%3DR.%2BL.%26aulast%3DDimasi%26aufirst%3DN.%26aulast%3DFeng%26aufirst%3DH.%26aulast%3DToader%26aufirst%3DD.%26aulast%3DYuan%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DDixit%26aufirst%3DR.%26aulast%3DOsbourn%26aufirst%3DJ.%2BK.%26aulast%3DCoats%26aufirst%3DS.%2BR.%26atitle%3DA%2520biparatopic%2520HER2-targeting%2520antibody-drug%2520conjugate%2520induces%2520tumor%2520regression%2520in%2520primary%2520models%2520refractory%2520to%2520or%2520ineligible%2520for%2520HER2-targeted%2520therapy%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D29%26spage%3D117%26epage%3D129%26doi%3D10.1016%2Fj.ccell.2015.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mullard, A.</span></span> <span> </span><span class="NLM_article-title">Maturing antibody-drug conjugate pipeline hits 30</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1038/nrd4009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1038%2Fnrd4009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=23629491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1Oiurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=329-332&author=A.+Mullard&title=Maturing+antibody-drug+conjugate+pipeline+hits+30&doi=10.1038%2Fnrd4009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Maturing antibody-drug conjugate pipeline hits 30</span></div><div class="casAuthors">Mullard, Asher</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">329-332</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Driven by recent clin. breakthroughs and technol. progress, 30 antibody-drug conjugates against over 24 targets are now in trials for blood cancers and solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO0a4pT6o-p7Vg90H21EOLACvtfcHk0liHtf2sB_N_Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1Oiurc%253D&md5=ac0fd840838077375f99e17a6e3ba303</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fnrd4009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4009%26sid%3Dliteratum%253Aachs%26aulast%3DMullard%26aufirst%3DA.%26atitle%3DMaturing%2520antibody-drug%2520conjugate%2520pipeline%2520hits%252030%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D329%26epage%3D332%26doi%3D10.1038%2Fnrd4009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasamon, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Claro, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenthal, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA approval summary: Brentuximab Vedotin in first-line treatment of peripheral T-Cell lymphoma</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">180</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2019-0098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1634%2Ftheoncologist.2019-0098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=30914464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFKhs7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=180-187&author=N.+C.+Richardsonauthor=Y.+L.+Kasamonauthor=H.+Chenauthor=R.+A.+de+Claroauthor=J.+Yeauthor=G.+M.+Blumenthalauthor=A.+T.+Farrellauthor=R.+Pazdur&title=FDA+approval+summary%3A+Brentuximab+Vedotin+in+first-line+treatment+of+peripheral+T-Cell+lymphoma&doi=10.1634%2Ftheoncologist.2019-0098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma</span></div><div class="casAuthors">Richardson, Nicholas C.; Kasamon, Yvette L.; Chen, Haiyan; de Claro, R. Angelo; Ye, Jingjing; Blumenthal, Gideon M.; Farrell, Ann T.; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e180-e187</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1549-490X</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">Approval was based on ECHELON-2, a randomized, double-blind, actively controlled trial that compared BV+CHP with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in 452 patients with newly diagnosed, CD30-expressing PTCL.  Efficacy was based on independent review facility-assessed progression-free survival (PFS).  The median PFS was 48.2 mo with BV+CHP vs. 20.8 mo with CHOP, resulting in a hazard ratio (HR) of 0.71 (95% confidence interval).  The trial also demonstrated improvement in overall survival (HR 0.66; 95% CI: 0.46-0.95), complete response rate (68% vs. 56%), and overall response rate (83% vs. 72%) with BV+CHP.  The most common adverse reactions (incidence ≥20%) obsd. ≥2% more with BV+CHP were nausea, diarrhea, fatigue or asthenia, mucositis, pyrexia, vomiting, and anemia.  Peripheral neuropathy rates were similar (52% with BV+CHP, 55% with CHOP).  Through the Real-Time Oncol. Review pilot program, which allows FDA early access to key data, FDA granted this approval less than 2 wk after official submission of the application.  Implications for Practice : This is the first U.S. Food and Drug Administration approval for treatment of patients with newly diagnosed peripheral T-cell lymphomas (PTCL).  Improvement in progression-free and overall survival over cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy, which has been the std. of care for decades, is unprecedented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEhAAcx2pjcbVg90H21EOLACvtfcHk0lhABluyzxcuZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFKhs7fF&md5=1508f5760132350665aaa03a10ed0623</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2019-0098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2019-0098%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DN.%2BC.%26aulast%3DKasamon%26aufirst%3DY.%2BL.%26aulast%3DChen%26aufirst%3DH.%26aulast%3Dde%2BClaro%26aufirst%3DR.%2BA.%26aulast%3DYe%26aufirst%3DJ.%26aulast%3DBlumenthal%26aufirst%3DG.%2BM.%26aulast%3DFarrell%26aufirst%3DA.%2BT.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520approval%2520summary%253A%2520Brentuximab%2520Vedotin%2520in%2520first-line%2520treatment%2520of%2520peripheral%2520T-Cell%2520lymphoma%26jtitle%3DOncologist%26date%3D2019%26volume%3D24%26spage%3D180%26epage%3D187%26doi%3D10.1634%2Ftheoncologist.2019-0098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Komlodi-Pasztor, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sackett, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkerson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fojo, T.</span></span> <span> </span><span class="NLM_article-title">Mitosis is not a key target of microtubule agents in patient tumors</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">244</span>– <span class="NLM_lpage">250</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2010.228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1038%2Fnrclinonc.2010.228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=21283127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFKlsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=244-250&author=E.+Komlodi-Pasztorauthor=D.+Sackettauthor=J.+Wilkersonauthor=T.+Fojo&title=Mitosis+is+not+a+key+target+of+microtubule+agents+in+patient+tumors&doi=10.1038%2Fnrclinonc.2010.228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Mitosis is not a key target of microtubule agents in patient tumors</span></div><div class="casAuthors">Komlodi-Pasztor, Edina; Sackett, Dan; Wilkerson, Julia; Fojo, Tito</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">244-250</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In this Perspective, the clin. disappointment of mitosis-specific agents is explained in the context of the mechanism of action of microtubule-targeting agents.  The authors propose a new paradigm for the anticancer activity of microtubule-targeting agents and suggest that mitosis-specific inhibitors will not result in significant clin. impact.  Mitosis-specific agents have, to date, not been clin. successful.  By contrast, microtubule-targeting agents (MTAs) have a long record of success, usually attributed to the induction of mitotic arrest.  Indeed, it was this success that led to the search for mitosis-specific inhibitors.  We believe the clin. disappointment of mitosis-specific inhibitors stands as evidence that MTAs have been successful not only by interfering with mitosis but, more importantly, by disrupting essential interphase cellular mechanisms.  In this Perspective we will review literature that supports a paradigm shift in how we think about one of our most widely used classes of chemotherapeutics-MTAs.  We believe that the steady presence and const. physiol. role of microtubules are responsible for the overall success of MTAs.  While mitosis-specific inhibitors are effective on only a small fraction of the tumor mass (dividing cells), MTAs target tubulin, a protein that has crucial roles in both mitotic and non-mitotic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYOmCILGEs2LVg90H21EOLACvtfcHk0lhABluyzxcuZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFKlsLY%253D&md5=2a72541e9b990534b74e88c18265e4c8</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2010.228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2010.228%26sid%3Dliteratum%253Aachs%26aulast%3DKomlodi-Pasztor%26aufirst%3DE.%26aulast%3DSackett%26aufirst%3DD.%26aulast%3DWilkerson%26aufirst%3DJ.%26aulast%3DFojo%26aufirst%3DT.%26atitle%3DMitosis%2520is%2520not%2520a%2520key%2520target%2520of%2520microtubule%2520agents%2520in%2520patient%2520tumors%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D8%26spage%3D244%26epage%3D250%26doi%3D10.1038%2Fnrclinonc.2010.228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Komlodi-Pasztor, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sackett, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fojo, A. T.</span></span> <span> </span><span class="NLM_article-title">Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-0999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1158%2F1078-0432.CCR-11-0999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=22215906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFWnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=51-63&author=E.+Komlodi-Pasztorauthor=D.+L.+Sackettauthor=A.+T.+Fojo&title=Inhibitors+targeting+mitosis%3A+tales+of+how+great+drugs+against+a+promising+target+were+brought+down+by+a+flawed+rationale&doi=10.1158%2F1078-0432.CCR-11-0999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale</span></div><div class="casAuthors">Komlodi-Pasztor, Edina; Sackett, Dan L.; Fojo, Antonio Tito</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-63</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Although they have been advocated with an understandable enthusiasm, mitosis-specific agents such as inhibitors of mitotic kinases and kinesin spindle protein have not been successful clin.  These drugs were developed as agents that would build on the success of microtubule-targeting agents while avoiding the neurotoxicity that encumbers drugs such as taxanes and vinca alkaloids.  The rationale for using mitosis-specific agents was based on the thesis that the clin. efficacy of microtubule-targeting agents could be ascribed to the induction of mitotic arrest.  However, the latter concept, which has long been accepted as dogma, is likely important only in cell culture and rapidly growing preclin. models, and irrelevant in patient tumors, where interference with intracellular trafficking on microtubules is likely the principal mechanism of action.  Here we review the preclin. and clin. data for a diverse group of inhibitors that target mitosis and identify the reasons why these highly specific, myelosuppressive compds. have failed to deliver on their promise.  Clin Cancer Res; 18(1); 51-63.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZXlw38i-HRLVg90H21EOLACvtfcHk0ljjKWLEm547XA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFWnuw%253D%253D&md5=f99140d6004600cb2f364f7d87f24f5d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0999%26sid%3Dliteratum%253Aachs%26aulast%3DKomlodi-Pasztor%26aufirst%3DE.%26aulast%3DSackett%26aufirst%3DD.%2BL.%26aulast%3DFojo%26aufirst%3DA.%2BT.%26atitle%3DInhibitors%2520targeting%2520mitosis%253A%2520tales%2520of%2520how%2520great%2520drugs%2520against%2520a%2520promising%2520target%2520were%2520brought%2520down%2520by%2520a%2520flawed%2520rationale%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D51%26epage%3D63%26doi%3D10.1158%2F1078-0432.CCR-11-0999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitchison, T. J.</span></span> <span> </span><span class="NLM_article-title">The proliferation rate paradox in antimitotic chemotherapy</span>. <i>Mol. Biol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1091/mbc.e10-04-0335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1091%2Fmbc.e10-04-0335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=22210845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVylsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=1-6&author=T.+J.+Mitchison&title=The+proliferation+rate+paradox+in+antimitotic+chemotherapy&doi=10.1091%2Fmbc.e10-04-0335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The proliferation rate paradox in antimitotic chemotherapy</span></div><div class="casAuthors">Mitchison, Timothy J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology of the Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">MBCEEV</span>;
        ISSN:<span class="NLM_cas:issn">1939-4586</span>.
    
            (<span class="NLM_cas:orgname">American Society for Cell Biology</span>)
        </div><div class="casAbstract">A review.  Cytotoxic cancer chemotherapy drugs are believed to gain selectivity by targeting cells that proliferate rapidly.  However, the proliferation rate is low in many chemosensitive human cancers, and it is not clear how a drug that only kills dividing cells could promote tumor regression.  Four potential solns. to this "proliferation rate paradox" are discussed for the microtubule-stabilizing drug paclitaxel: drug retention in tumors, killing of quiescent cells, targeting of noncancer cells in the tumor, and bystander effects.  Testing these potential mechanisms of drug action will facilitate rational improvement of antimitotic chemotherapy and perhaps cytotoxic chemotherapy more generally.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGostPy_gyyJCLVg90H21EOLACvtfcHk0ljjKWLEm547XA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVylsA%253D%253D&md5=32fea5a5b4d14d23feca77c5f5ab6823</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1091%2Fmbc.e10-04-0335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.e10-04-0335%26sid%3Dliteratum%253Aachs%26aulast%3DMitchison%26aufirst%3DT.%2BJ.%26atitle%3DThe%2520proliferation%2520rate%2520paradox%2520in%2520antimitotic%2520chemotherapy%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D2012%26volume%3D23%26spage%3D1%26epage%3D6%26doi%3D10.1091%2Fmbc.e10-04-0335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanakkanthara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. H.</span></span> <span> </span><span class="NLM_article-title">Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">5050</span>– <span class="NLM_lpage">5059</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.02.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.bmc.2014.02.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=24650703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksVWqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=5050-5059&author=J.+J.+Fieldauthor=A.+Kanakkantharaauthor=J.+H.+Miller&title=Microtubule-targeting+agents+are+clinically+successful+due+to+both+mitotic+and+interphase+impairment+of+microtubule+function&doi=10.1016%2Fj.bmc.2014.02.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function</span></div><div class="casAuthors">Field, Jessica J.; Kanakkanthara, Arun; Miller, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5050-5059</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Microtubules undergo continual dynamic changes in mitotic cells as the mitotic spindle forms and is broken down and in interphase cells where they play a central role in intracellular trafficking, cell signaling, cell migration, and angiogenesis.  Compds. that target the microtubule have been hugely successful in the clinic as chemotherapeutics, and this success is likely due to their ability to target cells regardless of their cell cycle stage.  Addnl., new generation antibody-conjugated microtubule-targeting agents are improving the targeting of these drugs to tumors.  Microtubule-targeting agents have been shown to have anti-angiogenic and vascular-disrupting properties as well as effects on cellular migration, intracellular trafficking, and cell secretion.  There are a no. of these compds. in development that target the vasculature, and different formulations of clin. used drugs are being developed to take advantage of these anti-angiogenic properties.  Microtubule-targeting agents have also been shown to have the potential to treat neurodegenerative diseases, such as Alzheimer's disease.  Thus, drugs that target the microtubule will continue to have a major impact in oncol. not only as anti-mitotics but also as potent inhibitors of interphase functions, and in future may also prove to be effective in reducing the consequences of neurodegenerative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2d-DR0ciixrVg90H21EOLACvtfcHk0ljjKWLEm547XA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksVWqsrw%253D&md5=e3ec8c5c15dfe25d1c527cecaec20d2f</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.02.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.02.035%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DJ.%2BJ.%26aulast%3DKanakkanthara%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DJ.%2BH.%26atitle%3DMicrotubule-targeting%2520agents%2520are%2520clinically%2520successful%2520due%2520to%2520both%2520mitotic%2520and%2520interphase%2520impairment%2520of%2520microtubule%2520function%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D5050%26epage%3D5059%26doi%3D10.1016%2Fj.bmc.2014.02.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogden, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rida, P. C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aneja, R.</span></span> <span> </span><span class="NLM_article-title">Interphase microtubules: chief casualties in the war on cancer?</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">824</span>– <span class="NLM_lpage">829</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.10.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.drudis.2013.10.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=24201225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvValtbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=824-829&author=A.+Ogdenauthor=P.+C.+G.+Ridaauthor=M.+D.+Reidauthor=R.+Aneja&title=Interphase+microtubules%3A+chief+casualties+in+the+war+on+cancer%3F&doi=10.1016%2Fj.drudis.2013.10.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Interphase microtubules: chief casualties in the war on cancer?</span></div><div class="casAuthors">Ogden, Angela; Rida, Padmashree C. G.; Reid, Michelle D.; Aneja, Ritu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">824-829</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Microtubule-targeting agents (MTAs) profoundly affect interphase cells, such as by disrupting axonal transport, transcription, translation, mitochondrial permeability, immune cell function, directional migration and centrosome clustering.  This finding is antithetical to the conventionally held notion that MTAs act on mitosis to trigger arrest-mediated apoptotic cell death.  Furthermore, the paucity of mitotic cells in patient tumors and lack of correlation of MTA efficacy with tumor proliferation rate provide strong impetus to re-examine the mechanistic basis of action of MTAs, with an eye toward interphase activities.  Whereas targeted antimitotics have unequivocally failed their promise across clin. studies, MTAs constitute a mainstay of chemotherapy.  This paradox necessitates the conclusion that MTAs exert mitosis-independent effects, spurring a dramatic paradigm shift in our understanding of the mode of action of MTAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ1qu2htK9XLVg90H21EOLACvtfcHk0ljjKWLEm547XA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvValtbjK&md5=adedd47ce4b6fdf0239e9d107c62c751</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.10.022%26sid%3Dliteratum%253Aachs%26aulast%3DOgden%26aufirst%3DA.%26aulast%3DRida%26aufirst%3DP.%2BC.%2BG.%26aulast%3DReid%26aufirst%3DM.%2BD.%26aulast%3DAneja%26aufirst%3DR.%26atitle%3DInterphase%2520microtubules%253A%2520chief%2520casualties%2520in%2520the%2520war%2520on%2520cancer%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D824%26epage%3D829%26doi%3D10.1016%2Fj.drudis.2013.10.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoffski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littlefield, B. A.</span></span> <span> </span><span class="NLM_article-title">Multiple modes of action of eribulin mesylate: emerging data and clinical implications</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">190</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2018.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.ctrv.2018.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=30243063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslGmu7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2018&pages=190-198&author=J.+Cortesauthor=P.+Schoffskiauthor=B.+A.+Littlefield&title=Multiple+modes+of+action+of+eribulin+mesylate%3A+emerging+data+and+clinical+implications&doi=10.1016%2Fj.ctrv.2018.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple modes of action of eribulin mesylate: Emerging data and clinical implications</span></div><div class="casAuthors">Cortes, Javier; Schoffski, Patrick; Littlefield, Bruce A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">190-198</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Eribulin mesylate (eribulin) is a synthetic analog of the marine-sponge natural product halichondrin B.  Eribulin exhibits potent antiproliferative activities against a variety of human cancer cell types in vitro and in vivo, and is used for the treatment of certain patients with advanced breast cancer or liposarcoma who are refractory to other treatments.  The antiproliferative effects of eribulin have long been attributed to its antimitotic activities.  Unlike other microtubule-targeting agents, eribulin inhibits microtubule polymn. through specific plus end binding, thus interfering with microtubule dynamic instability.  Non-mitotic effects of eribulin on tumor biol. have also been established in lab. settings including: tumor vasculature remodeling, increased vascular perfusion, reduced hypoxia, and phenotypic changes involving reversal of epithelial-to-mesenchymal transition (EMT), resulting in reduced capacities for migration, invasion, and seeding lung metastases in exptl. models.  Preclin. data suggest that increased perfusion following eribulin treatment improves delivery of subsequent drugs.  Supporting evidence for eribulin's non-mitotic effects in the clin. setting include increased tumor oxygen satn., reduced hypoxia, phenotype changes consistent with EMT reversal, and genotype changes consistent with shifts from nonendocrine-responsive, luminal B, to endocrine-responsive, luminal A, breast cancer subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf9YvSLvGcq7Vg90H21EOLACvtfcHk0li_iTIlqkiW5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslGmu7jN&md5=dca422e5d6cf4ecd36c77b5697e0d4c2</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2018.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2018.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DSchoffski%26aufirst%3DP.%26aulast%3DLittlefield%26aufirst%3DB.%2BA.%26atitle%3DMultiple%2520modes%2520of%2520action%2520of%2520eribulin%2520mesylate%253A%2520emerging%2520data%2520and%2520clinical%2520implications%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2018%26volume%3D70%26spage%3D190%26epage%3D198%26doi%3D10.1016%2Fj.ctrv.2018.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bates, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, A.</span></span> <span> </span><span class="NLM_article-title">Microtubule destabilizing agents: far more than just antimitotic anticancer drugs</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">268</span>, <span class="refDoi"> DOI: 10.1111/bcp.13126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1111%2Fbcp.13126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=27620987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFajs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2017&pages=255-268&author=D.+Batesauthor=A.+Eastman&title=Microtubule+destabilizing+agents%3A+far+more+than+just+antimitotic+anticancer+drugs&doi=10.1111%2Fbcp.13126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule destabilizing agents: far more than just antimitotic anticancer drugs</span></div><div class="casAuthors">Bates, Darcy; Eastman, Alan</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">255-268</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Vinca alkaloids have been approved as anticancer drugs for more than 50 years.  They have been classified as cytotoxic chemotherapy drugs that act during cellular mitosis, enabling them to target fast growing cancer cells.  With the evolution of cancer drug development there has been a shift towards new "targeted" therapies to avoid the side effects and general toxicities of "cytotoxic chemotherapies" such as the vinca alkaloids.  Due to their original classification, many have overlooked the fact that vinca alkaloids, taxanes and related drugs do have a specific mol. target: tubulin.  They continue to be some of the most effective anticancer drugs, perhaps because their actions upon the microtubule network extend far beyond the ability to halt cells in mitosis, and include the induction of apoptosis at all phases of the cell cycle.  In this review, we highlight the numerous cellular consequences of disrupting microtubule dynamics, expanding the textbook knowledge of microtubule destabilizing agents and providing novel opportunities for their use in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob4cJkJIQJPLVg90H21EOLACvtfcHk0li_iTIlqkiW5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFajs74%253D&md5=e859fcd74dd984b711065f278abb5479</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1111%2Fbcp.13126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.13126%26sid%3Dliteratum%253Aachs%26aulast%3DBates%26aufirst%3DD.%26aulast%3DEastman%26aufirst%3DA.%26atitle%3DMicrotubule%2520destabilizing%2520agents%253A%2520far%2520more%2520than%2520just%2520antimitotic%2520anticancer%2520drugs%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2017%26volume%3D83%26spage%3D255%26epage%3D268%26doi%3D10.1111%2Fbcp.13126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindamulage, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karthikeyan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knockleby, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span> <span> </span><span class="NLM_article-title">Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">10298</span> <span class="refDoi"> DOI: 10.1038/s41598-017-10972-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1038%2Fs41598-017-10972-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=28860494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A280%3ADC%252BC1cbjsFyiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&author=I.+K.+Lindamulageauthor=H.+Y.+Vuauthor=C.+Karthikeyanauthor=J.+Knocklebyauthor=Y.+F.+Leeauthor=P.+Trivediauthor=H.+Lee&title=Novel+quinolone+chalcones+targeting+colchicine-binding+pocket+kill+multidrug-resistant+cancer+cells+by+inhibiting+tubulin+activity+and+MRP1+function&doi=10.1038%2Fs41598-017-10972-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function</span></div><div class="casAuthors">Lindamulage I Kalhari; Vu Hai-Yen; Knockleby James; Lee Yi-Fang; Lee Hoyun; Lindamulage I Kalhari; Lee Hoyun; Karthikeyan Chandrabose; Trivedi Piyush; Lee Hoyun</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10298</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Agents targeting colchicine-binding pocket usually show a minimal drug-resistance issue, albeit often associated with high toxicity.  Chalcone-based compounds, which may bind to colchicine-binding site, are found in many edible fruits, suggesting that they can be effective drugs with less toxicity.  Therefore, we synthesized and examined 24 quinolone chalcone compounds, from which we identified ((E)-3-(3-(2-Methoxyphenyl)-3-oxoprop-1-enyl) quinolin-2(1H)-one) (CTR-17) and ((E)-6-Methoxy-3-(3-(2-methoxyphenyl)-3-oxoprop-1-enyl) quinolin-2(1H)-one) (CTR-20) as promising leads.  In particular, CTR-20 was effective against 65 different cancer cell lines originated from 12 different tissues, largely in a cancer cell-specific manner.  We found that both CTR-17 and CTR-20 reversibly bind to the colchicine-binding pocket on β-tubulin.  Interestingly however, both the CTRs were highly effective against multidrug-resistant cancer cells while colchicine, paclitaxel and vinblastine were not.  Our study with CTR-20 showed that it overcomes multidrug-resistance through its ability to impede MRP1 function while maintaining strong inhibition against microtubule activity.  Data from mice engrafted with the MDA-MB-231 triple-negative breast cancer cells showed that both CTR-17 and CTR-20 possess strong anticancer activity, alone or in combination with paclitaxel, without causing any notable side effects.  Together, our data demonstrates that both the CTRs can be effective and safe drugs against many different cancers, especially against multidrug-resistant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRAuKrO7n1L5_h3YQQtAhNufW6udTcc2eaXICmzgTk3orntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbjsFyiuw%253D%253D&md5=78ff36072df15e19d4396fc05e1761f7</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-10972-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-10972-0%26sid%3Dliteratum%253Aachs%26aulast%3DLindamulage%26aufirst%3DI.%2BK.%26aulast%3DVu%26aufirst%3DH.%2BY.%26aulast%3DKarthikeyan%26aufirst%3DC.%26aulast%3DKnockleby%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DY.%2BF.%26aulast%3DTrivedi%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DH.%26atitle%3DNovel%2520quinolone%2520chalcones%2520targeting%2520colchicine-binding%2520pocket%2520kill%2520multidrug-resistant%2520cancer%2520cells%2520by%2520inhibiting%2520tubulin%2520activity%2520and%2520MRP1%2520function%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26doi%3D10.1038%2Fs41598-017-10972-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loveless, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">3040</span>– <span class="NLM_lpage">3052</span>, <span class="refDoi"> DOI: 10.1007/s11095-012-0726-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1007%2Fs11095-012-0726-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=22410804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Gls7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=3040-3052&author=Z.+Wangauthor=J.+Chenauthor=J.+Wangauthor=S.+Ahnauthor=C.+M.+Liauthor=Y.+Luauthor=V.+S.+Lovelessauthor=J.+T.+Daltonauthor=D.+D.+Millerauthor=W.+Li&title=Novel+tubulin+polymerization+inhibitors+overcome+multidrug+resistance+and+reduce+melanoma+lung+metastasis&doi=10.1007%2Fs11095-012-0726-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Tubulin Polymerization Inhibitors Overcome Multidrug Resistance and Reduce Melanoma Lung Metastasis</span></div><div class="casAuthors">Wang, Zhao; Chen, Jianjun; Wang, Jin; Ahn, Sunjoo; Li, Chien-Ming; Lu, Yan; Loveless, Vivian S.; Dalton, James T.; Miller, Duane D.; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3040-3052</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: To evaluate abilities of 2-aryl-4-benzoyl-imidazoles (ABI) to overcome multidrug resistance (MDR), define their cellular target, and assess in vivo antimelanoma efficacy.  Methods: MDR cell lines that overexpressed P-glycoprotein, MDR-assocd. proteins, and breast cancer resistance protein were used to evaluate ABI ability to overcome MDR.  Cell cycle anal., mol. modeling, and microtubule imaging were used to define ABI cellular target.  SHO mice bearing A375 human melanoma xenograft were used to evaluate ABI in vivo antitumor activity.  B16-F10/C57BL mouse melanoma lung metastasis model was used to test ABI efficacy to inhibit tumor lung metastasis.  Results: ABIs showed similar potency to MDR cells compared to matching parent cells.  ABIs were identified to target tubulin on the colchicine binding site.  After 31 days of treatment, ABI-288 dosed at 25 mg/kg inhibited melanoma tumor growth by 69%; dacarbazine at 60 mg/kg inhibited growth by 52%.  ABI-274 dosed at 25 mg/kg showed better lung metastasis inhibition than dacarbazine at 60 mg/kg.  Conclusions: This new class of antimitotic compds. can overcome several clin. important drug resistant mechanisms in vitro and are effective in inhibiting melanoma lung metastasis in vivo, supporting their further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiBeRzq7uMtrVg90H21EOLACvtfcHk0lgHQR2-lY9Ovg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Gls7c%253D&md5=962529ba6111c68b909c7df593f4b072</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs11095-012-0726-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-012-0726-4%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DC.%2BM.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLoveless%26aufirst%3DV.%2BS.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DNovel%2520tubulin%2520polymerization%2520inhibitors%2520overcome%2520multidrug%2520resistance%2520and%2520reduce%2520melanoma%2520lung%2520metastasis%26jtitle%3DPharm.%2520Res.%26date%3D2012%26volume%3D29%26spage%3D3040%26epage%3D3052%26doi%3D10.1007%2Fs11095-012-0726-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siemann, D. W.</span></span> <span> </span><span class="NLM_article-title">The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2010.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.ctrv.2010.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=20570444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFajs7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2011&pages=63-74&author=D.+W.+Siemann&title=The+unique+characteristics+of+tumor+vasculature+and+preclinical+evidence+for+its+selective+disruption+by+tumor-vascular+disrupting+agents&doi=10.1016%2Fj.ctrv.2010.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents</span></div><div class="casAuthors">Siemann, Dietmar W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-74</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The vasculature of solid tumors is fundamentally different from that of normal vasculature and offers a unique target for anti-cancer therapy.  Direct vascular-targeting with Tumor-Vascular Disrupting Agents (Tumor-VDAs) is distinctly different from anti-angiogenic strategies, and offers a complementary approach to std. therapies.  Tumor-VDAs therefore have significant potential when combined with chemotherapy, radiotherapy, and angiogenesis-inhibiting agents.  Preclin. studies with the different Tumor-VDA classes have demonstrated key tumor-selective anti-vascular and anti-tumor effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKL8nIIVWtVbVg90H21EOLACvtfcHk0lgHQR2-lY9Ovg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFajs7vI&md5=85fe2cb36db459ad473bf53bbcae60af</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2010.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2010.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DSiemann%26aufirst%3DD.%2BW.%26atitle%3DThe%2520unique%2520characteristics%2520of%2520tumor%2520vasculature%2520and%2520preclinical%2520evidence%2520for%2520its%2520selective%2520disruption%2520by%2520tumor-vascular%2520disrupting%2520agents%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2011%26volume%3D37%26spage%3D63%26epage%3D74%26doi%3D10.1016%2Fj.ctrv.2010.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, M.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, P.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris-Natschke, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo-Hsiung Lee, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span> <span> </span><span class="NLM_article-title">In vivo and mechanistic studies on antitumor lead 7-methoxy-4-(2-methylquinazolin-4-yl)-3,4-dihydroquinoxalin-2(1<i>H</i>)-one and its modification as a novel class of tubulin-binding tumor-vascular disrupting agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5586</span>– <span class="NLM_lpage">5598</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00273</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00273" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVGrsL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5586-5598&author=M.-T.+Cuiauthor=L.+Jiangauthor=M.+Gotoauthor=P.-L.+Hsuauthor=L.+Liauthor=Q.+Zhangauthor=L.+Weiauthor=S.-J.+Yuanauthor=E.+Hamelauthor=S.+L.+Morris-Natschkeauthor=K.-H.+Kuo-Hsiung+Leeauthor=L.+Xie&title=In+vivo+and+mechanistic+studies+on+antitumor+lead+7-methoxy-4-%282-methylquinazolin-4-yl%29-3%2C4-dihydroquinoxalin-2%281H%29-one+and+its+modification+as+a+novel+class+of+tubulin-binding+tumor-vascular+disrupting+agents&doi=10.1021%2Facs.jmedchem.7b00273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">In Vivo and Mechanistic Studies on Antitumor Lead 7-Methoxy-4-(2-methylquinazolin-4-yl)-3,4-dihydroquinoxalin-2(1H)-one and Its Modification as a Novel Class of Tubulin-Binding Tumor-Vascular Disrupting Agents</span></div><div class="casAuthors">Cui, Mu-Tian; Jiang, Li; Goto, Masuo; Hsu, Pei-Ling; Li, Linna; Zhang, Qi; Wei, Lei; Yuan, Shou-Jun; Hamel, Ernest; Morris-Natschke, Susan L.; Lee, Kuo-Hsiung; Xie, Lan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5586-5598</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">7-Methoxy-4-(2-methylquinazolin-4-yl)-3,4-dihydroquinoxalin-2(1H)-one (2), a promising anticancer lead previously identified by us, inhibited tumor growth by 62% in mice at 1.0 mg/kg without obvious signs of toxicity.  Moreover, compd. 2 exhibited extremely high antiproliferative activity in the NIH-NCI 60 human tumor cell line panel, with low to sub-nanomolar GI50 values (10-10 M level).  It also showed a suitable balance between aq. soly. and lipophilicity, as well as moderate metabolic stability in vivo.  Mechanistic studies using Mayer's hematoxylin and eosin and immunohistochem. protocols on xenograft tumor tissues showed that 2 inhibited tumor cell proliferation, induced apoptosis, and disrupted tumor vasculature.  Moreover, evaluation of new synthetic analogs (6a-6t) of 2 indicated that appropriate 2-substitution on the quinazoline ring could enhance antitumor activity and improve druglike properties.  Compd. 2 and its analogs with a 4-(2-methylquinazolin-4-yl)-3,4-dihydroquinoxalin-2(1H)-one scaffold thus represent a novel class of tubulin-binding tumor-vascular disrupting agents (tumor-VDAs) that target established blood vessels in tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgHYAB0W82OLVg90H21EOLACvtfcHk0lgh1KlDqghWYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVGrsL3J&md5=5a78f8afb2320b74e74f2f0193eca685</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00273%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DM.-T.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DGoto%26aufirst%3DM.%26aulast%3DHsu%26aufirst%3DP.-L.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DS.-J.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DMorris-Natschke%26aufirst%3DS.%2BL.%26aulast%3DKuo-Hsiung%2BLee%26aufirst%3DK.-H.%26aulast%3DXie%26aufirst%3DL.%26atitle%3DIn%2520vivo%2520and%2520mechanistic%2520studies%2520on%2520antitumor%2520lead%25207-methoxy-4-%25282-methylquinazolin-4-yl%2529-3%252C4-dihydroquinoxalin-2%25281H%2529-one%2520and%2520its%2520modification%2520as%2520a%2520novel%2520class%2520of%2520tubulin-binding%2520tumor-vascular%2520disrupting%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5586%26epage%3D5598%26doi%3D10.1021%2Facs.jmedchem.7b00273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of (2-(phenylamino)thieno[3,2-<i>d</i>]pyrimidin-4-yl)(3,4,5-trimethoxyphenyl)methanone analogues as potent anti-tubulin polymerization agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>183</i></span>, <span class="NLM_elocation-id">111679</span> <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.ejmech.2019.111679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=31541870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVanurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2019&author=C.+Tianauthor=X.+Chenauthor=Z.+Zhangauthor=X.+Wangauthor=J.+Liu&title=Design+and+synthesis+of+%282-%28phenylamino%29thieno%5B3%2C2-d%5Dpyrimidin-4-yl%29%283%2C4%2C5-trimethoxyphenyl%29methanone+analogues+as+potent+anti-tubulin+polymerization+agents&doi=10.1016%2Fj.ejmech.2019.111679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of (2-(phenylamino)thieno[3,2-d]pyrimidin-4-yl)(3,4,5-trimethoxyphenyl)methanone analogues as potent anti-tubulin polymerization agents</span></div><div class="casAuthors">Tian, Chao; Chen, Xuanzhen; Zhang, Zhili; Wang, Xiaowei; Liu, Junyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111679pp.</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Anti-tubulin polymn. agents can disrupt tumor-vascular to exhibit anti-cancer potency.  In this study, a series of substituted (2-(phenylamino)thieno[3,2-d]pyrimidin-4-yl)(3,4,5-trimethoxyphenyl)methanone analogs I (R = H, 4-CH3, 4-CN etc.; X = NH, NCH3, O, CO) were designed and synthesized as anti-tubulin polymn. agents that interact with colchicine binding site.  The most potent compd. I [R = 3-CH3; X = NH (II)] was selected to assay its inhibition on the tubulin polymn. which displayed potent inhibition with an IC50 value of 4.1 +/- 0.1 μM.  The colchicine competition assay demonstrated that the above compd. inhibited tubulin polymn. by binding to the colchicine-binding site of tubulin and the mol. modeling study elucidated the binding mode of the compd. in the colchicine binding site.  The result of confocal immunofluorescent study proved that compd. II can quickly disrupt the microtubules of Hela cells in a concn. dependent manner.  Some expts. at cellular level were conducted to investigate the effects of compd. II on cellular morphol., cell colony formation, cell cycle distribution, cell apoptosis and mitochondrial changes.  The results demonstrated that the above compd. is a potent anti-tubulin agent with strong concn. dependent effect of inhibition of colony formation, induction of G2/M arrest and induction of apoptosis through mitochondrial pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpolw4xNUQJZ7Vg90H21EOLACvtfcHk0lgh1KlDqghWYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVanurfN&md5=97c993ea076431e1150a94283de37bb5</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111679%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520%25282-%2528phenylamino%2529thieno%255B3%252C2-d%255Dpyrimidin-4-yl%2529%25283%252C4%252C5-trimethoxyphenyl%2529methanone%2520analogues%2520as%2520potent%2520anti-tubulin%2520polymerization%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D183%26doi%3D10.1016%2Fj.ejmech.2019.111679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">442</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.11.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.ejmech.2018.11.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=30530194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVKqtrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2019&pages=428-442&author=W.+Liauthor=W.+Shuaiauthor=H.+Sunauthor=F.+Xuauthor=Y.+Biauthor=J.+Xuauthor=C.+Maauthor=H.+Yaoauthor=Z.+Zhuauthor=S.+Xu&title=Design%2C+synthesis+and+biological+evaluation+of+quinoline-indole+derivatives+as+anti-tubulin+agents+targeting+the+colchicine+binding+site&doi=10.1016%2Fj.ejmech.2018.11.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site</span></div><div class="casAuthors">Li, Wenlong; Shuai, Wen; Sun, Honghao; Xu, Feijie; Bi, Yi; Xu, Jinyi; Ma, Cong; Yao, Hequan; Zhu, Zheying; Xu, Shengtao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">428-442</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel isocombretastatin A-4 (isoCA-4) analogs were designed and synthesized by replacing 3,4,5-trimethoylphenyl and isovanillin of isoCA-4 with quinoline and indole moieties, resp.  The structure activity relationships (SARs) of these synthesized quinoline-indole derivs. have been intensively investigated.  Two compds. I (R1 = Me, CH2OH) exhibited the most potent activities against five cancer cell lines with IC50 values ranging from 2 to 11 nM, which were comparable to those of Combretastatin A-4 (CA-4).  Further mechanism investigations revealed that I (R1 = CH2OH) effectively inhibited the microtubule polymn. by binding to the colchicine site of tubulin.  Further cellular mechanism studies elucidated that I (R1 = CH2OH) disrupted cell microtubule networks, arrested the cell cycle at G2/M phase, induced apoptosis and depolarized mitochondria of K562 cells.  Moreover, I (R1 = CH2OH) displayed potent anti-vascular activity in both wound healing and tube formation assays.  Importantly, I (R1 = Me, CH2OH) significantly inhibited tumor growth in H22 xenograft models without apparent toxicity, suggesting that I (R1 = Me, CH2OH) deserve further research as potent antitumor agents for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGtdO0IJYx1LVg90H21EOLACvtfcHk0lgh1KlDqghWYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVKqtrrN&md5=c1e12a0b0fb8e38c72c2579166c57b38</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.11.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.11.070%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DShuai%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DBi%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520quinoline-indole%2520derivatives%2520as%2520anti-tubulin%2520agents%2520targeting%2520the%2520colchicine%2520binding%2520site%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D163%26spage%3D428%26epage%3D442%26doi%3D10.1016%2Fj.ejmech.2018.11.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-P.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of 1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazole analogues as potential anticancer agents targeting tubulin colchicine binding site</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5341</span>– <span class="NLM_lpage">5355</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00071</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00071" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC28XnslCqtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5341-5355&author=Y.-N.+Liuauthor=J.-J.+Wangauthor=Y.-T.+Jiauthor=G.-D.+Zhaoauthor=L.-Q.+Tangauthor=C.-M.+Zhangauthor=X.-L.+Guoauthor=Z.-P.+Liu&title=Design%2C+synthesis%2C+and+biological+evaluation+of+1-methyl-1%2C4-dihydroindeno%5B1%2C2-c%5Dpyrazole+analogues+as+potential+anticancer+agents+targeting+tubulin+colchicine+binding+site&doi=10.1021%2Facs.jmedchem.6b00071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of 1-Methyl-1,4-dihydroindeno[1,2-c]pyrazole Analogues as Potential Anticancer Agents Targeting Tubulin Colchicine Binding Site</span></div><div class="casAuthors">Liu, Yan-Na; Wang, Jing-Jing; Ji, Ya-Ting; Zhao, Guo-Dong; Tang, Long-Qian; Zhang, Cheng-Mei; Guo, Xiu-Li; Liu, Zhao-Peng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5341-5355</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By targeting a new binding region at the interface between αβ-tubulin heterodimers at the colchicine binding site, the authors designed a series of 7-substituted 1-methyl-1,4-dihydroindeno[1,2-c]pyrazoles as potential tubulin polymn. inhibitors.  Among the compds. synthesized, 2-(6-ethoxy-3-(3-ethoxyphenylamino)-1-methyl-1,4-dihydroindeno[1,2-c]pyrazol-7-yloxy)acetamide (I), and 2-(6-ethoxy-3-(3-ethoxyphenylamino)-1-methyl-1,4-dihydroindeno[1,2-c]pyrazol-7-yloxy)-N-hydroxyacetamide, (II), showed noteworthy low nanomolar potency against HepG2, Hela, PC3, and MCF-7 cancer cell lines.  In mechanism studies, I inhibited tubulin polymn. and disorganized microtubule in A549 cells by binding to the tubulin colchicine binding site.  I arrested A549 cells in G2/M phase that was related to the alterations in the expression of cyclin B1 and p-cdc2.  I induced A549 cells apoptosis through the activation of caspase-3 and PARP.  In addn., I inhibited capillary tube formation in a concn.-dependent manner.  In a nonsmall cell lung cancer xenograft mouse model, I suppressed tumor growth by 59.1% at a dose of 50 mg/kg (i.p.) without obvious toxicity, indicating its in vivo potential as anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ-hoobIDuqrVg90H21EOLACvtfcHk0lgatHW7PnFaZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnslCqtrY%253D&md5=ba4652575e64aa805d859734ea5b3903</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00071%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.-N.%26aulast%3DWang%26aufirst%3DJ.-J.%26aulast%3DJi%26aufirst%3DY.-T.%26aulast%3DZhao%26aufirst%3DG.-D.%26aulast%3DTang%26aufirst%3DL.-Q.%26aulast%3DZhang%26aufirst%3DC.-M.%26aulast%3DGuo%26aufirst%3DX.-L.%26aulast%3DLiu%26aufirst%3DZ.-P.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%25201-methyl-1%252C4-dihydroindeno%255B1%252C2-c%255Dpyrazole%2520analogues%2520as%2520potential%2520anticancer%2520agents%2520targeting%2520tubulin%2520colchicine%2520binding%2520site%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5341%26epage%3D5355%26doi%3D10.1021%2Facs.jmedchem.6b00071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-P.</span></span> <span> </span><span class="NLM_article-title">Tubulin colchicine site binding agent LL01 displays potent antitumor efficiency both in vitro and in vivo with suitable drug-like properties</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1007/s10637-019-00753-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1007%2Fs10637-019-00753-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=30887253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVyru77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=29-38&author=J.-D.+Wuauthor=Y.-J.+Cuiauthor=Y.-G.+Zhouauthor=L.-Q.+Tangauthor=C.-M.+Zhangauthor=Z.-P.+Liu&title=Tubulin+colchicine+site+binding+agent+LL01+displays+potent+antitumor+efficiency+both+in+vitro+and+in+vivo+with+suitable+drug-like+properties&doi=10.1007%2Fs10637-019-00753-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulin colchicine site binding agent LL01 displays potent antitumor efficiency both in vitro and in vivo with suitable drug-like properties</span></div><div class="casAuthors">Wu, Jing-De; Cui, Ying-Jie; Zhou, Yi-Gang; Tang, Long-Qian; Zhang, Cheng-Mei; Liu, Zhao-Peng</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-38</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Through rational drug design, we previously identified an indenoprazole deriv., 2-(6-ethoxy-3-(3-ethoxyphenylamino)-1-methyl-1,4-dihydroindeno[1,2-c]pyrazol-7-yloxy)acetamide (LL01), as a potent tubulin polymn. inhibitor targeting the tubulin colchicine binding site.  In this study, we further demonstrated that LL01 was not a P-gp substrate.  It potently inhibited the growth of a variety of tumor cells, including those with multidrug resistance, with GI50 values in the low nanomole ranges.  In vitro liver microsome stability assay, LL01 was modest stable in the liver microsomes of human, mouse and rat, but was fast metabolized in dog.  After single oral administration of LL01 at a dose of 10 mg/kg in SD male rats, LL01 showed acceptable PK properties with a mean bioavailability of 41%.  In human HepG2 hepatoma xenograft, at the oral doses of 25 mg/kg/day and 12.5 mg/kg/day, LL01 inhibited the tumor growth by 61.27%, and 43.74%, resp., which is much better than the pos. drug sorafenib (29.45%; 30 mg/kg/day).  Therefore, LL01 might be a potential drug candidate for further investigation for hepatocellular carcinoma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2xAaKO0FjP7Vg90H21EOLACvtfcHk0lgatHW7PnFaZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVyru77J&md5=0436d33ae1d41c15aa4ffd0aa58ff19d</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1007%2Fs10637-019-00753-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-019-00753-z%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.-D.%26aulast%3DCui%26aufirst%3DY.-J.%26aulast%3DZhou%26aufirst%3DY.-G.%26aulast%3DTang%26aufirst%3DL.-Q.%26aulast%3DZhang%26aufirst%3DC.-M.%26aulast%3DLiu%26aufirst%3DZ.-P.%26atitle%3DTubulin%2520colchicine%2520site%2520binding%2520agent%2520LL01%2520displays%2520potent%2520antitumor%2520efficiency%2520both%2520in%2520vitro%2520and%2520in%2520vivo%2520with%2520suitable%2520drug-like%2520properties%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2020%26volume%3D38%26spage%3D29%26epage%3D38%26doi%3D10.1007%2Fs10637-019-00753-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, F.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Z.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.-L.</span></span> <span> </span><span class="NLM_article-title">DHPAC, a novel synthetic microtubule destabilizing agent, possess high anti-tumor activity in vincristine-resistant oral epidermoid carcinoma in vitro and in vivo</span>. <i>Int. J. Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1016/j.biocel.2017.10.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.biocel.2017.10.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=29074436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsleltLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2017&pages=1-11&author=Y.+Zhangauthor=F.-L.+Gongauthor=Z.-N.+Luauthor=H.-Y.+Wangauthor=Y.-N.+Chengauthor=Z.-P.+Liuauthor=L.-G.+Yuauthor=H.-H.+Zhangauthor=X.-L.+Guo&title=DHPAC%2C+a+novel+synthetic+microtubule+destabilizing+agent%2C+possess+high+anti-tumor+activity+in+vincristine-resistant+oral+epidermoid+carcinoma+in+vitro+and+in+vivo&doi=10.1016%2Fj.biocel.2017.10.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">DHPAC, a novel synthetic microtubule destabilizing agent, possess high anti-tumor activity in vincristine-resistant oral epidermoid carcinoma in vitro and in vivo</span></div><div class="casAuthors">Zhang, Ying; Gong, Fu-Lian; Lu, Zhen-Ning; Wang, Hong-Yuan; Cheng, Yan-Na; Liu, Zhao-Peng; Yu, Lu-Gang; Zhang, Hui-Hui; Guo, Xiu-Li</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-11</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Multidrug resistance (MDR) is one of major obstacles to effective chemotherapeutic treatment of cancer.  This study showed that DHPAC, 2-(6-ethoxy-3-(3-ethoxyphenylamino) -1-methyl-1,4-dihydroindeno[1,2-c]pyrazol-7-yloxy) acetamide, a novel compd. that binds to the same site on microtubules as colchicine, has high anti-tumor activity in vincristine-resistant oral epidermoid carcinoma (KB/V) cells.  It found that the presence of DHPAC strongly inhibited KB/V cell growth in vivo and in mice xenograft.  The inhibitory effect of DHPAC is much stronger than that by colchicine in these KB/V cells (IC50: 64.4 nM and 458.0 nM resp.).  Treatment of the cells with DHPAC induced cell apoptosis by reducing mitochondrial membrane potential and altered the expression of several apoptosis-related proteins such as Bcl-2, Bax, Caspase-9, Cytochrome c and PARP.  DHPAC treatment also caused cell rest in G2/M phase by regulating of the expression of a no. of cell cycle-related proteins (e.g. Cyclin B1, Cdc2, Cdc25b, Cdc25c, RSK2).  Furthermore, DHPAC presence inhibits PTEN phosphorylation and PTEN/Akt/NF-κB signalling.  Thus, DHPAC has potent anti-cancer activity in MDR tumors and may be a potential therapeutic agent for the treatment of vincristine-resistant human oral epidermoid carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq26_W87zyH1LVg90H21EOLACvtfcHk0lgatHW7PnFaZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsleltLbI&md5=99078c235610f2b8e998ed4cfd829712</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2017.10.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2017.10.012%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DF.-L.%26aulast%3DLu%26aufirst%3DZ.-N.%26aulast%3DWang%26aufirst%3DH.-Y.%26aulast%3DCheng%26aufirst%3DY.-N.%26aulast%3DLiu%26aufirst%3DZ.-P.%26aulast%3DYu%26aufirst%3DL.-G.%26aulast%3DZhang%26aufirst%3DH.-H.%26aulast%3DGuo%26aufirst%3DX.-L.%26atitle%3DDHPAC%252C%2520a%2520novel%2520synthetic%2520microtubule%2520destabilizing%2520agent%252C%2520possess%2520high%2520anti-tumor%2520activity%2520in%2520vincristine-resistant%2520oral%2520epidermoid%2520carcinoma%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2017%26volume%3D93%26spage%3D1%26epage%3D11%26doi%3D10.1016%2Fj.biocel.2017.10.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-P.</span></span> <span> </span><span class="NLM_article-title">The discovery of novel indazole derivatives as tubulin colchicine site binding agents that displayed potent antitumor activity both in vitro and in vivo</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>187</i></span>, <span class="NLM_elocation-id">111968</span> <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111968</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.ejmech.2019.111968" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=31865012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVKgtL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2020&author=Y.-J.+Cuiauthor=C.-C.+Maauthor=C.-M.+Zhangauthor=L.-Q.+Tangauthor=Z.-P.+Liu&title=The+discovery+of+novel+indazole+derivatives+as+tubulin+colchicine+site+binding+agents+that+displayed+potent+antitumor+activity+both+in+vitro+and+in+vivo&doi=10.1016%2Fj.ejmech.2019.111968"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of novel indazole derivatives as tubulin colchicine site binding agents that displayed potent antitumor activity both in vitro and in vivo</span></div><div class="casAuthors">Cui, Ying-Jie; Ma, Chen-Chen; Zhang, Cheng-Mei; Tang, Long-Qian; Liu, Zhao-Peng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111968</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Tubulin inhibitors that bind to the colchicine site are widely studied anticancer agents.  In continuous our researches, we designed a series of novel indazole derivs. as microtubule-targeting agents (MTAs).  The structure-activity relationships (SARs) investigations indicated that a 3,4,5-trimethoxyphenyl moiety and a Me or methoxy substitution were preferred for the better antiproliferative activity.  The indazole derivs. 3c and 3f showed noteworthy low nanomolar potency against HepG2, HCT116, SW620, HT29 and A549 tumor cells.  In mechanism studies, 3c and 3f were proved to target the colchicine site, inhibited tubulin polymn. and disrupted cellular microtubule networks, arrested HCT116 cell in G2/M phase and induced cell apoptosis.  In the HCT116 xenografts mouse model, 3c and 3f suppressed tumor growth by 45.3% and 58.9% at an orally dose of 25 mg/kg without causing obvious wt. loss.  The indazole 3f may serve as a good lead or drug candidate for colorectal cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIJP_S76-BH7Vg90H21EOLACvtfcHk0ljzNCzjaYkCrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVKgtL%252FN&md5=0a66f7e3c5e84b31cb3cfe984914d56a</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111968%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DY.-J.%26aulast%3DMa%26aufirst%3DC.-C.%26aulast%3DZhang%26aufirst%3DC.-M.%26aulast%3DTang%26aufirst%3DL.-Q.%26aulast%3DLiu%26aufirst%3DZ.-P.%26atitle%3DThe%2520discovery%2520of%2520novel%2520indazole%2520derivatives%2520as%2520tubulin%2520colchicine%2520site%2520binding%2520agents%2520that%2520displayed%2520potent%2520antitumor%2520activity%2520both%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D187%26doi%3D10.1016%2Fj.ejmech.2019.111968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of in vitro and in vivo anticancer activity of 4-substituted coumarins: a novel class of potent tubulin polymerization inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5721</span>– <span class="NLM_lpage">5739</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00158</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00158" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC28Xotlalu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5721-5739&author=D.+Caoauthor=Y.+Liuauthor=W.+Yanauthor=C.+Wangauthor=P.+Baiauthor=T.+Wangauthor=M.+Tangauthor=X.+Wangauthor=Z.+Yangauthor=B.+Maauthor=L.+Maauthor=L.+Leiauthor=F.+Wangauthor=B.+Xuauthor=Y.+Zhouauthor=T.+Yangauthor=L.+Chen&title=Design%2C+synthesis%2C+and+evaluation+of+in+vitro+and+in+vivo+anticancer+activity+of+4-substituted+coumarins%3A+a+novel+class+of+potent+tubulin+polymerization+inhibitors&doi=10.1021%2Facs.jmedchem.6b00158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of in Vitro and in Vivo Anticancer Activity of 4-Substituted Coumarins: A Novel Class of Potent Tubulin Polymerization Inhibitors</span></div><div class="casAuthors">Cao, Dong; Liu, Yibin; Yan, Wei; Wang, Chunyu; Bai, Peng; Wang, Taijin; Tang, Minghai; Wang, Xiaoyan; Yang, Zhuang; Ma, Buyun; Ma, Liang; Lei, Lei; Wang, Fang; Xu, Bixue; Zhou, Yuanyuan; Yang, Tao; Chen, Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5721-5739</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, a series of novel 4-substituted coumarin derivs. were synthesized.  Among these compds. exhibited significant antiproliferative activity toward a panel of tumor cell lines at subnanomolar IC50 values.  Compd. I showed potent antiproliferative ability (IC50 values of 7-47 nM) and retained full activity in multidrug resistant cancer cells.  Compd. I caused G2/M phase arrest and interacted with the colchicine-binding site in tubulin, as confirmed by immune-fluorescence staining, microtubule dynamics assays, and competition assays with N,N'-ethylene-bis(iodoacetamide).  Compd. I reduced the cell migration and disrupted capillary-like tube formation in HUVEC cells.  Importantly, compd. I significantly and dose-dependently reduced tumor growth in four xenografts models including paclitaxel sensitive and resistant ovarian tumors (A2780s and A2780/T), adrmicycin sensitive and resistant breast tumors (MCF-7 and MCF-7/ADR), suggesting that compd. I is a promising novel antimitotic compd. for the potential treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0i0RqD2mFz7Vg90H21EOLACvtfcHk0ljzNCzjaYkCrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xotlalu7s%253D&md5=f466b56c86172479fdca8db106fdbd44</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00158%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DBai%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DLei%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520in%2520vitro%2520and%2520in%2520vivo%2520anticancer%2520activity%2520of%25204-substituted%2520coumarins%253A%2520a%2520novel%2520class%2520of%2520potent%2520tubulin%2520polymerization%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5721%26epage%3D5739%26doi%3D10.1021%2Facs.jmedchem.6b00158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garikapati, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makani, V. K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shareef, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal-Bhadra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, C. G.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of 1,4-dihydroindeno[1,2-c]pyrazole linked oxindole analogues as potential anticancer agents targeting tubulin and inducing p53 dependent apoptosis</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">104</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.12.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.ejmech.2017.12.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=29268127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvF2ntr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2018&pages=104-115&author=I.+Khanauthor=K.+R.+Garikapatiauthor=A.+B.+Shaikauthor=V.+K.+K.+Makaniauthor=A.+Rahimauthor=M.+A.+Shareefauthor=V.+G.+Reddyauthor=M.+Pal-Bhadraauthor=A.+Kamalauthor=C.+G.+Kumar&title=Design%2C+synthesis+and+biological+evaluation+of+1%2C4-dihydroindeno%5B1%2C2-c%5Dpyrazole+linked+oxindole+analogues+as+potential+anticancer+agents+targeting+tubulin+and+inducing+p53+dependent+apoptosis&doi=10.1016%2Fj.ejmech.2017.12.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of 1, 4-dihydroindeno[1,2-c]pyrazole linked oxindole analogues as potential anticancer agents targeting tubulin and inducing p53 dependent apoptosis</span></div><div class="casAuthors">Khan, Irfan; Garikapati, Koteswara Rao; Shaik, Anver Basha; Makani, Venkata Krishna Kanth; Rahim, Abdul; Shareef, Mohd. Adil; Reddy, V. Ganga; Pal-Bhadra, Manika; Kamal, Ahmed; Kumar, C. Ganesh</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104-115</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 1,4-dihydroindeno-[1,2-c] pyrazole linked oxindole conjugates, I [R1 = H, OMe, R2 = H, OMe, R3 = H, OMe, 5-Cl, etc.] were synthesized by using Knoevenagel condensation method and further evaluated for their antiproliferative activity against HeLa, A549 and MDA-MB-231 human cancer cell lines along with HEK-293 (normal human embryonic kidney cells).  Among the derivs., compds. I [R1 = R2 = OMe, R3 = H, OMe, 6-Cl] showed excellent cytotoxicity with IC50 values ranging between 1.33 to 4.33 μM.  Furthermore, detailed biol. assays showed that there was accumulation of mitotic cells in G2/M phase, disruption of microtubule network and increase in the G2/M checkpoint proteins (Cyclin B1 and CDK1).  Moreover, compd. I [R1 = R2 = OMe, R3 = 6-Cl] with IC50 value of 1.33 μM showed significant upregulation of tumor suppressor proteins like p53, p21 and pro-apoptotic Bax.  The mol. docking anal. demonstrated that these congeners occupy the colchicine binding pocket of the tubulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVZN2WhF50uLVg90H21EOLACvtfcHk0lglTtkUfojsFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvF2ntr%252FO&md5=452eb1025b4ab93ef30e685dc523aac5</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DI.%26aulast%3DGarikapati%26aufirst%3DK.%2BR.%26aulast%3DShaik%26aufirst%3DA.%2BB.%26aulast%3DMakani%26aufirst%3DV.%2BK.%2BK.%26aulast%3DRahim%26aufirst%3DA.%26aulast%3DShareef%26aufirst%3DM.%2BA.%26aulast%3DReddy%26aufirst%3DV.%2BG.%26aulast%3DPal-Bhadra%26aufirst%3DM.%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DC.%2BG.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%25201%252C4-dihydroindeno%255B1%252C2-c%255Dpyrazole%2520linked%2520oxindole%2520analogues%2520as%2520potential%2520anticancer%2520agents%2520targeting%2520tubulin%2520and%2520inducing%2520p53%2520dependent%2520apoptosis%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D144%26spage%3D104%26epage%3D115%26doi%3D10.1016%2Fj.ejmech.2017.12.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohkoshi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, D.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris-Natschke, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span> <span> </span><span class="NLM_article-title">Optimization of 4-(<i>N</i>-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1390</span>– <span class="NLM_lpage">1402</span>, <span class="refDoi"> DOI: 10.1021/jm4016526</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4016526" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVart7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1390-1402&author=X.-F.+Wangauthor=F.+Guanauthor=E.+Ohkoshiauthor=W.+Guoauthor=L.+Wangauthor=D.-Q.+Zhuauthor=S.-B.+Wangauthor=L.-T.+Wangauthor=E.+Hamelauthor=D.+Yangauthor=L.+Liauthor=K.+Qianauthor=S.+L.+Morris-Natschkeauthor=S.+Yuanauthor=K.-H.+Leeauthor=L.+Xie&title=Optimization+of+4-%28N-cycloamino%29phenylquinazolines+as+a+novel+class+of+tubulin-polymerization+inhibitors+targeting+the+colchicine+site&doi=10.1021%2Fjm4016526"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of 4-(N-Cycloamino)phenylquinazolines as a Novel Class of Tubulin-Polymerization Inhibitors Targeting the Colchicine Site</span></div><div class="casAuthors">Wang, Xiao-Feng; Guan, Fang; Ohkoshi, Emika; Guo, Wanjun; Wang, Lili; Zhu, Dong-Qing; Wang, Sheng-Biao; Wang, Li-Ting; Hamel, Ernest; Yang, Dexuan; Li, Linna; Qian, Keduo; Morris-Natschke, Susan L.; Yuan, Shoujun; Lee, Kuo-Hsiung; Xie, Lan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1390-1402</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The 6-methoxy-1,2,3,4-tetrahydroquinoline moiety in prior leads 2-chloro- and 2-methyl-4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)quinazoline was modified to produce 4-(N-cycloamino)quinazolines.  The new compds. were evaluated in cytotoxicity and tubulin inhibition assays, resulting in the discovery of new tubulin-polymn. inhibitors. 7-Methoxy-4-(2-methylquinazolin-4-yl)-3,4-dihydroquinoxalin- 2(1H)-one, the most potent compd., exhibited high in vitro cytotoxic activity (GIC50 1.9-3.2 nM), significant potency against tubulin assembly (IC50 0.77 μM), and substantial inhibition of colchicine binding (99% at 5 μM).  In mechanism studies, 5f caused cell arrest in G2/M phase, disrupted microtubule formation, and competed mostly at the colchicine site on tubulin.  Compd. 5f and N-methylated analog 5g were evaluated in nude mouse MCF7 xenograft models to validate their antitumor activity.  Compd. 5g displayed significant in vivo activity (tumor inhibitory rate 51%) at a dose of 4 mg/kg without obvious toxicity, whereas 5f unexpectedly resulted in toxicity and death at the same dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnOMs8LwZNSLVg90H21EOLACvtfcHk0lglTtkUfojsFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVart7k%253D&md5=c55675f32145d4e566aca81b9d288647</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm4016526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4016526%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.-F.%26aulast%3DGuan%26aufirst%3DF.%26aulast%3DOhkoshi%26aufirst%3DE.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DD.-Q.%26aulast%3DWang%26aufirst%3DS.-B.%26aulast%3DWang%26aufirst%3DL.-T.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DQian%26aufirst%3DK.%26aulast%3DMorris-Natschke%26aufirst%3DS.%2BL.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DK.-H.%26aulast%3DXie%26aufirst%3DL.%26atitle%3DOptimization%2520of%25204-%2528N-cycloamino%2529phenylquinazolines%2520as%2520a%2520novel%2520class%2520of%2520tubulin-polymerization%2520inhibitors%2520targeting%2520the%2520colchicine%2520site%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1390%26epage%3D1402%26doi%3D10.1021%2Fjm4016526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tingting  Liang</span>, <span class="hlFld-ContribAuthor ">Xiaomin  Zhou</span>, <span class="hlFld-ContribAuthor ">Lu  Lu</span>, <span class="hlFld-ContribAuthor ">Haiyang  Dong</span>, <span class="hlFld-ContribAuthor ">Yanan  Zhang</span>, <span class="hlFld-ContribAuthor ">Yungen  Xu</span>, <span class="hlFld-ContribAuthor ">Jianguo  Qi</span>, <span class="hlFld-ContribAuthor ">Yahong  Zhang</span>, <span class="hlFld-ContribAuthor ">Jianhong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-activity relationships and antiproliferative effects of 1,2,3,4-4H-quinoxaline derivatives as tubulin polymerization inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>110 </em>, 104793. <a href="https://doi.org/10.1016/j.bioorg.2021.104793" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104793</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104793%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DStructure-activity%252Brelationships%252Band%252Bantiproliferative%252Beffects%252Bof%252B1%25252C2%25252C3%25252C4-4H-quinoxaline%252Bderivatives%252Bas%252Btubulin%252Bpolymerization%252Binhibitors%26aulast%3DLiang%26aufirst%3DTingting%26date%3D2021%26volume%3D110%26spage%3D104793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Colchicine site ligands.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of indenopyrazole derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0012.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 1-Methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazoles <b>ID01</b>–<b>ID06</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) MOMCl, DIPEA, DMF, rt, 12 h; (b) TBSCl, imidazole, DMF, rt, 4 h; (c) (1) LiHMDS, 3-EtOPhNCS, THF, −78 °C to rt, 17 h; (2) NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O, 1,4-dioxane/EtOH, 55 °C; 36 h; (3) (CH<sub>3</sub>)<sub>2</sub>SO<sub>4</sub>, DIPEA, DCM, rt, 7 h; (d) TBAF, THF, rt, 0.5 h; (e) ClCH<sub>2</sub>CO<sub>2</sub>Me, K<sub>2</sub>CO<sub>3</sub>, acetone, 65 °C, 6 h; (f) NH<sub>3</sub>·H<sub>2</sub>O, MeOH, reflux, 1.5 h; (g) CSA, MeOH, 40 °C, 2 h; (h) (CH<sub>3</sub>)<sub>2</sub>SO<sub>4</sub> or PrBr or BuBr or <i>p</i>-MeOBnCl, K<sub>2</sub>CO<sub>3</sub>, DMF, 40 °C, 2.5–8 h; (i) PrBr, K<sub>2</sub>CO<sub>3</sub>, acetone, 65 °C, 8 h; (j) CSA, MeOH, 40 °C, 2 h.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0013.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 1-Methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazoles <b>ID07</b>–<b>ID11</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (1) LiHMDS, 3-EtOPhNCS, THF, −78 °C to rt; 16 h; (2) NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O, 1,4-dioxane/EtOH, 55 °C, 26 h; (3) (CH<sub>3</sub>)<sub>2</sub>SO<sub>4</sub>, DIPEA, DCM, rt; 6 h; (b) TBAF, THF, rt, 1 h; (c) ClCH<sub>2</sub>CO<sub>2</sub>Me, K<sub>2</sub>CO<sub>3</sub>, acetone, 65 °C, 6 h; (d) LiOH, MeOH/H<sub>2</sub>O, 30 °C, 2 h; (e) 3-bromo-1-propanol, K<sub>2</sub>CO<sub>3</sub>, DMF, 75 °C, 10 h; (f) MOMCl, DIPEA, DMF, rt, 8 h; (g) CSA, MeOH, 40 °C, 2 h; (h) BocNHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>Br, K<sub>2</sub>CO<sub>3</sub>, acetone, 65 °C, 8 h; (i) CH<sub>3</sub>COCl, EtOH, rt, 0.5 h; (j) (CH<sub>3</sub>CO)<sub>2</sub>O, Et<sub>3</sub>N, DCM, rt, 4 h; (k) PrBr, K<sub>2</sub>CO<sub>3</sub>, acetone, 65 °C, 12 h.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0014.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 1-Methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazoles <b>ID12</b>–<b>ID22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (1) LiHMDS, R-Ph-NCS, THF, −78 °C to rt, 16–20 h; (2) NH<sub>2</sub>NH<sub>2</sub><b>·</b>H<sub>2</sub>O, 1,4-dioxane/EtOH, 55 °C, 20–36 h; (3) (CH<sub>3</sub>)<sub>2</sub>SO<sub>4</sub>, DIPEA, DCM, rt, 8–16 h; (b) TBAF, THF, rt, 1 h; (c) ClCH<sub>2</sub>CO<sub>2</sub>Me, K<sub>2</sub>CO<sub>3</sub>, acetone, 65 °C, 8–12 h; (d) NH<sub>3</sub><b>·</b>H<sub>2</sub>O, MeOH, reflux, 2–4 h; (e) CH<sub>3</sub>COCl, EtOH, rt, 1 h; (f) CH<sub>3</sub>NH<sub>2</sub>, MeOH, reflux, 4 h; (g) (1) LiHMDS, 6-EtO-Py-2-NCS, THF, −78 °C to rt, 18 h; (2) NH<sub>2</sub>NH<sub>2</sub><b>·</b>H<sub>2</sub>O, 1,4-dioxane/EtOH, 55 °C, 30 h; (3) (CH<sub>3</sub>)<sub>2</sub>SO<sub>4</sub>, DIPEA, DCM, rt, 14 h.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0015.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of 1-Methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazoles <b>ID23</b>–<b>ID30</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (1) LiHMDS or NaH, R-Ph-NCS, THF, −78 °C to rt, 16–20 h; (2) NH<sub>2</sub>NH<sub>2</sub><b>·</b>H<sub>2</sub>O, 1,4-dioxane/EtOH, 55 °C, 20–34 h; (3) (CH<sub>3</sub>)<sub>2</sub>SO<sub>4</sub>, DIPEA, DCM, rt, 8–12 h; (b) CSA, MeOH, rt, 2 h; (c) LiOH, MeOH, H<sub>2</sub>O, 40 °C, 2 h; (d) (1) LiHMDS, 6-EtO-Py-2NCS, THF, −78 °C to rt, 18 h; (2) NH<sub>2</sub>NH<sub>2</sub><b>·</b>H<sub>2</sub>O, 1,4-dioxane/EtOH, 55 °C, 26 h; (3) (CH<sub>3</sub>)<sub>2</sub>SO<sub>4</sub>, DIPEA, DCM, rt, 12 h.</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0016.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of 1-Methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazoles <b>ID31</b>–<b>ID33</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BocNHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>Br, K<sub>2</sub>CO<sub>3</sub>, acetone, 65 °C, 12–18 h; (b) TFA, DCM, rt, 2 h; (c) CH<sub>3</sub>COCl, EtOH, rt, 0.5 h.</p></p></figure><figure data-id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effects of <b>ID09</b> and <b>ID33</b> on cellular microtubule networks. HepG2 cells were treated with dimethyl sulfoxide (DMSO), <b>ID09</b> (2.5, 5, and 10 nM), <b>ID33</b> (2.5, 5, and 10 nM), and colchicine (10 nM) for 24 h. Microtubules were visualized with an anti-α-tubulin antibody (red), and the cell nucleus was visualized with Hoechst 33342 (blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. EBI assay confirmed that <b>ID09</b> and <b>ID33</b> targeted the colchicine-binding site: the competition assay of <b>ID09</b> and <b>ID33</b> (0.2, 1, 5, 25 μM), VCR (5 μM), and colchicine (5 μM) with EBI (100 μM) on HepG2 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0006.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of <b>ID09</b> and <b>ID33</b> on HepG2 cell cycle progress. Cells were treated with <b>ID09</b> or <b>ID33</b> at 5, 10, and 20 nM for 24 h and then analyzed by flow cytometry.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0007.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. <b>ID09</b> and <b>ID33</b> induce HepG2 cell apoptosis. Exposed to <b>ID09</b> or <b>ID33</b> for 12h (A) or 24 h (B), HepG2 cells were harvested and stained with annexin V-PE/7-AAD for analysis. The different cell stages were assigned as live (annexin V-PE<sup>–</sup>/7-AAD<sup>–</sup>), early apoptotic (annexin V-PE<sup>+</sup>/7-AAD<sup>–</sup>), late apoptotic (annexin V-PE<sup>+</sup>/ 7-AAD<sup>+</sup>), and necrotic cells (annexin V-PE<sup>–</sup>/7-AAD<sup>+</sup>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0008.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effects of <b>ID09</b> on apoptosis-related proteins. HepG2 cells were incubated with <b>ID09</b> (2.5, 5, 10, and 20 nM) and colchicine 20 nM for 24 h followed by the analysis of the expression of Bax, Bcl-2, cleaved caspase-3, and cleaved PARP by western blotting. *<i>P</i> < 0.05, <sup>**</sup><i>P</i> < 0.01, <sup>***</sup><i>P</i> < 0.001 vs control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0009.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Effect of <b>ID09</b> on HepG2 cell migration. HepG2 cells (5 × 10<sup>5</sup> cells) suspended in free serum DMEM containing <b>ID09</b> and CA-4 (2.5, 5, and 10 nM) for 24 h were photographed by phase contrast microscopy (magnification, 200×). *<i>P</i> < 0.05, <sup>**</sup><i>P</i> < 0.01, <sup>***</sup><i>P</i> < 0.001 vs control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0010.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Orally antitumor efficiency of <b>ID09</b> and <b>ID33</b> on HepG2 xenografts. (A) Tumor images, (B) tumor volume changes, (C) body weight changes, and (D) tumor weight changes. <sup>**</sup><i>P</i> < 0.01, <sup>***</sup><i>P</i> < 0.001 vs vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/medium/jm0c01345_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0011.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Antitumor efficiency of <b>ID09</b> on HepG2 xenografts via iv injection injection. (A) Tumor images, (B) tumor volume changes, (C) body weight changes, and (D) tumor weight changes. <sup>**</sup><i>P</i> < 0.01, <sup>***</sup><i>P</i> < 0.001 vs vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01345/20201203/images/large/jm0c01345_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01345&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i125">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75074" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75074" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 55 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schummel, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, R.</span></span> <span> </span><span class="NLM_article-title">Modulation of the polymerization kinetics of α/β-tubulin by osmolytes and macromolecular crowding</span>. <i>ChemPhysChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1002/cphc.201601032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1002%2Fcphc.201601032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=27813294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFOgsrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=189-197&author=P.+H.+Schummelauthor=M.+Gaoauthor=R.+Winter&title=Modulation+of+the+polymerization+kinetics+of+%CE%B1%2F%CE%B2-tubulin+by+osmolytes+and+macromolecular+crowding&doi=10.1002%2Fcphc.201601032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of the Polymerization Kinetics of α/β-Tubulin by Osmolytes and Macromolecular Crowding</span></div><div class="casAuthors">Schummel, Paul Hendrik; Gao, Mimi; Winter, Roland</div><div class="citationInfo"><span class="NLM_cas:title">ChemPhysChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">189-197</span>CODEN:
                <span class="NLM_cas:coden">CPCHFT</span>;
        ISSN:<span class="NLM_cas:issn">1439-4235</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Tubulin is one of the main components of the cytoskeleton and can be found in nearly all eukaryotic cells.  In this study, we explored the effects of kosmotropic and chaotropic osmolytes, such as trimethylamine-N-oxide (TMAO) and the metabolic waste product urea, as well as the crowding agents Ficoll and sucrose on the polymn. reaction of α/β-tubulin.  Time-dependent turbidimetry and fluorescence anisotropy expts. were performed to explore the kinetics of the polymn. reaction.  Under different solvent conditions, diverse changes in the lag time, the half-life of the polymn. reaction, and the crit. concn. of the polymn. reaction were obsd.  The apparent growth rate of the formation of microtubules was dramatically decreased in the presence of urea but significantly increased in the presence of TMAO.  Measurements using mixts. of these two cosolvents showed that TMAO was able to counteract the deteriorating effect of urea on the polymn. reaction of tubulin.  To create a more cell-like environment, Ficoll was added as a macromol. crowding agent.  The presence of 10 wt % Ficoll increased the apparent growth rate by one order of magnitude.  Our results clearly show that the polymn. of tubulin is very sensitive to the surrounding solvent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEUW8oqtQSqrVg90H21EOLACvtfcHk0lixbbi6Tg2n-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFOgsrjJ&md5=25efe4c88864f4860ea81c8d84436e77</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fcphc.201601032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcphc.201601032%26sid%3Dliteratum%253Aachs%26aulast%3DSchummel%26aufirst%3DP.%2BH.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DWinter%26aufirst%3DR.%26atitle%3DModulation%2520of%2520the%2520polymerization%2520kinetics%2520of%2520%25CE%25B1%252F%25CE%25B2-tubulin%2520by%2520osmolytes%2520and%2520macromolecular%2520crowding%26jtitle%3DChemPhysChem%26date%3D2017%26volume%3D18%26spage%3D189%26epage%3D197%26doi%3D10.1002%2Fcphc.201601032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Honore, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braguer, D.</span></span> <span> </span><span class="NLM_article-title">Understanding microtubule dynamics for improved cancer therapy</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3039</span>– <span class="NLM_lpage">3056</span>, <span class="refDoi"> DOI: 10.1007/s00018-005-5330-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1007%2Fs00018-005-5330-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=16314924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BD28Xms1Grug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2005&pages=3039-3056&author=S.+Honoreauthor=E.+Pasquierauthor=D.+Braguer&title=Understanding+microtubule+dynamics+for+improved+cancer+therapy&doi=10.1007%2Fs00018-005-5330-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding microtubule dynamics for improved cancer therapy</span></div><div class="casAuthors">Honore, S.; Pasquier, E.; Braguer, D.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">3039-3056</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review.  Microtubules (MTs), key components of the cytoskeleton, are dynamic polymers of tubulin that form a well-organized network of polarized tube filaments.  MT dynamics are highly regulated both spacially and temporally by several MT-related proteins, themselves regulated by several kinases and phosphatases via signaling cascades, and also by coordinated interactions with actin cytoskeleton and adhesion sites.  Regulation of MT dynamics is crucial for mitosis, cell migration, cell signaling and trafficking.  MT-targeted drugs (MTDs), which constitute a major anticancer drug family with antimitotic and antiangiogenic properties, inhibit tumor progression mainly by altering MT dynamics in both cancer and endothelial cells.  Identification of proteins regulating the MT network will lead to a better understanding of tumor progression regulators and will be helpful in improving cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEtWtWfzglTLVg90H21EOLACvtfcHk0lhL2rpClNIBrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xms1Grug%253D%253D&md5=a34099222d0c01876f46c1b704c3d995</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs00018-005-5330-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-005-5330-x%26sid%3Dliteratum%253Aachs%26aulast%3DHonore%26aufirst%3DS.%26aulast%3DPasquier%26aufirst%3DE.%26aulast%3DBraguer%26aufirst%3DD.%26atitle%3DUnderstanding%2520microtubule%2520dynamics%2520for%2520improved%2520cancer%2520therapy%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2005%26volume%3D62%26spage%3D3039%26epage%3D3056%26doi%3D10.1007%2Fs00018-005-5330-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cantero, M. D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarinci, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantiello, H. F.</span></span> <span> </span><span class="NLM_article-title">Two-dimensional brain microtubule structures behave as memristive devices</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">12398</span> <span class="refDoi"> DOI: 10.1038/s41598-019-48677-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1038%2Fs41598-019-48677-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=31455820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A280%3ADC%252BB3Mrit1Krsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&author=M.+D.+R.+Canteroauthor=P.+L.+Perezauthor=N.+Scarinciauthor=H.+F.+Cantiello&title=Two-dimensional+brain+microtubule+structures+behave+as+memristive+devices&doi=10.1038%2Fs41598-019-48677-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Two-Dimensional Brain Microtubule Structures Behave as Memristive Devices</span></div><div class="casAuthors">Cantero Maria Del Rocio; Perez Paula L; Scarinci Noelia; Cantiello Horacio F</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12398</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Microtubules (MTs) are cytoskeletal structures that play a central role in a variety of cell functions including cell division and cargo transfer.  MTs are also nonlinear electrical transmission lines that produce and conduct electrical oscillations elicited by changes in either electric field and/or ionic gradients.  The oscillatory behavior of MTs requires a voltage-sensitive gating mechanism to enable the electrodiffusional ionic movement through the MT wall.  Here we explored the electrical response of non-oscillating rat brain MT sheets to square voltage steps.  To ascertain the nature of the possible gating mechanism, the electrical response of non-oscillating rat brain MT sheets (2D arrays of MTs) to square pulses was analyzed under voltage-clamping conditions.  A complex voltage-dependent nonlinear charge movement was observed, which represented the summation of two events.  The first contribution was a small, saturating, voltage-dependent capacitance with a maximum charge displacement in the range of 4 fC/μm(2).  A second, major contribution was a non-saturating voltage-dependent charge transfer, consistent with the properties of a multistep memristive device.  The memristive capabilities of MTs could drive oscillatory behavior, and enable voltage-driven neuromorphic circuits and architectures within neurons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0DeQVzutqW9K0qsdY6Nc1fW6udTcc2eY1MBvNvhDB5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mrit1Krsg%253D%253D&md5=f0842c5cb0ac7c4fbd48d9870fd05dd6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-48677-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-48677-1%26sid%3Dliteratum%253Aachs%26aulast%3DCantero%26aufirst%3DM.%2BD.%2BR.%26aulast%3DPerez%26aufirst%3DP.%2BL.%26aulast%3DScarinci%26aufirst%3DN.%26aulast%3DCantiello%26aufirst%3DH.%2BF.%26atitle%3DTwo-dimensional%2520brain%2520microtubule%2520structures%2520behave%2520as%2520memristive%2520devices%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26doi%3D10.1038%2Fs41598-019-48677-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akhmanova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span> <span> </span><span class="NLM_article-title">Control of microtubule organization and dynamics: two ends in the limelight</span>. <i>Nat. Rev. Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">726</span>, <span class="refDoi"> DOI: 10.1038/nrm4084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1038%2Fnrm4084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=26562752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVOgt7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=711-726&author=A.+Akhmanovaauthor=M.+O.+Steinmetz&title=Control+of+microtubule+organization+and+dynamics%3A+two+ends+in+the+limelight&doi=10.1038%2Fnrm4084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Control of microtubule organization and dynamics: two ends in the limelight</span></div><div class="casAuthors">Akhmanova, Anna; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">711-726</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Microtubules have fundamental roles in many essential biol. processes, including cell division and intracellular transport.  They assemble and disassemble from their two ends, denoted the plus end and the minus end.  Significant advances have been made in our understanding of microtubule plus-end-tracking proteins (+TIPs) such as end-binding protein 1 (EB1), XMAP215, selected kinesins and dynein.  By contrast, information on microtubule minus-end-targeting proteins (-TIPs), such as the calmodulin-regulated spectrin-assocd. proteins (CAMSAPs) and Patronin, has only recently started to emerge.  Here, we review our current knowledge of factors, including microtubule-targeting agents, that assoc. with microtubule ends to control the dynamics and function of microtubules during the cell cycle and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps4xzvh0o6PbVg90H21EOLACvtfcHk0lhGA2GoX8mSQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVOgt7%252FI&md5=7c941bcce8d5d51aef6a8deb140356d3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrm4084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm4084%26sid%3Dliteratum%253Aachs%26aulast%3DAkhmanova%26aufirst%3DA.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DControl%2520of%2520microtubule%2520organization%2520and%2520dynamics%253A%2520two%2520ends%2520in%2520the%2520limelight%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell.%2520Biol.%26date%3D2015%26volume%3D16%26spage%3D711%26epage%3D726%26doi%3D10.1038%2Fnrm4084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bakhoum, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compton, D. A.</span></span> <span> </span><span class="NLM_article-title">Kinetochores and disease: keeping microtubule dynamics in check!</span>. <i>Curr. Opin. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/j.ceb.2011.11.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.ceb.2011.11.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=22196931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjtlyjt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2012&pages=64-70&author=S.+F.+Bakhoumauthor=D.+A.+Compton&title=Kinetochores+and+disease%3A+keeping+microtubule+dynamics+in+check%21&doi=10.1016%2Fj.ceb.2011.11.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetochores and disease: keeping microtubule dynamics in check!</span></div><div class="casAuthors">Bakhoum, Samuel F.; Compton, Duane A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">64-70</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The essential role of microtubules in cell division has long been known.  Yet the mechanism by which microtubule attachment to chromosomes at kinetochores is regulated has only been recently revealed.  Here, we review the role of kinetochore-microtubule (kMT) attachment dynamics in the cell cycle as well as emerging evidence linking deregulation of kMT attachments to diseases where chromosome mis-segregation and aneuploidy play a central role.  Evidence indicates that the dynamic behavior of kMTs must fall within narrow permissible boundaries, which simultaneously allow a level of stability sufficient to establish and maintain chromosome-microtubule attachments and a degree of instability that permits error correction required for accurate chromosome segregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpULXbDP_rma7Vg90H21EOLACvtfcHk0lhGA2GoX8mSQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjtlyjt7c%253D&md5=bc1e4555cf34706ca3698b3152a0f6a3</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2011.11.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2011.11.012%26sid%3Dliteratum%253Aachs%26aulast%3DBakhoum%26aufirst%3DS.%2BF.%26aulast%3DCompton%26aufirst%3DD.%2BA.%26atitle%3DKinetochores%2520and%2520disease%253A%2520keeping%2520microtubule%2520dynamics%2520in%2520check%2521%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2012%26volume%3D24%26spage%3D64%26epage%3D70%26doi%3D10.1016%2Fj.ceb.2011.11.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vildanova, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smirnova, E. A.</span></span> <span> </span><span class="NLM_article-title">Specific organization of Golgi apparatus in plant cells</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">894</span>– <span class="NLM_lpage">906</span>, <span class="refDoi"> DOI: 10.1134/S0006297914090065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1134%2FS0006297914090065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=25385017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFCgs7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2014&pages=894-906&author=M.+S.+Vildanovaauthor=W.+Wangauthor=E.+A.+Smirnova&title=Specific+organization+of+Golgi+apparatus+in+plant+cells&doi=10.1134%2FS0006297914090065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Specific organization of Golgi apparatus in plant cells</span></div><div class="casAuthors">Vildanova, M. S.; Wang, W.; Smirnova, E. A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry (Moscow)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">894-906</span>CODEN:
                <span class="NLM_cas:coden">BIORAK</span>;
        ISSN:<span class="NLM_cas:issn">0006-2979</span>.
    
            (<span class="NLM_cas:orgname">SP MAIK Nauka/Interperiodica</span>)
        </div><div class="casAbstract">A review.  Microtubules, actin filaments, and Golgi app. are connected both directly and indirectly, but it is manifested differently depending on the cell organization and specialization, and these connections are considered in many original studies and reviews.  In this review we would like to discuss what underlies differences in the structural organization of the Golgi app. in animal and plant cells: specific features of the microtubule cytoskeleton organization, the use of different cytoskeleton components for Golgi app. movement and maintenance of its integrity, or specific features of synthetic and secretory processes.  We suppose that a dispersed state of the Golgi app. in higher plant cells cannot be explained only by specific features of the microtubule system organization and by the absence of centrosome as an active center of their organization because the Golgi app. is organized similarly in the cells of other organisms that possess the centrosome and centrosomal microtubules.  One of the key factors detg. the Golgi app. state in plant cells is the functional uniformity or functional specialization of stacks.  The functional specialization does not suggest the joining of the stacks to form a ribbon; therefore, the disperse state of the Golgi app. needs to be supported, but it also can exist "by default".  We believe that the dispersed state of the Golgi app. in plants is supported, on one hand, by dynamic connections of the Golgi app. stacks with the actin filament system and, on the other hand, with the endoplasmic reticulum exit sites distributed throughout the endoplasmic reticulum.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLnei71jhXVLVg90H21EOLACvtfcHk0lgCnt8sJjsp9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFCgs7bN&md5=5ccbcb308e57938c3ab094c88a41e93b</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1134%2FS0006297914090065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1134%252FS0006297914090065%26sid%3Dliteratum%253Aachs%26aulast%3DVildanova%26aufirst%3DM.%2BS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSmirnova%26aufirst%3DE.%2BA.%26atitle%3DSpecific%2520organization%2520of%2520Golgi%2520apparatus%2520in%2520plant%2520cells%26jtitle%3DBiochemistry%26date%3D2014%26volume%3D79%26spage%3D894%26epage%3D906%26doi%3D10.1134%2FS0006297914090065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janke, C.</span></span> <span> </span><span class="NLM_article-title">The tubulin code: molecular components, readout mechanisms and functions</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>206</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">472</span>, <span class="refDoi"> DOI: 10.1083/jcb.201406055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1083%2Fjcb.201406055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=25135932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVWrtLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=206&publication_year=2014&pages=461-472&author=C.+Janke&title=The+tubulin+code%3A+molecular+components%2C+readout+mechanisms+and+functions&doi=10.1083%2Fjcb.201406055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The tubulin code: molecular components, readout mechanisms, and functions</span></div><div class="casAuthors">Janke, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">206</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">461-472</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">A review.  Microtubules are cytoskeletal filaments that are dynamically assembled from α/β-tubulin heterodimers.  The primary sequence and structure of the tubulin proteins and, consequently, the properties and architecture of microtubules are highly conserved in eukaryotes.  Despite this conservation, tubulin is subject to heterogeneity that is generated in two ways: by the expression of different tubulin isotypes and by posttranslational modifications (PTMs).  Identifying the mechanisms that generate and control tubulin heterogeneity and how this heterogeneity affects microtubule function are long-standing goals in the field.  Recent work on tubulin PTMs has shed light on how these modifications could contribute to a "tubulin code" that coordinates the complex functions of microtubules in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDsM7qNQVrL7Vg90H21EOLACvtfcHk0lgCnt8sJjsp9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVWrtLjN&md5=b4419d7fa17ea78a978b6e28c61e5993</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1083%2Fjcb.201406055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.201406055%26sid%3Dliteratum%253Aachs%26aulast%3DJanke%26aufirst%3DC.%26atitle%3DThe%2520tubulin%2520code%253A%2520molecular%2520components%252C%2520readout%2520mechanisms%2520and%2520functions%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2014%26volume%3D206%26spage%3D461%26epage%3D472%26doi%3D10.1083%2Fjcb.201406055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.-X.</span></span> <span> </span><span class="NLM_article-title">Kinesins in MAPK cascade: how kinesin motors are involved in the MAPK pathway</span>. <i>Gene</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>684</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1016/j.gene.2018.10.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.gene.2018.10.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=30342167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOnur7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=684&publication_year=2019&pages=1-9&author=Y.-J.+Liangauthor=W.-X.+Yang&title=Kinesins+in+MAPK+cascade%3A+how+kinesin+motors+are+involved+in+the+MAPK+pathway&doi=10.1016%2Fj.gene.2018.10.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Kinesins in MAPK cascade: How kinesin motors are involved in the MAPK pathway?</span></div><div class="casAuthors">Liang, Ya-Jing; Yang, Wan-Xi</div><div class="citationInfo"><span class="NLM_cas:title">Gene</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">684</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-9</span>CODEN:
                <span class="NLM_cas:coden">GENED6</span>;
        ISSN:<span class="NLM_cas:issn">0378-1119</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Kinesins are essential for the transport and positioning of several biomols. through moving along the microtubule in eukaryotic cells.  Up to now, there are 14 kinesin family proteins known.  The MAPK pathway which is composed of multiple proteins constituting a complex cascade also plays important roles in cell proliferation, differentiation and apoptosis in eukaryotic cells.  MAPK pathway includes three main kinases: MAPK Kinase Kinase, MAPK Kinase and mitogen-activated protein kinase that activate and phosphorylate downstream step by step in which abundant proteins scaffold together in complex ways.  To accomplish the transmission of a variety of signals, nos. of kinesins are closely assocd. with the MAPK cascade such as Kinesin-1, Kinesin-3, Kinesin-5, Kinesin-8, Kinesin-11 and Kinesin-13 families in mammals and two kinds of kinesin-like proteins in plants.  Studies have indicated that Kinesin-1 light chain KLC1, Kinesin-1 heavy chain KIF5B and Kinesin-11 family motor KIF26B interact with extracellular signal-regulated kinase ERK closely to regulate neuronal differentiation and mediate the chemosensitivity of osteosarcoma cells to drugs, Kinesin-3 family motor KIF13B and Kinesin-5 family motor Eg5 perform functions in regulating p38 to regulate the myelination of nervous system and facilitate the spindle elongation and tension, Kinesin-8 family motor MS-KIF18A and three isoforms of kinesin-13 can also connect and interact with MAPK pathway to transport estrogen receptor to the nucleus and control cell migration.  In plant cells, NPK1-activating kinesin-like protein 1 NACK and AtNACK1 (HIK) kinesin-like protein HINKEL are two members of the plant-specific kinesin-7.  They function as Ras at the upstream of MAPK pathway to regulate cytokinesis.  This review summarizes the novel roles of kinesins in MAPK cascade and tries to discuss the mechanism of the interaction between them using mammalian and plant cells as models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8wxknZIiBWbVg90H21EOLACvtfcHk0lgCnt8sJjsp9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOnur7O&md5=82e54bc4dd19e82db139452c1c2cad6e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.gene.2018.10.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gene.2018.10.042%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DY.-J.%26aulast%3DYang%26aufirst%3DW.-X.%26atitle%3DKinesins%2520in%2520MAPK%2520cascade%253A%2520how%2520kinesin%2520motors%2520are%2520involved%2520in%2520the%2520MAPK%2520pathway%26jtitle%3DGene%26date%3D2019%26volume%3D684%26spage%3D1%26epage%3D9%26doi%3D10.1016%2Fj.gene.2018.10.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalous, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tetkova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubelka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Susor, A.</span></span> <span> </span><span class="NLM_article-title">Importance of ERK1/2 in regulation of protein translation during oocyte meiosis</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">698</span>, <span class="refDoi"> DOI: 10.3390/ijms19030698</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.3390%2Fijms19030698" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVOntrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=698&author=J.+Kalousauthor=A.+Tetkovaauthor=M.+Kubelkaauthor=A.+Susor&title=Importance+of+ERK1%2F2+in+regulation+of+protein+translation+during+oocyte+meiosis&doi=10.3390%2Fijms19030698"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Importance of ERK1/2 in regulation of protein translation during oocyte meiosis</span></div><div class="casAuthors">Kalous, Jaroslav; Tetkova, Anna; Kubelka, Michal; Susor, Andrej</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">698/1-698/21</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Although the involvement of the extracellular signal-regulated kinases 1 and 2 (ERK1/2) pathway in the regulation of cytostatic factor (CSF) activity; as well as in microtubules organization during meiotic maturation of oocytes; has already been described in detail; rather less attention has been paid to the role of ERK1/2 in the regulation of mRNA translation.  However; important data on the role of ERK1/2 in translation during oocyte meiosis have been documented.  This review focuses on recent findings regarding the regulation of translation and the role of ERK1/2 in this process in the meiotic cycle of mammalian oocytes.  The specific role of ERK1/2 in the regulation of mammalian target of rapamycin (mTOR); eukaryotic translation initiation factor 4E (eIF4E) and cytoplasmic polyadenylation element binding protein 1 (CPEB1) activity is addressed along with addnl. focus on the other key players involved in protein translation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSNTBV1Ab8DbVg90H21EOLACvtfcHk0liGvf_HjmzdTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVOntrjJ&md5=e1557d9f6a9f7eea269f72982ca5dfcc</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3390%2Fijms19030698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19030698%26sid%3Dliteratum%253Aachs%26aulast%3DKalous%26aufirst%3DJ.%26aulast%3DTetkova%26aufirst%3DA.%26aulast%3DKubelka%26aufirst%3DM.%26aulast%3DSusor%26aufirst%3DA.%26atitle%3DImportance%2520of%2520ERK1%252F2%2520in%2520regulation%2520of%2520protein%2520translation%2520during%2520oocyte%2520meiosis%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26spage%3D698%26doi%3D10.3390%2Fijms19030698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laflamme, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leary, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascariu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DʼAmours, D.</span></span> <span> </span><span class="NLM_article-title">Interphase microtubules safeguard mitotic progression by suppressing an Aurora B-dependent arrest induced by DNA replication stress</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2875</span>– <span class="NLM_lpage">2889</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2019.02.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.celrep.2019.02.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=30865880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVelu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=2875-2889&author=G.+Laflammeauthor=S.+Simauthor=A.+Learyauthor=M.+Pascariuauthor=J.+Vogelauthor=D.+D%CA%BCAmours&title=Interphase+microtubules+safeguard+mitotic+progression+by+suppressing+an+Aurora+B-dependent+arrest+induced+by+DNA+replication+stress&doi=10.1016%2Fj.celrep.2019.02.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Interphase Microtubules Safeguard Mitotic Progression by Suppressing an Aurora B-Dependent Arrest Induced by DNA Replication Stress</span></div><div class="casAuthors">Laflamme, Guillaume; Sim, Shannon; Leary, Allen; Pascariu, Mirela; Vogel, Jackie; D'Amours, Damien</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2875-2889.e3</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The segregation of chromosomes is a crit. step during cell division.  This process is driven by the elongation of spindle microtubules and is tightly regulated by checkpoint mechanisms.  It is unknown whether microtubules affect checkpoint responses as passive contributors or active regulators of the process.  We show here that interphase microtubules are essential to temporally restrict the effects of DNA replication stress to S phase in Saccharomyces cerevisiae.  Tubulin mutants hypersensitive to DNA damage experience a strong but delayed mitotic checkpoint arrest after exposure to genotoxic stress in S phase.  This untimely arrest is dependent on the Aurora B kinase but, surprisingly, not on the DNA damage checkpoint.  Impaired microtubule-kinetochore interaction is the apparent cause for this unusual phenotype.  Collectively, our results reveal that core components of microtubules potentiate the detection of DNA lesions created in S phase, thereby suppressing untimely activation of mitotic checkpoints after DNA replication stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9S9nYbylbhLVg90H21EOLACvtfcHk0liGvf_HjmzdTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVelu7o%253D&md5=e73e067130396d37caaf9131cc72a19d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2019.02.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2019.02.051%26sid%3Dliteratum%253Aachs%26aulast%3DLaflamme%26aufirst%3DG.%26aulast%3DSim%26aufirst%3DS.%26aulast%3DLeary%26aufirst%3DA.%26aulast%3DPascariu%26aufirst%3DM.%26aulast%3DVogel%26aufirst%3DJ.%26aulast%3DD%25CA%25BCAmours%26aufirst%3DD.%26atitle%3DInterphase%2520microtubules%2520safeguard%2520mitotic%2520progression%2520by%2520suppressing%2520an%2520Aurora%2520B-dependent%2520arrest%2520induced%2520by%2520DNA%2520replication%2520stress%26jtitle%3DCell%2520Rep.%26date%3D2019%26volume%3D26%26spage%3D2875%26epage%3D2889%26doi%3D10.1016%2Fj.celrep.2019.02.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vindya, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethiraj, K. R.</span></span> <span> </span><span class="NLM_article-title">Tubulins–the target for anticancer therapy</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">82</span>, <span class="refDoi"> DOI: 10.2174/1568026615666150112115805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.2174%2F1568026615666150112115805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=25579568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKgsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=73-82&author=N.+G.+Vindyaauthor=N.+Sharmaauthor=M.+Yadavauthor=K.+R.+Ethiraj&title=Tubulins%E2%80%93the+target+for+anticancer+therapy&doi=10.2174%2F1568026615666150112115805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulins - The Target for Anticancer Therapy</span></div><div class="casAuthors">Vindya, N. G.; Sharma, Nishant; Yadav, Mukesh; Ethiraj, K. R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-82</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Tubulin has picked up great focus as a major target in drug discovery and consequently, tubulin inhibitors have pulling in a considerable attention as anticancer agents.  Numerable naturally occurring agents have focused on tubulin system act as an imperative target of cancer chemotherapy.  Substantial no. of tubulin inhibitors has been discovered so far and these agents are classified as indicated by their interaction.  They are colchicine site binder, vinca- alkaloid related drugs and those interacting with the Taxol binding site and functioning as stabilizing agents.  We review the recent advances in the advancement of tubulin interfering agents and will render the current trend in the improvement of tubulin inhibitors as anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3tIyc1PffELVg90H21EOLACvtfcHk0liGvf_HjmzdTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKgsbo%253D&md5=8805a32e1f038693336ceb464c67193d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2174%2F1568026615666150112115805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026615666150112115805%26sid%3Dliteratum%253Aachs%26aulast%3DVindya%26aufirst%3DN.%2BG.%26aulast%3DSharma%26aufirst%3DN.%26aulast%3DYadav%26aufirst%3DM.%26aulast%3DEthiraj%26aufirst%3DK.%2BR.%26atitle%3DTubulins%25E2%2580%2593the%2520target%2520for%2520anticancer%2520therapy%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2015%26volume%3D15%26spage%3D73%26epage%3D82%26doi%3D10.2174%2F1568026615666150112115805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stanton, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gernert, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nettles, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aneja, R.</span></span> <span> </span><span class="NLM_article-title">Drugs that target dynamic microtubules: a new molecular perspective</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1002/med.20242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1002%2Fmed.20242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=21381049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksVKlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=443-481&author=R.+A.+Stantonauthor=K.+M.+Gernertauthor=J.+H.+Nettlesauthor=R.+Aneja&title=Drugs+that+target+dynamic+microtubules%3A+a+new+molecular+perspective&doi=10.1002%2Fmed.20242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs that target dynamic microtubules: A new molecular perspective</span></div><div class="casAuthors">Stanton, Richard A.; Gernert, Kim M.; Nettles, James H.; Aneja, Ritu</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">443-481</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Microtubules have long been considered an ideal target for anticancer drugs because of the essential role they play in mitosis, forming the dynamic spindle app.  As such, there is a wide variety of compds. currently in clin. use and in development that act as antimitotic agents by altering microtubule dynamics.  Although these diverse mols. are known to affect microtubule dynamics upon binding to one of the three established drug domains (taxane, vinca alkaloid, or colchicine site), the exact mechanism by which each drug works is still an area of intense speculation and research.  In this study, we review the effects of microtubule-binding chemotherapeutic agents from a new perspective, considering how their mode of binding induces conformational changes and alters biol. function relative to the mol. vectors of microtubule assembly or disassembly.  These "biol. vectors" can thus be used as a spatiotemporal context to describe mol. mechanisms by which microtubule-targeting drugs work. © 2011 Wiley Periodicals, Inc.  Med Res Rev, 31, No. 3, 443-481, 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB6_lcUQbXYrVg90H21EOLACvtfcHk0lgQC-_84DYaNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksVKlsLs%253D&md5=acce5b9cc89581a7dab0236072b68c72</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2Fmed.20242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20242%26sid%3Dliteratum%253Aachs%26aulast%3DStanton%26aufirst%3DR.%2BA.%26aulast%3DGernert%26aufirst%3DK.%2BM.%26aulast%3DNettles%26aufirst%3DJ.%2BH.%26aulast%3DAneja%26aufirst%3DR.%26atitle%3DDrugs%2520that%2520target%2520dynamic%2520microtubules%253A%2520a%2520new%2520molecular%2520perspective%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2011%26volume%3D31%26spage%3D443%26epage%3D481%26doi%3D10.1002%2Fmed.20242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coderch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morreale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gago, F.</span></span> <span> </span><span class="NLM_article-title">Tubulin-based structure-affinity relationships for antimitotic vinca alkaloids</span>. <i>Anticancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.2174/187152012800228841</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.2174%2F187152012800228841" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=22044006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A280%3ADC%252BC38zntVarsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=219-225&author=C.+Coderchauthor=A.+Morrealeauthor=F.+Gago&title=Tubulin-based+structure-affinity+relationships+for+antimitotic+vinca+alkaloids&doi=10.2174%2F187152012800228841"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulin-based structure-affinity relationships for antimitotic Vinca alkaloids</span></div><div class="casAuthors">Coderch Claire; Morreale Antonio; Gago Federico</div><div class="citationInfo"><span class="NLM_cas:title">Anti-cancer agents in medicinal chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">219-25</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Vinca alkaloids are a group of widely used anticancer drugs, originally extracted from the Madagascar periwinkle, that disrupt microtubule dynamics in mammalian cells by interfering with proper assembly of α,β-tubulin heterodimers.  They favor curved tubulin assemblies that destabilize microtubules and induce formation of spiral aggregates.  Their binding energy profiles have been characterized by means of sedimentation velocity assays and the binding site of vinblastine at the interface between two tubulin dimers (α1β1 .replace. α2β2) has been ascertained by X-ray crystallographic studies on a complex of tubulin with the stathmin-like domain of protein RB3, albeit at relatively low resolution.  Here we use molecular modeling and simulation techniques to build, refine and perform a comparative analysis of the three-dimensional complexes of vinblastine, vincristine, vinorelbine and vinflunine with a β1α2-tubulin interface in explicit water to rationalize the binding affinity differences in structural and energetic terms.  Our results shed some more light into the binding determinants and the structure-activity relationships of these clinically useful agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcROoDr1706CUb0AGQpJZWpJfW6udTcc2eat69YtmWbtYLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38zntVarsw%253D%253D&md5=204cce5f118540a0d8a6c9af29adfb16</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F187152012800228841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152012800228841%26sid%3Dliteratum%253Aachs%26aulast%3DCoderch%26aufirst%3DC.%26aulast%3DMorreale%26aufirst%3DA.%26aulast%3DGago%26aufirst%3DF.%26atitle%3DTubulin-based%2520structure-affinity%2520relationships%2520for%2520antimitotic%2520vinca%2520alkaloids%26jtitle%3DAnticancer%2520Agents%2520Med.%2520Chem.%26date%3D2012%26volume%3D12%26spage%3D219%26epage%3D225%26doi%3D10.2174%2F187152012800228841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span> <span> </span><span class="NLM_article-title">Microtubule-targeting agents: strategies to hijack the cytoskeleton</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">776</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1016/j.tcb.2018.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.tcb.2018.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=29871823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpslaksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=776-792&author=M.+O.+Steinmetzauthor=A.+E.+Prota&title=Microtubule-targeting+agents%3A+strategies+to+hijack+the+cytoskeleton&doi=10.1016%2Fj.tcb.2018.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton</span></div><div class="casAuthors">Steinmetz, Michel O.; Prota, Andrea E.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">776-792</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Microtubule-targeting agents (MTAs) such as paclitaxel and the vinca alkaloids are among the most important medical weapons available to combat cancer.  MTAs interfere with intracellular transport, inhibit eukaryotic cell proliferation, and promote cell death by suppressing microtubule dynamics.  Recent advances in the structural anal. of MTAs have enabled the extensive characterization of their interactions with microtubules and their building block tubulin.  We review here our current knowledge on the mol. mechanisms used by MTAs to hijack the microtubule cytoskeleton, and discuss dual inhibitors that target both kinases and microtubules.  We further formulate some outstanding questions related to MTA structural biol. and present possible routes for future investigations of this fascinating class of antimitotic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0akrt04GstbVg90H21EOLACvtfcHk0lgQC-_84DYaNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpslaksL0%253D&md5=b6ec960a802f658b3f21e030e687c60e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2018.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2018.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26aulast%3DProta%26aufirst%3DA.%2BE.%26atitle%3DMicrotubule-targeting%2520agents%253A%2520strategies%2520to%2520hijack%2520the%2520cytoskeleton%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2018%26volume%3D28%26spage%3D776%26epage%3D792%26doi%3D10.1016%2Fj.tcb.2018.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shuai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and anticancer properties of isocombretapyridines as potent colchicine binding site inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>197</i></span>, <span class="NLM_elocation-id">112308</span> <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.ejmech.2020.112308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=32339853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BB3cXosVSqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=197&publication_year=2020&author=W.+Shuaiauthor=X.+Liauthor=W.+Liauthor=F.+Xuauthor=L.+Luauthor=H.+Yaoauthor=L.+Yangauthor=H.+Zhuauthor=S.+Xuauthor=Z.+Zhuauthor=J.+Xu&title=Design%2C+synthesis+and+anticancer+properties+of+isocombretapyridines+as+potent+colchicine+binding+site+inhibitors&doi=10.1016%2Fj.ejmech.2020.112308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and anticancer properties of isocombretapyridines as potent colchicine binding site inhibitors</span></div><div class="casAuthors">Shuai, Wen; Li, Xinnan; Li, Wenlong; Xu, Feijie; Lu, Lixue; Yao, Hong; Yang, Limei; Zhu, Huajian; Xu, Shengtao; Zhu, Zheying; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">197</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112308</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel isocombretapyridines were designed and synthesized based on a lead compd. isocombretastatin A-4 (isoCA-4) by replacing 3,4,5-trimethoxylphenyl with substituent pyridine nucleus.  The MTT assay results showed that compd. I possessed the most potent activities against all tested cell lines with IC50 values at nanomolar concn. ranges.  Moreover, I inhibited tubulin polymn. at a micromolar level and also displayed potent anti-vascular activity in vitro.  Further mechanistic studies were conducted to demonstrate that compd. I could bind to the colchicine site of tubulin,and disrupte the cell microtubule networks, induce G2/M phase arrest, promote apoptosis and depolarize mitochondria of K562 cells in a dose-dependent manner.  Notably, I exhibited more potent tumor growth inhibition activity with 68.7% tumor growth inhibition than that of isoCA-4 in H22 allograft mouse model without apparent toxicity.  The present results suggested that compd. I may serve as a promising potent microtubule-destabilizing agent candidate for the development of therapeutics to treat cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMDR0o7MfBmLVg90H21EOLACvtfcHk0liHSCM5QBW3fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosVSqsLs%253D&md5=c448b8f1e4636a50908a1fd31d2fbc5c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112308%26sid%3Dliteratum%253Aachs%26aulast%3DShuai%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520anticancer%2520properties%2520of%2520isocombretapyridines%2520as%2520potent%2520colchicine%2520binding%2520site%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D197%26doi%3D10.1016%2Fj.ejmech.2020.112308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lobert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correia, J. J.</span></span> <span> </span><span class="NLM_article-title">Energetics of vinca alkaloid interactions with tubulin</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>323</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1016/S0076-6879(00)23362-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2FS0076-6879%2800%2923362-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10944748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsVGhsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2000&pages=77-103&author=S.+Lobertauthor=J.+J.+Correia&title=Energetics+of+vinca+alkaloid+interactions+with+tubulin&doi=10.1016%2FS0076-6879%2800%2923362-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Energetics of vinca alkaloid interactions with tubulin</span></div><div class="casAuthors">Lobert, Sharon; Correia, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">Energetics of Biological Macromolecules, Part C</span>),
    <span class="NLM_cas:pages">77-103</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review with 71 refs. is presented regarding the energetics of interactions between Vinca rosa L. (vinca) alkaloids, antimitotic chemotherapeutic agents, and tubulin, the major protein constituent of microtubules and the mitotic spindle.  Topics discussed include the use of sedimentation velocity, the qual. fitting of wt. av. sedimentation coeff. data, and its applicability to extg. the energetics of vinca alkaloid-tubulin interactions.  Also, results obtained with four clin. useful vinca alkaloid congeners were compared.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_d0_exxQc1bVg90H21EOLACvtfcHk0liHSCM5QBW3fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsVGhsrw%253D&md5=bf6f2b0002d85e0a9e1789d7a8b28554</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2800%2923362-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252800%252923362-4%26sid%3Dliteratum%253Aachs%26aulast%3DLobert%26aufirst%3DS.%26aulast%3DCorreia%26aufirst%3DJ.%2BJ.%26atitle%3DEnergetics%2520of%2520vinca%2520alkaloid%2520interactions%2520with%2520tubulin%26jtitle%3DMethods%2520Enzymol.%26date%3D2000%26volume%3D323%26spage%3D77%26epage%3D103%26doi%3D10.1016%2FS0076-6879%2800%2923362-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargsten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuevas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liniger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuhaus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span> <span> </span><span class="NLM_article-title">A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">13817</span>– <span class="NLM_lpage">13821</span>, <span class="refDoi"> DOI: 10.1073/pnas.1408124111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1073%2Fpnas.1408124111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=25114240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCju7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=13817-13821&author=A.+E.+Protaauthor=K.+Bargstenauthor=J.+F.+Diazauthor=M.+Marshauthor=C.+Cuevasauthor=M.+Linigerauthor=C.+Neuhausauthor=J.+M.+Andreuauthor=K.-H.+Altmannauthor=M.+O.+Steinmetz&title=A+new+tubulin-binding+site+and+pharmacophore+for+microtubule-destabilizing+anticancer+drugs&doi=10.1073%2Fpnas.1408124111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs</span></div><div class="casAuthors">Prota, Andrea E.; Bargsten, Katja; Diaz, J. Fernando; Marsh, May; Cuevas, Carmen; Liniger, Marc; Neuhaus, Christian; Andreu, Jose M.; Altmann, Karl-Heinz; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">13817-13821</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The recent success of antibody-drug conjugates (ADCs) in the treatment of cancer has led to a revived interest in microtubule-destabilizing agents.  Here, we detd. the high-resoln. crystal structure of the complex between tubulin and maytansine, which is part of an ADC that is approved by the US Food and Drug Administration (FDA) for the treatment of advanced breast cancer.  We found that the drug binds to a site on β-tubulin that is distinct from the vinca domain and that blocks the formation of longitudinal tubulin interactions in microtubules.  We also solved crystal structures of tubulin in complex with both a variant of rhizoxin and the phase 1 drug PM060184.  Consistent with biochem. and mutagenesis data, we found that the two compds. bound to the same site as maytansine and that the structures revealed a common pharmacophore for the three ligands.  Our results delineate a distinct mol. mechanism of action for the inhibition of microtubule assembly by clin. relevant agents.  They further provide a structural basis for the rational design of potent microtubule-destabilizing agents, thus opening opportunities for the development of next-generation ADCs for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX4icqk698gLVg90H21EOLACvtfcHk0liHSCM5QBW3fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCju7vM&md5=798cae320e427ff76c2099387d9e6ba4</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1408124111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1408124111%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DDiaz%26aufirst%3DJ.%2BF.%26aulast%3DMarsh%26aufirst%3DM.%26aulast%3DCuevas%26aufirst%3DC.%26aulast%3DLiniger%26aufirst%3DM.%26aulast%3DNeuhaus%26aufirst%3DC.%26aulast%3DAndreu%26aufirst%3DJ.%2BM.%26aulast%3DAltmann%26aufirst%3DK.-H.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DA%2520new%2520tubulin-binding%2520site%2520and%2520pharmacophore%2520for%2520microtubule-destabilizing%2520anticancer%2520drugs%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2014%26volume%3D111%26spage%3D13817%26epage%3D13821%26doi%3D10.1073%2Fpnas.1408124111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waight, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargsten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span> <span> </span><span class="NLM_article-title">Pironetin binds covalently to αCys316 and perturbs a major loop and helix of α-tubulin to inhibit microtubule formation</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>428</i></span>,  <span class="NLM_fpage">2981</span>– <span class="NLM_lpage">2988</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2016.06.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.jmb.2016.06.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=27395016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFentL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=428&publication_year=2016&pages=2981-2988&author=A.+E.+Protaauthor=J.+Setterauthor=A.+B.+Waightauthor=K.+Bargstenauthor=J.+Murgaauthor=J.+F.+Diazauthor=M.+O.+Steinmetz&title=Pironetin+binds+covalently+to+%CE%B1Cys316+and+perturbs+a+major+loop+and+helix+of+%CE%B1-tubulin+to+inhibit+microtubule+formation&doi=10.1016%2Fj.jmb.2016.06.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Pironetin binds covalently to αCys316 and perturbs a major loop and helix of α-tubulin to inhibit microtubule formation</span></div><div class="casAuthors">Prota, Andrea E.; Setter, Jocelyn; Waight, Andrew B.; Bargsten, Katja; Murga, Juan; Diaz, Jose Fernando; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">428</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2981-2988</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Microtubule-targeting agents are among the most powerful drugs used in chemotherapy to treat cancer patients.  Pironetin (I) is a natural product that displays promising anticancer properties by binding to and potently inhibiting tubulin assembly into microtubules; however, its mol. mechanism of action remained obscure.  Here, the authors solved the crystal structure of the tubulin-I complex and found that the compd. covalently binds to Cys-316 of α-tubulin.  The structure further revealed that I perturbs the T7 loop and helix H8 of α-tubulin.  Since both of these elements are essential for establishing longitudinal tubulin contacts in microtubules, this result explains how I inhibits the formation of microtubules.  Together, the data define the mol. details of the I binding site on α-tubulin and thus offer a promising basis for the rational design of I variants with improved activity profiles.  They further extend knowledge on strategies evolved by natural products to target and perturb the microtubule cytoskeleton.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYXbbv8loGDLVg90H21EOLACvtfcHk0lg6ygL_pvzF-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFentL%252FP&md5=66e945caa3adaf0f3a5a20a702b3b406</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2016.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2016.06.023%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DSetter%26aufirst%3DJ.%26aulast%3DWaight%26aufirst%3DA.%2BB.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DMurga%26aufirst%3DJ.%26aulast%3DDiaz%26aufirst%3DJ.%2BF.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DPironetin%2520binds%2520covalently%2520to%2520%25CE%25B1Cys316%2520and%2520perturbs%2520a%2520major%2520loop%2520and%2520helix%2520of%2520%25CE%25B1-tubulin%2520to%2520inhibit%2520microtubule%2520formation%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2016%26volume%3D428%26spage%3D2981%26epage%3D2988%26doi%3D10.1016%2Fj.jmb.2016.06.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botting, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naismith, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Pironetin reacts covalently with cysteine-316 of α-tubulin to destabilize microtubule</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">12103</span> <span class="refDoi"> DOI: 10.1038/ncomms12103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1038%2Fncomms12103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=27357539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFSqtLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&author=J.+Yangauthor=Y.+Wangauthor=T.+Wangauthor=J.+Jiangauthor=C.+H.+Bottingauthor=H.+Liuauthor=Q.+Chenauthor=J.+H.+Naismithauthor=X.+Zhuauthor=L.+Chen&title=Pironetin+reacts+covalently+with+cysteine-316+of+%CE%B1-tubulin+to+destabilize+microtubule&doi=10.1038%2Fncomms12103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Pironetin reacts covalently with cysteine-316 of α-tubulin to destabilize microtubule</span></div><div class="casAuthors">Yang, Jianhong; Wang, Yuxi; Wang, Taijing; Jiang, Jian; Botting, Catherine H.; Liu, Huanting; Chen, Qiang; Yang, Jinliang; Naismith, James H.; Zhu, Xiaofeng; Chen, Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12103</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mols. that alter the normal dynamics of microtubule assembly and disassembly include many anticancer drugs in clin. use.  So far all such therapeutics target β-tubulin, and structural biol. has explained the basis of their action and permitted design of new drugs.  However, by shifting the profile of β-tubulin isoforms, cancer cells become resistant to treatment.  Compds. that bind to α-tubulin are less well characterized and unexploited.  The natural product pironetin is known to bind to α-tubulin and is a potent inhibitor of microtubule polymn.  Previous reports had identified that pironetin reacts with lysine-352 residue however analogs designed on this model had much lower potency, which was difficult to explain, hindering further development.  We report crystallog. and mass spectrometric data that reveal that pironetin forms a covalent bond to cysteine-316 in α-tubulin via a Michael addn. reaction.  These data provide a basis for the rational design of α-tubulin targeting chemotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpA2PMsYegjrbVg90H21EOLACvtfcHk0lg6ygL_pvzF-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFSqtLfM&md5=25eadc388dddb3f88581651762d09aa5</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fncomms12103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms12103%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DBotting%26aufirst%3DC.%2BH.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DNaismith%26aufirst%3DJ.%2BH.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DPironetin%2520reacts%2520covalently%2520with%2520cysteine-316%2520of%2520%25CE%25B1-tubulin%2520to%2520destabilize%2520microtubule%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26doi%3D10.1038%2Fncomms12103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barakat, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huzil, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuszynski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schriemer, D. C.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of the laulimalide-microtubule binding mode by mass shift perturbation mapping</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">725</span>– <span class="NLM_lpage">734</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.chembiol.2010.05.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=20659685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptleitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=725-734&author=M.+J.+Bennettauthor=K.+Barakatauthor=J.+T.+Huzilauthor=J.+Tuszynskiauthor=D.+C.+Schriemer&title=Discovery+and+characterization+of+the+laulimalide-microtubule+binding+mode+by+mass+shift+perturbation+mapping&doi=10.1016%2Fj.chembiol.2010.05.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of the Laulimalide-Microtubule Binding Mode by Mass Shift Perturbation Mapping</span></div><div class="casAuthors">Bennett, Melissa J.; Barakat, Khaled; Huzil, J. Torin; Tuszynski, Jack; Schriemer, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">725-734</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Conventional approaches to site mapping have so far failed to identify the laulimalide binding site on microtubules.  Using mass shift perturbation anal. and data-directed docking, we demonstrate that laulimalide binds to the exterior of the microtubule on β-tubulin, in a region previously unknown to support ligand binding and well removed from the paclitaxel site.  Shift maps for docetaxel and laulimalide are otherwise identical, indicating a common state of microtubule stability induced by occupancy of the distinct sites.  The preferred binding mode highlights the penetration of the laulimalide side chain into a deep, narrow cavity through a unique conformation not strongly populated in soln., akin to a "striking cobra".  This mode supports the development of a pharmacophore model and reveals the importance of the C1-C15 axis in the macrocycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbYV4W7lV1KLVg90H21EOLACvtfcHk0lg6ygL_pvzF-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptleitLo%253D&md5=0219ce6a7590b9e2990be4d9a9170de5</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DBennett%26aufirst%3DM.%2BJ.%26aulast%3DBarakat%26aufirst%3DK.%26aulast%3DHuzil%26aufirst%3DJ.%2BT.%26aulast%3DTuszynski%26aufirst%3DJ.%26aulast%3DSchriemer%26aufirst%3DD.%2BC.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520the%2520laulimalide-microtubule%2520binding%2520mode%2520by%2520mass%2520shift%2520perturbation%2520mapping%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D725%26epage%3D734%26doi%3D10.1016%2Fj.chembiol.2010.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rohena, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooberry, S. L.</span></span> <span> </span><span class="NLM_article-title">Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities</span>. <i>Nat. Prod. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">355</span>, <span class="refDoi"> DOI: 10.1039/C3NP70092E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1039%2FC3NP70092E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=24481420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVagsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2014&pages=335-355&author=C.+C.+Rohenaauthor=S.+L.+Mooberry&title=Recent+progress+with+microtubule+stabilizers%3A+new+compounds%2C+binding+modes+and+cellular+activities&doi=10.1039%2FC3NP70092E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities</span></div><div class="casAuthors">Rohena, Cristina C.; Mooberry, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">335-355</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Covering: late 2008 to August 2013Nature has yielded numerous classes of chem. distinct microtubule stabilizers.  Several of these, including paclitaxel (Taxol) and docetaxel (Taxotere), are important drugs used in the treatment of cancer.  New microtubule stabilizers and novel formulations of these agents continue to provide advances in cancer therapy.  In this review we cover recent progress in the chem. and biol. of these diverse microtubule stabilizers focusing on the wide range of organisms that produce these compds., their mechanisms of inhibiting microtubule-dependent processes, mechanisms of drug resistance, and their interactions with tubulin including their distinct binding sites and modes.  A new potential role for microtubule stabilizers in neurodegenerative diseases is reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGbuNICZ6-bLVg90H21EOLACvtfcHk0lgDUh4_oZhiVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVagsro%253D&md5=50febeef8c139e67374a92250e7e2a7a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1039%2FC3NP70092E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC3NP70092E%26sid%3Dliteratum%253Aachs%26aulast%3DRohena%26aufirst%3DC.%2BC.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DRecent%2520progress%2520with%2520microtubule%2520stabilizers%253A%2520new%2520compounds%252C%2520binding%2520modes%2520and%2520cellular%2520activities%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2014%26volume%3D31%26spage%3D335%26epage%3D355%26doi%3D10.1039%2FC3NP70092E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, L.</span></span> <span> </span><span class="NLM_article-title">Microtubules as a target for anticancer drugs</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.1038/nrc1317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1038%2Fnrc1317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=15057285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=253-265&author=M.+A.+Jordanauthor=L.+Wilson&title=Microtubules+as+a+target+for+anticancer+drugs&doi=10.1038%2Fnrc1317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubules as a target for anticancer drugs</span></div><div class="casAuthors">Jordan, Mary Ann; Wilson, Leslie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">253-265</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Highly dynamic mitotic-spindle microtubules are among the most successful targets for anticancer therapy.  Microtubule-targeted drugs, including paclitaxel and Vinca alkaloids, were previously considered to work primarily by increasing or decreasing the cellular microtubule mass.  Although these effects might have a role in their chemotherapeutic actions, we now know that at lower concns., microtubule-targeted drugs can suppress microtubule dynamics without changing microtubule mass; this action leads to mitotic block and apoptosis.  In addn. to the expanding array of chem. diverse antimitotic agents, some microtubule-targeted drugs can act as vascular-targeting agents, rapidly depolymg. microtubules of newly formed vasculature to shut down the blood supply to tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRJbrFnzwqjbVg90H21EOLACvtfcHk0lgDUh4_oZhiVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D&md5=bbbf212e03ffe6763098fc41f21a8158</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnrc1317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1317%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DM.%2BA.%26aulast%3DWilson%26aufirst%3DL.%26atitle%3DMicrotubules%2520as%2520a%2520target%2520for%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D253%26epage%3D265%26doi%3D10.1038%2Fnrc1317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dumontet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, M. A.</span></span> <span> </span><span class="NLM_article-title">Microtubule-binding agents: a dynamic field of cancer therapeutics</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">790</span>– <span class="NLM_lpage">803</span>, <span class="refDoi"> DOI: 10.1038/nrd3253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1038%2Fnrd3253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=20885410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1akur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=790-803&author=C.+Dumontetauthor=M.+A.+Jordan&title=Microtubule-binding+agents%3A+a+dynamic+field+of+cancer+therapeutics&doi=10.1038%2Fnrd3253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-binding agents: a dynamic field of cancer therapeutics</span></div><div class="casAuthors">Dumontet, Charles; Jordan, Mary Ann</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">790-803</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Microtubules are dynamic filamentous cytoskeletal proteins composed of tubulin and are an important therapeutic target in tumor cells.  Agents that bind to microtubules have been part of the pharmacopoeia of anticancer therapy for decades and until the advent of targeted therapy, microtubules were the only alternative to DNA as a therapeutic target in cancer.  The screening of a range of botanical species and marine organisms has yielded promising new antitubulin agents with novel properties.  In the current search for novel microtubule-binding agents, enhanced tumor specificity, reduced neurotoxicity and insensitivity to chemoresistance mechanisms are the three main objectives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ43DyXjdN7rVg90H21EOLACvtfcHk0lgDUh4_oZhiVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1akur%252FI&md5=9fc6fd966859785605936ecbe6dca44e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnrd3253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3253%26sid%3Dliteratum%253Aachs%26aulast%3DDumontet%26aufirst%3DC.%26aulast%3DJordan%26aufirst%3DM.%2BA.%26atitle%3DMicrotubule-binding%2520agents%253A%2520a%2520dynamic%2520field%2520of%2520cancer%2520therapeutics%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D790%26epage%3D803%26doi%3D10.1038%2Fnrd3253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noble, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutts, J. H.</span></span> <span> </span><span class="NLM_article-title">Role of chance observations in chemotherapy: vinca rosea</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1958</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">882</span>– <span class="NLM_lpage">894</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.1958.tb54906.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1111%2Fj.1749-6632.1958.tb54906.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=13627916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A280%3ADyaG1M%252FlslCltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1958&pages=882-894&author=R.+L.+Nobleauthor=C.+T.+Beerauthor=J.+H.+Cutts&title=Role+of+chance+observations+in+chemotherapy%3A+vinca+rosea&doi=10.1111%2Fj.1749-6632.1958.tb54906.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Role of chance observations in chemotherapy: Vinca rosea</span></div><div class="casAuthors">NOBLE R L; BEER C T; CUTTS J H</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">1958</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">882-94</span>
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQcvofRkfg0eJotVjB3IRIyfW6udTcc2eZ_Tc-FtUB2wbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaG1M%252FlslCltQ%253D%253D&md5=a728fef90a06da248a734bfbed91a985</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.1958.tb54906.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.1958.tb54906.x%26sid%3Dliteratum%253Aachs%26aulast%3DNoble%26aufirst%3DR.%2BL.%26aulast%3DBeer%26aufirst%3DC.%2BT.%26aulast%3DCutts%26aufirst%3DJ.%2BH.%26atitle%3DRole%2520of%2520chance%2520observations%2520in%2520chemotherapy%253A%2520vinca%2520rosea%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D1958%26volume%3D76%26spage%3D882%26epage%3D894%26doi%3D10.1111%2Fj.1749-6632.1958.tb54906.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svoboda, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlantis, J.</span></span> <span> </span><span class="NLM_article-title">Antitumor principles derived from vinca rosea. I. vincaleukoblastine and leurosine</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1960</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1016</span>– <span class="NLM_lpage">1022</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=14407465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADyaF3sXmt1Sgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1960&pages=1016-1022&author=I.+S.+Johnsonauthor=H.+F.+Wrightauthor=G.+H.+Svobodaauthor=J.+Vlantis&title=Antitumor+principles+derived+from+vinca+rosea.+I.+vincaleukoblastine+and+leurosine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor principles derived from Vinca rosea. I. Vincaleukoblastine and leurosine</span></div><div class="casAuthors">Johnson, Irving S.; Wright, Howard F.; Svobada, Gordon H.; Vlantis, Janet</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1960</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1016-22</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">The exptl. activity of a new clin. confirmed antitumor compd., vincaleukoblastine (C15H58O9N4), (VLB) as the sulfate is described.  Greatest activity was seen against the P-1534 acute lymphocytic leukemia in DBA/2 mice.  Late as well as early stages of this leukemia were significantly affected by this compd.  No synergistic or additive effects were observed in combination with other antitumor compds.  A second indole-indoline alkaloid, leurosine, isomeric with VLB, was also obtained from Vinca rosea, with similar demonstrable exptl. antitumor activity.  Two other alkaloids, vindoline (C25H32O2) and catharanthine (C21H22O2N2), also obtained from V. rosea, were devoid of antitumor activity singly or in equimolar concns., but were postulated as the biogenetic precursors of VLB and leurosine.  Preliminary studies in vitro demonstrated that certain compds. were capable of reversing the growth-inhibitory activity of VLB against human monocytic leukemia cells.  These compds. were coenzyme A, aspartic acid, tryptophan, α-ketoglutaric acid, ornithine, citrulline, arginine, and glutamic acid.  VLB and leurosine are representatives of a new class of clin. active antitumor compds. which may interfere with the cellular metabolic pathways leading from glutamic acid to urea, and from glutamic acid to the citric acid cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrccExPV6hVf7Vg90H21EOLACvtfcHk0lgyuZVXfwYwrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3sXmt1Sgtg%253D%253D&md5=574735669c0e4c9e267af3f20ce36c22</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DI.%2BS.%26aulast%3DWright%26aufirst%3DH.%2BF.%26aulast%3DSvoboda%26aufirst%3DG.%2BH.%26aulast%3DVlantis%26aufirst%3DJ.%26atitle%3DAntitumor%2520principles%2520derived%2520from%2520vinca%2520rosea.%2520I.%2520vincaleukoblastine%2520and%2520leurosine%26jtitle%3DCancer%2520Res.%26date%3D1960%26volume%3D20%26spage%3D1016%26epage%3D1022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dybdal-Hargreaves, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risinger, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooberry, S. L.</span></span> <span> </span><span class="NLM_article-title">Eribulin Mesylate: mechanism of action of a unique microtubule-targeting agent</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2445</span>– <span class="NLM_lpage">2452</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-3252</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1158%2F1078-0432.CCR-14-3252" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=25838395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXps1aktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2445-2452&author=N.+F.+Dybdal-Hargreavesauthor=A.+L.+Risingerauthor=S.+L.+Mooberry&title=Eribulin+Mesylate%3A+mechanism+of+action+of+a+unique+microtubule-targeting+agent&doi=10.1158%2F1078-0432.CCR-14-3252"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Eribulin Mesylate: Mechanism of Action of a Unique Microtubule-Targeting Agent</span></div><div class="casAuthors">Dybdal-Hargreaves, Nicholas F.; Risinger, April L.; Mooberry, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2445-2452</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Eribulin mesylate (eribulin), an analog of the marine natural product halichondrin B, is a microtubule-depolymg. drug that has utility in the treatment of patients with breast cancer.  Clin. trial results have demonstrated that eribulin treatment provides a survival advantage to patients with metastatic or locally advanced breast cancer previously treated with an anthracycline and a taxane.  Furthermore, a pooled anal. of two pivotal phase III trials has demonstrated that eribulin also improves overall survival in several patient subgroups, including in women with HER2-neg. disease and triple-neg. breast cancer.  This review covers the preclin. research that led to the clin. testing and approval of eribulin, as well as subsequent research that was prompted by distinct and unexpected effects of eribulin in the clinic.  Initial studies with halichondrin B demonstrated unique effects on tubulin binding that resulted in distinct microtubule-dependent events and antitumor actions.  Consistent with the actions of the natural product, eribulin has potent microtubule-depolymg. activities and properties that distinguish it from other microtubule-targeting agents.  Here, we review new results that further differentiate the effects of eribulin from other agents on peripheral nerves, angiogenesis, vascular remodeling, and epithelial-to-mesenchymal transition.  Together, these data highlight the distinct properties of eribulin and begin to delineate the mechanisms behind the increased survival benefit provided by eribulin for patients.  Clin Cancer Res; 21(11); 2445-52. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU-LpLOesxd7Vg90H21EOLACvtfcHk0lgyuZVXfwYwrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXps1aktb4%253D&md5=a2d259232081c3aa4bfce80110c21eb8</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-3252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-3252%26sid%3Dliteratum%253Aachs%26aulast%3DDybdal-Hargreaves%26aufirst%3DN.%2BF.%26aulast%3DRisinger%26aufirst%3DA.%2BL.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DEribulin%2520Mesylate%253A%2520mechanism%2520of%2520action%2520of%2520a%2520unique%2520microtubule-targeting%2520agent%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D2445%26epage%3D2452%26doi%3D10.1158%2F1078-0432.CCR-14-3252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Canta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiorazzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavaletti, G.</span></span> <span> </span><span class="NLM_article-title">Tubulin: a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1315</span>– <span class="NLM_lpage">1324</span>, <span class="refDoi"> DOI: 10.2174/092986709787846488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.2174%2F092986709787846488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=19355888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltVeqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=1315-1324&author=A.+Cantaauthor=A.+Chiorazziauthor=G.+Cavaletti&title=Tubulin%3A+a+target+for+antineoplastic+drugs+into+the+cancer+cells+but+also+in+the+peripheral+nervous+system&doi=10.2174%2F092986709787846488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulin as a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system</span></div><div class="casAuthors">Canta, Annalisa; Chiorazzi, Alessia; Cavaletti, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1315-1324</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Since the introduction into clin. practice of vinca alkaloids, tubulin has become a key and well-established target of modern antineoplastic chemotherapy.  When taxanes became available their broad spectrum of activity was striking and opened up new horizons for cancer patients' treatment.  However, taxanes' susceptibility to drug resistance caused by the drug efflux pump protein, P-glycoprotein, is not infrequent and their use may be limited by poor soly., synthetic problems and toxicity.  The epothilones are a new class of chemotherapeutic agents with a mechanism of action similar to that of taxanes, but different enough to escape, for example, the multidrug resistance caused by P-glycoprotein.  Moreover, the epothilones (that are strong promoters of tubulin polymn.) have significant antitumor activity against human cancer cells that are taxane-resistant, express the multidrug resistance gene MDR-1, and have acquired tubulin mutations.  Finally, starting from the natural mols., several synthetic analogs have been developed.  Besides their antineoplastic efficacy, all the antitubulin drugs share a common toxicity on the peripheral nervous system and peripheral neurotoxicity is a major, potentially dose-limiting side effect also of the epothilones.  The current knowledge regarding the features of epothilones' peripheral neurotoxicity and their comparison with taxanes will be reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrud9z8vnFGFLVg90H21EOLACvtfcHk0lgwXAMCdj5kpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltVeqsbo%253D&md5=88fe8b8400cb3ec5be160439503c914f</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2174%2F092986709787846488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986709787846488%26sid%3Dliteratum%253Aachs%26aulast%3DCanta%26aufirst%3DA.%26aulast%3DChiorazzi%26aufirst%3DA.%26aulast%3DCavaletti%26aufirst%3DG.%26atitle%3DTubulin%253A%2520a%2520target%2520for%2520antineoplastic%2520drugs%2520into%2520the%2520cancer%2520cells%2520but%2520also%2520in%2520the%2520peripheral%2520nervous%2520system%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2009%26volume%3D16%26spage%3D1315%26epage%3D1324%26doi%3D10.2174%2F092986709787846488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, S.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wing, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaney, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorsic, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroetz, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolan, M. E.</span></span> <span> </span><span class="NLM_article-title">Pharmacoethnicity in paclitaxel-induced sensory peripheral neuropathy</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">4337</span>– <span class="NLM_lpage">4346</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-0133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1158%2F1078-0432.CCR-15-0133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=26015512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1antLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=4337-4346&author=M.+Komatsuauthor=H.+E.+Wheelerauthor=S.+Chungauthor=S.-K.+Lowauthor=C.+Wingauthor=S.+M.+Delaneyauthor=L.+K.+Gorsicauthor=A.+Takahashiauthor=M.+Kuboauthor=D.+L.+Kroetzauthor=W.+Zhangauthor=Y.+Nakamuraauthor=M.+E.+Dolan&title=Pharmacoethnicity+in+paclitaxel-induced+sensory+peripheral+neuropathy&doi=10.1158%2F1078-0432.CCR-15-0133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy</span></div><div class="casAuthors">Komatsu, Masaaki; Wheeler, Heather E.; Chung, Suyoun; Low, Siew-Kee; Wing, Claudia; Delaney, Shannon M.; Gorsic, Lidija K.; Takahashi, Atsushi; Kubo, Michiaki; Kroetz, Deanna L.; Zhang, Wei; Nakamura, Yusuke; Dolan, M. Eileen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4337-4346</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Paclitaxel is used worldwide in the treatment of breast, lung, ovarian, and other cancers.  Sensory peripheral neuropathy is an assocd. adverse effect that cannot be predicted, prevented, or mitigated.  To better understand the contribution of germline genetic variation to paclitaxel-induced peripheral neuropathy, we undertook an integrative approach that combines genome-wide assocn. study (GWAS) data generated from HapMap lymphoblastoid cell lines (LCL) and Asian patients.  Methods: GWAS was performed with paclitaxel-induced cytotoxicity generated in 363 LCLs and with paclitaxel-induced neuropathy from 145 Asian patients.  A gene-based approach was used to identify overlapping genes and compare with a European clin. cohort of paclitaxel-induced neuropathy.  Neurons derived from human-induced pluripotent stem cells were used for functional validation of candidate genes.  Results: SNPs near AIPL1 were significantly assocd. with paclitaxel-induced cytotoxicity in Asian LCLs (P < 10-6).  Decreased expression of AIPL1 resulted in decreased sensitivity of neurons to paclitaxel by inducing neurite morphol. changes as measured by increased relative total outgrowth, no. of processes and mean process length.  Using a gene-based anal., there were 32 genes that overlapped between Asian LCL cytotoxicity and Asian patient neuropathy (P < 0.05), including BCR.  Upon BCR knockdown, there was an increase in neuronal sensitivity to paclitaxel as measured by neurite morphol. characteristics.  Conclusions: We identified genetic variants assocd. with Asian paclitaxel-induced cytotoxicity and functionally validated the AIPL1 and BCR in a neuronal cell model.  Furthermore, the integrative pharmacogenomics approach of LCL/patient GWAS may help prioritize target genes assocd. with chemotherapeutic-induced peripheral neuropathy.  Clin Cancer Res; 21(19); 4337-46. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvaD38LNLR5LVg90H21EOLACvtfcHk0lgwXAMCdj5kpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1antLrP&md5=7a16c73389400e62255b8f581fdc6b87</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-0133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-0133%26sid%3Dliteratum%253Aachs%26aulast%3DKomatsu%26aufirst%3DM.%26aulast%3DWheeler%26aufirst%3DH.%2BE.%26aulast%3DChung%26aufirst%3DS.%26aulast%3DLow%26aufirst%3DS.-K.%26aulast%3DWing%26aufirst%3DC.%26aulast%3DDelaney%26aufirst%3DS.%2BM.%26aulast%3DGorsic%26aufirst%3DL.%2BK.%26aulast%3DTakahashi%26aufirst%3DA.%26aulast%3DKubo%26aufirst%3DM.%26aulast%3DKroetz%26aufirst%3DD.%2BL.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DNakamura%26aufirst%3DY.%26aulast%3DDolan%26aufirst%3DM.%2BE.%26atitle%3DPharmacoethnicity%2520in%2520paclitaxel-induced%2520sensory%2520peripheral%2520neuropathy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D4337%26epage%3D4346%26doi%3D10.1158%2F1078-0432.CCR-15-0133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eckford, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharom, F. J.</span></span> <span> </span><span class="NLM_article-title">ABC efflux pump-based resistance to chemotherapy drugs</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">2989</span>– <span class="NLM_lpage">3011</span>, <span class="refDoi"> DOI: 10.1021/cr9000226</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr9000226" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlslSmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2009&pages=2989-3011&author=P.+D.+Eckfordauthor=F.+J.+Sharom&title=ABC+efflux+pump-based+resistance+to+chemotherapy+drugs&doi=10.1021%2Fcr9000226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">ABC Efflux Pump-Based Resistance to Chemotherapy Drugs</span></div><div class="casAuthors">Eckford, Paul D. W.; Sharom, Frances J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2989-3011</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Over 1 million new cases of all types of cancer are diagnosed each year in the United States alone, and 559, 650 cancer-related deaths were expected to occur in 2007.  Chemotherapeutic treatment of cancers is an important tool to combat this devastating disease.  However, chemotherapy can fail due to the development of tumor cell resistance to multiple drugs, a phenomenon known as multidrug resistance (MDR), and essentially all cancer-related deaths are considered to be a result of chemotherapy failure.  MDR can have many causes, but one important mechanism of drug resistance is the expression of active drug efflux pumps in the membranes of cancer cells.  The efflux pump proteins mediating MDR in human cancers belong to the ATP-Binding Cassette (ABC) superfamily of proteins.  This is a diverse group of (primarily) active membrane transporters and is one of the largest known protein families.  Its members include proteins that mediate a variety of transport processes, in both prokaryotes (e.g., membrane-embedded importers for sugars and amino acids, and drug exporters) and eukaryotes, where only ABC exporters are known.  The 49 ABC proteins identified in the human genome (there appear to be 48 functional proteins) are involved in the efflux of substrates such as phospholipids, sterols, bile salts, and amphipathic drugs.  While as many as 15 ABC transporters have been obsd. to export chemotherapy drugs using in vitro exptl. systems, only 3 transporters have thus far been implicated as major contributors to MDR in cancer.  Discovered over 30 years ago, P-glycoprotein (Pgp; MDR1; ABCB1), was the first mammalian ABC protein to be identified.  Multidrug resistance-assocd. protein 1 (MRP1 or ABCC1) and more recently ABCG2 (also termed the breast cancer resistance protein, BCRP, or mitoxantrone resistance protein, MXR) also appear to function as clin. relevant drug efflux pumps.  All three proteins were discovered as factors over-expressed in MDR cell lines in culture, and they have since been detected in MDR tumors in patients.  Considerable effort has been made to understand the structure and function of these three drug pumps, which possess a unique ability to recognize and transport a broad array of structurally diverse compds. out of the cell.  The development of compds. known as modulators, which are able to reverse MDR by blocking or inhibiting the ATP-dependent transport function of these proteins, is also an important goal of researchers in this field.  This review will summarize our understanding of the substrate specificity of the mammalian drug efflux pumps, their structure, the mol. mechanisms by which they exert their function, and the progress made to date in reversing pump-mediated MDR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZIkwCqe_qg7Vg90H21EOLACvtfcHk0lgwXAMCdj5kpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlslSmtbg%253D&md5=5009e7a7cac6977a296fd5bbf97d7df7</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fcr9000226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr9000226%26sid%3Dliteratum%253Aachs%26aulast%3DEckford%26aufirst%3DP.%2BD.%26aulast%3DSharom%26aufirst%3DF.%2BJ.%26atitle%3DABC%2520efflux%2520pump-based%2520resistance%2520to%2520chemotherapy%2520drugs%26jtitle%3DChem.%2520Rev.%26date%3D2009%26volume%3D109%26spage%3D2989%26epage%3D3011%26doi%3D10.1021%2Fcr9000226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargsten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuevas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liniger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuhaus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span> <span> </span><span class="NLM_article-title">A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">13817</span>– <span class="NLM_lpage">13821</span>, <span class="refDoi"> DOI: 10.1073/pnas.1408124111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1073%2Fpnas.1408124111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=25114240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCju7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=13817-13821&author=A.+E.+Protaauthor=K.+Bargstenauthor=J.+F.+Diazauthor=M.+Marshauthor=C.+Cuevasauthor=M.+Linigerauthor=C.+Neuhausauthor=J.+M.+Andreuauthor=K.+H.+Altmannauthor=M.+O.+Steinmetz&title=A+new+tubulin-binding+site+and+pharmacophore+for+microtubule-destabilizing+anticancer+drugs&doi=10.1073%2Fpnas.1408124111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs</span></div><div class="casAuthors">Prota, Andrea E.; Bargsten, Katja; Diaz, J. Fernando; Marsh, May; Cuevas, Carmen; Liniger, Marc; Neuhaus, Christian; Andreu, Jose M.; Altmann, Karl-Heinz; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">13817-13821</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The recent success of antibody-drug conjugates (ADCs) in the treatment of cancer has led to a revived interest in microtubule-destabilizing agents.  Here, we detd. the high-resoln. crystal structure of the complex between tubulin and maytansine, which is part of an ADC that is approved by the US Food and Drug Administration (FDA) for the treatment of advanced breast cancer.  We found that the drug binds to a site on β-tubulin that is distinct from the vinca domain and that blocks the formation of longitudinal tubulin interactions in microtubules.  We also solved crystal structures of tubulin in complex with both a variant of rhizoxin and the phase 1 drug PM060184.  Consistent with biochem. and mutagenesis data, we found that the two compds. bound to the same site as maytansine and that the structures revealed a common pharmacophore for the three ligands.  Our results delineate a distinct mol. mechanism of action for the inhibition of microtubule assembly by clin. relevant agents.  They further provide a structural basis for the rational design of potent microtubule-destabilizing agents, thus opening opportunities for the development of next-generation ADCs for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX4icqk698gLVg90H21EOLACvtfcHk0lg_2X7ErTcbrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCju7vM&md5=798cae320e427ff76c2099387d9e6ba4</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1408124111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1408124111%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DDiaz%26aufirst%3DJ.%2BF.%26aulast%3DMarsh%26aufirst%3DM.%26aulast%3DCuevas%26aufirst%3DC.%26aulast%3DLiniger%26aufirst%3DM.%26aulast%3DNeuhaus%26aufirst%3DC.%26aulast%3DAndreu%26aufirst%3DJ.%2BM.%26aulast%3DAltmann%26aufirst%3DK.%2BH.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DA%2520new%2520tubulin-binding%2520site%2520and%2520pharmacophore%2520for%2520microtubule-destabilizing%2520anticancer%2520drugs%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2014%26volume%3D111%26spage%3D13817%26epage%3D13821%26doi%3D10.1073%2Fpnas.1408124111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnst, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Tubulin inhibitor-based antibody-drug conjugates for cancer therapy</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1281</span>, <span class="refDoi"> DOI: 10.3390/molecules22081281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.3390%2Fmolecules22081281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=28763044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Cls7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1281&author=H.+Chenauthor=Z.+Linauthor=K.+E.+Arnstauthor=D.+D.+Millerauthor=W.+Li&title=Tubulin+inhibitor-based+antibody-drug+conjugates+for+cancer+therapy&doi=10.3390%2Fmolecules22081281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulin inhibitor-based antibody-drug conjugates for cancer therapy</span></div><div class="casAuthors">Chen, Hao; Lin, Zongtao; Arnst, Kinsie E.; Miller, Duane D.; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1281/1-1281/28</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) are a class of highly potent biopharmaceutical drugs generated by conjugating cytotoxic drugs with specific monoclonal antibodies through appropriate linkers.  Specific antibodies used to guide potent warheads to tumor tissues can effectively reduce undesired side effects of the cytotoxic drugs.  An in-depth understanding of antibodies, linkers, conjugation strategies, cytotoxic drugs, and their mol. targets has led to the successful development of several approved ADCs.  These ADCs are powerful therapeutics for cancer treatment, enabling wider therapeutic windows, improved pharmacokinetic/pharmacodynamic properties, and enhanced efficacy.  Since tubulin inhibitors are one of the most successful cytotoxic drugs in the ADC armamentarium, this review focuses on the progress in tubulin inhibitor-based ADCs, as well as lessons learned from the unsuccessful ADCs contg. tubulin inhibitors.  This review should be helpful to facilitate future development of new generations of tubulin inhibitor-based ADCs for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8A0aJYR6aBLVg90H21EOLACvtfcHk0lg_2X7ErTcbrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Cls7zI&md5=eb6efd4fdf44b5c0294a9becbeffab86</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22081281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22081281%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DArnst%26aufirst%3DK.%2BE.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DTubulin%2520inhibitor-based%2520antibody-drug%2520conjugates%2520for%2520cancer%2520therapy%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26spage%3D1281%26doi%3D10.3390%2Fmolecules22081281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueras, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borbely, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sewald, N.</span></span> <span> </span><span class="NLM_article-title">Cryptophycins: cytotoxic cyclodepsipeptides with potential for tumor targeting</span>. <i>J. Pept. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">514</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1002/psc.3015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1002%2Fpsc.3015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=28661555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVynsbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=514-531&author=C.+Weissauthor=E.+Figuerasauthor=A.+N.+Borbelyauthor=N.+Sewald&title=Cryptophycins%3A+cytotoxic+cyclodepsipeptides+with+potential+for+tumor+targeting&doi=10.1002%2Fpsc.3015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Cryptophycins: cytotoxic cyclodepsipeptides with potential for tumor targeting</span></div><div class="casAuthors">Weiss, Christine; Figueras, Eduard; Borbely, Adina N.; Sewald, Norbert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">514-531</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Cryptophycins are a class of 16-membered highly cytotoxic macrocyclic depsipeptides isolated from cyanobacteria.  The biol. activity is based on their ability to interact with tubulin.  They interfere with microtubule dynamics and prevent microtubules from forming correct mitotic spindles, which causes cell-cycle arrest and apoptosis.  Their strong antiproliferative activities with 100-fold to 1000-fold potency compared with those of paclitaxel and vinblastine have been obsd.  Cryptophycins are highly promising drug candidates, as their biol. activity is not neg. affected by P-glycoprotein, a drug efflux system commonly found in multidrug-resistant cancer cell lines and solid tumors.  Cryptophycin-52 had been investigated in phase II clin. trials but failed because of its high neurotoxicity.  Recently, cryptophycin conjugates with peptides and antibodies have been developed for targeted delivery in tumor therapy.  Copyright © 2017 European Peptide Society and John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXyzZ4nRHc1rVg90H21EOLACvtfcHk0lg_2X7ErTcbrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVynsbjO&md5=7323983af8ce00e5db1fc07fe14b23bd</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fpsc.3015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.3015%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DC.%26aulast%3DFigueras%26aufirst%3DE.%26aulast%3DBorbely%26aufirst%3DA.%2BN.%26aulast%3DSewald%26aufirst%3DN.%26atitle%3DCryptophycins%253A%2520cytotoxic%2520cyclodepsipeptides%2520with%2520potential%2520for%2520tumor%2520targeting%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2017%26volume%3D23%26spage%3D514%26epage%3D531%26doi%3D10.1002%2Fpsc.3015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muniz-Medina, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetzel, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebelatto, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinrichs, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezabeh, B. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimasi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toader, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixit, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osbourn, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coats, S. R.</span></span> <span> </span><span class="NLM_article-title">A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.ccell.2015.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=26766593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC28Xmsl2lsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=117-129&author=J.+Liauthor=S.+R.+Perryauthor=V.+Muniz-Medinaauthor=X.+Wangauthor=L.+K.+Wetzelauthor=M.+C.+Rebelattoauthor=M.+J.+Hinrichsauthor=B.+Z.+Bezabehauthor=R.+L.+Flemingauthor=N.+Dimasiauthor=H.+Fengauthor=D.+Toaderauthor=A.+Yuanauthor=L.+Xuauthor=J.+Linauthor=C.+Gaoauthor=H.+Wuauthor=R.+Dixitauthor=J.+K.+Osbournauthor=S.+R.+Coats&title=A+biparatopic+HER2-targeting+antibody-drug+conjugate+induces+tumor+regression+in+primary+models+refractory+to+or+ineligible+for+HER2-targeted+therapy&doi=10.1016%2Fj.ccell.2015.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy</span></div><div class="casAuthors">Li, John Y.; Perry, Samuel R.; Muniz-Medina, Vanessa; Wang, Xinzhong; Wetzel, Leslie K.; Rebelatto, Marlon C.; Hinrichs, Mary Jane Masson; Bezabeh, Binyam Z.; Fleming, Ryan L.; Dimasi, Nazzareno; Feng, Hui; Toader, Dorin; Yuan, Andy Q.; Xu, Lan; Lin, Jia; Gao, Changshou; Wu, Herren; Dixit, Rakesh; Osbourn, Jane K.; Coats, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">117-129</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Antibody-drug conjugate (ADC) which delivers cytotoxic drugs specifically into targeted cells through internalization and lysosomal trafficking has emerged as an effective cancer therapy.  We show that a bivalent biparatopic antibody targeting two non-overlapping epitopes on HER2 can induce HER2 receptor clustering, which in turn promotes robust internalization, lysosomal trafficking, and degrdn.  When conjugated with a tubulysin-based microtubule inhibitor, the biparatopic ADC demonstrates superior anti-tumor activity over ado-trastuzumab emtansine (T-DM1) in tumor models representing various patient subpopulations, including T-DM1 eligible, T-DM1 ineligible, and T-DM1 relapsed/refractory.  Our findings indicate that this biparatopic ADC has promising potential as an effective therapy for metastatic breast cancer and a broader patient population may benefit from this unique HER2-targeting ADC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp18b-9TGTzUbVg90H21EOLACvtfcHk0lheDvUc3Fp2OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xmsl2lsA%253D%253D&md5=bbd94b53427de32f8d636b63507dd139</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DPerry%26aufirst%3DS.%2BR.%26aulast%3DMuniz-Medina%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWetzel%26aufirst%3DL.%2BK.%26aulast%3DRebelatto%26aufirst%3DM.%2BC.%26aulast%3DHinrichs%26aufirst%3DM.%2BJ.%26aulast%3DBezabeh%26aufirst%3DB.%2BZ.%26aulast%3DFleming%26aufirst%3DR.%2BL.%26aulast%3DDimasi%26aufirst%3DN.%26aulast%3DFeng%26aufirst%3DH.%26aulast%3DToader%26aufirst%3DD.%26aulast%3DYuan%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DDixit%26aufirst%3DR.%26aulast%3DOsbourn%26aufirst%3DJ.%2BK.%26aulast%3DCoats%26aufirst%3DS.%2BR.%26atitle%3DA%2520biparatopic%2520HER2-targeting%2520antibody-drug%2520conjugate%2520induces%2520tumor%2520regression%2520in%2520primary%2520models%2520refractory%2520to%2520or%2520ineligible%2520for%2520HER2-targeted%2520therapy%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D29%26spage%3D117%26epage%3D129%26doi%3D10.1016%2Fj.ccell.2015.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mullard, A.</span></span> <span> </span><span class="NLM_article-title">Maturing antibody-drug conjugate pipeline hits 30</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1038/nrd4009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1038%2Fnrd4009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=23629491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1Oiurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=329-332&author=A.+Mullard&title=Maturing+antibody-drug+conjugate+pipeline+hits+30&doi=10.1038%2Fnrd4009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Maturing antibody-drug conjugate pipeline hits 30</span></div><div class="casAuthors">Mullard, Asher</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">329-332</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Driven by recent clin. breakthroughs and technol. progress, 30 antibody-drug conjugates against over 24 targets are now in trials for blood cancers and solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO0a4pT6o-p7Vg90H21EOLACvtfcHk0lheDvUc3Fp2OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1Oiurc%253D&md5=ac0fd840838077375f99e17a6e3ba303</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fnrd4009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4009%26sid%3Dliteratum%253Aachs%26aulast%3DMullard%26aufirst%3DA.%26atitle%3DMaturing%2520antibody-drug%2520conjugate%2520pipeline%2520hits%252030%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D329%26epage%3D332%26doi%3D10.1038%2Fnrd4009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasamon, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Claro, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenthal, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA approval summary: Brentuximab Vedotin in first-line treatment of peripheral T-Cell lymphoma</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">180</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2019-0098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1634%2Ftheoncologist.2019-0098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=30914464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFKhs7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=180-187&author=N.+C.+Richardsonauthor=Y.+L.+Kasamonauthor=H.+Chenauthor=R.+A.+de+Claroauthor=J.+Yeauthor=G.+M.+Blumenthalauthor=A.+T.+Farrellauthor=R.+Pazdur&title=FDA+approval+summary%3A+Brentuximab+Vedotin+in+first-line+treatment+of+peripheral+T-Cell+lymphoma&doi=10.1634%2Ftheoncologist.2019-0098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma</span></div><div class="casAuthors">Richardson, Nicholas C.; Kasamon, Yvette L.; Chen, Haiyan; de Claro, R. Angelo; Ye, Jingjing; Blumenthal, Gideon M.; Farrell, Ann T.; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e180-e187</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1549-490X</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">Approval was based on ECHELON-2, a randomized, double-blind, actively controlled trial that compared BV+CHP with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in 452 patients with newly diagnosed, CD30-expressing PTCL.  Efficacy was based on independent review facility-assessed progression-free survival (PFS).  The median PFS was 48.2 mo with BV+CHP vs. 20.8 mo with CHOP, resulting in a hazard ratio (HR) of 0.71 (95% confidence interval).  The trial also demonstrated improvement in overall survival (HR 0.66; 95% CI: 0.46-0.95), complete response rate (68% vs. 56%), and overall response rate (83% vs. 72%) with BV+CHP.  The most common adverse reactions (incidence ≥20%) obsd. ≥2% more with BV+CHP were nausea, diarrhea, fatigue or asthenia, mucositis, pyrexia, vomiting, and anemia.  Peripheral neuropathy rates were similar (52% with BV+CHP, 55% with CHOP).  Through the Real-Time Oncol. Review pilot program, which allows FDA early access to key data, FDA granted this approval less than 2 wk after official submission of the application.  Implications for Practice : This is the first U.S. Food and Drug Administration approval for treatment of patients with newly diagnosed peripheral T-cell lymphomas (PTCL).  Improvement in progression-free and overall survival over cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy, which has been the std. of care for decades, is unprecedented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEhAAcx2pjcbVg90H21EOLACvtfcHk0lheDvUc3Fp2OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFKhs7fF&md5=1508f5760132350665aaa03a10ed0623</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2019-0098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2019-0098%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DN.%2BC.%26aulast%3DKasamon%26aufirst%3DY.%2BL.%26aulast%3DChen%26aufirst%3DH.%26aulast%3Dde%2BClaro%26aufirst%3DR.%2BA.%26aulast%3DYe%26aufirst%3DJ.%26aulast%3DBlumenthal%26aufirst%3DG.%2BM.%26aulast%3DFarrell%26aufirst%3DA.%2BT.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520approval%2520summary%253A%2520Brentuximab%2520Vedotin%2520in%2520first-line%2520treatment%2520of%2520peripheral%2520T-Cell%2520lymphoma%26jtitle%3DOncologist%26date%3D2019%26volume%3D24%26spage%3D180%26epage%3D187%26doi%3D10.1634%2Ftheoncologist.2019-0098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Komlodi-Pasztor, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sackett, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkerson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fojo, T.</span></span> <span> </span><span class="NLM_article-title">Mitosis is not a key target of microtubule agents in patient tumors</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">244</span>– <span class="NLM_lpage">250</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2010.228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1038%2Fnrclinonc.2010.228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=21283127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFKlsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=244-250&author=E.+Komlodi-Pasztorauthor=D.+Sackettauthor=J.+Wilkersonauthor=T.+Fojo&title=Mitosis+is+not+a+key+target+of+microtubule+agents+in+patient+tumors&doi=10.1038%2Fnrclinonc.2010.228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Mitosis is not a key target of microtubule agents in patient tumors</span></div><div class="casAuthors">Komlodi-Pasztor, Edina; Sackett, Dan; Wilkerson, Julia; Fojo, Tito</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">244-250</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In this Perspective, the clin. disappointment of mitosis-specific agents is explained in the context of the mechanism of action of microtubule-targeting agents.  The authors propose a new paradigm for the anticancer activity of microtubule-targeting agents and suggest that mitosis-specific inhibitors will not result in significant clin. impact.  Mitosis-specific agents have, to date, not been clin. successful.  By contrast, microtubule-targeting agents (MTAs) have a long record of success, usually attributed to the induction of mitotic arrest.  Indeed, it was this success that led to the search for mitosis-specific inhibitors.  We believe the clin. disappointment of mitosis-specific inhibitors stands as evidence that MTAs have been successful not only by interfering with mitosis but, more importantly, by disrupting essential interphase cellular mechanisms.  In this Perspective we will review literature that supports a paradigm shift in how we think about one of our most widely used classes of chemotherapeutics-MTAs.  We believe that the steady presence and const. physiol. role of microtubules are responsible for the overall success of MTAs.  While mitosis-specific inhibitors are effective on only a small fraction of the tumor mass (dividing cells), MTAs target tubulin, a protein that has crucial roles in both mitotic and non-mitotic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYOmCILGEs2LVg90H21EOLACvtfcHk0liOudxsN23xWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFKlsLY%253D&md5=2a72541e9b990534b74e88c18265e4c8</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2010.228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2010.228%26sid%3Dliteratum%253Aachs%26aulast%3DKomlodi-Pasztor%26aufirst%3DE.%26aulast%3DSackett%26aufirst%3DD.%26aulast%3DWilkerson%26aufirst%3DJ.%26aulast%3DFojo%26aufirst%3DT.%26atitle%3DMitosis%2520is%2520not%2520a%2520key%2520target%2520of%2520microtubule%2520agents%2520in%2520patient%2520tumors%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D8%26spage%3D244%26epage%3D250%26doi%3D10.1038%2Fnrclinonc.2010.228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Komlodi-Pasztor, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sackett, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fojo, A. T.</span></span> <span> </span><span class="NLM_article-title">Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-0999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1158%2F1078-0432.CCR-11-0999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=22215906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFWnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=51-63&author=E.+Komlodi-Pasztorauthor=D.+L.+Sackettauthor=A.+T.+Fojo&title=Inhibitors+targeting+mitosis%3A+tales+of+how+great+drugs+against+a+promising+target+were+brought+down+by+a+flawed+rationale&doi=10.1158%2F1078-0432.CCR-11-0999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale</span></div><div class="casAuthors">Komlodi-Pasztor, Edina; Sackett, Dan L.; Fojo, Antonio Tito</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-63</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Although they have been advocated with an understandable enthusiasm, mitosis-specific agents such as inhibitors of mitotic kinases and kinesin spindle protein have not been successful clin.  These drugs were developed as agents that would build on the success of microtubule-targeting agents while avoiding the neurotoxicity that encumbers drugs such as taxanes and vinca alkaloids.  The rationale for using mitosis-specific agents was based on the thesis that the clin. efficacy of microtubule-targeting agents could be ascribed to the induction of mitotic arrest.  However, the latter concept, which has long been accepted as dogma, is likely important only in cell culture and rapidly growing preclin. models, and irrelevant in patient tumors, where interference with intracellular trafficking on microtubules is likely the principal mechanism of action.  Here we review the preclin. and clin. data for a diverse group of inhibitors that target mitosis and identify the reasons why these highly specific, myelosuppressive compds. have failed to deliver on their promise.  Clin Cancer Res; 18(1); 51-63.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZXlw38i-HRLVg90H21EOLACvtfcHk0liOudxsN23xWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFWnuw%253D%253D&md5=f99140d6004600cb2f364f7d87f24f5d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0999%26sid%3Dliteratum%253Aachs%26aulast%3DKomlodi-Pasztor%26aufirst%3DE.%26aulast%3DSackett%26aufirst%3DD.%2BL.%26aulast%3DFojo%26aufirst%3DA.%2BT.%26atitle%3DInhibitors%2520targeting%2520mitosis%253A%2520tales%2520of%2520how%2520great%2520drugs%2520against%2520a%2520promising%2520target%2520were%2520brought%2520down%2520by%2520a%2520flawed%2520rationale%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D51%26epage%3D63%26doi%3D10.1158%2F1078-0432.CCR-11-0999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitchison, T. J.</span></span> <span> </span><span class="NLM_article-title">The proliferation rate paradox in antimitotic chemotherapy</span>. <i>Mol. Biol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1091/mbc.e10-04-0335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1091%2Fmbc.e10-04-0335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=22210845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVylsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=1-6&author=T.+J.+Mitchison&title=The+proliferation+rate+paradox+in+antimitotic+chemotherapy&doi=10.1091%2Fmbc.e10-04-0335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The proliferation rate paradox in antimitotic chemotherapy</span></div><div class="casAuthors">Mitchison, Timothy J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology of the Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">MBCEEV</span>;
        ISSN:<span class="NLM_cas:issn">1939-4586</span>.
    
            (<span class="NLM_cas:orgname">American Society for Cell Biology</span>)
        </div><div class="casAbstract">A review.  Cytotoxic cancer chemotherapy drugs are believed to gain selectivity by targeting cells that proliferate rapidly.  However, the proliferation rate is low in many chemosensitive human cancers, and it is not clear how a drug that only kills dividing cells could promote tumor regression.  Four potential solns. to this "proliferation rate paradox" are discussed for the microtubule-stabilizing drug paclitaxel: drug retention in tumors, killing of quiescent cells, targeting of noncancer cells in the tumor, and bystander effects.  Testing these potential mechanisms of drug action will facilitate rational improvement of antimitotic chemotherapy and perhaps cytotoxic chemotherapy more generally.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGostPy_gyyJCLVg90H21EOLACvtfcHk0liOudxsN23xWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVylsA%253D%253D&md5=32fea5a5b4d14d23feca77c5f5ab6823</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1091%2Fmbc.e10-04-0335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.e10-04-0335%26sid%3Dliteratum%253Aachs%26aulast%3DMitchison%26aufirst%3DT.%2BJ.%26atitle%3DThe%2520proliferation%2520rate%2520paradox%2520in%2520antimitotic%2520chemotherapy%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D2012%26volume%3D23%26spage%3D1%26epage%3D6%26doi%3D10.1091%2Fmbc.e10-04-0335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanakkanthara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. H.</span></span> <span> </span><span class="NLM_article-title">Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">5050</span>– <span class="NLM_lpage">5059</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.02.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.bmc.2014.02.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=24650703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksVWqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=5050-5059&author=J.+J.+Fieldauthor=A.+Kanakkantharaauthor=J.+H.+Miller&title=Microtubule-targeting+agents+are+clinically+successful+due+to+both+mitotic+and+interphase+impairment+of+microtubule+function&doi=10.1016%2Fj.bmc.2014.02.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function</span></div><div class="casAuthors">Field, Jessica J.; Kanakkanthara, Arun; Miller, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5050-5059</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Microtubules undergo continual dynamic changes in mitotic cells as the mitotic spindle forms and is broken down and in interphase cells where they play a central role in intracellular trafficking, cell signaling, cell migration, and angiogenesis.  Compds. that target the microtubule have been hugely successful in the clinic as chemotherapeutics, and this success is likely due to their ability to target cells regardless of their cell cycle stage.  Addnl., new generation antibody-conjugated microtubule-targeting agents are improving the targeting of these drugs to tumors.  Microtubule-targeting agents have been shown to have anti-angiogenic and vascular-disrupting properties as well as effects on cellular migration, intracellular trafficking, and cell secretion.  There are a no. of these compds. in development that target the vasculature, and different formulations of clin. used drugs are being developed to take advantage of these anti-angiogenic properties.  Microtubule-targeting agents have also been shown to have the potential to treat neurodegenerative diseases, such as Alzheimer's disease.  Thus, drugs that target the microtubule will continue to have a major impact in oncol. not only as anti-mitotics but also as potent inhibitors of interphase functions, and in future may also prove to be effective in reducing the consequences of neurodegenerative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2d-DR0ciixrVg90H21EOLACvtfcHk0liOudxsN23xWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksVWqsrw%253D&md5=e3ec8c5c15dfe25d1c527cecaec20d2f</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.02.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.02.035%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DJ.%2BJ.%26aulast%3DKanakkanthara%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DJ.%2BH.%26atitle%3DMicrotubule-targeting%2520agents%2520are%2520clinically%2520successful%2520due%2520to%2520both%2520mitotic%2520and%2520interphase%2520impairment%2520of%2520microtubule%2520function%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D5050%26epage%3D5059%26doi%3D10.1016%2Fj.bmc.2014.02.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogden, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rida, P. C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aneja, R.</span></span> <span> </span><span class="NLM_article-title">Interphase microtubules: chief casualties in the war on cancer?</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">824</span>– <span class="NLM_lpage">829</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.10.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.drudis.2013.10.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=24201225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvValtbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=824-829&author=A.+Ogdenauthor=P.+C.+G.+Ridaauthor=M.+D.+Reidauthor=R.+Aneja&title=Interphase+microtubules%3A+chief+casualties+in+the+war+on+cancer%3F&doi=10.1016%2Fj.drudis.2013.10.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Interphase microtubules: chief casualties in the war on cancer?</span></div><div class="casAuthors">Ogden, Angela; Rida, Padmashree C. G.; Reid, Michelle D.; Aneja, Ritu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">824-829</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Microtubule-targeting agents (MTAs) profoundly affect interphase cells, such as by disrupting axonal transport, transcription, translation, mitochondrial permeability, immune cell function, directional migration and centrosome clustering.  This finding is antithetical to the conventionally held notion that MTAs act on mitosis to trigger arrest-mediated apoptotic cell death.  Furthermore, the paucity of mitotic cells in patient tumors and lack of correlation of MTA efficacy with tumor proliferation rate provide strong impetus to re-examine the mechanistic basis of action of MTAs, with an eye toward interphase activities.  Whereas targeted antimitotics have unequivocally failed their promise across clin. studies, MTAs constitute a mainstay of chemotherapy.  This paradox necessitates the conclusion that MTAs exert mitosis-independent effects, spurring a dramatic paradigm shift in our understanding of the mode of action of MTAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ1qu2htK9XLVg90H21EOLACvtfcHk0liH3-TX6UE-fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvValtbjK&md5=adedd47ce4b6fdf0239e9d107c62c751</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.10.022%26sid%3Dliteratum%253Aachs%26aulast%3DOgden%26aufirst%3DA.%26aulast%3DRida%26aufirst%3DP.%2BC.%2BG.%26aulast%3DReid%26aufirst%3DM.%2BD.%26aulast%3DAneja%26aufirst%3DR.%26atitle%3DInterphase%2520microtubules%253A%2520chief%2520casualties%2520in%2520the%2520war%2520on%2520cancer%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D824%26epage%3D829%26doi%3D10.1016%2Fj.drudis.2013.10.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoffski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littlefield, B. A.</span></span> <span> </span><span class="NLM_article-title">Multiple modes of action of eribulin mesylate: emerging data and clinical implications</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">190</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2018.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.ctrv.2018.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=30243063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslGmu7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2018&pages=190-198&author=J.+Cortesauthor=P.+Schoffskiauthor=B.+A.+Littlefield&title=Multiple+modes+of+action+of+eribulin+mesylate%3A+emerging+data+and+clinical+implications&doi=10.1016%2Fj.ctrv.2018.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple modes of action of eribulin mesylate: Emerging data and clinical implications</span></div><div class="casAuthors">Cortes, Javier; Schoffski, Patrick; Littlefield, Bruce A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">190-198</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Eribulin mesylate (eribulin) is a synthetic analog of the marine-sponge natural product halichondrin B.  Eribulin exhibits potent antiproliferative activities against a variety of human cancer cell types in vitro and in vivo, and is used for the treatment of certain patients with advanced breast cancer or liposarcoma who are refractory to other treatments.  The antiproliferative effects of eribulin have long been attributed to its antimitotic activities.  Unlike other microtubule-targeting agents, eribulin inhibits microtubule polymn. through specific plus end binding, thus interfering with microtubule dynamic instability.  Non-mitotic effects of eribulin on tumor biol. have also been established in lab. settings including: tumor vasculature remodeling, increased vascular perfusion, reduced hypoxia, and phenotypic changes involving reversal of epithelial-to-mesenchymal transition (EMT), resulting in reduced capacities for migration, invasion, and seeding lung metastases in exptl. models.  Preclin. data suggest that increased perfusion following eribulin treatment improves delivery of subsequent drugs.  Supporting evidence for eribulin's non-mitotic effects in the clin. setting include increased tumor oxygen satn., reduced hypoxia, phenotype changes consistent with EMT reversal, and genotype changes consistent with shifts from nonendocrine-responsive, luminal B, to endocrine-responsive, luminal A, breast cancer subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf9YvSLvGcq7Vg90H21EOLACvtfcHk0liH3-TX6UE-fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslGmu7jN&md5=dca422e5d6cf4ecd36c77b5697e0d4c2</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2018.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2018.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DSchoffski%26aufirst%3DP.%26aulast%3DLittlefield%26aufirst%3DB.%2BA.%26atitle%3DMultiple%2520modes%2520of%2520action%2520of%2520eribulin%2520mesylate%253A%2520emerging%2520data%2520and%2520clinical%2520implications%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2018%26volume%3D70%26spage%3D190%26epage%3D198%26doi%3D10.1016%2Fj.ctrv.2018.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bates, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, A.</span></span> <span> </span><span class="NLM_article-title">Microtubule destabilizing agents: far more than just antimitotic anticancer drugs</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">268</span>, <span class="refDoi"> DOI: 10.1111/bcp.13126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1111%2Fbcp.13126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=27620987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFajs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2017&pages=255-268&author=D.+Batesauthor=A.+Eastman&title=Microtubule+destabilizing+agents%3A+far+more+than+just+antimitotic+anticancer+drugs&doi=10.1111%2Fbcp.13126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule destabilizing agents: far more than just antimitotic anticancer drugs</span></div><div class="casAuthors">Bates, Darcy; Eastman, Alan</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">255-268</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Vinca alkaloids have been approved as anticancer drugs for more than 50 years.  They have been classified as cytotoxic chemotherapy drugs that act during cellular mitosis, enabling them to target fast growing cancer cells.  With the evolution of cancer drug development there has been a shift towards new "targeted" therapies to avoid the side effects and general toxicities of "cytotoxic chemotherapies" such as the vinca alkaloids.  Due to their original classification, many have overlooked the fact that vinca alkaloids, taxanes and related drugs do have a specific mol. target: tubulin.  They continue to be some of the most effective anticancer drugs, perhaps because their actions upon the microtubule network extend far beyond the ability to halt cells in mitosis, and include the induction of apoptosis at all phases of the cell cycle.  In this review, we highlight the numerous cellular consequences of disrupting microtubule dynamics, expanding the textbook knowledge of microtubule destabilizing agents and providing novel opportunities for their use in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob4cJkJIQJPLVg90H21EOLACvtfcHk0liH3-TX6UE-fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFajs74%253D&md5=e859fcd74dd984b711065f278abb5479</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1111%2Fbcp.13126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.13126%26sid%3Dliteratum%253Aachs%26aulast%3DBates%26aufirst%3DD.%26aulast%3DEastman%26aufirst%3DA.%26atitle%3DMicrotubule%2520destabilizing%2520agents%253A%2520far%2520more%2520than%2520just%2520antimitotic%2520anticancer%2520drugs%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2017%26volume%3D83%26spage%3D255%26epage%3D268%26doi%3D10.1111%2Fbcp.13126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindamulage, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karthikeyan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knockleby, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span> <span> </span><span class="NLM_article-title">Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">10298</span> <span class="refDoi"> DOI: 10.1038/s41598-017-10972-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1038%2Fs41598-017-10972-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=28860494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A280%3ADC%252BC1cbjsFyiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&author=I.+K.+Lindamulageauthor=H.+Y.+Vuauthor=C.+Karthikeyanauthor=J.+Knocklebyauthor=Y.+F.+Leeauthor=P.+Trivediauthor=H.+Lee&title=Novel+quinolone+chalcones+targeting+colchicine-binding+pocket+kill+multidrug-resistant+cancer+cells+by+inhibiting+tubulin+activity+and+MRP1+function&doi=10.1038%2Fs41598-017-10972-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function</span></div><div class="casAuthors">Lindamulage I Kalhari; Vu Hai-Yen; Knockleby James; Lee Yi-Fang; Lee Hoyun; Lindamulage I Kalhari; Lee Hoyun; Karthikeyan Chandrabose; Trivedi Piyush; Lee Hoyun</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10298</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Agents targeting colchicine-binding pocket usually show a minimal drug-resistance issue, albeit often associated with high toxicity.  Chalcone-based compounds, which may bind to colchicine-binding site, are found in many edible fruits, suggesting that they can be effective drugs with less toxicity.  Therefore, we synthesized and examined 24 quinolone chalcone compounds, from which we identified ((E)-3-(3-(2-Methoxyphenyl)-3-oxoprop-1-enyl) quinolin-2(1H)-one) (CTR-17) and ((E)-6-Methoxy-3-(3-(2-methoxyphenyl)-3-oxoprop-1-enyl) quinolin-2(1H)-one) (CTR-20) as promising leads.  In particular, CTR-20 was effective against 65 different cancer cell lines originated from 12 different tissues, largely in a cancer cell-specific manner.  We found that both CTR-17 and CTR-20 reversibly bind to the colchicine-binding pocket on β-tubulin.  Interestingly however, both the CTRs were highly effective against multidrug-resistant cancer cells while colchicine, paclitaxel and vinblastine were not.  Our study with CTR-20 showed that it overcomes multidrug-resistance through its ability to impede MRP1 function while maintaining strong inhibition against microtubule activity.  Data from mice engrafted with the MDA-MB-231 triple-negative breast cancer cells showed that both CTR-17 and CTR-20 possess strong anticancer activity, alone or in combination with paclitaxel, without causing any notable side effects.  Together, our data demonstrates that both the CTRs can be effective and safe drugs against many different cancers, especially against multidrug-resistant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRAuKrO7n1L5_h3YQQtAhNufW6udTcc2ealjYQq_BD7RLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbjsFyiuw%253D%253D&md5=78ff36072df15e19d4396fc05e1761f7</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-10972-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-10972-0%26sid%3Dliteratum%253Aachs%26aulast%3DLindamulage%26aufirst%3DI.%2BK.%26aulast%3DVu%26aufirst%3DH.%2BY.%26aulast%3DKarthikeyan%26aufirst%3DC.%26aulast%3DKnockleby%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DY.%2BF.%26aulast%3DTrivedi%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DH.%26atitle%3DNovel%2520quinolone%2520chalcones%2520targeting%2520colchicine-binding%2520pocket%2520kill%2520multidrug-resistant%2520cancer%2520cells%2520by%2520inhibiting%2520tubulin%2520activity%2520and%2520MRP1%2520function%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26doi%3D10.1038%2Fs41598-017-10972-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loveless, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">3040</span>– <span class="NLM_lpage">3052</span>, <span class="refDoi"> DOI: 10.1007/s11095-012-0726-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1007%2Fs11095-012-0726-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=22410804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Gls7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=3040-3052&author=Z.+Wangauthor=J.+Chenauthor=J.+Wangauthor=S.+Ahnauthor=C.+M.+Liauthor=Y.+Luauthor=V.+S.+Lovelessauthor=J.+T.+Daltonauthor=D.+D.+Millerauthor=W.+Li&title=Novel+tubulin+polymerization+inhibitors+overcome+multidrug+resistance+and+reduce+melanoma+lung+metastasis&doi=10.1007%2Fs11095-012-0726-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Tubulin Polymerization Inhibitors Overcome Multidrug Resistance and Reduce Melanoma Lung Metastasis</span></div><div class="casAuthors">Wang, Zhao; Chen, Jianjun; Wang, Jin; Ahn, Sunjoo; Li, Chien-Ming; Lu, Yan; Loveless, Vivian S.; Dalton, James T.; Miller, Duane D.; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3040-3052</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: To evaluate abilities of 2-aryl-4-benzoyl-imidazoles (ABI) to overcome multidrug resistance (MDR), define their cellular target, and assess in vivo antimelanoma efficacy.  Methods: MDR cell lines that overexpressed P-glycoprotein, MDR-assocd. proteins, and breast cancer resistance protein were used to evaluate ABI ability to overcome MDR.  Cell cycle anal., mol. modeling, and microtubule imaging were used to define ABI cellular target.  SHO mice bearing A375 human melanoma xenograft were used to evaluate ABI in vivo antitumor activity.  B16-F10/C57BL mouse melanoma lung metastasis model was used to test ABI efficacy to inhibit tumor lung metastasis.  Results: ABIs showed similar potency to MDR cells compared to matching parent cells.  ABIs were identified to target tubulin on the colchicine binding site.  After 31 days of treatment, ABI-288 dosed at 25 mg/kg inhibited melanoma tumor growth by 69%; dacarbazine at 60 mg/kg inhibited growth by 52%.  ABI-274 dosed at 25 mg/kg showed better lung metastasis inhibition than dacarbazine at 60 mg/kg.  Conclusions: This new class of antimitotic compds. can overcome several clin. important drug resistant mechanisms in vitro and are effective in inhibiting melanoma lung metastasis in vivo, supporting their further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiBeRzq7uMtrVg90H21EOLACvtfcHk0liPIQvcj1kMkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Gls7c%253D&md5=962529ba6111c68b909c7df593f4b072</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs11095-012-0726-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-012-0726-4%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DC.%2BM.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLoveless%26aufirst%3DV.%2BS.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DNovel%2520tubulin%2520polymerization%2520inhibitors%2520overcome%2520multidrug%2520resistance%2520and%2520reduce%2520melanoma%2520lung%2520metastasis%26jtitle%3DPharm.%2520Res.%26date%3D2012%26volume%3D29%26spage%3D3040%26epage%3D3052%26doi%3D10.1007%2Fs11095-012-0726-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siemann, D. W.</span></span> <span> </span><span class="NLM_article-title">The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2010.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.ctrv.2010.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=20570444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFajs7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2011&pages=63-74&author=D.+W.+Siemann&title=The+unique+characteristics+of+tumor+vasculature+and+preclinical+evidence+for+its+selective+disruption+by+tumor-vascular+disrupting+agents&doi=10.1016%2Fj.ctrv.2010.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents</span></div><div class="casAuthors">Siemann, Dietmar W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-74</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The vasculature of solid tumors is fundamentally different from that of normal vasculature and offers a unique target for anti-cancer therapy.  Direct vascular-targeting with Tumor-Vascular Disrupting Agents (Tumor-VDAs) is distinctly different from anti-angiogenic strategies, and offers a complementary approach to std. therapies.  Tumor-VDAs therefore have significant potential when combined with chemotherapy, radiotherapy, and angiogenesis-inhibiting agents.  Preclin. studies with the different Tumor-VDA classes have demonstrated key tumor-selective anti-vascular and anti-tumor effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKL8nIIVWtVbVg90H21EOLACvtfcHk0liPIQvcj1kMkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFajs7vI&md5=85fe2cb36db459ad473bf53bbcae60af</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2010.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2010.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DSiemann%26aufirst%3DD.%2BW.%26atitle%3DThe%2520unique%2520characteristics%2520of%2520tumor%2520vasculature%2520and%2520preclinical%2520evidence%2520for%2520its%2520selective%2520disruption%2520by%2520tumor-vascular%2520disrupting%2520agents%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2011%26volume%3D37%26spage%3D63%26epage%3D74%26doi%3D10.1016%2Fj.ctrv.2010.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, M.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, P.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris-Natschke, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo-Hsiung Lee, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span> <span> </span><span class="NLM_article-title">In vivo and mechanistic studies on antitumor lead 7-methoxy-4-(2-methylquinazolin-4-yl)-3,4-dihydroquinoxalin-2(1<i>H</i>)-one and its modification as a novel class of tubulin-binding tumor-vascular disrupting agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5586</span>– <span class="NLM_lpage">5598</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00273</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00273" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVGrsL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5586-5598&author=M.-T.+Cuiauthor=L.+Jiangauthor=M.+Gotoauthor=P.-L.+Hsuauthor=L.+Liauthor=Q.+Zhangauthor=L.+Weiauthor=S.-J.+Yuanauthor=E.+Hamelauthor=S.+L.+Morris-Natschkeauthor=K.-H.+Kuo-Hsiung+Leeauthor=L.+Xie&title=In+vivo+and+mechanistic+studies+on+antitumor+lead+7-methoxy-4-%282-methylquinazolin-4-yl%29-3%2C4-dihydroquinoxalin-2%281H%29-one+and+its+modification+as+a+novel+class+of+tubulin-binding+tumor-vascular+disrupting+agents&doi=10.1021%2Facs.jmedchem.7b00273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">In Vivo and Mechanistic Studies on Antitumor Lead 7-Methoxy-4-(2-methylquinazolin-4-yl)-3,4-dihydroquinoxalin-2(1H)-one and Its Modification as a Novel Class of Tubulin-Binding Tumor-Vascular Disrupting Agents</span></div><div class="casAuthors">Cui, Mu-Tian; Jiang, Li; Goto, Masuo; Hsu, Pei-Ling; Li, Linna; Zhang, Qi; Wei, Lei; Yuan, Shou-Jun; Hamel, Ernest; Morris-Natschke, Susan L.; Lee, Kuo-Hsiung; Xie, Lan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5586-5598</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">7-Methoxy-4-(2-methylquinazolin-4-yl)-3,4-dihydroquinoxalin-2(1H)-one (2), a promising anticancer lead previously identified by us, inhibited tumor growth by 62% in mice at 1.0 mg/kg without obvious signs of toxicity.  Moreover, compd. 2 exhibited extremely high antiproliferative activity in the NIH-NCI 60 human tumor cell line panel, with low to sub-nanomolar GI50 values (10-10 M level).  It also showed a suitable balance between aq. soly. and lipophilicity, as well as moderate metabolic stability in vivo.  Mechanistic studies using Mayer's hematoxylin and eosin and immunohistochem. protocols on xenograft tumor tissues showed that 2 inhibited tumor cell proliferation, induced apoptosis, and disrupted tumor vasculature.  Moreover, evaluation of new synthetic analogs (6a-6t) of 2 indicated that appropriate 2-substitution on the quinazoline ring could enhance antitumor activity and improve druglike properties.  Compd. 2 and its analogs with a 4-(2-methylquinazolin-4-yl)-3,4-dihydroquinoxalin-2(1H)-one scaffold thus represent a novel class of tubulin-binding tumor-vascular disrupting agents (tumor-VDAs) that target established blood vessels in tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgHYAB0W82OLVg90H21EOLACvtfcHk0liopvDlmDNBYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVGrsL3J&md5=5a78f8afb2320b74e74f2f0193eca685</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00273%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DM.-T.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DGoto%26aufirst%3DM.%26aulast%3DHsu%26aufirst%3DP.-L.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DS.-J.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DMorris-Natschke%26aufirst%3DS.%2BL.%26aulast%3DKuo-Hsiung%2BLee%26aufirst%3DK.-H.%26aulast%3DXie%26aufirst%3DL.%26atitle%3DIn%2520vivo%2520and%2520mechanistic%2520studies%2520on%2520antitumor%2520lead%25207-methoxy-4-%25282-methylquinazolin-4-yl%2529-3%252C4-dihydroquinoxalin-2%25281H%2529-one%2520and%2520its%2520modification%2520as%2520a%2520novel%2520class%2520of%2520tubulin-binding%2520tumor-vascular%2520disrupting%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5586%26epage%3D5598%26doi%3D10.1021%2Facs.jmedchem.7b00273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of (2-(phenylamino)thieno[3,2-<i>d</i>]pyrimidin-4-yl)(3,4,5-trimethoxyphenyl)methanone analogues as potent anti-tubulin polymerization agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>183</i></span>, <span class="NLM_elocation-id">111679</span> <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.ejmech.2019.111679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=31541870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVanurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2019&author=C.+Tianauthor=X.+Chenauthor=Z.+Zhangauthor=X.+Wangauthor=J.+Liu&title=Design+and+synthesis+of+%282-%28phenylamino%29thieno%5B3%2C2-d%5Dpyrimidin-4-yl%29%283%2C4%2C5-trimethoxyphenyl%29methanone+analogues+as+potent+anti-tubulin+polymerization+agents&doi=10.1016%2Fj.ejmech.2019.111679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of (2-(phenylamino)thieno[3,2-d]pyrimidin-4-yl)(3,4,5-trimethoxyphenyl)methanone analogues as potent anti-tubulin polymerization agents</span></div><div class="casAuthors">Tian, Chao; Chen, Xuanzhen; Zhang, Zhili; Wang, Xiaowei; Liu, Junyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111679pp.</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Anti-tubulin polymn. agents can disrupt tumor-vascular to exhibit anti-cancer potency.  In this study, a series of substituted (2-(phenylamino)thieno[3,2-d]pyrimidin-4-yl)(3,4,5-trimethoxyphenyl)methanone analogs I (R = H, 4-CH3, 4-CN etc.; X = NH, NCH3, O, CO) were designed and synthesized as anti-tubulin polymn. agents that interact with colchicine binding site.  The most potent compd. I [R = 3-CH3; X = NH (II)] was selected to assay its inhibition on the tubulin polymn. which displayed potent inhibition with an IC50 value of 4.1 +/- 0.1 μM.  The colchicine competition assay demonstrated that the above compd. inhibited tubulin polymn. by binding to the colchicine-binding site of tubulin and the mol. modeling study elucidated the binding mode of the compd. in the colchicine binding site.  The result of confocal immunofluorescent study proved that compd. II can quickly disrupt the microtubules of Hela cells in a concn. dependent manner.  Some expts. at cellular level were conducted to investigate the effects of compd. II on cellular morphol., cell colony formation, cell cycle distribution, cell apoptosis and mitochondrial changes.  The results demonstrated that the above compd. is a potent anti-tubulin agent with strong concn. dependent effect of inhibition of colony formation, induction of G2/M arrest and induction of apoptosis through mitochondrial pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpolw4xNUQJZ7Vg90H21EOLACvtfcHk0liopvDlmDNBYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVanurfN&md5=97c993ea076431e1150a94283de37bb5</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111679%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520%25282-%2528phenylamino%2529thieno%255B3%252C2-d%255Dpyrimidin-4-yl%2529%25283%252C4%252C5-trimethoxyphenyl%2529methanone%2520analogues%2520as%2520potent%2520anti-tubulin%2520polymerization%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D183%26doi%3D10.1016%2Fj.ejmech.2019.111679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">442</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.11.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.ejmech.2018.11.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=30530194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVKqtrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2019&pages=428-442&author=W.+Liauthor=W.+Shuaiauthor=H.+Sunauthor=F.+Xuauthor=Y.+Biauthor=J.+Xuauthor=C.+Maauthor=H.+Yaoauthor=Z.+Zhuauthor=S.+Xu&title=Design%2C+synthesis+and+biological+evaluation+of+quinoline-indole+derivatives+as+anti-tubulin+agents+targeting+the+colchicine+binding+site&doi=10.1016%2Fj.ejmech.2018.11.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site</span></div><div class="casAuthors">Li, Wenlong; Shuai, Wen; Sun, Honghao; Xu, Feijie; Bi, Yi; Xu, Jinyi; Ma, Cong; Yao, Hequan; Zhu, Zheying; Xu, Shengtao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">428-442</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel isocombretastatin A-4 (isoCA-4) analogs were designed and synthesized by replacing 3,4,5-trimethoylphenyl and isovanillin of isoCA-4 with quinoline and indole moieties, resp.  The structure activity relationships (SARs) of these synthesized quinoline-indole derivs. have been intensively investigated.  Two compds. I (R1 = Me, CH2OH) exhibited the most potent activities against five cancer cell lines with IC50 values ranging from 2 to 11 nM, which were comparable to those of Combretastatin A-4 (CA-4).  Further mechanism investigations revealed that I (R1 = CH2OH) effectively inhibited the microtubule polymn. by binding to the colchicine site of tubulin.  Further cellular mechanism studies elucidated that I (R1 = CH2OH) disrupted cell microtubule networks, arrested the cell cycle at G2/M phase, induced apoptosis and depolarized mitochondria of K562 cells.  Moreover, I (R1 = CH2OH) displayed potent anti-vascular activity in both wound healing and tube formation assays.  Importantly, I (R1 = Me, CH2OH) significantly inhibited tumor growth in H22 xenograft models without apparent toxicity, suggesting that I (R1 = Me, CH2OH) deserve further research as potent antitumor agents for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGtdO0IJYx1LVg90H21EOLACvtfcHk0liopvDlmDNBYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVKqtrrN&md5=c1e12a0b0fb8e38c72c2579166c57b38</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.11.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.11.070%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DShuai%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DBi%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520quinoline-indole%2520derivatives%2520as%2520anti-tubulin%2520agents%2520targeting%2520the%2520colchicine%2520binding%2520site%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D163%26spage%3D428%26epage%3D442%26doi%3D10.1016%2Fj.ejmech.2018.11.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-P.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of 1-methyl-1,4-dihydroindeno[1,2-<i>c</i>]pyrazole analogues as potential anticancer agents targeting tubulin colchicine binding site</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5341</span>– <span class="NLM_lpage">5355</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00071</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00071" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC28XnslCqtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5341-5355&author=Y.-N.+Liuauthor=J.-J.+Wangauthor=Y.-T.+Jiauthor=G.-D.+Zhaoauthor=L.-Q.+Tangauthor=C.-M.+Zhangauthor=X.-L.+Guoauthor=Z.-P.+Liu&title=Design%2C+synthesis%2C+and+biological+evaluation+of+1-methyl-1%2C4-dihydroindeno%5B1%2C2-c%5Dpyrazole+analogues+as+potential+anticancer+agents+targeting+tubulin+colchicine+binding+site&doi=10.1021%2Facs.jmedchem.6b00071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of 1-Methyl-1,4-dihydroindeno[1,2-c]pyrazole Analogues as Potential Anticancer Agents Targeting Tubulin Colchicine Binding Site</span></div><div class="casAuthors">Liu, Yan-Na; Wang, Jing-Jing; Ji, Ya-Ting; Zhao, Guo-Dong; Tang, Long-Qian; Zhang, Cheng-Mei; Guo, Xiu-Li; Liu, Zhao-Peng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5341-5355</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By targeting a new binding region at the interface between αβ-tubulin heterodimers at the colchicine binding site, the authors designed a series of 7-substituted 1-methyl-1,4-dihydroindeno[1,2-c]pyrazoles as potential tubulin polymn. inhibitors.  Among the compds. synthesized, 2-(6-ethoxy-3-(3-ethoxyphenylamino)-1-methyl-1,4-dihydroindeno[1,2-c]pyrazol-7-yloxy)acetamide (I), and 2-(6-ethoxy-3-(3-ethoxyphenylamino)-1-methyl-1,4-dihydroindeno[1,2-c]pyrazol-7-yloxy)-N-hydroxyacetamide, (II), showed noteworthy low nanomolar potency against HepG2, Hela, PC3, and MCF-7 cancer cell lines.  In mechanism studies, I inhibited tubulin polymn. and disorganized microtubule in A549 cells by binding to the tubulin colchicine binding site.  I arrested A549 cells in G2/M phase that was related to the alterations in the expression of cyclin B1 and p-cdc2.  I induced A549 cells apoptosis through the activation of caspase-3 and PARP.  In addn., I inhibited capillary tube formation in a concn.-dependent manner.  In a nonsmall cell lung cancer xenograft mouse model, I suppressed tumor growth by 59.1% at a dose of 50 mg/kg (i.p.) without obvious toxicity, indicating its in vivo potential as anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ-hoobIDuqrVg90H21EOLACvtfcHk0lgR07IH-FUYqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnslCqtrY%253D&md5=ba4652575e64aa805d859734ea5b3903</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00071%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.-N.%26aulast%3DWang%26aufirst%3DJ.-J.%26aulast%3DJi%26aufirst%3DY.-T.%26aulast%3DZhao%26aufirst%3DG.-D.%26aulast%3DTang%26aufirst%3DL.-Q.%26aulast%3DZhang%26aufirst%3DC.-M.%26aulast%3DGuo%26aufirst%3DX.-L.%26aulast%3DLiu%26aufirst%3DZ.-P.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%25201-methyl-1%252C4-dihydroindeno%255B1%252C2-c%255Dpyrazole%2520analogues%2520as%2520potential%2520anticancer%2520agents%2520targeting%2520tubulin%2520colchicine%2520binding%2520site%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5341%26epage%3D5355%26doi%3D10.1021%2Facs.jmedchem.6b00071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-P.</span></span> <span> </span><span class="NLM_article-title">Tubulin colchicine site binding agent LL01 displays potent antitumor efficiency both in vitro and in vivo with suitable drug-like properties</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1007/s10637-019-00753-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1007%2Fs10637-019-00753-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=30887253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVyru77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=29-38&author=J.-D.+Wuauthor=Y.-J.+Cuiauthor=Y.-G.+Zhouauthor=L.-Q.+Tangauthor=C.-M.+Zhangauthor=Z.-P.+Liu&title=Tubulin+colchicine+site+binding+agent+LL01+displays+potent+antitumor+efficiency+both+in+vitro+and+in+vivo+with+suitable+drug-like+properties&doi=10.1007%2Fs10637-019-00753-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulin colchicine site binding agent LL01 displays potent antitumor efficiency both in vitro and in vivo with suitable drug-like properties</span></div><div class="casAuthors">Wu, Jing-De; Cui, Ying-Jie; Zhou, Yi-Gang; Tang, Long-Qian; Zhang, Cheng-Mei; Liu, Zhao-Peng</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-38</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Through rational drug design, we previously identified an indenoprazole deriv., 2-(6-ethoxy-3-(3-ethoxyphenylamino)-1-methyl-1,4-dihydroindeno[1,2-c]pyrazol-7-yloxy)acetamide (LL01), as a potent tubulin polymn. inhibitor targeting the tubulin colchicine binding site.  In this study, we further demonstrated that LL01 was not a P-gp substrate.  It potently inhibited the growth of a variety of tumor cells, including those with multidrug resistance, with GI50 values in the low nanomole ranges.  In vitro liver microsome stability assay, LL01 was modest stable in the liver microsomes of human, mouse and rat, but was fast metabolized in dog.  After single oral administration of LL01 at a dose of 10 mg/kg in SD male rats, LL01 showed acceptable PK properties with a mean bioavailability of 41%.  In human HepG2 hepatoma xenograft, at the oral doses of 25 mg/kg/day and 12.5 mg/kg/day, LL01 inhibited the tumor growth by 61.27%, and 43.74%, resp., which is much better than the pos. drug sorafenib (29.45%; 30 mg/kg/day).  Therefore, LL01 might be a potential drug candidate for further investigation for hepatocellular carcinoma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2xAaKO0FjP7Vg90H21EOLACvtfcHk0lgR07IH-FUYqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVyru77J&md5=0436d33ae1d41c15aa4ffd0aa58ff19d</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1007%2Fs10637-019-00753-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-019-00753-z%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.-D.%26aulast%3DCui%26aufirst%3DY.-J.%26aulast%3DZhou%26aufirst%3DY.-G.%26aulast%3DTang%26aufirst%3DL.-Q.%26aulast%3DZhang%26aufirst%3DC.-M.%26aulast%3DLiu%26aufirst%3DZ.-P.%26atitle%3DTubulin%2520colchicine%2520site%2520binding%2520agent%2520LL01%2520displays%2520potent%2520antitumor%2520efficiency%2520both%2520in%2520vitro%2520and%2520in%2520vivo%2520with%2520suitable%2520drug-like%2520properties%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2020%26volume%3D38%26spage%3D29%26epage%3D38%26doi%3D10.1007%2Fs10637-019-00753-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, F.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Z.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.-L.</span></span> <span> </span><span class="NLM_article-title">DHPAC, a novel synthetic microtubule destabilizing agent, possess high anti-tumor activity in vincristine-resistant oral epidermoid carcinoma in vitro and in vivo</span>. <i>Int. J. Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1016/j.biocel.2017.10.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.biocel.2017.10.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=29074436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsleltLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2017&pages=1-11&author=Y.+Zhangauthor=F.-L.+Gongauthor=Z.-N.+Luauthor=H.-Y.+Wangauthor=Y.-N.+Chengauthor=Z.-P.+Liuauthor=L.-G.+Yuauthor=H.-H.+Zhangauthor=X.-L.+Guo&title=DHPAC%2C+a+novel+synthetic+microtubule+destabilizing+agent%2C+possess+high+anti-tumor+activity+in+vincristine-resistant+oral+epidermoid+carcinoma+in+vitro+and+in+vivo&doi=10.1016%2Fj.biocel.2017.10.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">DHPAC, a novel synthetic microtubule destabilizing agent, possess high anti-tumor activity in vincristine-resistant oral epidermoid carcinoma in vitro and in vivo</span></div><div class="casAuthors">Zhang, Ying; Gong, Fu-Lian; Lu, Zhen-Ning; Wang, Hong-Yuan; Cheng, Yan-Na; Liu, Zhao-Peng; Yu, Lu-Gang; Zhang, Hui-Hui; Guo, Xiu-Li</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-11</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Multidrug resistance (MDR) is one of major obstacles to effective chemotherapeutic treatment of cancer.  This study showed that DHPAC, 2-(6-ethoxy-3-(3-ethoxyphenylamino) -1-methyl-1,4-dihydroindeno[1,2-c]pyrazol-7-yloxy) acetamide, a novel compd. that binds to the same site on microtubules as colchicine, has high anti-tumor activity in vincristine-resistant oral epidermoid carcinoma (KB/V) cells.  It found that the presence of DHPAC strongly inhibited KB/V cell growth in vivo and in mice xenograft.  The inhibitory effect of DHPAC is much stronger than that by colchicine in these KB/V cells (IC50: 64.4 nM and 458.0 nM resp.).  Treatment of the cells with DHPAC induced cell apoptosis by reducing mitochondrial membrane potential and altered the expression of several apoptosis-related proteins such as Bcl-2, Bax, Caspase-9, Cytochrome c and PARP.  DHPAC treatment also caused cell rest in G2/M phase by regulating of the expression of a no. of cell cycle-related proteins (e.g. Cyclin B1, Cdc2, Cdc25b, Cdc25c, RSK2).  Furthermore, DHPAC presence inhibits PTEN phosphorylation and PTEN/Akt/NF-κB signalling.  Thus, DHPAC has potent anti-cancer activity in MDR tumors and may be a potential therapeutic agent for the treatment of vincristine-resistant human oral epidermoid carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq26_W87zyH1LVg90H21EOLACvtfcHk0lgR07IH-FUYqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsleltLbI&md5=99078c235610f2b8e998ed4cfd829712</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2017.10.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2017.10.012%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DF.-L.%26aulast%3DLu%26aufirst%3DZ.-N.%26aulast%3DWang%26aufirst%3DH.-Y.%26aulast%3DCheng%26aufirst%3DY.-N.%26aulast%3DLiu%26aufirst%3DZ.-P.%26aulast%3DYu%26aufirst%3DL.-G.%26aulast%3DZhang%26aufirst%3DH.-H.%26aulast%3DGuo%26aufirst%3DX.-L.%26atitle%3DDHPAC%252C%2520a%2520novel%2520synthetic%2520microtubule%2520destabilizing%2520agent%252C%2520possess%2520high%2520anti-tumor%2520activity%2520in%2520vincristine-resistant%2520oral%2520epidermoid%2520carcinoma%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2017%26volume%3D93%26spage%3D1%26epage%3D11%26doi%3D10.1016%2Fj.biocel.2017.10.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-P.</span></span> <span> </span><span class="NLM_article-title">The discovery of novel indazole derivatives as tubulin colchicine site binding agents that displayed potent antitumor activity both in vitro and in vivo</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>187</i></span>, <span class="NLM_elocation-id">111968</span> <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111968</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.ejmech.2019.111968" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=31865012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVKgtL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2020&author=Y.-J.+Cuiauthor=C.-C.+Maauthor=C.-M.+Zhangauthor=L.-Q.+Tangauthor=Z.-P.+Liu&title=The+discovery+of+novel+indazole+derivatives+as+tubulin+colchicine+site+binding+agents+that+displayed+potent+antitumor+activity+both+in+vitro+and+in+vivo&doi=10.1016%2Fj.ejmech.2019.111968"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of novel indazole derivatives as tubulin colchicine site binding agents that displayed potent antitumor activity both in vitro and in vivo</span></div><div class="casAuthors">Cui, Ying-Jie; Ma, Chen-Chen; Zhang, Cheng-Mei; Tang, Long-Qian; Liu, Zhao-Peng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111968</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Tubulin inhibitors that bind to the colchicine site are widely studied anticancer agents.  In continuous our researches, we designed a series of novel indazole derivs. as microtubule-targeting agents (MTAs).  The structure-activity relationships (SARs) investigations indicated that a 3,4,5-trimethoxyphenyl moiety and a Me or methoxy substitution were preferred for the better antiproliferative activity.  The indazole derivs. 3c and 3f showed noteworthy low nanomolar potency against HepG2, HCT116, SW620, HT29 and A549 tumor cells.  In mechanism studies, 3c and 3f were proved to target the colchicine site, inhibited tubulin polymn. and disrupted cellular microtubule networks, arrested HCT116 cell in G2/M phase and induced cell apoptosis.  In the HCT116 xenografts mouse model, 3c and 3f suppressed tumor growth by 45.3% and 58.9% at an orally dose of 25 mg/kg without causing obvious wt. loss.  The indazole 3f may serve as a good lead or drug candidate for colorectal cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIJP_S76-BH7Vg90H21EOLACvtfcHk0lgFh3UpNfS5Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVKgtL%252FN&md5=0a66f7e3c5e84b31cb3cfe984914d56a</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111968%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DY.-J.%26aulast%3DMa%26aufirst%3DC.-C.%26aulast%3DZhang%26aufirst%3DC.-M.%26aulast%3DTang%26aufirst%3DL.-Q.%26aulast%3DLiu%26aufirst%3DZ.-P.%26atitle%3DThe%2520discovery%2520of%2520novel%2520indazole%2520derivatives%2520as%2520tubulin%2520colchicine%2520site%2520binding%2520agents%2520that%2520displayed%2520potent%2520antitumor%2520activity%2520both%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D187%26doi%3D10.1016%2Fj.ejmech.2019.111968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of in vitro and in vivo anticancer activity of 4-substituted coumarins: a novel class of potent tubulin polymerization inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5721</span>– <span class="NLM_lpage">5739</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00158</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00158" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC28Xotlalu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5721-5739&author=D.+Caoauthor=Y.+Liuauthor=W.+Yanauthor=C.+Wangauthor=P.+Baiauthor=T.+Wangauthor=M.+Tangauthor=X.+Wangauthor=Z.+Yangauthor=B.+Maauthor=L.+Maauthor=L.+Leiauthor=F.+Wangauthor=B.+Xuauthor=Y.+Zhouauthor=T.+Yangauthor=L.+Chen&title=Design%2C+synthesis%2C+and+evaluation+of+in+vitro+and+in+vivo+anticancer+activity+of+4-substituted+coumarins%3A+a+novel+class+of+potent+tubulin+polymerization+inhibitors&doi=10.1021%2Facs.jmedchem.6b00158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of in Vitro and in Vivo Anticancer Activity of 4-Substituted Coumarins: A Novel Class of Potent Tubulin Polymerization Inhibitors</span></div><div class="casAuthors">Cao, Dong; Liu, Yibin; Yan, Wei; Wang, Chunyu; Bai, Peng; Wang, Taijin; Tang, Minghai; Wang, Xiaoyan; Yang, Zhuang; Ma, Buyun; Ma, Liang; Lei, Lei; Wang, Fang; Xu, Bixue; Zhou, Yuanyuan; Yang, Tao; Chen, Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5721-5739</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, a series of novel 4-substituted coumarin derivs. were synthesized.  Among these compds. exhibited significant antiproliferative activity toward a panel of tumor cell lines at subnanomolar IC50 values.  Compd. I showed potent antiproliferative ability (IC50 values of 7-47 nM) and retained full activity in multidrug resistant cancer cells.  Compd. I caused G2/M phase arrest and interacted with the colchicine-binding site in tubulin, as confirmed by immune-fluorescence staining, microtubule dynamics assays, and competition assays with N,N'-ethylene-bis(iodoacetamide).  Compd. I reduced the cell migration and disrupted capillary-like tube formation in HUVEC cells.  Importantly, compd. I significantly and dose-dependently reduced tumor growth in four xenografts models including paclitaxel sensitive and resistant ovarian tumors (A2780s and A2780/T), adrmicycin sensitive and resistant breast tumors (MCF-7 and MCF-7/ADR), suggesting that compd. I is a promising novel antimitotic compd. for the potential treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0i0RqD2mFz7Vg90H21EOLACvtfcHk0lgFh3UpNfS5Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xotlalu7s%253D&md5=f466b56c86172479fdca8db106fdbd44</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00158%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DBai%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DLei%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520in%2520vitro%2520and%2520in%2520vivo%2520anticancer%2520activity%2520of%25204-substituted%2520coumarins%253A%2520a%2520novel%2520class%2520of%2520potent%2520tubulin%2520polymerization%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5721%26epage%3D5739%26doi%3D10.1021%2Facs.jmedchem.6b00158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garikapati, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makani, V. K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shareef, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal-Bhadra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, C. G.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of 1,4-dihydroindeno[1,2-c]pyrazole linked oxindole analogues as potential anticancer agents targeting tubulin and inducing p53 dependent apoptosis</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">104</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.12.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=10.1016%2Fj.ejmech.2017.12.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=29268127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvF2ntr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2018&pages=104-115&author=I.+Khanauthor=K.+R.+Garikapatiauthor=A.+B.+Shaikauthor=V.+K.+K.+Makaniauthor=A.+Rahimauthor=M.+A.+Shareefauthor=V.+G.+Reddyauthor=M.+Pal-Bhadraauthor=A.+Kamalauthor=C.+G.+Kumar&title=Design%2C+synthesis+and+biological+evaluation+of+1%2C4-dihydroindeno%5B1%2C2-c%5Dpyrazole+linked+oxindole+analogues+as+potential+anticancer+agents+targeting+tubulin+and+inducing+p53+dependent+apoptosis&doi=10.1016%2Fj.ejmech.2017.12.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of 1, 4-dihydroindeno[1,2-c]pyrazole linked oxindole analogues as potential anticancer agents targeting tubulin and inducing p53 dependent apoptosis</span></div><div class="casAuthors">Khan, Irfan; Garikapati, Koteswara Rao; Shaik, Anver Basha; Makani, Venkata Krishna Kanth; Rahim, Abdul; Shareef, Mohd. Adil; Reddy, V. Ganga; Pal-Bhadra, Manika; Kamal, Ahmed; Kumar, C. Ganesh</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104-115</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 1,4-dihydroindeno-[1,2-c] pyrazole linked oxindole conjugates, I [R1 = H, OMe, R2 = H, OMe, R3 = H, OMe, 5-Cl, etc.] were synthesized by using Knoevenagel condensation method and further evaluated for their antiproliferative activity against HeLa, A549 and MDA-MB-231 human cancer cell lines along with HEK-293 (normal human embryonic kidney cells).  Among the derivs., compds. I [R1 = R2 = OMe, R3 = H, OMe, 6-Cl] showed excellent cytotoxicity with IC50 values ranging between 1.33 to 4.33 μM.  Furthermore, detailed biol. assays showed that there was accumulation of mitotic cells in G2/M phase, disruption of microtubule network and increase in the G2/M checkpoint proteins (Cyclin B1 and CDK1).  Moreover, compd. I [R1 = R2 = OMe, R3 = 6-Cl] with IC50 value of 1.33 μM showed significant upregulation of tumor suppressor proteins like p53, p21 and pro-apoptotic Bax.  The mol. docking anal. demonstrated that these congeners occupy the colchicine binding pocket of the tubulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVZN2WhF50uLVg90H21EOLACvtfcHk0lhDgHUogf89tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvF2ntr%252FO&md5=452eb1025b4ab93ef30e685dc523aac5</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DI.%26aulast%3DGarikapati%26aufirst%3DK.%2BR.%26aulast%3DShaik%26aufirst%3DA.%2BB.%26aulast%3DMakani%26aufirst%3DV.%2BK.%2BK.%26aulast%3DRahim%26aufirst%3DA.%26aulast%3DShareef%26aufirst%3DM.%2BA.%26aulast%3DReddy%26aufirst%3DV.%2BG.%26aulast%3DPal-Bhadra%26aufirst%3DM.%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DC.%2BG.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%25201%252C4-dihydroindeno%255B1%252C2-c%255Dpyrazole%2520linked%2520oxindole%2520analogues%2520as%2520potential%2520anticancer%2520agents%2520targeting%2520tubulin%2520and%2520inducing%2520p53%2520dependent%2520apoptosis%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D144%26spage%3D104%26epage%3D115%26doi%3D10.1016%2Fj.ejmech.2017.12.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohkoshi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, D.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris-Natschke, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span> <span> </span><span class="NLM_article-title">Optimization of 4-(<i>N</i>-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1390</span>– <span class="NLM_lpage">1402</span>, <span class="refDoi"> DOI: 10.1021/jm4016526</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4016526" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVart7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1390-1402&author=X.-F.+Wangauthor=F.+Guanauthor=E.+Ohkoshiauthor=W.+Guoauthor=L.+Wangauthor=D.-Q.+Zhuauthor=S.-B.+Wangauthor=L.-T.+Wangauthor=E.+Hamelauthor=D.+Yangauthor=L.+Liauthor=K.+Qianauthor=S.+L.+Morris-Natschkeauthor=S.+Yuanauthor=K.-H.+Leeauthor=L.+Xie&title=Optimization+of+4-%28N-cycloamino%29phenylquinazolines+as+a+novel+class+of+tubulin-polymerization+inhibitors+targeting+the+colchicine+site&doi=10.1021%2Fjm4016526"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of 4-(N-Cycloamino)phenylquinazolines as a Novel Class of Tubulin-Polymerization Inhibitors Targeting the Colchicine Site</span></div><div class="casAuthors">Wang, Xiao-Feng; Guan, Fang; Ohkoshi, Emika; Guo, Wanjun; Wang, Lili; Zhu, Dong-Qing; Wang, Sheng-Biao; Wang, Li-Ting; Hamel, Ernest; Yang, Dexuan; Li, Linna; Qian, Keduo; Morris-Natschke, Susan L.; Yuan, Shoujun; Lee, Kuo-Hsiung; Xie, Lan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1390-1402</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The 6-methoxy-1,2,3,4-tetrahydroquinoline moiety in prior leads 2-chloro- and 2-methyl-4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)quinazoline was modified to produce 4-(N-cycloamino)quinazolines.  The new compds. were evaluated in cytotoxicity and tubulin inhibition assays, resulting in the discovery of new tubulin-polymn. inhibitors. 7-Methoxy-4-(2-methylquinazolin-4-yl)-3,4-dihydroquinoxalin- 2(1H)-one, the most potent compd., exhibited high in vitro cytotoxic activity (GIC50 1.9-3.2 nM), significant potency against tubulin assembly (IC50 0.77 μM), and substantial inhibition of colchicine binding (99% at 5 μM).  In mechanism studies, 5f caused cell arrest in G2/M phase, disrupted microtubule formation, and competed mostly at the colchicine site on tubulin.  Compd. 5f and N-methylated analog 5g were evaluated in nude mouse MCF7 xenograft models to validate their antitumor activity.  Compd. 5g displayed significant in vivo activity (tumor inhibitory rate 51%) at a dose of 4 mg/kg without obvious toxicity, whereas 5f unexpectedly resulted in toxicity and death at the same dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnOMs8LwZNSLVg90H21EOLACvtfcHk0lhDgHUogf89tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVart7k%253D&md5=c55675f32145d4e566aca81b9d288647</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm4016526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4016526%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.-F.%26aulast%3DGuan%26aufirst%3DF.%26aulast%3DOhkoshi%26aufirst%3DE.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DD.-Q.%26aulast%3DWang%26aufirst%3DS.-B.%26aulast%3DWang%26aufirst%3DL.-T.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DQian%26aufirst%3DK.%26aulast%3DMorris-Natschke%26aufirst%3DS.%2BL.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DK.-H.%26aulast%3DXie%26aufirst%3DL.%26atitle%3DOptimization%2520of%25204-%2528N-cycloamino%2529phenylquinazolines%2520as%2520a%2520novel%2520class%2520of%2520tubulin-polymerization%2520inhibitors%2520targeting%2520the%2520colchicine%2520site%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1390%26epage%3D1402%26doi%3D10.1021%2Fjm4016526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i121"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01345">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_16335"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01345?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01345</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Results of the in vitro tubulin polymerization assay as well as some bioassays, NMR spectra, and HPLC charts for all of the screening compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01345/suppl_file/jm0c01345_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01345/suppl_file/jm0c01345_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01345/suppl_file/jm0c01345_si_001.pdf">jm0c01345_si_001.pdf (6.04 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01345/suppl_file/jm0c01345_si_002.csv">jm0c01345_si_002.csv (3.4 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01345&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-23%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01345%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01345" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                10MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67997e6c690a1964","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
